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Abstract 
Typhoid fever is a life-threating systemic infection caused by Salmonella enterica 
sub-species enterica serovars Typhi (S. Typhi) and Paratyphi A (S. Paratyphi A). 
While the disease is mainly travel-associated in developed countries, it still causes 
significant burden in the poorest areas in developing countries where safe water and 
adequate sanitation and food hygiene remain limited. Typhoid management largely 
relies on antimicrobial therapy; however, antimicrobial resistance (AMR) in these 
causative pathogens has become a global threat, compromising the effectiveness of 
the treatment therapy and signifying the burden of this disease. Understanding the 
epidemiology of typhoid fever in different endemic settings as well as the impact of 
AMR on the disease outcome is crucial for disease control and management. 
 
First, this thesis utilized whole genome sequences of S. Typhi combined with clinical 
data from a randomized controlled trial to investigate the impact of AMR and 
bacterial genotype on the disease outcome. A novel subclade of ciprofloxacin-
resistant H58 S. Typhi associated with increased treatment failure was identified and 
these organisms were likely widespread in Indian subcontinent. Subsequently, this 
study combined bacterial genomics with conventional epidemiological tools to reveal 
the population structure and spatiotemporal dynamics of S. Paratyphi A isolates in 
Nepal. The Nepalese S. Paratyphi A population was highly dynamic with evidences of 
regular inter-country transmission, clonal expansion and replacement of distinct 
genotypes during the study period. A number of localized spatiotemporal clusters of 
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S. Paratyphi A cases were also identified. A molecular epidemiological investigation 
was also performed to provide insights into the AMR, epidemiological features and 
population structure and dynamics of S. Typhi in rural areas of Siem Reap, Cambodia. 
A substantial burden of pediatric typhoid fever was revealed and communes with 
high-risk of infection were identified. Multidrug resistant H58 S. Typhi with reduced 
susceptibility to fluoroquinolones was dominant in this setting. This study also 
investigated the phylogenetic relationship between acute and carriage S. Typhi 
isolates in Nepal and deciphered the genetic characteristics associated with carriage 
isolates. My study suggested that typhoid carriage was likely not an important source 
of new infections in endemic area.  
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Introduction 
1.1 The genus Salmonella 
The genus Salmonella belongs to the family Enterobacteriaceae, which is a large and 
diverse group of bacteria found in soil, water, waste, plants, and the gastrointestinal 
tracts of animals 1. This large family is composed of genetically and phenotypically 
closely related bacteria.  
 
Salmonella are facultatively anaerobic, non-spore forming, Gram-negative bacilli, 2 to 
5 μm long and 0.8 to 1.5 μm wide, usually motile by peritrichous flagella. The 
bacteria are catalase positive, oxidase negative, ferment glucose, mannitol and 
sorbitol to produce acid and gas, and can use citrate as a sole carbon source. They also 
do not hydrolyze urea or deaminate phenylalanine, but usually produce hydrogen 
sulfide on triple sugar iron agar. Salmonella yield negative Voges-Proskauer and 
positive methyl red tests and do not produce cytochrome oxide. Most Salmonella are 
positive for lysine decarboxylase and ornithine decarboxylase, except for Salmonella 
Typhi and Salmonella Paratyphi A. Salmonella is most closely related to Escherichia 
coli (E. coli); the geneses are thought to have shared a common ancestor more than 
100 million years ago 2. During their evolution, E. coli have become lactose positive 
while Salmonella are generally identified as being non-lactose fermenting 3. 
Salmonella can be identified from biochemical tests based on lactose fermentation, 
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acid and gas production from glucose, mannitol, maltose, sorbitol, and the production 
of hydrogen sulfide 4. 
 
1.2 Salmonella serology 
The Salmonella are traditionally classified into different serotypes (also referred to as 
serovars) by the Kauffmann-White scheme, the system was established to categorise 
all identified Salmonella serotypes 5. The documentation of this scheme is updated 
annually by the World Heath Organization’s (WHO) Collaborating Centre for 
Reference and Research on Salmonella at the Pasteur Institute, Paris, France. Up until 
2002, The U.S. Centers for Disease Control and Prevention (CDC) used a marginally 
different version of the scheme, but have since also adopted the Kauffmann-White 
Scheme 6.  
 
Salmonella serotyping is based on antibody agglutination reactions with the bacterial 
surface structures, the O antigen (somatic) and H antigen (flagella). The O antigen is a 
polysaccharide polymerized from O subunits, with each subunit typically comprised 
of four to six sugars depending on the O antigen. It is the outermost component of the 
lipopolysaccharides (LPS) found in the outer membrane of Gram-negative bacteria. 
Variation in the sugar components of the subunit, the covalent bond between the 
sugars of the subunit or the linkage between O subunits that form the O antigen 
polymer results in O antigen diversity. O antigens are classified as primary O factors 
that define O serogroups (O groups) and additional O factors that are often variably 
present or expressed in some O groups. For instance, S. Typhi possess type 9 and 12 
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O antigens and belong to serogroup O:9 or D1, whereas S. Paratyphi A carry type 1, 2 
and 12 O antigens and belong to serogroup O:2 or A.  
 
The H antigen is made up of protein subunits called flagellin and is the filamentous 
portion of the bacterial peritrichous flagellar. Salmonella is unique among enteric 
bacteria as it can express two forms (phases) of H antigens, which are encoded by 
different genes. The expression of these two genes is regulated so that only one 
flagellar antigen is expressed at a time in a single bacterial cell, a phenomenon known 
as phase variation 7. Most Salmonella are diphasic and can express both phase 1 and 
phase 2 H antigen; however, some Salmonella serovars like S. Typhi, S. Paratyphi A 
and S. Enteritidis are naturally monophasic and can only express a single flagellin 
type due to disruption of the gene encoding phase 1 or phase 2 antigen.  
 
Identification can also be performed by agglutination with another surface antigen, 
such as the virulence (Vi) polysaccharide capsular antigen that can be found on some 
Salmonella serovars, including S. Typhi, S. Paratyphi C and S. Dublin. The Vi capsule 
typically blankets the O antigen and blocks O agglutination but can be selectively 
removed by heat treatment prior to the O agglutination assay. Vi agglutination is used 
widely to identify S. Typhi isolates. As of 2002, the Kauffmann-White scheme was 
comprised of 2,541 serotypes 8. This classification scheme is essential for laboratory 
and clinical identification of the Salmonella as well as for international 
communication between scientists, health officials, and the public. Although more 
advanced molecular typing techniques have been introduced, Salmonella serotyping 
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remains important in epidemiological surveillance and outbreak investigation and is 
widely used in most microbiology laboratories in the world 9,10. 
 
1.3 Salmonella nomenclature 
The nomenclature of Salmonella has been controversial as the original classification 
of the genus was not based on DNA relatedness; rather, names were originally given 
according to the particular disease caused, the animal from which the organism was 
isolated (e.g., S. Typhi causing human typhoid and S. Typhimurium causing typhoid-
like in murine), or by the geographical location where the strain was first identified 
(e.g., S. Montevideo, S. Newport). Classification of Salmonella evolved over time 
beginning from the one serotype-one species concept that was originally proposed by 
Kauffmann in 1966 11. However if this concept were used today, it would result in the 
distinction of over 2,500 species.  
 
Several classical Salmonella nomenclatural systems were subsequently proposed and 
inconsistently and confusingly divided the genus Salmonella into species, subspecies, 
subgenera, groups, subgroups and serotypes 12. The turning point for Salmonella 
nomenclature occurred in the early 1970s when DNA-DNA hybridization 
experiments demonstrated that all Salmonella serotypes share greater than 85 percent 
of their genetic information and thus form a single species 13. In 1986, Le Minor and 
Popoff proposed to designate this single species as Salmonella enterica, which 
became widely accepted 14. Based on DNA relatedness, Salmonella enterica species 
were further divided into seven subgroups corresponding to seven subspecies (I, II, 
IIIa, IIIb, IV, V, VI), with subspecies V being the most distantly related of the 
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subgroups. In 1989, Reeves et al. published and classified subspecies V (Salmonella 
enterica subsp bongori) as a separate species (Salmonella bongori)15. 
 
According to the current Salmonella nomenclature used by CDC, the genus 
Salmonella comprises of two species, Salmonella enterica (S. enterica) and 
Salmonella bongori. Salmonella enterica is further divided into six subspecies, which 
are referred to by a Roman numeral and a name: I, S. enterica subsp. enterica; II, S. 
enterica subsp. salamae; IIIa, S. enterica subsp. arizonae; IIIb, S. enterica subsp. 
diarizonae; IV, S. enterica subsp. houtenae; and VI, S. enterica subsp. indica 12.  The 
majority (59%) of the Salmonella serotypes belong to subspecies I (S. enterica subsp. 
enterica) 16. Within this subspecies I, the most common O serogroups are A, B, C1, 
C2, D and E, which cause approximately 99% of Salmonella infections in humans and 
warm-blooded animals 16. Serotypes of other subspecies and Salmonella bongori are 
usually found in cold-blooded animals and the environment, and are rarely associated 
with disease in humans 17. 
 
1.4 Salmonella, the host and disease 
Salmonella are widely distributed in nature and can colonize the gastrointestinal tracts 
of both cold- and warm-blooded animals, including humans. Even though there are 
more than 2,500 Salmonella serovars, most serotypes are not pathogenic in their 
natural hosts and the majority of infections in humans and animals are caused by a 
small number of serotypes within subspecies I 18. The manifestation of disease largely 
depends on both host susceptibility and the infecting Salmonella enterica serotype, 
and is generally associated with one of the four major syndromes: typhoid fever, 
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enterocolitis/diarrhea, bacteremia and chronic asymptomatic carriage 19. For instance, 
in humans, most Salmonella serotypes are associated with acute and self-limiting 
gastroenteritis, whereas other serotypes (e.g, S. Typhi, S. Paratyphi and S. Sendai) 
cause enteric fever and a few serotypes (e.g, S. Choleraesuis and S. Dublin) are more 
likely to cause bacteremia than diarrhea.  
 
Regarding host adaptability, the majority of Salmonella serotypes (e.g, S. 
Typhimurium, S. Enteritidis) have a wide host range including animals and humans; 
however, other serotypes are largely adapted to specific animals and are infrequently 
found in humans (e.g, S. Dublin in cattle, S. Gallinarum in poultry, S. Abortusequi in 
horses, S. Abortusovis in sheep and S. Choleraesuis in pigs). Furthermore, a small 
number of serotypes such as S. Typhi, S. Paratyphi A, B, C and S. Sendai are fully 
adapted to humans and higher primates and are unable to cause disease in other hosts 
20. Host adaptation in Salmonella can be defined as the ability of a pathogen to 
circulate and cause disease in a particular host population 21. Host-adapted Salmonella 
serovars (e.g., S. Typhi, S. Choleraesuis) tend to be more virulent and cause systemic 
infections with a higher mortality rates in their hosts compared to broad-host-range 
serovars (e.g., S. Typhimurium or S. Enteritidis), which are often associated with non-
invasive infections 22.  
 
1.5 Typhoid fever 
1.5.1 Clinical features of typhoid fever 
Typhoid fever is a life-threatening systemic infection predominantly caused by 
Salmonella enterica subsp enterica serovar Typhi (S. Typhi) and Salmonella enterica 
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subsp enterica serovar Paratyphi A (S. Paratyphi A). The onset of symptoms is 
marked with prolonged fever, headache, malaise, anorexia, nausea, dry cough and 
disturbances of bowel function (constipation or diarrhea), which typically occurs after 
the end of first week. A coated tongue, hepatomegaly and splenomegaly are also 
common. The fever is low grade during the first week but rises gradually; by the 
second week, the temperature increases, reaching a plateau of 39 to 40oC. Rose spots 
on the chest, abdomen and back are reported in 5 to 30 percent of cases. The clinical 
manifestations and severity of typhoid fever are highly variable due to factors such as 
duration of illness before appropriate therapy, virulence and antimicrobial resistance 
of the causative agents, selection of antimicrobial therapy, patient age, previous 
exposure or vaccination, inoculum size, host factors (HLA type, AIDS or other 
immune suppression) and antacid consumption 23–32. Depending on the clinical setting 
and quality of available heathcare, serious complications can occur in 10 to 15 percent 
of typhoid patients, particularly in those who have been sick for more than two weeks. 
A wide range of complications are described, of which gastrointestinal bleeding, 
intestinal perforation, and typhoid encephalopathy are the most common and likely 
associated with risk of death 33,34. 
 
In the pre-antimicrobial era, case fatality rates were as high as 10 to 30 percent 35,36. 
Currently, with effective antimicrobial treatment, the average case fatality rate is 
usually less than 1 percent. However, case fatality rates vary significantly among 
different regions of the world, ranging from less than 2 percent in Pakistan and 
Vietnam to 30 to 50 percent in some areas of Indonesia and Papua New Guinea 37–40. 
Poor outcomes are highest among children less than one year of age and the elderly, 
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and often result from delayed treatment with effective antimicrobials 41. Relapse can 
occur 1 to 3 weeks after the patient recovers from the first episode, with milder 
symptoms than those experienced during the initial illness 34. The relapse rate is 5 to 
10 percent in untreated cases but still occurs after antimicrobial treatment, especially 
in those treated with first line drugs (chloramphenicol, trimethoprim-
sulfamethoxazole, and ampicillin). Relapse rates in patients treated with newer 
antimicrobials including fluoroquinolones (1.5%) or broad-spectrum cephalosporins 
(5%) are normally lower than those treated with first line drugs 42–48. Typically, 
relapses are caused by the same isolate as the original episode and can be 
distinguished from reinfection by molecular typing 47. Clinical features of S. Paratyphi 
A infections are commonly considered milder, with fewer complications than 
infections caused by S. Typhi. However, in the largest comparison to date there were 
no significant differences between clinical presentation, duration or outcome of 
typhoid caused by these organisms 15.  
 
1.5.2 Pathogenesis of typhoid fever 
As S. Typhi and S. Paratyphi A only cause disease in humans, pathogenesis studies of 
typhoid fever are hindered by the lack of a suitable animal model. Much of the 
understanding of pathogenic features of typhoid fever has arisen from Salmonella 
enterica serovar Typhimurium infection in a susceptible murine model that is thought 
to mimic human typhoid. The infectious dose has been determined in human 
challenge studies and varies between 1,000 and 1 million organisms, depending on the 
individual and the settings 26,49–52. After ingestion, the bacteria have to survive the 
gastric acid before reaching the small intestine. In the small intestine, bacteria can 
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adhere to the intestinal mucosa and subsequently invade the gut mucosa, probably 
through specialized epithelial cells overlaying the Peyer’s patches known as the M 
cells 53. After penetration, the invading bacteria translocate to the intestinal lymphoid 
follicles and are drained into mesenteric lymph nodes and the thoracic duct, and 
eventually into the bloodstream. In this primary bacteremia (within 24 hours of their 
ingestion), the organisms reach the liver, spleen, bone marrow and other parts of the 
mononuclear phagocyte systems where they can survive and multiply within the cells 
of monocytic lineage 54. After an incubation period of 7-14 days (depending on 
bacterial load, virulence and host response), bacteria are shed back into the 
bloodstream causing secondary, sustained bacteremia and marking the onset of the 
clinical symptoms. The most common sites of secondary infection are the spleen, 
liver, bone marrow, gallbladder and Peyer’s patches of the terminal ileum. 
Gallbladder colonisation occurs either directly from blood or by retrograde spread 
from the bile. Organisms are shed via the bile duct into the small intestine resulting in 
fecal shedding.  
 
There are some notable differences in the pathogenesis of typhoid fever compared to 
infections caused by nontyphoidal Salmonella serovars.  S. Typhi can translocate 
across the intestinal mucosa during an early phase of infection without causing any 
physical cellular damage and therefore without triggering a rapid acute inflammatory 
response as normally seen in gastrointestinal infections caused by nontyphoidal 
Salmonella. After infection, the incubation period may not always be followed by 
clinical symptoms 55. Furthermore, S. Typhi can survive and multiply in monocytes, 
which is essential for dissemination and persistence within the host, whereas 
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nontyphoidal Salmonella serovars, like Typhimurium, are effectively cleared by 
human monocytes 56. It is also noteworthy that the number of recoverable S. Typhi 
from patients with typhoid fever is low, with a median of 1 cfu/ml of blood and 10 
cfu/ml of bone marrow, which has a negative impact on diagnostics 57–59.  
 
1.5.3 Typhoid diagnosis 
The clinical diagnosis of typhoid fever is challenging in endemic regions as it is 
difficult to distinguish typhoid from other acute febrile illnesses such as malaria or 
dengue. Currently, blood culture followed by microbiological identification is still the 
gold standard diagnostic method, with a sensitivity of approximately 80 percent 33. 
Even though blood culture is the most reliable method and can be standardized, it 
remains costly and requires specialist facilities and personnel and therefore is 
generally only utilised in major hospitals in developing countries. The sensitivity of 
blood culture largely relies on the volume of blood taken from typhoid patients due to 
a low number of circulating organisms. To achieve the highest recovery rates, 10-15 
ml of blood from school children and adults and 2-4 ml from toddlers and preschool 
children are required. In some areas, it can be challenging to obtain such large 
volumes of blood, especially in children, which undermines diagnosis. Bone marrow 
culture is more sensitive than blood culture because the number of organisms in bone 
marrow is comparatively high 58,59. The culturing of bone marrow can be valuable for 
patients who have been treated with antimicrobials regardless of duration of illness 60–
62. However, this is an invasive procedure and thus not widely accepted, particularly 
in children, and is rarely performed outside of specialist hospitals. Stool culture has a 
positive rate of 30 percent in acute typhoid patients and its sensitivity depends on the 
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amount of feces cultured as well as the duration of the illness 61. Stool culture can be 
used to detect typhoid carriers but requires that multiple samples be examined, as 
shedding is sporadic and may persist at low levels. Instead, a Vi agglutination assay 
has been used to identify typhoid carriers because these individuals may produce high 
levels of Vi antibodies over a longer period compared to acutely infected patients 63,64.  
 
The Felix-Widal test was developed in 1896 and is the first serological method used 
to diagnose typhoid fever. This method is based on the measurement of agglutinating 
antibody levels against the O and H antigens of S. Typhi. The sensitivity and 
specificity of this test are moderate as S. Typhi share O and H antigens with other 
Salmonella serovars and also have cross-reacting epitopes with members of 
Enterobacteriaceae, which can result in a high false positive rate 65–68. Additionally, 
typhoid patients might not develop detectable antibodies or show demonstrable 
increases in antibody titers. This problem also presents in commercial serological tests 
such as Tubex and Typhidot, which demonstrated moderate sensitivity and specificity 
for the diagnosis of typhoid fever in Papua New Guinea, India and Bangladesh. In 
these studies, the sensitivity and specificity of these commercial kits varied from 51.1-
60 % and 58-88.3 %, respectively (Tubex) and 56-70.0 % and 54-88 %, respectively 
(Typhidot) 69–71. Despite these limitations, the use of the Felix-Widal test with suitable 
local cut-off values for positive diagnosis can be helpful in areas where access to 
alternative, more expensive methods is limited 72–74. PCR-based assays have also been 
developed for typhoid diagnosis. However, they are either unreliable or have poor 
sensitivity when performed on DNA extracted from blood samples 57,75. As a result, 
these methods are not widely used and also considered impractical in many typhoid 
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endemic areas. Serological assays based on novel S. Typhi-specific immunogenic 
proteins are under development which could potentially be converted into cheap and 
rapid diagnostic kits 76,77. Alternative approaches based on host-specific biomarkers 
such as metabolomics are also promising and warrant further investigation 78. 
 
1.5.4 Typhoid treatment  
In endemic areas, up to 90 percent of typhoid cases are managed at home with oral 
antimicrobials, supportive care and regular follow-up for complications 31,79. For 
hospitalized patients with severe symptoms, effective antimicrobials, good nursing 
care, maintenance of appropriate nutrition and hydration, and timely recognition and 
treatment are crucial to prevent serious complications and deaths. Appropriate 
antimicrobial therapy is critical to cure typhoid and avoid complications. The 
selection of antimicrobial drugs depends on a number of important criteria such as 
availability, efficacy and cost. An ideal drug should have fast time to defervescence 
and clinical improvement, render blood and stool cultures sterile during and after 
treatment, prevent relapse, and be available through oral and intravenous routes for 
both adults and children with low cost and minimal adverse effects 80.    
 
Prior to the 1990s, chloramphenicol, ampicillin and trimethoprim-sulphamethoxazole 
were the first drugs of choice for typhoid treatment as these drugs are inexpensive, 
widely available and rarely associated with side effects. However, the emergence and 
global dissemination of plasmid-mediated multidrug resistant S. Typhi in the 1990s 
rendered these drugs ineffective and resulted in the widespread use of 
fluoroquinolones as the treatment of choice 33. Data from published clinical trials 
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demonstrated that fluoroquinolones were the most effective drugs for typhoid 
treatment. They were rapidly effective even with short courses of treatment (3-7 
days), clearing fever and symptoms in 3 to 5 days with a cure rate exceeding 96 
percent and very low rates of post-treatment carriage (less than 2 percent) 81–86. 
However, nalidixic acid resistant S. Typhi and S. Paratyphi A exhibiting reduced 
susceptibility to fluoroquinolones have since emerged and become endemic in many 
South and Southeast Asian countries, and are associated with increased rates of 
fluoroquinolone treatment failure 87–90. For patients infected with nalidixic acid 
resistant organisms, treatment with the maximal recommended dose of 
fluoroquinolones should be given for a minimum of 10 to 14 days and patients should 
be followed up carefully to assess the shedding of bacteria in their stools. Third 
generation cephalosporins (ceftriaxone, cefixime, cefotaxime, and cefoperazone) and 
the macrolide, azithromycin, have been successfully used for typhoid treatment and 
can be used as effective alternative drugs for treating S. Typhi and S. Paratyphi A with 
reduced susceptibility to fluoroquinolones 87,91–100.  In areas where fluoroquinolones 
are not available or unaffordable, first line drugs (chloramphenicol, ampicillin and 
trimethoprim-sulphamethoxazole) remain appropriate for the treatment of typhoid if 
bacteria are still susceptible to these drugs. For severe typhoid, parenteral 
fluoroquinolones are often the drugs of choice and are given for a minimum of 10 
days 33. A high dose of intravenous dexamethasone and antimicrobials should be 
given promptly to adults and children with severe symptoms to reduce mortality 37. 
Relapse should be treated in the same manner as primary infection. The majority of 
chronic carriers can be cured with a prolonged course of antimicrobials 101–103.  
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1.6 The epidemiology of typhoid fever 
1.6.1 Epidemiological features of typhoid fever 
S. Typhi and S. Paratyphi A are human-restricted pathogens and humans are the only 
known natural hosts and reservoir of infection 34. The disease is transmitted via the 
fecal-oral route. The most common mode of typhoid transmission is by ingestion of 
water or food contaminated with human feces. Direct person-to-person transmission 
through contact with patients or chronic carriers who are shedding the organisms is 
uncommon 33. In endemic areas, water contaminated with human feces and food 
contaminated with contaminated water or by food handlers who are typhoid carriers 
are the main sources of infection 104. The incubation period and attack rate of typhoid 
fever are affected by the inoculum size and the vehicle of transmission. Waterborne 
transmission usually requires smaller inoculum, whereas foodborne transmission is 
associated with a larger inoculum and a higher attack rate over short periods 105,106. 
Bacteria causing typhoid fever can survive for weeks or months in the environment, 
including in seawater, sewage, pond, stream and lake water 107,108. Shellfish grown in 
polluted water, fruits and vegetables fertilized with sewage, milk and milk products 
have been documented as potential sources of infection 109. Often, large typhoid 
outbreaks occur when the source of drinking water serving large populations is 
contaminated or the water supply is disrupted 110,111. In developed countries, typhoid 
occurs sporadically and is mainly associated with travellers returning from endemic 
areas 112–118.  
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1.6.2 Typhoid carriage 
Asymptomatic carriage and the shedding of bacteria in feces can occur after patients 
recover from acute infection. Carriage can be divided into different periods depending 
on the duration of shedding: convalescent (three weeks to three months), temporary 
(three to twelve month) and chronic (more than one year) 34. In endemic regions, the 
chronic carriage rate is estimated to be 2-5 percent of the population, most of which 
are asymptomatic; up to 25 percent of chronic carriers have no clinical history of 
infection 34,119.  The relative importance of short-term and convalescent fecal carriers 
versus chronic carriers in the transmission dynamics of typhoid in endemic regions is 
largely unknown, probably due to a lack of follow-up and the absence of a robust 
method for detecting S. Typhi carriers. Risk factors associated with persistent carriage 
are not extensively studied, as this population is very challenging to identify 
prospectively. Previous studies have found that risk of becoming a chronic carrier 
following acute infection increases with age, and is higher in women and patients with 
cholelithiasis and cholecystitis 120,121. Data from a murine model and electron 
micrographic observation of gallstones retrieved from S. Typhi human carriers have 
suggested that colonization of the gallbladder epithelial cells and biofilm formation on 
the gallstones are the primary mechanisms by which Salmonella survives and persists 
in the gallbladder environment 122–126. 
 
Chronic carriage and fecal shedding have been long considered as central dogma 
determining the transmission and persistence of typhoid fever, as chronic carriers 
intermittently shed the bacteria into the local environment and may spread the disease 
in the community; additionally, these people can act as reservoirs for maintaining 
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specific genotypes 127,128. However, epidemiological studies have shown that direct 
transmission between household members primarily occurs through close contact with 
convalescent carriers rather than chronically infected individuals 129,130. Furthermore, 
recent advanced molecular epidemiological investigations in endemic regions such as 
Vietnam, Indonesia, and Nepal have demonstrated that acute typhoid is generally 
caused by a wide diversity of genotypes rather than singular local genotypes 131–134. 
Therefore, environmental transmission pathway appears to be most important 
transmission route rather than direct person-to-person contact in endemic regions 
Conversely, in areas where public health interventions have been successful in 
reducing typhoid burden, chronic carriage might play an important role in maintaining 
the disease in the population, probably via foodborne transmission from 
asymptomatic chronic carriers who are food preparers or handlers as reported during 
outbreaks of typhoid fever in the United States 135. As a result, the detection and 
treatment of chronic carriers is thought to be essential for eliminating typhoid from a 
population.  
 
1.6.3 The global burden of typhoid fever 
Typhoid fever remains a significant public health problem in many low and middle-
income countries where there may be a lack of safe water and adequate sanitation. 
Global estimates suggested that 21.7 million new cases and 217 000 deaths due to 
typhoid fever caused by S. Typhi occurred in the year 2000 alone, whilst S. Paratyphi 
A also caused 5.4 million cases with an unknown case fatality rate 118. The majority of 
illness occurred among infants, children and adolescents, with south-central and 
south-eastern Asia exhibiting the highest disease burden (>100 cases per 100 000 per 
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year) 118. More recently, Buckle and colleagues estimated that 13.5-26.9 million 
episodes of typhoid occurred worldwide in 2010 136. In the context of informing 
vaccine policy, Vittal-Mogasale and colleagues re-estimated the burden of typhoid 
fever with a focus on low- and middle-income countries. After adjusting for blood 
culture sensitivity and water-related risk, they estimated that 11.9 million typhoid 
fever illnesses and 129 000 deaths occurred in low and middle-income countries 
during 2010, and also suggested that typhoid burden is higher in Africa than 
previously thought 137. Between 2010 and 2014, multi-country population-based 
standardized surveillance for invasive Salmonella infection was conducted in 13 
sentinel sites across 10 countries in sub-Saharan Africa and identified a number of 
sites with remarkably high burden of typhoid fever, especially in children less than 15 
years of age (overall adjusted incidence rate >100 per 100 000 person-years of 
observation) 138. Additionally, data from this study also demonstrated that many rural 
populations exhibited similar or even higher typhoid incidences than urban 
populations.  
 
Simultaneously, typhoid fever caused by S. Paratyphi A has emerged at an 
unprecedented rate in many Asian countries, including Nepal, China, Pakistan and 
India 139. In some regions, the isolation rate of S. Paratyphi A from typhoid patients is 
similar or even higher than that of S. Typhi 140,141. The rapid emergence of S. 
Paratyphi A infections poses a significant public health concern as S. Paratyphi A 
display differences in epidemiology compared to S. Typhi and, thus, effective control 
and preventive measures for S. Typhi may not protect against S. Paratyphi A 129,142. 
Currently, there is no vaccine for S. Paratyphi A and the licensed typhoid vaccines do 
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not provide protection against S. Paratyphi A infections. Additionally, it has been 
reported that typhoid fever caused by S. Paratyphi A increased after typhoid vaccine 
implementation in Guangxi, China, which suggests that the role of S. Paratyphi A in 
the epidemiology of typhoid fever may impede the progress in typhoid management, 
and calls into question the impact of vaccines in areas where these two pathogens co-
circulate 143.  
 
1.6.4 Typhoid control and prevention 
As contaminated water and food are important vehicles for typhoid transmission, 
improvements in water, sanitation, and hygienic food preparation represent the 
ultimate solutions for reducing the burden of disease. Historical surveillance data 
suggest that rate of typhoid fever in Western Europe and North America substantially 
declined in parallel with the introduction of water treatment, pasteurization of dairy 
products and exclusion of human feces from food production 144. Recent reductions in 
typhoid fever incidence have also been reported in Latin America and some Asian 
countries, in parallel with water and sanitation improvements and economic transition 
118,145. However, such structural improvements remain challenging in low and middle-
income countries given the huge economic costs and long timelines that are often 
required to improve water quality and sanitation. In view of the continued burden of 
typhoid fever and the increasing antimicrobial resistance of the organisms, in 2008 the 
World Health Organization (WHO) recommended the programmatic use of licensed 
typhoid vaccines for endemic and epidemic disease control 146. There are currently 
two internationally licensed typhoid vaccines, the parenteral Vi-based polysaccharide 
vaccine and the live oral Ty21a vaccine, both of which have been proven to be safe 
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and efficacious in children aged > 2 years. Many Asian countries such as Vietnam and 
China have successfully used the Vi polysaccharide vaccine to reduce the burden of 
typhoid fever, and several other countries also have national policies targeting high-
risk groups such as food handlers 147. Additionally, a mass vaccination campaign with 
the Vi polysaccharide vaccine was also conducted in Fiji in cyclone-affected and 
high-risk areas 148. Despite the recommendation of WHO, strong evidence for the 
disease burden and the low cost, availability, and efficacy of typhoid vaccines, neither 
of these vaccines has been widely used in endemic low-resource settings. This might 
be due to a lack of epidemiological data in endemic settings as well as the short 
duration of vaccine-induced protection; further, none of these vaccines are licensed 
for children less than 2 years of age 149. A number of typhoid conjugate vaccines are 
under development, including Vi-rEPA (US National Institutes of Health), Typbar-
TCV (Bharat Biotech International Ltd) and Vi-CRM197 (Scla Behring Vaccines for 
Global Health) 150–152. Indeed, Typbar-TCV has been prequalified by the WHO and is 
currently being evaluated in Nepal, Bangladesh and Malawi. These new generation 
typhoid vaccines are expected to provide higher efficacy and longer duration of 
protection, and can be given to infants and young children. Efforts are also being 
made to develop a vaccine for S. Paratyphi A as well as a bivalent vaccine that can 
protect against both S. Typhi and S. Paratyphi A infections 147. 
 
1.7 Antimicrobial resistance in Typhoidal Salmonella 
1.7.1 Global dissemination of multidrug resistant Typhoidal Salmonella 
Antimicrobial therapy is crucial for the management of typhoid fever and for reducing 
mortality. In the pre-antibiotic era, reported case-fatality ratios ranged from 10 to 37 
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percent 153. In 1948, chloramphenicol was first used to treat typhoid fever and became 
the standard drug of choice 154. Fifteen years after the introduction of 
chloramphenicol, the mortality rate decreased from 12 to 1 percent 155. This drug was 
the mainstay for typhoid treatment until mid-1970, when antimicrobial resistant 
organisms started to emerge and subsequently caused epidemics in Mexico, India, 
Vietnam and South Korea 156–161. The outbreak strains carried a transferable resistant 
factor (R factor) located on a self-transmissible plasmid of the HI1 incompatibility 
group (IncHI1), which was responsible for resistance to chloramphenicol and also to 
streptomycin, sulphonamides and tetracyclines 162. The spread of chloramphenicol 
resistant S. Typhi lead to the increased use of the other two first line drugs, 
amoxicillin and trimethoprim-sulfamethoxazole. However, toward the end of the 
1980s and the 1990s, S. Typhi developed multidrug resistance (MDR) to all first line 
drugs of treatment, including chloramphenicol, trimethoprim-sulfamethoxazole and 
ampicillin 163. Outbreaks of multidrug resistant S. Typhi infections were subsequently 
reported in many countries in South Asia, Southeast Asia, Middle East and Africa 
40,164–171. These MDR S. Typhi carried self-transmissible plasmids of the HI1 
incompatibility type with typical size from 100 to 120 MDa 166,167,172–174. Recently, 
there have also been reports about chromosome-mediated MDR in S. Typhi isolates in 
Bangladesh, India, Pakistan, Iraq, and Fiji 175,176. MDR S. Typhi are currently 
considered to be endemic in many areas of South, Southeast Asia and Africa. 
Compared to S. Typhi, S. Paratyphi A have predominantly been found to be more 
susceptible to antimicrobials; however, MDR S. Paratyphi A isolates have also 
commonly reported since the 1990s in many settings in Asia 177–179. These MDR S. 
Paratyphi A isolates also harbored IncHI1 plasmids that share a common backbone 
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with other IncHI1 plasmids found in S. Typhi and acquired similar mobile elements, 
conferring a multidrug resistant phenotype 180.  
 
1.7.2 Emergence of fluoroquinolone resistance 
The global distribution and dominance of MDR S. Typhi led to the extensive use of 
fluoroquinolones (ciprofloxacin, ofloxacin) as alternative drugs of choice in the 
1990s. Again, the rampant use of ciprofloxacin not only for typhoid but also for other 
infections resulted in the emergence of S. Typhi isolates that were resistant to 
nalidixic acid (a quinolone) and reduced susceptibility to ciprofloxacin with MICs 
ranging from 0.125 to 1 μg/ml, ten times higher than the usual values for fully 
susceptible strains. Since the early 1990s, S. Typhi isolates with reduced susceptibility 
to ciprofloxacin have become a major problem in many developing countries in Asia 
89,164,181–183. Further, patients infected with S. Typhi with reduced susceptibility to 
ciprofloxacin are prone to exhibiting prolonged fever clearance times and increased 
rates of treatment failure 89,90,183. In 1997, a massive outbreak caused by such isolates 
occurred in Tajikistan, infecting 8000 people and causing 150 deaths 111. The first 
highly ciprofloxacin resistant S. Typhi isolate was identified in 2005 in India with an 
MIC of ciprofloxacin > 32 μg/ml 184.  Subsequent reports of increased incidence of 
infections caused by fully ciprofloxacin resistant S. Typhi later emerged in South Asia 
and travellers from developed countries who returned from this region 185–192. It is 
unclear if the emergence of highly ciprofloxacin resistant S. Typhi isolates was due to 
clonal expansion of a particular genotype or independent acquisition of resistance in 
multiple genotypes. Similarly, S. Paratyphi A isolates with reduced susceptibility to 
ciprofloxacin also emerged and subsequently disseminated throughout South Asia 
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over the same period and were associated with infections among travellers returning 
home from travel to these endemic areas 179,193–199. Alarmingly, S. Paratyphi A have 
shown a tendency to be more resistant to ciprofloxacin compared to S. Typhi 197,200. 
Highly ciprofloxacin resistant S. Paratyphi A isolates have also been sporadically 
reported in India and Japan 201,202.  Together with the widespread use of ciprofloxacin, 
there have been reports of a decline in chloramphenicol resistance and MDR S. Typhi 
isolates in some areas; however, the reintroduction of first line antibiotics is likely to 
result in the reemergence of MDR S. Typhi 203–207.  
 
Fluoroquinolone resistance is chromosome-mediated via point mutations occurring in 
various chromosomal genes (gyrA, gyrB, parC and parE). These single point 
mutations alter the enzymes, DNA gyrase and topoisomerase IV, all of which are 
targets for the quinolones. A single point mutation in the quinolone resistance 
determining region in the gyrA gene (frequently at codon 83 or codon 87) can result in 
decreased susceptibility to fluoroquinolones 181,183. Double mutation in the gyrA gene 
(two single point mutations at codon 83 and codon 87) results in reduced 
susceptibility to ciprofloxacin, whilst an additional mutation in the parC gene 
(typically at codon 80) is required for high level resistance to ciprofloxacin 196,208,209. 
Plasmid-mediated quinolone resistance was also reported in the late 1990s and was 
predominantly associated with qnr proteins that can protect DNA gyrase from 
ciprofloxacin and also by aminoglycoside-modifying enzyme (aac(6’)-Ib-cr), which 
acetylates ciprofloxacin 210. Resistance genes associated with these plasmids, such as 
qnrS1, qnrB, aac(6’)-Ib-cr, have been sporadically detected in S. Typhi isolates from 
India and from travellers returning from South Asian countries 211,212.  
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1.7.3 Resistance to third generation cephalosporins and macrolides 
In areas where MDR S. Typhi and S. Typhi with reduced susceptibility to 
ciprofloxacin are highly prevalent, azithromycin and third generation cephalosporins 
(ceftriaxone, cefixime, cefotaxime and cefoperazone) tend to be used as alternative 
drugs of treatment for uncomplicated typhoid fever. These drugs have become 
important for typhoid treatment as they have been proven effective during clinical 
trials and the prevalence of resistance to these agents is very low 45,93,213. However, 
since 2008, S. Typhi isolates gaining resistance to third generation cephalosporins 
have been reported in many countries, including India, Bangladesh, Pakistan, the 
Philippines, Germany, Congo, and Guatemala 214–220. There have been a number of 
extended-spectrum beta-lactamase (ESBL) enzymes identified among those isolates, 
such as SHV-12, CTX-M types, and AmpC of the ACC-1 type. In 2013, an MDR S. 
Paratyphi A isolate harboring a CTX-M-15 beta-lactamase was also reported from a 
Japanese traveler returning from India 221. Recently, outbreaks of typhoid fever 
caused by ESBL-producing S. Typhi have drawn significant public and scientific 
attention in India and Pakistan 222. For azithromycin, S. Typhi isolates frequently have 
an MIC ranging from 4 to 16 μg/ml and are found to respond well to a short-course of 
azithromycin treatment 223. The high effectiveness of azithromycin in clearing the 
infection is probably due to azithromycin’s remarkable property of high intracellular 
concentration (50 times more than in blood) 224.  However, treatment failures even 
with low azithromycin MIC of S. Typhi and S. Paratyphi A as well as high MIC of 
azithromycin (64 μg/ml) S. Paratyphi A have been sporadically reported in India and 
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travellers returning from Pakistan and India 225–227. The mechanism for azithromycin 
resistance in typhoidal Salmonella is not well described. 
 
1.8 The convergent evolution of Salmonella Typhi and Salmonella Paratyphi A 
While most of the Salmonella enterica serovars can infect a broad range of host 
species and are usually associated with self-limiting gastrointestinal infections, Typhi 
and Paratyphi A are human-restricted serovars and cause life-threatening systemic 
disease 228. There is a high level of similarity in pathological and epidemiological 
characteristics between these two typhoidal serovars. For instance, Typhi and 
Paratyphi A display similar pathogenic features during the course of infection, clearly 
distinguishing them from non-typhoidal Salmonella enterica serovars 153. This likely 
results in the indistinguishable clinical features and severity of infections caused by 
these two serovars as shown in the largest comparison up to date 197. Further, both can 
establish chronic infections in the human gall bladder, which could be a strategy to 
increase their transmissibility 130. Regarding their transmission patterns, Typhi and 
Paratyphi A generally infect via similar transmission routes, namely contaminated 
water or food, and both can also be transmitted directly from person to person 229.   
 
In the early 1990s, the population structure of Salmonella enterica was described 
based on multilocus enzyme electrophoresis (MLEE), through which Typhi and 
Paratyphi A were shown to belong to distinct lineages, suggesting that these two 
Salmonella serovars have different evolutionary histories and may have evolved 
independently to become human-adapted with identical disease phenotype 15,230. 
Multiple complete genomes of Typhi and Paratyphi A were subsequently generated, 
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followed by genome-wide comparisons between these two serovars as well as to other 
host-generalized serovars like Typhimurium; these studies provided unprecedented 
insights into the evolutionary processes of these organisms. Typhi and Paratyphi A 
are much more closely related to each other at the DNA level than Typhimurium 231. 
This is a consequence of extensive homologous recombination within a quarter of 
their genomes, which results in similar gene content and much lower nucleotide 
divergence (0.18%) compared to the rest of their genomes (1.2%) 232. These 
recombination events might play a role in the host restriction/pathogenesis of these 
two serovars, although this remains unproven. Further, the genomes of Typhi and 
Paratyphi A contain an exceptionally high level of pseudogenes (about 4% of coding 
sequences in each genome), much higher than the pseudogene contents of 
Typhimurium (0.9%) and E. coli (0.7%) 231,233–235. Pseudogenes are coding sequences 
that are putatively inactivated by mutations (such as nonsense substitution, 
frameshifts, gene truncation by deletion or rearrangement), causing the loss of their 
gene functions. Pseudogenes are not unique to the Salmonella, and are abundant in 
other host-adapted bacteria such as Shigella flexneri, Yersinia pestis, Rickettsia 
prowazekii, and Mycobacterium leprae 236–239 . Even though there are only a limited 
number of pseudogenes shared between Typhi and Paratyphi A, these genes are 
known to be involved in adaptation to their comparable niches and the interaction 
between Salmonella and host. For examples, loss of gene functions related to 
intestinal colonization and persistence (typhoidal Salmonella are less efficient in 
intestinal colonization and more favorable of systemic sites 55); pathogenicity 
(disruption in genes encoding for Salmonella-translocating effector proteins of 
Salmonella pathogenicity island I and II); chemotaxis receptor; iron metabolism and 
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surface-exposed proteins 231,233,240. Similar loss of protein functions also occurs in 
genes belonging to the same pathway, which often results in phenotypic convergence. 
For instance, disruption of fimbrial clusters in both Typhi and Paratyphi A can have 
important implications for host interaction or disruption in the hin gene but through 
different mechanisms, resulting in the loss of phase variation in both Typhi and 
Paratyphi A (both serovars are monophasic for phase 1 flagella whilst most 
Salmonella enterica subspecies 1 have a switching mechanism leading to diphasic 
flagella) 231. Gene degradation is likely the most important evolutionary force that 
alters the pathogenesis and narrows the host range of both Typhi and Paratyphi A 
233,234,240. There are also some specific gene clusters gained by lateral gene transfer 
that are present in both Typhi and Paratyphi A; however, most of their functions are 
unknown and unlikely to have a role in phenotypic differences from other Salmonella 
enterica serovars 231.  
 
1.9 Genomics and molecular epidemiology of typhoid fever 
1.9.1 Genomics and its role in molecular epidemiological studies in Asia and 
Africa 
In the pre-genomic era, it was very challenging to study the population structures and 
genetic characteristics of both S. Typhi and S. Paratyphi A as they showed very little 
genetic variation by conventional typing methods such as MLEE, PFGE and MLST 
15,241–243.  At the turn of the 21st century, the first complete genome of S. Typhi 
multidrug resistant strain, CT18, was published, with the first S. Paratyphi A genome 
strain, ATCC9150, released a few years later 231,233. The availability of these genomes 
provided novel insights into the genetic traits, virulence, resistant determinants and 
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host adaptation of these pathogens. The S. Typhi CT18 genome comprises of a 
chromosome (4,809,037 bp), a multidrug resistant plasmid of incompatibility type 
HI1 (pHCM1- 218,150 bp) and a cryptic plasmid (pHCM2-106,516 bp), whilst the S. 
Paratyphi A ATCC9150 genome is about 200 kb smaller (4,585,299 bp) and does not 
harbor any plasmid. The difference in chromosome size between these two serovars is 
primarily reflected in the prophage content and other mobile elements; for instance, S. 
Typhi carry SPI-7 (a 134 kb region containing the Vi polysaccharide biosynthetic 
operon, sopE prophage and type IVB pili operon), which is absent from S. Paratyphi 
A. On the other hand, S. Paratyphi A carries three prophage regions that are not 
present in S. Typhi, including a sopE prophage (SPA-2-SopE) 231,233. Subsequently, 
additional genomes of S. Typhi (strain Ty2) and S. Paratyphi A (strain AKU12601) 
became available and allowed extensive genomic comparisons among S. Typhi 
isolates (CT18 versus Ty2) and S. Paratyphi A isolates (ATCC9150 versus 
AKU12601). Comparative genomics exhibited an exceptionally high level of 
pseudogenes and distinctly conserved genomic backbones in both serovars 235,240. 
More than 98 percent of the two Typhi genomes are shared and only 282 single 
nucleotide polymorphisms were identified 235. Similarly, the two Paratyphi A 
genomes are collinear and highly similar, with only 188 single nucleotide 
polymorphisms detected 240. The clonal natures of both Typhi and Paratyphi A have 
imposed significant challenges in understanding their bacterial population structures 
and molecular epidemiological characteristics.  
 
In 2006, Roumagnac and co-workers were the first to describe the global population 
structure and evolutionary history of S. Typhi by using a mutation discovery method 
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to characterize SNPs within 200 gene fragments (1.85% of the Typhi genome) from a 
globally representative strain collection. The selection of gene fragments was based 
on the available complete genomes of strains CT18 and Ty2. Eighty-eight SNPs were 
detected and used to resolve Typhi into a rooted, maximally parsimonious 
phylogenetic tree defining 59 genetically distinct haplotypes (H1-H59) 128. This study 
also gave an early warning of the emergence and global spread of H58 S. Typhi, 
which was particularly associated with nalidixic acid resistant mutations in the gyrA 
gene 128. Latterly, Holt et al. paved the way for using a whole-genome approach to 
study the population structure and evolutionary traits of S. Typhi 244. Their study 
identified 1,787 SNPs among 17 Typhi isolates belonging to diverse haplotypes, 
providing much better resolution for the Typhi phylogenetic tree, which also 
established an important framework for further molecular investigations.  
 
Between 2008 and 2012, molecular epidemiological investigations were performed in 
highly endemic settings including Indonesia, Nepal, Kenya, Vietnam, Cambodia, and 
India by using SNP-based approaches to characterize the local S. Typhi population 
structure and investigate the transmission patterns of typhoid fever 131–134,245–247. 
These studies revealed that local bacterial populations are usually highly diverse and 
involve multiple co-circulating haplotypes, and showed that environmental 
transmission is dominant in urban settings. The findings also highlighted the 
increasing frequency of H58 S. Typhi in many parts of the world (except for 
Indonesia); in many locations, it was observed that the H58 lineage might be 
replacing locally existing haplotypes. This particularly successful clone of S. Typhi is 
predominantly non-susceptible to fluoroquinolones and associated with an MDR 
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phenotype, suggesting that the heavy use of antimicrobials for typhoid treatment has 
exerted significant selective pressure for the maintenance and expansion of the H58 S. 
Typhi population 128. 
 
1.9.2 The origin and global dissemination of H58 Salmonella Typhi 
The rapid emergence and subsequent global dissemination of antimicrobial resistant 
H58 S. Typhi throughout South Asian, Southeast Asian and African countries has 
become an important public health threat, which urgently requires further 
investigation on the origin, population structure, transmission and antimicrobial 
resistance determinants of this particular lineage. Additionally, the global dominance 
of H58 S. Typhi has also revealed the limitations of SNP-based typing methods, 
which show a lack of resolution within H58 isolates and have thus been recognised as 
less effective methods for use in molecular epidemiological studies of typhoid fever. 
Consequently, the whole genome approach is preferred as an ultimate solution to 
better understand the origin and evolution of H58 Typhi, as well as to track their 
global transmission. Over the last decade, the advances of next generation sequencing 
technology have allowed large-scale bacterial genome sequencing, marking the dawn 
of the genomic era and revolutionizing the molecular surveillance of infectious 
diseases. Using an integrative approach of genomics and conventional epidemiology, 
Wong and colleagues performed whole genome sequencing and phylogeographical 
analyses of the largest ever collection of S. Typhi (1,832 isolates from 63 countries, 
including 832 H58 isolates collected from 1992 to 2013) to investigate the 
evolutionary history, population structure and global transmission of H58 S. Typhi 248. 
This study confirmed that the global H58 S. Typhi population is highly clonal 
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compared to non-H58 populations, an indicator of recent clonal expansion. Their 
findings also provided strong evidence that H58 lineage emerged in South Asia and 
expanded dramatically from the early 1990s. There were numerous international 
transmission events reconstructed from phylogeographical analyses, which 
demonstrated the propagation of H58 S. Typhi from South Asia to many countries in 
Southeast Asia, Western Asia, East and South Africa and Fiji, followed by local and 
region-wide transmission in different endemic areas. In particular, this study 
underlined the silent ongoing epidemic of MDR H58 S. Typhi across many countries 
in Eastern and Southern Africa, probably driven by antimicrobial use considering 
most of the non-H58 isolates in these regions were drug susceptible. The H58 lineage 
is associated with an MDR phenotype and reduced susceptibility to fluoroquinolones; 
however, this study showed that the pattern clearly differs between geographical 
regions, likely due to differences in regional antimicrobial usage. H58 S. Typhi 
isolates from Southeast Asia were commonly multidrug resistant and possessed gyrA 
mutations, yielding simultaneous factors contributing to reduced susceptibility to 
fluoroquinolones, whereas most of the South Asian H58 isolates from recent years 
were non-MDR and harbored gyrA mutations. In Africa, however, the majority of 
H58 isolates were multidrug resistant but did not possess gyrA mutations 248. 
Importantly, the MDR gene cassette (Tn2670-like) is largely found in plasmids but 
can also be inserted into the chromosome at different positions, which can affect the 
bacterial fitness while still maintain the MDR phenotype 248.  
 
The global expansion of H58 S. Typhi population has been reshaping the global 
population structure of S. Typhi and changing the epidemiology of the disease; for 
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instance, African countries have recently experienced a surge of MDR typhoid fever 
which had previously been uncommon 249–252. Wong and her colleagues’ work set 
milestones in understanding the molecular epidemiology of S. Typhi, providing a 
global population framework and valid methodology for further local investigations 
into the transmission of antimicrobial resistant lineages of S. Typhi in different 
endemic areas. Their study also demonstrated the invaluable role of genomics in 
understanding the S. Typhi population structure and tracking the emergence and 
global transmission of antimicrobial resistant organisms.  
 
1.10 Aims of this study 
The emergence of fluoroquinolone resistant S. Typhi in South Asia, particularly 
Nepal, has caused significant challenges in typhoid management and has been 
sporadically reported to be associated with treatment failure. However, the bacterial 
population structure, antimicrobial resistance determinants and the association 
between fluoroquinolone resistant phenotype/bacterial genotype with clinical 
outcomes of typhoid fever have not yet been well characterized. Concurrently, S. 
Paratyphi A infections have also increased rapidly in Nepal and little is known about 
the bacterial population dynamics, antimicrobial resistance and epidemiological 
features in this settings. Previous epidemiological surveillance studies of typhoid 
fever have primarily focused on urban populations, where high incidences of typhoid 
fever have been reported. There has been a large gap in knowledge about the burden 
of typhoid fever as well as risk factors, transmission patterns and antimicrobial 
resistance in rural settings such as described in this thesis for Siem Reap, Cambodia. 
One of the most long-lasting and elusive research questions related to typhoid fever is 
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about the role of chronic carriage in disease transmission and bacterial persistence. 
Genomic characterization and comparison between chronic and acute S. Typhi 
isolates is necessary to provide novel understanding into the relative importance of 
chronic carriage. 
 
In order to fill in these current gaps in typhoid research, the aims of my study are as 
follows: 
 
• To use a combined genomic and clinical approach to characterize the 
population structure and dynamics of S. Typhi in Nepal, identify 
fluoroquinolone resistant determinants and understand the clinical features of 
typhoid fever. 
• To characterize the spatiotemporal dynamics, antimicrobial resistance 
patterns/determinants and phylogenetics of S. Paratyphi A in Kathmandu, 
Nepal. 
• Combine genomics and conventional epidemiological approaches to 
understand the molecular and spatial epidemiology of typhoid fever in rural 
areas in Siem Reap, Cambodia. 
•  Describe the genomic traits of carrier S. Typhi isolates and the genetic 
relationship between carrier and acute S. Typhi to provide insights into the 
role of typhoid carriage in the disease transmission 
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Methods 
2.1 Study sites and settings 
2.1.1 Patan Hospital in Kathmandu, Nepal 
The majority of bacterial isolates and associated metadata in my study originated from 
typhoid studies conducted in Patan Hospital in Kathmandu, Nepal. Kathmandu, the 
capital city of Nepal, has a population of 1.5 million and is situated at an altitude of 
1300m. The climate varies from cold winter months (December to February) to spring 
(March to May), the hot monsoon season (June to August) and autumn (September to 
November). Traditionally, the monsoon is characterized by a heavy burden of enteric 
infections. Patan Hospital, a 318-bed government hospital located in the Lalitpur Sub-
Metropolitan City (LSMC) in the Kathmandu Valley providing both emergency and 
elective inpatient services. Each year, Patan Hospital has 300,000 outpatients and 
16,000 inpatients, and the bed occupancy is approximately 85%. Ninety per cent of 
patients are from the immediate Kathmandu Valley and Lalitpur area. Enteric fever is 
common at the outpatient clinic at Patan Hospital, which has approximately 200,000 
outpatient visits annually. The population of LSMC is generally poor, with most 
living in overcrowded conditions and obtaining their water from stone spouts or 
sunken wells. Antimicrobials are available without prescription in the community in a 
variety of public and private outlets and there are numerous private physician clinics 
where patients may seek advice and clinical diagnosis for febrile disease. There has 
been no widespread implementation of a typhoid vaccine in this area, yet a generic 
typhoid Vi vaccine is available for purchase in some health care settings. 
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2.1.2 Angkor Hospital for Children in Siem Reap, Cambodia 
Angkor Hospital for Children (AHC) is one of two pediatric hospitals in Siem Reap 
City and has approximately 125,000 attendees and 4,000 admissions per year. The 
patients attending AHC are <16 years of age and come from a wide geographical 
radius and attend the hospital for various conditions. The majority of patients reside in 
the province of Siem Reap, which is located in northwest Cambodia and is bordered 
in the south by the Tonle Sap Lake, the largest freshwater lake in Southeast Asia. 
According to available census data, the province had a population of 896,443 people 
living in an area of 10,299 km2 in 2008; the province is subdivided administratively 
into 12 districts, 100 communes (which are within districts) and 907 villages 253. 
Cambodia has a tropical climate with a dry and wet season each year. During the wet 
season (April–October) the area of the Tonle Sap Lake can expand dramatically, 
increasing from 3,500 km2 up to approximately 14,500 km2, with the depth increasing 
from 0.5m up to 6-9m 254.  
 
2.2 Bacterial identification and antimicrobial susceptibility testing 
2.2.1 Blood culture 
Routine diagnosis of typhoid fever was performed by blood culture. Blood (1-3 ml for 
children; 5-10 ml for adults) was taken from all patients for bacterial culture on 
enrolment. Adult blood samples were inoculated into media containing tryptone soya 
broth and sodium polyanethol sulphonate, up to a total volume of 50 ml. Bactec Peds 
Plus culture bottles (Becton Dickinson, New Jersey, USA) were used for paediatric 
blood samples. The bottles were incubated at 37oC and examined daily for bacterial 
growth up to 7 days. Positive bottles were subcultured onto blood, chocolate and 
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MacConkey agar and presumptive Salmonella colonies were identified using standard 
biochemical tests and serotype-specific antisera (Murex Biotech, Dartford, England) 
 
2.2.2 Bile and stool culture 
Bile and stool were collected for culture from all patients undergoing 
cholecystectomy or laparotomy surgery between June 2007 and October 2010. Bile 
was inoculated into equal volumes of Selenite F broth and Peptone broth and 
incubated at 37oC overnight. Broths were subcultured onto MacConkey agar and 
Xylene Lysine Deoxycholate (XLD) agar. After overnight incubation at 37oC the 
plates were examined for the growth of Gram-negative bacteria and colonies were 
identified by standard microbiological methods and identified by API20E 
manufactured by bioMerieux, Inc. S. Typhi and S. Paratyphi A isolates were 
confirmed by slide agglutination by specific antisera (Murex Biotech, Biotech, 
England). 
 
2.2.3 Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed by the modified Bauer-Kirby disc 
diffusion method 255 with zone size interpretation based on Clinical and Laboratory 
Standards Institute guidelines (CLSI, 2012) 256. The control strains used for all 
susceptibility tests were E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 
and Staphylococcus aureus ATCC 29213. Etests were used to determine the minimum 
inhibitory concentrations (MICs), following the manufacturer's recommendations 
(bioMérieux, France). Ciprofloxacin MICs were used to categorize S. Typhi and S. 
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Paratyphi A isolates as susceptible (≤0.06 μg/mL), intermediate (0.12–0.5 μg/mL) and 
resistant (≥1 μg/mL) following CLSI guidelines (CLSI, 2012) 256. 
 
2.3 Vi agglutination assay  
The two carriage isolates lacking ViaB operon (GB003 and GB428) were grown in 
LB agar plates with different NaCl concentrations (1mM, 85mM and 170mM). 
Agglutination tests were performed on glass microscope slides by mixing 10μl of 
suspensions of single colonies with 50μl of antisera against Vi (Murex Biotech, 
Biotech, England). Agglutination was read after rocking the slide for 1 minute. Two 
other carriage isolates (GB125 and GB169) were used as controls for this experiment. 
  
2.4 Data sources and bacterial isolates 
2.4.1 Data sources and bacterial isolates in chapter 3   
The S. Typhi isolates and corresponding clinical data for chapter 3 originated from an 
open-label, randomized, controlled, superiority trial conducted at Patan Hospital and 
the Civil Services Hospital in the Kathmandu valley, Nepal between 2011 and 2014. 
The trial was registered at www.clinicaltrials.gov (ISRCTN63006567). Briefly, 
patients were randomly assigned to seven days of treatment with either oral 
gatifloxacin (400 mg tablets, Square Pharmaceuticals Limited, Bangladesh) at a dose 
of 10 mg/kg once daily or intravenous ceftriaxone (Powercef, 1000mg injection vial, 
Wock- hardt Ltd, India), injected over 10 min at a dose of 60 mg/kg up to a maximum 
of two grams (aged 2 to 13 years) or two grams (≥ 14 years) once daily. The trained 
community medical auxiliaries (CMAs) visited each patient assigned to treatment 
twice per day for at least 10 days or until the patient was asymptomatic. The CMAs 
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gave the drugs, and recorded drug doses, administration times, oral temperatures, 
symptoms, and potential adverse effects in a standard case-record form. Complete 
blood count, serum creatinine, liver-function parameters and serum glucose at 
enrolment and on day 8 of treatment were measured. Blood from all patients was 
subjected to bacterial culture at enrolment and on day 8 after randomization if S. 
Typhi or S. Paratyphi were isolated at enrolment, or if their symptoms suggested a 
clinical relapse. 
 
The primary endpoint was a composite of treatment failure, defined as the occurrence 
of at least one of the following events: fever clearance time (FCT) (time from the first 
dose of a study drug until the temperature dropped to 37.5˚C and remained there for at 
least two days) more than seven days post-treatment initiation; requirement for rescue 
treatment as judged by the treating physician; blood culture positivity for S. Typhi or 
S. Paratyphi on day eight of treatment (microbiological failure); culture-confirmed or 
syndromic enteric fever relapse within 28 days of initiation of treatment; and the 
development of any enteric fever-related complication (e.g. clinically significant 
bleeding, fall in the Glasgow Coma Score, perforation of the gastrointestinal tract and 
hospital admission) within 28 days after the initiation of treatment. Time to treatment 
failure was defined as the time from the first dose of treatment until the date of the 
earliest failure event. FCTs were calculated electronically using twice-daily recorded 
temperatures and treated as interval-censored outcomes. Patients without fever 
clearance or relapse, respectively, were censored at the time of their last follow-up 
visit. 
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There was a total of 78 S. Typhi isolates identified from this trial. Additionally, 58 S. 
Typhi isolates from previous studies conducted between 2008 and 2013 in Patan 
Hospital and genome sequences of 19 S. Typhi isolates from a recent international 
study of the H58 lineage were also included for phylogenetic analysis. Details about 
these S. Typhi isolates and their corresponding sequencing metadata are shown in 
appendix A.  
 
2.4.2 Data sources and bacterial isolates in chapter 4 
223 S. Paratyphi A isolates were collected from several studies conducted at Patan 
Hospital, Nepal between 2005 and 2014. Of which, 206 S. Paratyphi A isolates were 
collected from acutely infected people (defined as acute S. Paratyphi A isolate) from 
four randomized control trials: gatifloxacin vs cefixime (2005) 257, gatifloxacin versus 
chloramphenicol (2006-2008) 258, gatifloxacin versus ofloxacin (2008-2011) 259, 
gatifloxacin versus ceftriaxone (2011-2014) 260 and a matched case-control study 
(2011) 129. 17 S. Paratyphi A isolates were recovered from gallbladder bile of people 
who underwent cholecystectomy or laparotomy surgery for symptomatic 
cholelithiasis from 2007 to 2010 130. These 17 S. Paratyphi A isolates were defined as 
carrier S. Paratyphi A isolates given the fact that they were isolated from the 
gallbladder of asymptomatic carriers and the duration of carriage was unknown. 
Additionally, epidemiological and clinical information was respectively collected 
from the above studies where available. Major reported variables included age, sex, 
main water sources, water treatment methods, clinical symptoms at presentation, 
antimicrobial resistance information and individual GPS location. Details about the S. 
Paratyphi A isolates and their associated metadata are shown in appendix B.  
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2.4.3 Data sources and bacterial isolates in chapter 5   
The S. Typhi isolates and associated metadata described in chapter 5 originated from a 
retrospective study of invasive salmonellosis conducted at Angkor Hospital for 
Children (AHC) in Siem Reap City in Cambodia between January 2007 and 
December 2014 (appendix C). Case and control populations were identified from the 
electronic hospital and laboratory information system of AHC. For this investigation, 
the case population was defined as the population of hospital inpatients from whom S. 
Typhi was isolated from a blood culture. The control population was defined as the 
patient population admitted to AHC who did not have typhoid fever based on the 
recorded discharge diagnosis (International Classification of Disease (ICD)-10 code). 
Patients with a discharge diagnosis of typhoid fever but without blood culture 
confirmation (n=410) were not included in the risk factor analysis. Additionally, for 
the mapping and population risk factor analyses, cases that lived outside of a 100km 
radius from AHC were excluded. Data on age, sex, home location (commune level), 
admission and discharge dates for cases and controls were extracted from the 
electronic hospital information system. If a case or control was readmitted to the 
hospital with the same discharge diagnosis within a seven-day period, only the initial 
admission was included in the analysis.  
 
Commune-level census data were obtained from the Cambodian National Report on 
General Population Census of 2008 253. The extracted information included details 
regarding demographic indicators, age structure, literacy and education, housing and 
household characteristics, and access to toilet facilities and drinking water. Based on 
this report, a commune was classified as urban if the population density exceeded 
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200/km2, less than half of men were employed in agriculture and the total population 
exceeded 2,000. Monthly average precipitation was collected from Siem Reap 
Weather Station and MRCS (Mekong River Commission Secretariat) 261. Shuttle 
Radar Topography Mission (SRTM) elevation data were obtained from the CGIAR 
Consortium for Spatial Information (CGIAR-CSI) 262. Shapefile layers containing 
2008 commune-level population census data were accessed from Open Development 
Cambodia, an open-access data website providing data on Cambodia and its economic 
and social development (http://www.opendevelopmentcambodia.net). 
 
2.4.4 Data sources and bacterial isolates in chapter 6 
Between June 2007 and October 2010, a study of microbiology and epidemiology of 
invasive Salmonella carriage was conducted at Patan Hospital in Kathmandu 130. Bile 
samples from 1377 individuals who underwent cholecystectomy for acute or chronic 
cholecystitis were subjected to microbiological examination. 24 S. Typhi isolates 
identified from the positive bile samples and their associated metadata were 
retrospectively collected. These S. Typhi isolates were defined as carrier S. Typhi 
isolates as they were isolated from gallbladder of asymptomatic carriers and the 
duration of carriage was unknown. Additionally, 96 S. Typhi isolates recovered from 
acute typhoid patients (defined as acute S. Typhi isolates) during a randomized 
controlled trial conducted in Patan Hospital between July 2008 and August 2011 were 
also included 259. Details about these S. Typhi are shown in appendix D. 
 
2.5 Whole genome sequencing  
2.5.1 DNA extraction 
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Bacterial isolates grown overnight on Nutrient Agar plates were subjected to DNA 
extraction using the Wizard Genomic DNA Purification Kit (Promega, Wisconsin, 
USA). This DNA extraction kit includes nuclei lysis solution, RNase solution, protein 
precipitation solution and DNA rehydration solution. 
There are four main steps: 
• Cell lysis 
• RNA digestion 
• Removal of proteins by salt precipitation (DNA left in solution) 
• Isopropanol precipitation to concentrate and desalt the DNA 
Procedure: 
− Scrape the surface the overnight culture plate and add into 1 ml of sterile 
saline to the appropriately labelled 1.5ml microcentrifuge tube 
− Centrifuge the tubes at 13,000 rpm for 2 minutes to pellet the cells 
− Remove and discard the supernatants from the tubes 
− Add 600 μl nuclei lysis solution to the tubes and gently pipette until the cells 
are fully re-suspended 
− Incubate at 80oC for 5 min to lyse the cells; then cool to room temperature 
− Add 3 μl of RNase solution to the cell lysates. Invert the tubes 2-5 times to 
mix 
− Incubate at 37oC for 5 min. Cool the samples to room temperature 
− Add 200 μl of protein precipitation solution to each lysate. Vortex vigorously 
for 20 seconds to mix the protein precipitation solution with the cell lysates 
− Incubate the samples on ice for 5 min 
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− Centrifuge at 13,000 rpm for 3 min 
− Pipette 600 μl isopropanol into the newly labeled tubes 
− Transfer the supernatants containing the DNA to the appropriately labeled 
microcentrifuge tubes containing 600 μl of isopropanol 
− Gently mix by inversion until the thread like strands of DNA form a visible 
mass 
− Centrifuge at 13 000 rpm for 2 min 
− Carefully pour off the supernatants and drain the tubes on clean absorbent 
paper 
− Add 600 μl of room temperature 70% ethanol to each tube and gently invert 
the tubes several times to wash the DNA pellet 
− Centrifuge at 13,000 rpm for 2 minutes and carefully aspirate the ethanol 
− Drain the tubes on clean absorbent paper and allow the pellet to air-dry (will 
take approximately 10-15 minutes) 
− Add 200 μl of DNA rehydration solution to the tubes and incubate at 65oC for 
1 hour. Periodically mix the solution gently. Alternatively the DNA can rehydrate by 
incubating overnight at room temperature or at 4°C 
−  Store the DNA at -20oC until required 
 
2.5.2 DNA quantification 
Qubit dsDNA high sensitivity kit (Thermo Fisher Scientific, Waltham, MA, USA) 
was used to accurately quantify the DNA concentration. The kit includes concentrated 
assay reagent, dilution buffer, and prediluted DNA standards. 
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Procedure: 
• Prepare thin-wall, clear, 0.5 ml PCR tubes 
• Prepare the Qubit working solution by diluting Qubit HS reagent 1:200 with 
Qubit HS buffer in a plastic tube 
• For 2 standards (positive and negative):  
o 10 μl each standard 
o 190 μl working solution 
• For DNA samples 
o 2 μl each DNA sample 
o 198 μl working solution 
• Incubate all tubes at room temperature for 2 minutes 
• Proceed to “reading standards and samples using Qubit 3.0 fluorometer 
 
2.5.3 DNA library preparation 
DNA samples were subjected to library construction using Nextera DNA sample prep 
kit (Illumina, USA). Nextera DNA library prep protocol can fragment and add adapter 
sequences onto template DNA with a single tube Nextera reaction to generate 
multiplexed pair-end sequencing libraries.  
 
2.5.3.1 Tagment genomic DNA 
Nextera library preparation procedure combines DNA fragmentation, end-polishing, 
and adaptor-ligation steps into one, termed tagmentation.  
Procedure: 
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• Add 20 μl of genomic DNA at 2.5 ng/μl (50 ng total) to each 0.2 ml tube 
• Add 25 μl of TD Buffer to the tubes containing genomic DNA 
• Add 5 μl of TDE1 to the tubes containing genomic DNA and TD Buffer 
• Pipette up and down 10 times (or more) to mix thoroughly. Quick spin 
• Place on the thermal cycler with a heated lid and run the program 
  55°C for 5 minutes 
  Hold at 10°C 
 
2.5.3.2 Clean up Tagmented DNA 
The tagmented DNA is purified from the Nextera transposome as the transposome can 
bind tightly to DNA ends and interfere with downstream reactions. 
Procedure: 
• Transfer 50 μl from each tube to a new eppendorf, add 300 μl DNA binding 
buffer (Zymo), mix and transfer the mixture to Zymo-Spin column in a collection tube 
• Centrifuge 13,200 rpm for 1 minute 
• Discard the flow-through 
• Wash twice as follow 
o Add 500 μl wash buffer (Zymo) to each Zymo-Spin column 
o Centrifuge 13,200 rpm for 30 seconds 
o Discard the flow-through 
• Centrifuge at 13,200 rpm for 1 minute to make sure there is no residual wash 
buffer 
• Transfer the Zymo-spin column to a new eppendorf 
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• Add 25 μl of RSB (Resuspension Buffer) directly to the Zymo-Spin column 
• Incubate for 2 minutes at room temperature 
• Centrifuge at 13,200 rpm for 2 minutes 
 
2.5.3.3 Amplify Tagmented DNA 
Purified tagmented DNA is amplified using a 5-cycle PCR program. This step adds 
index 1 (i7) and index 2 (i5) and adapters (P5, P7) required for cluster generation and 
sequencing. Arrange index 1 (i7) and index 2 (i5) in an Index Plate as follow: 
Columns 1-12: Index 1 (i7) adapter (orange caps) 
Rows A-H: Index 2 (i5) adapter (white caps) 
Procedure: 
• Prepare a new 0.2ml tubes 
• Add 5 μl each index 1 adapter down each column 
• Add 5 μl each index 2 adapter across each row  
• Add 15 μl NPM (Nextera PCR Master Mix) 
• Add 5 μl PPC (PCR Primer Cocktail) 
• Add 20 μl each purified tagmented DNA (from step 3) 
• Mix by pipetting up and down or vortex briefly. Quick spin   
• Place on a thermal cycle with a heated lid and run the PCR program: 
72°C for 3 minutes 
98°C for 30 seconds 
5 cycles of: 
98°C for 10 seconds 
63°C for 30 seconds 
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72°C for 3 minutes 
 Hold at 10°C 
 
2.5.3.4 Clean up libraries 
This step uses AMPure XP beads to purify the library DNA and perform size 
selection to remove short library fragments. 
− Prepare fresh 80% ethanol from absolute ethanol. 
− Bring the AMPure XP beads to room temperature. 
Procedure: 
• Vortex AMPure beads rigorously to ensure beads are homogenous. 
• Add 30 μl AMPure beads to each tube containing amplified library  
• Mix by pipetting up and down 
• Incubate at room temperature for 5 minutes  
• Place on a magnetic stand and wait until the liquid is clear. Keep the tubes on 
the magnetic stand for the following steps.  
• Discard supernatant 
• Wash twice as follows: 
o Add 200 μl fresh 80% Ethanol. Avoid disturbing the beads 
o Incubate on the magnetic stand until the supernatant is clear 
o Remove and discard the supernatant from each tube 
• Remove residual Ethanol using white tip with pipette P20   
• Air-dry beads for 10 minutes 
• Remove the tubes from the magnetic stand  
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• Add 32.5 μl RSB (Resuspension Buffer) and pipette up and down to mix  
• Incubate at room temperature for 5 minutes 
• Place the tubes on the magnetic stand and wait until the supernatant is clear  
• Transfer 30 μl supernatant to a new tube, avoid bead carryover 
 
2.5.3.5 Library quantification 
Library quantification was performed using KAPA SYBR® FAST qPCR Kit (Kapa 
Biosystems, Wilmington, USA). KAPA Library Quantification Kits enable accurate 
and reproducible qPCR-based quantification of libraries prepared for Illumina 
sequencing. The kit contains six DNA standards (a 10-fold dilution series of a linear, 
452 bp template ranging from 0.0002 pM up to 20 pM), Library Quantification Primer 
Premix (10X) and KAPA SYBR® FAST qPCR Master Mix (2X). 
Procedure: 
• Make 1:1000 dilution of dsDNA library using Molecular Grade (MG) Water 
(or 10mM Tris-HCl, pH 8 + 0.05% Tween 20) 
• Prepare qPCR mix as follows: 
KAPA SYBR FAST qPCR Master Mix containing Primer Premix  6 μl 
Diluted library DNA or DNA Standard (1-6)    4 μl 
• Run qPCR protocol 
  Initial activation 95oC 5 min 
35 cycles: 
  Denaturation     95oC  30 sec 
  Annealing/extension/data acquisition   60oC  45 sec 
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 Melting curve analysis (optional) 
• Analyze the data and calculate the library concentration 
o Confirm 90-100% reaction efficiency for standards 
o Calculate the concentration of diluted library as determined by qPCR in 
relation to concentrations of DNA Standards 1-6 
o Perform a size adjusted calculation for the difference in the size between 
average fragment length of library and the DNA Standard (452 bp) 
o Calculate the undiluted library by taking into account the dilution factor 
and volume used per reaction (4 μl) 
 
2.5.3.6 Normalize and Pool libraries  
DNA Libraries were normalized to 4 nM and diluted to 20 pM before loading into the 
flow cell for Illumina sequencing on Miseq System.  
Procedure: 
Normalize and pooling 
• Dilute each library to 4 nM using MG water (or 10mM Tris-HCl, pH 8 + 0.05% 
Tween 20) 
• Transfer 5 μl each normalized library to a new eppendorf 
• Vortex and spin down. 
These are pooled libraries, next step is to denature with 0.2 N NaOH and dilute to 20 
pM 
Denaturing and Diluting 
• Prepare 0.2 N NaOH (to denature the pooled libraries) as follows: 
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o MG water:     800 μl 
o 1.0 N NaOH:  200 μl 
o Vortex and spin down (use only within 12 hours) 
• Thaw HT1 (hybridization buffer) and store on ice until you are ready to dilute 
denatured library 
• Combine the following volumes in a 0.2 ml tube 
 4 nM pooled libraries (5 μl) 
 0.2 N NaOH        (5 μl) 
• Vortex briefly and spin down 
• Incubate at room temperature for 5 minutes 
• Denature at 95oC for 2 minutes (optional) 
• Add 990 μl prechilled HT1 to the tube containing the denatured library. Keep on 
ice. This step results in 1 ml of a 20 pM denatured library ready for loading into the 
flow cell. 
 
2.5.4 Perform a run on Miseq 
Prepared pooled libraries were sequenced using Miseq Reagent v2 (300/500 cycles). 
The sequencing kit contains: Reagent Cartridge, buffer HT1, PR2 Bottle and Miseq 
Flow Cell. 
Procedure: 
• Clean the flow cell thoroughly using ELGA water prior to use 
• Remove the reagent cartridge from -20oC, thaw in a water bath at room 
temperature (take about an hour) 
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• When thawed, remove the cartridge from water bath, gently tap it to the bench 
and dry the base.  
• Invert the cartridge ten times to check if all the reagents are thawed 
• Gently tap the cartridge on the bench to reduce air bubbles 
• Load 600 μl of your prepared library onto the reagent cartridge in the reservoir 
labeled “Load Samples” (position 17)  
• Using the illumina Experiment Manager to set up sample sheet 
• Using the Miseq Control Sofware (MCS) interface, follow the run setup steps to 
load the flow cell and reagents and then start the run 
 
2.6 Single Nucleotide Polymorphism (SNP) detection and analysis 
2.6.1 SNP detection and analysis for Salmonella Typhi genomes 
2.6.1.1 SNP detection and annotation 
All raw Illumina reads were mapped to the reference sequence of S. Typhi strain 
CT18 (Accession no: AL513382), plasmid pHCM1 (AL513383) and pHCM2 
(AL513384) using SMALT (version 0.7.4). Candidate single nucleotide 
polymorphisms (SNPs) were called against the reference sequence using SAMtools 
263 and filtered with a minimal Phred quality of 30 and a quality cut-off of 0.75. The 
allele at each locus in each isolate was determined by reference to the consensus base 
in that genome, using samtools mpileup and removing low confidence alleles with 
consensus base quality ≤20, read depth ≤5 or a heterozygous base call. SNPs called in 
phage regions, repetitive sequences or recombinant regions identified previously were 
excluded 244. Gubbins was also used to identify recombinant regions from the whole 
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genome alignment produced by SNP-calling isolates 264 and SNPs detected within 
these regions were also removed. SNPs were annotated using the parseSNPTable.py 
script in the RedDog pipeline (https://github. com/katholt/RedDog). Strains belonging 
to haplotype H58 were defined by the SNP glpA-C1047T (position 2,348,902 in S. 
Typhi CT18, BiP33, as previously described 128,244).  
 
2.6.1.2 Salmonella Typhi genotyping 
From the detected SNPs in Salmonella Typhi genomes, a subset of 68 SNPs was used 
to assign Salmonella Typhi isolates to previously defined lineages according to an 
extended S. Typhi genotyping framework (Table 2.1). This SNP-based genotyping 
framework included four primary clusters, 16 clades and 49 subclades, developed 
from whole genome data of more than 1800 globally representative S. Typhi isolates 
265. Under this genotype nomenclature, the globally disseminated haplotype H58 
belongs to subclade 4.3.1.  
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Table 2.1 Canonical SNPs for genotyping Salmonella Typhi into Clades and Subclades 265 
 
Group N In Out CT18 position Gene Product Nt Codon ns s %Div 
0.1 11 T C 655112 STY0653 alkyl hydroperoxide reductase c22 protein 547 183 0 2 0.35 
0.0.1 2 A G 773487 STY0776 succinate dehydrogenase hydrophobic membrane anchor protein 333 111 0 1 0.29 
0.0.2 2 C T 1804415 STY1910 putative ATP/GTP-binding protein 996 332 0 3 0.27 
0.0.3 2 A G 1840727 STY1951 putative ATP-dependent helicase 1302 434 1 6 0.37 
0.1.1 2 A G 3640678 STY3775 primosomal protein replication factor 825 275 0 10 0.46 
0.1.2 1 T C 270120 STY0255 acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha 196 66 0 1 0.10 
0.1.3 1 A G 102135 STY0104 CorD protein 330 110 0 1 0.26 
1 7 C T 316489 STY0304 conserved hypothetical protein 117 39 14 6 1.49 
1.1 6 T C 4105384 STY4239 conserved hypothetical protein 267 89 0 1 0.17 
1.1.1 1 A C 555826 STY0548 putative ABC transporter ATP-binding protein 117 39 0 2 0.30 
1.1.2 2 T C 2360997 STY2526 Ais protein 273 91 2 5 1.15 
1.1.3 2 T C 4664137 STY4803 ornithine carbamoyltransferase 213 71 11 13 2.39 
1.1.4 1 A G 2166082 STY2335 uridine kinase 81 27 0 1 0.16 
1.2 1 T C 30192 STY0031 fimbrial subunit 195 65 0 1 0.19 
1.2.1 1 T C 4288272 STY4419 putative lipoprotein 588 196 0 2 0.31 
2 319 A G 2737027 STY2867 hypothetical protein 171 57 1 3 0.72 
2.0.1 9 G T 1215983 STY1260 putative ROK-family protein 651 217 2 2 0.44 
2.0.2 4 A G 4132985 STY4268 gluconate utilization operon repressor 237 79 3 3 0.60 
2.1  A G 146673 STY0144 UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate--D-alanalanyl ligase 297 99 0 4 0.29 2.1.1 3 A G 2517324 STY2682 putative oxidoreductase 283 95 0 3 0.38 
2.1.2 2 T C 3920009 STY4059 conserved hypothetical protein 768 256 2 5 0.80 
2.1.3 3 A G 3276735 STY3432 D-galactarate dehydratase 909 303 0 1 0.06 
2.1.4 1 T C 1173984 STY1220 flagellar P-ring protein precursor 360 120 2 4 0.54 
2.1.5 2 A G 2683312 STY2819 putative oxidoreductase 168 56 4 4 0.87 
2.1.6 9 A G 4013386 STY4154 putative DNA-binding protein 73 25 1 3 0.98 
2.1.7 49 A G 4094437 STY4227 nickel responsive regulator 222 74 0 1 0.25 
2.1.8 6 A G 827036 STY0829 biotin synthesis protein BioC 93 31 1 1 0.26 
2.1.9 12 T C 3476114 STY3622 uroporphyrinogen III synthase 195 65 3 3 0.81 
2.2  C T 4355243 STY4468 lysR family regulatory protein 156 52 0 3 0.34 2.2.1 11 A G 2723847 STY2853 putative sigma(54) modulation protein 300 100 0 2 0.59 
2.2.2 9 C T 4388609 STY4497 alpha-galactosidase 1092 364 3 2 0.37 
2.2.3 7 A G 703762 STY0707 glutamate/aspartate transport ATP-binding protein GltL 255 85 0 4 0.55 
2.2.4 4 A G 431216 STY0419 pyrroline-5-carboxylate reductase 351 117 0 2 0.25 
2.3 72 A G 3095443 STY3228 D-erythrose 4-phosphate dehydrogenase 717 239 2 7 0.86 
2.3.1a 21 T C 316186 STY0303 probable lipoprotein 354 118 0 2 0.37 
2.3.2 15 T C 1934711 STY2080 putative cation transporter 468 156 1 2 0.34 
2.3.3 9 T C 2811222 STY2937 glycine betaine-binding periplasmic protein precursor 48 16 2 1 0.30 
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2.3.4 12 T C 3092900 STY3226 fructose 1,6-bisphosphate aldolase 927 309 1 3 0.37 
2.3.5b 15 G A 2723724 STY2853 putative sigma(54) modulation protein 177 59 0 2 0.59 
2.4 38 C A 3437570 STY3584 sec-independent protein translocase protein 621 207 0 3 0.389 
2.4.1 24 A G 1780319 STY1876 hypothetical protein 126 42 0 1 0.57 
2.5 42 T C 1535365 STY1588 pyridine nucleotide transhydrogenase subunit-beta 342 114 4 5 0.65 
2.5.1 21 T C 1792810 STY1897 2-dehydro-3-deoxyphosphooctonate aldolase 54 18 0 2 0.23 
3c 399 T C 3062270 STY3196 lysyl tRNA synthetase (LysRS) 989 323 3 4 0.46 
3.0.1 2 C T 1799842 STY1906 ribose-phosphate pyrophosphokinase 480 160 0 4 0.42 
3.0.2 2 T C 432732 STY0421 shikimate kinase II 387 129 0 2 0.37 
3.1 66 G A 3069182 STY3203 conserved hypothetical protein 9 3 0 1 0.37 
3.1.1 25 A G 2732615 STY2863 30S ribosomal subunit protein S16 154 52 1 3 1.60 
3.1.2 27 T C 3770391 STY3909 ATP synthase subunit B 177 59 0 2 0.42 
3.2 58 A G 2269835 STY2438 endonuclease IV 819 273 2 3 0.58 
3.2.1 44 T C 4215341 STY4333 phosphoribulokinase 294 98 1 3 0.46 
3.2.2 12 T C 4602946 STY4741 probable sugar phosphotransferase 444 148 1 2 0.65 
3.3 62 T C 3368641 STY3527 conserved hypothetical protein 177 59 2 2 0.99 
3.3.1 32 A G 2245432 STY2413 cytidine deaminase 684 228 1 2 0.34 
3.4 56 A C 3164162 STY3316 hydrogenase-2 component protein 30 10 1 2 0.61 
3.5 122 A G 3923165 STY4063 deoxyuridine 5'-triphosphate nucleotidohydrolase 411 137 0 1 0.22 
3.5.1 1 T C 1811809 STY1918 hydrogenase-1 operon protein HyaF 738 246 1 3 0.47 
3.5.2 5 T G 3729635 STY3874 glutamine synthetase 1317 439 1 2 0.21 
3.5.3d 6 T C 3817752 STY3949 hypothetical protein 586 196 4 2 0.53 
3.5.4 31 T C 183033 STY0176 dihydrolipoamide acetyltransferase component (E2) of pyruvate dehydrogenase 969 323 3 7 0.53 
4 1089 T C 1615350 STY1689 conserved hypothetical protein 105 35 1 3 1.15 
4.1 96 A G 2342045 STY2507 ribonucleoside-diphosphate reductase 1 beta chain 588 196 1 6 0.62 
4.1.1 18 T C 3996717 STY4134 alpha-amylase 1623 541 2 6 0.39 
4.2 140 A G 2640029 STY2781 SseB protein 210 70 2 2 0.51 
4.2.1 40 T C 989024 STY0994 killing factor KicB 312 104 2 3 0.38 
4.2.2 77 A G 3806278 STY3940 chromosomal replication initiator protein 1152 384 6 3 0.64 
4.2.3 12 A G 1611156 STY1683 putative oxidoreductase 502 168 1 4 0.56 
4.3.1 853 T C 2348902 STY2513 anaerobic glycerol-3-phosphate dehydrogenase subunit A 1047 349 2 8 0.61 
Key: Group = Primary cluster/Clade/Subclade; N = number of S. Typhi isolates in the Group; In = allele within the group; Out = allele outside of 
group; Nt = nucleotide position in the gene; Codon = codon position in the gene; ns = number of non-synonymous SNPs in the gene; s = number of 
synonymous SNPs in the gene; %Div = % of diversity in the gene; a nested in 2.3.2; b nested in 2.3.3;c BiP48; d nested in 3.5.4; e BiP33
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2.6.1.3 Functional analysis 
First, SNPs occurring exclusively in carrier isolates were identified. Genes containing 
these SNPs were subsequently grouped by their predicted function based on the 
Salmonella Typhi functional classification scheme used by the Sanger Institute 
(www.sanger.ac.uk). This functional classification scheme is based on the genome 
annotation of S. Typhi strain CT18 233. A summary of main functional classes in this 
scheme was shown in Table 2.2. Similar analyses were performed to classify genes 
containing SNPs that occurred exclusively in acute isolates to different functional 
classes for comparisons with that of carrier isolates. 
 
2.6.1.4 Pairwise SNP distance 
Pairwise genetic distances (defined as difference in the number of SNPs) within and 
between acute and carrier isolates were estimated from their SNP alignment using 
packages ape (v4.1) and adegenet (v2.0.1) in R (v3.3.2). Pairwise SNP distances were 
extracted and plotted using the function pairDistPlot in adegenet package. 
Subsequently, the Wilcoxon rank sum test was used for testing the difference in the 
average pairwise SNP distances between groups. 
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Table 2.2 Salmonella Typhi functional classification scheme 233 
1.A Degradation 1.G.1 Biotin 3.C.4 Murein sacculus, peptidoglycan 
1.A.1 Degradation of 
carbohydrate 1.G.10 Thioredoxin 4.A Transport/binding proteins 
1.A.2 Degradation of amino 
acids 1.G.11 Menaquinone 
4.A.1 Transport amino acid and 
amines 
1.B.1 Glycolysis 1.G.12 Heme and porphyrin 4.A.2 Transport Cations 
1.B.10 Glyoxylate Bypass 1.G.13 Cobalamin 4.A.3 Transport Carbohydrates, organic acids and alcohols 
1.B.2 Pyruvate dehydrogenase 1.G.14 Iron uptake and storage 4.A.5 Transport Anions 
1.B.3 Tricarboxylic acid cycle 1.G.2 Folic Acid 4.A.6 Transport Other 
1.B.5.b Non-oxydative branch 1.G.3 Lipoate 4.B Chaperones 
1.B.6 Entner-Doudoroff 
pathway 1.G.4 Molybdopterin 4.C Cell division 
1.B.7.a Aerobic Respiration 1.G.5 Pentothenate 4.D Chemotaxis and mobility 
1.B.7.b Anaerobic Respiration 1.G.6 Pyridoxine 4.G Detoxification 
1.B.7.c Electron Transport 1.G.7 Pyridine nucleotide 4.H Cell Killing 
1.B.8 Fermentation 1.G.8 Thiamine 4.I Pathogenicity 
1.B.9 ATP-proton motive force 1.G.9 Riboflavin 5.A IS element, Phage related 
1.C Central intermediary 
metabolism 1.H Fatty acid biosynthesis 5.B Colicin-related function 
1.C.2 Gluconeogenesis 2 Broad regulatory function 5.D Drug/Analogue sensitivity 
1.C.3 Sugar-nucleotide 
biosynthesis, conversions 
3.A.10 Polysaccharides - 
(cytoplasmic) 5.F Adaptions and atypical conditions 
1.C.4 Amino sugars 3.A.11 Phospholipids 5.H.a Hypothetical protein 
1.C.5 Sulphur Metabolism 3.A.2 Ribosomal proteins - synthesis, modification 5.H.b Hypothetical protein 
1.D Amino Acid Biosynthesis 3.A.3 Ribosomes - maturation and modification 5.I Unknown 
1.D.1 Glutamate Family 3.A.5 Amino acyl tRNA synthesis; tRNA modification SPI-1 
1.D.2 Aspartate Family 3.A.7 DNA - replication, repair, restriction./modification SPI-10 
1.D.3 Serine Family 3.A.8 Protein translation and modification SPI-2 
1.D.4 Aromatic Amino Acid 3.A.9 RNA synthesis, modification SPI-3 
1.D.5 Histidine 3.B.1 Degradation of RNA SPI-4 
1.D.6 Pyruvate Family 3.B.2 Degradation of DNA SPI-5 
1.E Polyamine synthesis 3.B.3 Degradation of proteins, peptides, glycoproteins SPI-6 
1.F.1 Purine ribonucleotide 
biosynthesis 
3.B.4 Degradations of 
polysaccharides SPI-7 
1.F.2 Pyrimidine ribonucle 3.C Cell envelope SPI-8 
1.F.3 2'-Deoxyribonucleotide 
metabolism 3.C.1 Membranes lipoprotein SPI-9 
1.F.4 Salvage of nucleosides 
and nucleotides 
3.C.2 Surface polysaccharides & 
antigens  
1.F.5 Miscellaneous 3.C.3 Surface structure  
 
 
 56 
 
 
 
2.6.2 SNP detection and analysis for Salmonella Paratyphi A genomes 
Raw Illumina reads were mapped to the reference sequence of S. Paratyphi A strain 
AKU_12601 (accession no: FM200053) and plasmid pAKU_12601 (accession no: 
AM412236) using SMALT version 0.7.4 
(http://www.sanger.ac.uk/resources/software/smalt/). Candidate single nucleotide 
polymorphisms (SNPs) were identified against the reference sequence using 
SAMtools 263 and filtered with a minimal Phred quality of 30 and a quality cut-off of 
0.75.  The allele at each locus in each isolate was determined by reference to the 
consensus base in that genome, using samtools mpileup and removing low confidence 
alleles with consensus base quality ≤20, read depth ≤5 or a heterozygous base call. 
SNPs called in prophage regions, repetitive sequences (IS elements, transposases, 
etc.) identified previously were excluded 231,240. Subsequently, Gubbins software was 
used to identify potential recombinant regions from whole genome alignment 
produced by SNP-calling isolates 264. Detected regions were manually checked and 
SNPs found in these regions were also removed. 
 
2.7 Phylogenetic analysis 
2.7.1 Phylogenetic analysis for chapter 3 
A maximum likelihood (ML) phylogeny was estimated using a 1440 SNP alignment 
of the 78 RCT isolates in RAxML (version 7.8.6) with the generalized time-reversible 
substitution model (GTR) and a gamma distribution, with support for the phylogeny 
assessed via 1000 bootstrap replicates. The alignment was then compared to a global 
S. Typhi sequence database, with a particular focus on identifying sequences with a 
mutational profile suggestive of shared ancestry with a divergent H58 clade identified 
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in the previous phylogeny. A secondary ML phylogenetic tree was then inferred from 
the SNP alignment (1642 SNPs) of the 136 Nepalese S. Typhi along with 19 recently 
described S. Typhi H58 with the aforementioned mutational profile, using the same 
parameters as above.  
 
2.7.2 Phylogenetic analysis for chapter 4 
The best-fit evolutionary model for the SNP alignment of 223 S. Paratyphi A isolates 
was identified based on the Bayesian Information Criterion in jModelTest 
implemented in IQ-TREE software 266 and maximum likelihood phylogenetic trees 
were subsequently reconstructed under the selected model (TVM). Clade support for 
this maximum likelihood tree was assessed via 1000 bootstrap pseudo-analyses. 
Phylogenetic subgrouping of major lineages in the phylogenetic tree was performed 
on the basis of monophyletic groups (at least three isolates) with moderately to highly 
supported bootstrap values (>60%). In order to investigate the population structure of 
Nepalese S. Paratyphi A in the global context, a secondary maximum likelihood 
phylogenetic tree was inferred from a separate alignment of 3958 SNPs of the 223 
Nepalese S. Paratyphi A along with 111 S. Paratyphi A isolates from a global 
sequence database described previously 267. Bootstrap support for this maximum 
likelihood tree was estimated from 100 pseudo-replicates.   
 
2.7.3 Phylogenetic analysis for chapter 5 
A maximum likelihood phylogenetic tree was constructed from a 188 chromosomal 
SNP alignment of H58 isolates with RAxML (version 7.8.6) using the generalized 
time-reversible model (GTR) and a gamma distribution to model site-specific rate 
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variation (GTR+Г nucleotide substitution model in RAxML). Support for the ML 
phylogeny was assessed via 1,000 bootstrap pseudo-analyses of the alignment data. 
Phylogenetic subgrouping was defined based on monophyletic groups (lineages) with 
bootstrap values indicative of strong support (≥85%). To investigate the short-term 
divergence within the bacterial population and the transmission within the local 
population, a minimum spanning tree was reconstructed from the SNP alignment of 
lineage III and lineage IV identified in the ML tree (accounting for 95% of isolates) 
using the goeBURST algorithm in Phyloviz software (version 1.1) 268. This algorithm 
identified seven sublineages based on similarity among allelic profiles and frequency 
of isolation within the population. Sequences with identical SNP profiles and isolated 
at the highest frequency within each sublineage were assigned as founder genotypes 
(viewed as the central nodes within each of the sublineages), with descendant 
genotypes (represented by terminal nodes surrounding the founder genotype) assigned 
based on similarity to founder SNP profiles. These descendent genotypes can differ 
from the parental genotype by a single or multiple SNPs. 
 
2.7.4 Phylogenetic analysis for chapter 6 
A maximum likelihood phylogenetic tree was reconstructed from the SNP alignment 
of 120 S. Typhi isolates, plus a S. Paratyphi A isolate included as an outgroup to root 
the tree, using RAxML version 8.2.8 with the generalized time-reversible model and a 
Gamma distribution to model the site-specific rate variation (GTR+Г). Support for the 
maximum likelihood tree was assessed via bootstrap analysis with 1000 
pseudoreplicates. To investigate the phylogenetic structure of Nepalese H58 S. Typhi 
in the global context, a secondary ML phylogenetic tree was inferred from a separate 
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SNP alignment of 78 Nepalese H58 S. Typhi along with 836 globally representative 
H58 S. Typhi described previously 248. Support for this ML tree was assessed via 100 
bootstrap replicates. 
 
2.8 Resistance gene and plasmid analysis 
Investigation of antimicrobial resistance genes and plasmids of S. Typhi and S. 
Paratyphi A isolates was performed using a local assembly approach with ARIBA 
(Antimicrobial Resistance Identifier by Assembly) 269. Resfinder 270 and 
Plasmidfinder 271 were used as databases of antimicrobial resistant genes and plasmid 
replicons, respectively. Briefly, reference sequences in the database are clustered by 
similarity (minimum 90% sequence identity) and paired sequence reads are mapped 
to the reference sequences to generate a set of reads for each cluster. The reads for 
each cluster are assembled independently and the closest reference sequence to the 
resulting contigs is identified. The reads for the cluster are subsequently mapped back 
to the assembled contig to identify variants. ARIBA not only reports the acquired 
antimicrobial resistance genes, but also the quality of assemblies and any variants 
detected between the sequencing reads and the reference sequences including known 
resistance SNPs. 
 
2.9 Pan-genome analysis 
Raw reads from each isolate were de novo assembled using the short-read assembler 
Velvet with parameters optimized by Velvet Optimizer 272. Contigs that were less 
than 300 bp long were excluded and the assembled contigs were annotated using 
Prokka 273. The pan-genome was subsequently reconstructed using Roary (rapid 
 60 
 
 
 
large-scale prokaryote pan-genome analysis) 274 with a threshold set to 95% sequence 
similarity at the amino-acid level. Unique and shared gene content between groups of 
isolates was identified based on set operations on the pan-genome. 
 
2.10 Spatiotemporal cluster analysis 
2.10.1 Cluster analysis for chapter 4 
Spatial and spatiotemporal clustering analyses were performed using SaTScan v9.4 
275. A Bernoulli model was used to examine the spatial clusters of each identified 
genotype, using all other genotypes as the background distribution of S. Paratyphi A 
cases in Lalitpur, Kathmandu. The upper limit for cluster detection was specified as 
25% of the study population over 25% of the study duration (for spatiotemporal 
clustering). The significance of the detected clusters was assessed by a likelihood 
ratio test, with a p-value obtained by 999 Monte Carlo simulations generated under 
the null hypothesis of a random spatial and spatiotemporal distribution. All maps 
were created in ArcGIS 10.2 (ESRI, Redlands, CA, USA). 
 
2.10.2 Spatiotemporal clustering detection for chapter 5 
Spatiotemporal clustering analysis of S. Typhi in Siem Reap, Cambodia was 
performed using Moran’s I and SaTScan methodologies. First, Moran’s I test was 
used to evaluate global autocorrelation amongst communes that reported at least one 
case (n=78) of typhoid fever in GeoDa software (v1.6.7, https://geodacenter.asu.edu/). 
This test statistic provides an evaluation of whether the rates across the area of 
interest are spatially random (Moran’s I=0), over-dispersed (Moran’s I<0) or 
clustered (Moran’s I>0) 276. Next, Kulldorff’s scan statistic in SaTScan (v9.1.1, 
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http://www.satscan.org/) was used to identify the location of clusters of communes 
with high rates of typhoid fever over space and time 275,277. A cylindrical window was 
used to scan the area for clusters, with the size of the circle corresponding to the 
spatial scan and the height of the cylinder corresponding to time. The significance of 
the detected clusters was assessed by a likelihood ratio test, with a p-value obtained 
by 999 Monte Carlo simulations generated under the null hypothesis of random 
spatiotemporal distribution. In this analysis, scan windows were used to fit discrete 
Poisson models. For the sublineage-specific analyses, all case communes were 
included and those without cases of a specific sublineage were classified as having 0 
cases. The upper limit for cluster detection was specified as 25% of the study 
population over each year. All maps were created in ArcGIS 10.2 (ESRI, Redlands, 
CA, USA). 
 
2.11 Statistical analysis 
2.11.1 Statistical analysis for chapter 3 
Comparison of baseline characteristics patient groups, stratified by the H58 status or 
susceptibility category of their corresponding S. Typhi isolates was performed using 
the Kruskal Wallis test for continuous variables and Fisher’s exact test for categorical 
variables. Time to treatment failure was analysed using Firth’s penalized maximum 
likelihood bias reduction method for Cox regression as a solution for the non-
convergence of likelihood function in the case of zero event counts in subgroups 278. 
For comparisons between treatment arms, H58 status, or ciprofloxacin susceptibility 
group, the model included treatment arm, H58 status, or susceptibility group as a 
single covariate. Confidence intervals (CI) and p-values were calculated by profile-
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penalized likelihood. FCT was analyzed as an interval-censored outcome, i.e. as the 
time interval from the last febrile temperature assessment until the first afebrile 
assessment, using parametric Weibull accelerated failure time models 279. Median and 
inter-quartile range (IQR) FCT calculations for subgroups were based on models for 
each subgroup separately. Acceleration factors were based on models that included 
treatment arm as the only covariate. The non-parametric maximum likelihood 
estimator (NPMLE) was used to visualize the distribution of FCT between groups. 
Heterogeneity between subgroups was tested with models that included an interaction 
between treatment arm and the sub-grouping variable. All analyses were performed 
using R software version 3.2.2 280.  
 
2.11.2 Statistical analysis for chapter 5 
Rates of hospitalized typhoid fever were calculated at the commune level using the 
population under the age of 15 years from 2008. Multivariable negative binomial 
regression was used to identify commune-level risk factors associated with the rate of 
cases per 1,000 population under the age of 15 years. Interaction between commune 
level factors was evaluated using the likelihood ratio test. Variables included in the 
evaluation of the final model included those with significant associations (p<0.10) in 
the univariate analysis and a priori sanitation and water source variables. Variables 
that did not add significantly to the fit of the final model (determined by the 
likelihood ratio test) were not included. All analyses were performed in STATA (v13, 
College Station, TX, USA) and plots were created in R v3.2.2 (R Foundation for 
Statistical Computing, Vienna, Austria, https://cran.r-project.org/) using ggplot2 281. 
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Emergence of a novel ciprofloxacin-resistant subclade of H58 
Salmonella Typhi associated with fluoroquinolone treatment failure 
in Nepal 
 
3.1 Introduction 
Antimicrobial treatment is essential to effectively manage typhoid fever and avoid 
serious complications. However, antimicrobial resistance in S. Typhi has now become 
a major global health problem, limiting the treatment options and increasing the 
treatment failure rates. Over the last 30 years, the extensive use of antimicrobials for 
typhoid treatment has successively driven the emergence and global dissemination of 
resistant organisms 282. First line drugs of choice such as chloramphenicol, 
amoxicillin and trimethoprim-sulfamethoxazole have been rendered ineffective due to 
the emergence of MDR S. Typhi since the 1980s. Fluoroquinolones were 
subsequently used in the 1990s and became standard drugs of choice after officially 
recommended by WHO for typhoid treatment in 2003 33. However, the effectiveness 
of this group of compounds has been diminished since S. Typhi isolates with reduced 
susceptibility to fluoroquinolones started to emerge 283. Reduced susceptibility to 
fluoroquinolones in S. Typhi isolates is induced by point mutation(s) in quinolone 
resistance determining region in the gyrA gene and such organisms appear to have a 
fitness advantage, even in the absence of antimicrobial exposure 284. It is now known 
that the widespread of S. Typhi isolates with reduced susceptibility to 
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fluoroquinolones has been partly facilitated by the dissemination of a specific MDR 
lineage (H58) across Asia and Africa 248. H58 lineage has been replacing other 
genotypes rapidly and reshaping the global population structure of S. Typhi.  
  
Previous studies have shown that patients infected with S. Typhi isolates with 
elevated Minimum Inhibitory Concentrations (MIC) against ciprofloxacin and 
ofloxacin are more likely to have prolonged fever clearance time (FCTs) and more 
frequent treatment failure 89,90,283,285. Whilst older fluoroquinolones have showed a 
reduced efficacy in curing the disease, the fourth-generation fluoroquinolone, 
gatifloxacin, has been demonstrated as highly efficacious for uncomplicated typhoid, 
even in patients infected with S. Typhi isolates displaying reduced susceptibility to 
ciprofloxacin (MIC ≥0.125 μg/ml) 257,259,286,287. However, during a randomised 
controlled trial (RCT) comparing gatifloxacin and ceftriaxone conducted recently in 
Nepal, there was an increased number of treatment failures associated with S. Typhi 
strains with high level of ciprofloxacin and gatifloxacin resistance (ciprofloxacin MIC 
>32μg/ml, gatifloxacin MIC >1μg/ml), prompting the data safety and monitoring 
board to stop the trial 288. In this study, I aimed to investigate the molecular 
epidemiology of the S. Typhi isolates from this trial and understand how bacterial 
genotype may affect the treatment outcome. All S. Typhi isolates were genome-
sequenced and stratified by genotype and the association between genotype and 
clinical presentation and outcome was assessed. The findings from my research were 
published in eLife journal in 2016 (appendix G) 289.  
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3.2 Results 
3.2.1 Salmonella Typhi whole genome sequencing  
I performed whole genome sequencing (WGS) on 78 S. Typhi isolates from patients 
in both RCT treatment arms (gatifloxacin and ceftriaxone) (Appendix A). The 
resulting phylogeny indicated that the majority of isolates (65/78; 83.3%) fell within 
the H58 lineage, while the remaining 13 (16.7%) represented eight different lineages 
(Figure 3.1). All but four of the H58 strains contained the common DNA gyrase 
(gyrA) mutation in codon 83 (S83F), which confers reduced susceptibility against 
fluoroquinolones (FQs) (ciprofloxacin MIC; 0.125- 0.5μg/ml) 290. Nested within the 
S83F H58 group but separated from the rest of the group by a branch defined by 30 
SNPs, was a H58 subclade comprised of 12 isolates containing the S83F gyrA 
mutation, a mutation in gyrA at codon 87 (D87N), and an additional mutation in the 
topoisomerase gene, parC (S80I) (H58 triple mutant). Notably, these H58 triple 
mutants shared high MICs against ciprofloxacin (≥24μg/ml). Further, an additional 
two non-H58 RCT isolates with ciprofloxacin MIC≥24μg/ml had the S83F gyrA 
mutation, an alternative mutation at codon 87 (D87V), the S80I parC mutation, and 
an A364V mutation in parE (Figure 3.1, Appendix A). 
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Figure 3.1 The phylogenetic structure of 78 Nepali Salmonella Typhi isolated during 
a gatifloxacin versus ceftriaxone randomised controlled trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maximum likelihood phylogeny based on core-genome SNPs of 78 Salmonella Typhi isolates 
with the corresponding metadata, including the presence of mutations (dark grey) in gyrA (S83F, 
D87V and D87N), parC (S80I) and parC (A364V) and susceptibility to ciprofloxacin 
(susceptible, light blue; intermediate, mid-blue and non-susceptible, dark blue) by Minimum 
Inhibitory Concentration (MIC). Missing metadata is indicated by black boxes. Red lines linking 
to metadata show isolates belonging to the Salmonella Typhi H58 lineage (with H58 triple 
mutants highlighted), other lineages (non-H58) are shown with black lines. The scale bar 
indicates the number of substitutions per variable site (see methods). Asterisks indicate ≥85% 
bootstrap support at nodes of interest. 
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3.2.2 Clinical presentation of Salmonella Typhi infections 
I stratified clinical data from the RCT by H58 status of the corresponding S. Typhi 
isolates (H58; N=65, non-H58; N=13) and compared baseline characteristics between 
these groups. I found no significant differences in demographics and no association 
between disease severity at presentation between those infected with an H58 S. Typhi 
isolate or a non-H58 isolate (Table 3.1). Next, I compared the baseline characteristics 
of patients stratified by ciprofloxacin susceptibility (susceptible, intermediate and 
resistant), and found no differences in disease severity or demographics on 
presentation; the only exception being FQ resistant S. Typhi were more frequently 
isolated from adults (Table 3.2). A significantly lower proportion of H58 S. Typhi 
(4/65; 6.2%) were susceptible to FQs compared to non-H58 isolates (6/13; 46%) 
(p=0.001) (Table 3.3) and, overall, H58 isolates had significantly higher MICs against 
the majority of tested antimicrobials than non-H58 isolates (Table 3.3). 
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Table 3.1 Baseline characteristics by Salmonella Typhi lineage 
 
Baseline characteristic n Non-H58 (N=13) n H58 (N=65) p value*  
Age (years) – median (IQR) 13 18.0 (13.0,21.0) 65 18.0 (13.0,22.0) 0.75 
Sex (male) 13 12 (92.3%) 65 46 (70.8%) 0.17 
Temperature (°C) - median (IQR) 13 39.0 (38.3,39.4) 62 39.0 (38.3,39.4) 0.77 
Days of illness before enrolment - median (IQR) 13 5.0 (4.0,7.0) 65 5.0 (4.0,7.0) 0.39 
Antimicrobials in last two weeks 13 1 (7.7%) 65 9 (13.8%) 1.00 
Previous history of typhoid 13 1 (7.7%) 65 5 (7.7%) 1.00 
Family history of typhoid 13 1 (7.7%) 65 8 (12.3%) 1.00 
Typhoid vaccination 13 1 (7.7%) 65 0 (0%) 0.17 
Fever 13 13 (100%) 64 64 (100%) NA 
Cough 12 4 (33.3%) 62 15 (24.2%) 0.49 
Constipation 12 1 (8.3%) 63 4 (6.3%) 1.00 
Headache 13 12 (92.3%) 64 59 (92.2%) 1.00 
Diarrhoea 12 5 (41.7%) 62 24 (38.7%) 1.00 
Vomiting 12 4 (33.3%) 63 16 (25.4%) 0.72 
Abdominal pain 12 2 (16.7%) 62 18 (29.0%) 0.49 
Anorexia 12 9 (75.0%) 64 53 (82.8%) 0.68 
Nausea 12 9 (75.0%) 61 38 (62.3%) 0.52 
Leucocyte count (×109/L) - median (IQR) 13 5.9 (4.5,6.6) 65 6.2 (4.8,7.3) 0.54 
Neutrophils (%) - median (IQR) 13 65.0 (60,73.0) 65 70 (65.0,75.0) 0.17 
Lymphocytes (%) - median (IQR) 13 33.0 (22.0,37.0) 65 28.0 (22.0,34.0) 0.32 
Haematocrit  (%) - median (IQR) 12 38.7 (37.1,41.2) 65 38.0 (35.0,41.4) 0.39 
Platelet count (×109/L) - median (IQR) 13 177.0 (165.0,189.0) 65 158.0 (140,210) 0.24 
AST (U/L) - median (IQR) 12 52.5 (38.2,64.8) 62 59.0 (44.0,83.8) 0.21 
ALT (U/L) - median (IQR) 13 46.0 (37.0,57.0) 63 50 (35.5,66.5) 0.18 
 
N refer to the number of patients in each group 
n refers to the number of observations with non-missing data for the respective characteristic 
*Comparisons between the two were done using Fisher’s exact test for categorical variables and the Wilcoxon rank 
sum test for continuous variables 
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Table 3.2 Baseline characteristics by Salmonella Typhi ciprofloxacin susceptibility 
 
Baseline characteristic n Susceptible 
(N=10) 
n Intermediate 
(N=52) 
n Resistant 
(N=16) 
p 
value* 
Age (years) – median (IQR) 10 14.0 (9.2,17.0) 52 18.0 (13.0,22.0) 16 20 (17.8,21.2) 0.05 
Sex (male) 10 8 (80%) 52 39 (75.0%) 16 11 (68.8%) 0.86 
Temperature (°C) - median (IQR) 10 39.0 (38.6,39.4) 49 39.0 (38.3,39.4) 16 38.8 
(38.3,39.3) 
0.42 
Days of illness before enrolment - 
median (IQR) 
10 4.0 (4.0,6.0) 52 5.0 (4.0,7.0) 16 5.0 (4.0,7.0) 0.88 
Antimicrobials in last two weeks 10 1 (10%) 52 7 (13.5%) 16 2 (12.5%) 1.00 
Previous history of typhoid 10 0 (0%) 52 6 (11.5%) 16 0 (0%) 0.34 
Family history of typhoid 10 1 (10%) 52 6 (11.5%) 16 2 (12.5%) 1.00 
Typhoid vaccination 10 1 (10%) 52 0 (0%) 16 0 (0%) 0.13 
Fever 10 10 (100%) 51 51 (100%) 16 16 (100%) 1.00 
Cough 10 2 (20%) 49 13 (26.5%) 15 4 (26.7%) 1.00 
Constipation 10 0 (0%) 50 4 (8.0%) 15 1 (6.7%) 1.00 
Headache 10 10 (100%) 51 45 (88.2%) 16 16 (100%) 0.34 
Diarrhoea 10 3 (30%) 50 21 (42.0%) 14 5 (35.7%) 0.82 
Vomiting 10 2 (20%) 50 14 (28.0%) 15 4 (26.7%) 0.93 
Abdominal pain 10 1 (10%) 50 16 (32.0%) 14 3 (21.4%) 0.38 
Anorexia 10 8 (80%) 51 41 (80.4%) 15 13 (86.7%) 0.91 
Nausea 10 6 (60%) 48 31 (64.6%) 15 10 (66.7%) 1.00 
 
N refers to the number of patients in each group  
n refers to the number of observations with non-missing data for the respective characteristic 
* Comparison between the three groups were done using Fisher’s exact test for categorical variables and the 
Kruskal-Wallis test for continuous variables 
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Table 3.3 Comparison of antimicrobial susceptibility by Salmonella Typhi lineage 
 
 
 
E test 
Non-H58 (N=13) H58 (N=65) p value* 
MIC50 MIC90 GM (range) MIC50 MIC90 GM (range)  
Amoxicillin 0.5 1 0.77 (0.38–38) 0.75 >256 1.43 (0.38–>256) 0.0412 
Chloramphenicol 3 4 2.7 (1.5–8) 4 12 5.7 (2–>256) 0.0147 
Ceftriaxone 0.06 0.06 0.06 (0.05–0.13) 0.09 0.19 0.11 (0.03–0.64) 0.0004 
Gatifloxacin 0.13 0.25 0.06 (0.01–2) 0.13 2 0.21 (0.01–3) 0.1197 
Nalidixic acid >256 >256 21.6 (1–>256) >256 >256 346.8 (1–>256) 0.0004 
Ofloxacin 0.25 0.75 0.24 (0.03–>32) 0.5 >32 1.09 (0.03–>32) 0.0240 
Trimethoprim sulphate 0.02 0.05 0.03 (0.02–0.05) 0.05 0.32 0.09 (0.01–>32) 0.0016 
Ciprofloxacin 0.13 0.75 0.11 (0.01–>32) 0.38 >32 0.80 (0.02–>32) 0.0051 
Ciprofloxacin susceptibility group   0.0008# 
- Susceptible 6 (46.2%) 4 (6.2%)  
- Intermediate 4 (30.8%) 48 (73.8%)  
- Resistant 3 (23.1%) 13 (20.0%)  
 
*Comparisons between Salmonella Typhi lineage for MICs and ciprofloxacin susceptibility groups were based on 
the Wilcoxon rank sum test and Fisher’s exact test, respectively. 
MIC: minimum inhibitory concentration, measured in µg/ml 
#p value for comparison of susceptible vs. intermediate/resistant combined between groups by Fisher’s exact test 
is 0.001. 
GM: geometric mean, the upper range of the values was determined by multiplying the MIC by 2 if the result was 
>X (for example, >256 = 256*2 = 512). 
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3.2.3 Treatment failure and fever clearance times  
The primary endpoint of the RCT in which these data were generated was a 
composite for treatment failure (method section 2.4.1). Treatment failure with H58 S. 
Typhi was significantly less common in the ceftriaxone group (3/31; 9.7%) than the 
gatifloxacin group (15/34; 44.1%) (Hazard Ratio (HR) of time to failure 0.19, 95%CI 
0.05-0.56, p=0.002) (Table 3.4). Conversely, there was no significant difference in 
treatment failure between those infected with non-H58 isolates treated with 
gatifloxacin (0/6; 0%) or ceftriaxone (2/7; 28.6%) (p=0.32). Similarly, time to fever 
clearance differed significantly between the two treatment groups in H58 infections, 
with median FCTs of 5.03 days (interquartile range (IQR): 3.18-7.21) in the 
gatifloxacin group and 3.07 days (IQR: 1.89-4.52) in the ceftriaxone group 
(p<0.0006). Again, this trend was not mirrored in the non-H58 S. Typhi infections, 
with FCTs of 2.87 (IQR: 2.08-3.7) and 3.12 (IQR: 2.2-4.12) days for gatifloxacin and 
ceftriaxone, respectively (p=0.61) (Table 3.4). Moreover, in the gatifloxacin arm, H58 
S. Typhi tended to be associated with a higher risk of treatment failure (p=0.06) 
(Figure 3.2.A, Table 3.5) and a lengthier fever clearance time (p=0.013) (Figure 
3.2.C, Table 3.4). 
 
As I identified two non-H58 isolates that were also FQ-resistant (Figure 3.1), I 
additionally stratified outcome for the gatifloxacin arm (N=40 patients) by FQ 
susceptibility of the infecting organism. Those infected with FQ-resistant S. Typhi 
failed gatifloxacin treatment more frequently (8/10; 80%) than those infected with an 
intermediately resistant organism (7/25; 28%) or a susceptible organism (0/5; 0%) 
(p=0.007) (Figure 3.2.B, Tables 3.6 and 3.7). Furthermore, in the gatifloxacin arm, 
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those infected with FQ-resistant organisms had significantly higher median FCTs than 
those infected with S. Typhi with alternative FQ susceptibility profiles (median FCTs 
(days): susceptible, 2.96 (IQR: 2.13-3.85), intermediate, 4.01 (IQR: 2.76-5.37) and 
resistant 8.2 (IQR: 5.99-10.5), respectively (p<0.0001)) (Figure 3.2.D, Table 3.6). 
Comparatively, the median FCT for those infected with an FQ resistant organism but 
randomised to ceftriaxone was 3.83 days (IQR: 2.96-4.7) (p<0.0001 for the between-
treatment comparison) (Table 3.6). 
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Table 3.4 Summary of time to treatment failure and fever clearance time by 
Salmonella Typhi lineage 
 
Time to treatment 
failure 
Gatifloxacin 
(events/N) 
Ceftriaxone 
(events/N) 
Hazard ratio of time to 
failure (95%CI); p value 
Heterogeneity 
test  
(p value) 
H58*    0.020 
- H58 15/34 3/31 0.19 (0.05, 0.56); p=0.002  
- Non-H58 0/6 2/7 3.87 (0.31, 534.24); p=0.32  
Fever clearance 
time 
Gatifloxacin 
median (IQR) days 
Ceftriaxone 
median (IQR) days 
Acceleration factor 
(95%CI); p value 
Heterogeneity 
test  
(p value) 
H58¥    0.07 
- H58 5.03 (3.18, 7.21) 3.07 (1.89, 4.52) 1.59 (1.22, 2.09); p=0.0006  
- Non-H58 2.87 (2.08, 3.7) 3.12 (2.2, 4.12) 0.90 (0.59, 1.36); p=0.61  
*Likelihood ratio test p=0.06 and 0.40 for comparison of time to treatment failure between H58 vs. 
non-H58 groups in gatifloxacin arm only and in all patients, respectively 
¥p=0.013 and p=0.029 for comparison of interval censored time to fever clearance between H58 vs. 
non-H58 groups in gatifloxacin arm only and in all patients, respectively 
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Table 3.5 Treatment failure in detail by Salmonella Typhi lineage in the gatifloxacin 
treatment group 
 
Characteristic 
Non-H58 
(N=6) 
H58  
(N=34) 
p value* 
Treatment failure 0 (0%) 15 (44.1%) 0.06 
- Fever past seven days 0 (0%) 7 (21.2%)   
- Rescue treatment required 0 (0%) 9 (27.3%)  
- Microbiological failure 0 (0%) 2 (6.5%)  
- Relapse within 28 days 0 (0%) 4 (14.8%)  
- Confirmed relapse within 28 days 0 (0%) 4 (14.8%)  
Any relapse during 6 month follow-up 1 (16.7%) 4 (11.8%) 0.62 
Confirmed relapse during 6 month 
follow-up 
1 (16.7%) 4 (11.8%)  
 
*Time to treatment failure and time to relapse were analyzed using Firth’s penalized 
maximum likelihood bias reduction method for Cox regression and p values were 
calculated from likelihood ratio tests 
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Table 3.6 Summary of time to treatment failure and fever clearance time by 
ciprofloxacin susceptibility 
 
Time to 
treatment 
failure 
Gatifloxacin 
(events/N) 
Ceftriaxone 
(events/N) 
Hazard ratio of time to 
failure (95%CI); p value 
Heterogeneity 
test  
(p value) 
Ciprofloxacin 
susceptibility 
group† 
   0.08 
- Susceptible 0/5 1/5 2.40 (0.13, 350.21); p=0.57  
- Intermediate 7/25 2/27 0.27 (0.05, 0.99); p=0.049  
- Resistant 8/10 2/6 0.27 (0.05, 1.01); p=0.052  
Fever clearance 
time 
Gatifloxacin 
median (IQR) 
days 
Ceftriaxone 
median (IQR) 
days 
Acceleration factor 
(95%CI); p value 
Heterogeneity 
test  
(p value) 
Ciprofloxacin 
susceptibility 
group‡    
0.015 
- Susceptible 2.96 (2.13, 3.85) 4.78 (4.01, 5.5) 0.71 (0.49, 1.02); p=0.07  
- Intermediate 4.01 (2.76, 5.37) 2.63 (1.52, 4.05) 1.31 (0.97, 1.76); p=0.07  
- Resistant 8.2 (5.99, 10.5) 3.83 (2.96, 4.7) 2.23 (1.57, 3.17); p<0.0001  
 
†Likelihood ratio test p=0.007 for comparison of time to treatment failure between MIC groups in 
gatifloxacin arm only 
‡p<0.0001 for comparison of interval censored time to fever clearance between MIC groups in 
gatifloxacin arm only 
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Table 3.7 Treatment failure in detail by ciprofloxacin susceptibility in the 
gatifloxacin treatment group 
 
Characteristic Susceptible (N=5) 
Intermediate 
(N=25) 
Resistant 
(N=10) 
p 
value* 
Treatment failure 0 (0%) 7 (28.0%) 8 (80%) 0.007 
- Fever past seven days 0 (0%) 2 (8.0%) 5 (55.6%)  
- Rescue treatment required 0 (0%) 3 (12.0%) 6 (66.7%)  
- Microbiological failure 0 (0%) 0 (0%) 2 (22.2%)  
- Relapse within 28 days 0 (0%) 2 (9.5%) 2 (28.6%)  
- Confirmed relapse within 28 days 0 (0%) 2 (9.5%) 2 (28.6%)  
Any relapse during 6 month follow-up 1 (20%) 2 (8.0%) 2 (20%) 0.31 
Confirmed relapse during 6 month 
 follow-up 1 (20%) 2 (8.0%) 2 (20%)  
 
*Time to treatment failure and time to relapse were analyzed using Firth’s penalized maximum 
likelihood bias reduction method for Cox regression and p values were calculated from 
likelihood ratio tests 
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Figure 3.2 The association of Salmonella Typhi lineage and ciprofloxacin 
susceptibility with treatment failure and fever clearance time in patients randomised 
to gatifloxacin 
 
 
 
 
 
 
A) Kaplan-Meier curve for time to treatment failure by H58 and non-H58 Salmonella Typhi. B) 
Kaplan-Meier curve for time to treatment failure by Salmonella Typhi susceptibility group 
(susceptible, intermediate, resistant) against ciprofloxacin. C) Non-parametric maximum likelihood 
estimators for interval-censored fever clearance time (see methods) by H58 and non-H58 Salmonella 
Typhi. D) Non-parametric maximum likelihood estimators for interval-censored fever clearance time 
by Salmonella Typhi susceptibility group (susceptible, intermediate, resistant against ciprofloxacin). 
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3.2.4 The emergence of fluoroquinolone-resistant Salmonella Typhi 
Given the unusual long branch leading to the H58 triple mutant subclade on the 
phylogenetic tree (Figure 3.1), I hypothesised that the H58 triple mutants represented 
a contemporary importation into Nepal. To explore this, I compared the genomes of 
the 78 RCT S. Typhi isolates with those from 58 supplementary S. Typhi isolated 
from previous studies conducted between 2008 and 2013 in this setting (Figure 3.3, 
Appendix A). I found that the majority of the local H58 isolates (84/121; 69.4%) were 
closely related; these organisms represented “endemic” Nepali H58 clade containing a 
single S83F gyrA mutation. Additionally, I identified a further five Nepali organism 
isolated in 2013 that belonged to the H58 triple mutant group, and had an MIC ≥24 
μg/ml against ciprofloxacin. Incorporating additional genome sequences from a recent 
international study of the H58 lineage 248, I found that all the Nepali H58 triple 
mutants were closely related (5 SNPs to nearest neighbour) to H58 triple mutants 
isolated in India between 2008 and 2012 (Figure 3.3). 
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Figure 3.3 The phylogenetic structure of fluoroquinolone resistant Salmonella Typhi 
H58 in a regional context 
 
 
 
 
 
 
 
 
 
Maximum likelihood phylogeny based on core-genome SNPs of 136 (78 from the RCT) 
Salmonella Typhi isolates from Nepal and neighbouring India (Appendix A). Main tree shows the 
overall phylogenetic structure and the presence of specific combinations of mutations in gyrA 
(S83F, D87V and D87N), parC (S80I) and parE (A364V). The inset shows a magnified view of 
the fluoroquinolone resistant Salmonella Typhi H58 triple mutants from Nepal and their close 
association with similarly fluoroquinolone resistant Salmonella Typhi H58 triple mutants from 
India. The scale bar on the primary tree indicates the number of substitutions per variable site, while 
that in the inset indicates genetic distance in number of SNPs. Asterisks indicate ≥85% bootstrap 
support at nodes of interest 
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3.3 Discussion  
My study shows that a new FQ resistant subclade of H58 S. Typhi has been 
introduced into Nepal and is associated with a lack of FQ efficacy. This subclade was 
associated with longer FCTs and treatment failure in patients treated with the FQ, 
gatifloxacin. For the first time I can conclusively show how enteric fever patients 
respond to FQ treatment when infected with a specific subclade of H58, thereby 
linking organism genotype with a treatment phenotype. Given the international 
significance of FQs for the treatment of enteric fever and other bacterial infections, 
my findings have major global health implications for the use of this group of 
antimicrobials.  
 
A single S. Typhi organism with the same combination of triple mutations was 
isolated in Nepal in 2011 291. This isolate was also associated with treatment failure, 
although, this organism was not genome sequenced and was assumed to be an isolated 
case. More significantly, several closely related bacteria were genome sequenced 
during an international study of H58 S. Typhi 248. These organisms had the same 
combination of triple FQ resistance mutations as those described here; my analysis 
shows they belong to the same subclade of H58. These isolates had equivalently high 
MICs against ciprofloxacin and were isolated in India between 2008 and 2012. 
However, there were no associated outcome data for these strains and other reports 
from India have been limited. My data strongly suggests this lineage was recently 
introduced into Nepal from India (or nearby) and has since entered in an endemic 
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transmission cycle in Kathmandu. Given the large extent of human movement 
between India and Nepal, I propose this is a likely route of introduction. 
 
Appropriate antimicrobial therapy is critical for enteric fever, as effective drugs 
curtail symptoms and prevent life threatening complications. My data has major 
repercussions for enteric fever treatment, and I advocate that FQs should no longer be 
used for empirical enteric fever therapy on the Indian subcontinent, as I predict these 
organisms are now widespread and may be associated with poor outcomes. Notably, 
one of the arms in the RCT used the newer generation FQ, gatifloxacin, which binds 
to a different location on the DNA gyrase than the older FQs and is not as susceptible 
to the common resistance mutations 292. The isolates in this study were not generally 
resistant to gatifloxacin according to the current CLSI guidelines 293; I suggest that 
these guidelines be modified to reflect these new clinical data. I additionally propose 
that S. Typhi genotyping, mapping and susceptibility testing is performed routinely 
and rapidly in reference laboratories outside South Asia to monitor the international 
spread of this lineage and to ensure the provision of alternative efficacious therapies 
to returning travellers 294,295. In cases of infection with these FQ-resistant isolates, I 
suggest that ceftriaxone and azithromycin are used as alternatives, and do not 
currently recommend a return to the use of first-line drugs without contemporary data 
on treatment outcome. Whilst none of the isolates in this study were MDR, a rapid 
recrudescence of MDR strains may occur if we return to older first-line alternatives. 
 
This study has limitations. First, the clinical data was collected from one study in a 
single location, thus limiting utility outside this setting. Second, the overall sample 
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size (and the gatifloxacin group subsampling) of those with culture-positive S. Typhi-
associated enteric fever was relatively small. Despite these limitations, I was able to 
show a highly significant association between disease outcome and susceptibility 
profile of the infecting organism. Further, by using WGS I was able to pinpoint 
causative mutations, identify the subclade responsible for treatment failure and relate 
these strains to other isolates circulating outside Nepal. The methodologies presented 
here, in which clinical outcome data is combined with genome sequences and 
antimicrobial susceptibility data, should become the gold standard for informing 
empiric treatment for enteric fever and understanding the role of bacterial genotype 
and resistance profile on disease outcome for other bacterial infections. 
 
In conclusion, my data show a significant association between S. Typhi genotype, 
antimicrobial susceptibility and disease outcome for those treated with gatifloxacin in 
a cohort of Nepali enteric fever patients. A FQ-resistant variant of Typhi H58 has 
emerged in Nepal and is associated with the clinical failure of FQs. My data suggest 
these isolates are likely widespread in the subcontinent and FQs should not be 
recommended for empirical enteric fever therapy in this setting. 
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The phylogenetics and spatiotemporal dynamics of Salmonella 
Paratyphi A in Kathmandu, Nepal 
 
 
4.1 Introduction 
Even though typhoid fever has been studied for more than one hundred years, it still 
causes significant disease burden in South and Southeast Asian countries, specifically 
in locations with limited access to clean water and improved sanitation. In the last 
decade, there have been major advances in typhoid research, which have provided a 
better understanding of the disease epidemiology and risk factors associated with 
typhoid fever as well as underlining the emergence and global dissemination of 
antimicrobial resistant organisms 138,248. These studies have had a major impact on the 
disease management and public health interventions. However, recent advances and 
most typhoid research have been focused mainly on S. Typhi, as this pathogen is 
considered to be more important than S. Paratyphi A, particularly with respect to 
disease magnitude and severity 296. This gap in knowledge and a lack of public 
attention have rendered S. Paratyphi A a neglected pathogen for many years. Since 
the turn of the 21st century, S. Paratyphi A has emerged at an unprecedented rate in 
many Asian countries including India, Pakistan, Nepal, Bangladesh, China, and 
Indonesia, becoming a increasingly important causative agent of typhoid (enteric) 
fever 139. Clinical and epidemiological investigations have revealed that typhoid fever 
caused by S. Paratyphi A is clinically indistinguishable from S. Typhi; furthermore, S. 
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Paratyphi A also displays dissimilar epidemiological features to S. Typhi infection, 
with infection more likely to arise outside the household 297,142. These studies 
highlight an underestimation of the clinical relevance of S. Paratyphi A infection and 
questions if the current control and preventive measures for typhoid would also 
protect against this pathogen. Currently, there is no vaccine against S. Paratyphi A 
and the licensed typhoid (S. Typhi) vaccines do not provide cross protection against S. 
Paratyphi A and are likely to be less effective for controlling typhoid fever in areas 
where these pathogens are co-circulating. 
 
In comparison to S. Typhi, there have been growing evidence suggesting that S. 
Paratyphi A is more likely to develop resistance to nalidixic acid, an indicator of 
reduced susceptibility to fluoroquinolones (the first line drug recommended by WHO) 
and they are generally less susceptible to various classes of antimicrobial frequently 
used as alternative treatments 298. S. Paratyphi A cases associated with organisms that 
are fully resistant to ciprofloxacin (MIC of 8 μg/ml), ceftriazone (MIC >16 μg/ml) 
and azithromycin (MIC >64 μg/ml) are also not uncommon 299,221,225. In endemic 
areas where there is a lack of safe drinking water and inadequate food hygiene, case 
detection and antimicrobial therapy become crucial for the management of typhoid 
fever. However, limited access to laboratory facilities, low sensitivity and specificity 
of current diagnostic methods and similar clinical manifestations caused by S. 
Paratyphi A and S. Typhi have imposed significant challenges for the diagnostic 
accuracy as well as the appropriate antimicrobial therapy 300. As a result, the actual 
burden of S. Paratyphi A infection remains unknown in many settings and empiric 
antimicrobial treatment may be problematic. At present, available epidemiological 
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data of S. Paratyphi A is very limited and remains unclear; moreover, conventional 
epidemiological approaches only describe the demographic and epidemiological 
features of reported cases without any characterization of the bacterial population 
structure and dynamics. Understanding the structure and changing dynamics of the 
pathogen population in time and space, as well as the driving forces governing these 
in an epidemiological context, is essential for providing compelling evidence and 
novel insights into the source of infection and the patterns of typhoid transmission 301. 
The fact that S. Paratyphi A isolates exhibit little genetic diversity makes whole-
genome sequencing technology a fundamental approach for understanding the 
population of this organism. However, this approach remains a big challenge in many 
endemic settings.  
 
Kathmandu, Nepal, is a highly endemic location for typhoid fever, and S. Paratyphi A 
infections have increased in recent years. During a period of sustained blood culture 
surveillance for typhoid fever at Patan hospital in Kathmandu between 1993 and 2003 
the proportion of typhoid fever caused by S. Paratyphi A increased annually with the 
highest isolation rate up to 34% of all cases 298. From 2005-2009, the isolation rate of 
S. Paratyphi A remained high and accounted for 31.5% of total confirmed typhoid 
cases; moreover, for some months, the number of S. Paratyphi A and S. Typhi 
infections was comparable 302. Despite the overall decline of typhoid fever during this 
study period, S. Paratyphi A emerged rapidly and coincided with ciprofloxacin non-
susceptibility. A previous case-control study demonstrated that S. Paratyphi A 
infection rate increased with age and was higher among those consuming street food, 
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suggesting that direct contact and consumption of contaminated food may play a 
significant role in the transmission of S. Paratyphi A in this region 129.  
 
Approximately 1-5% of typhoid patients become chronic carriers and these people 
can act as reservoirs for the persistence and transmission of typhoid fever, especially 
if they are food handlers. Chronic carriage of S. Paratyphi A has been reported, and 
the prevalence was 1.6% among those undergoing cholecystectomy in Nepal 130. This 
is comparable to the chronic carrier rate of S. Typhi, even though the number of 
acutely infected S. Paratyphi A patients was lower during the same period 130. Little is 
known about genetic relatedness between acute and chronic S. Paratyphi A isolates as 
well as the relative role of chronic carriage in the transmission cycle of this pathogen. 
Additionally, all previous epidemiological investigations of S. Paratyphi A infections 
in Nepal have not included a detailed characterization of bacterial population and, as a 
result, have overlooked disease transmission dynamics. Here, I have, for the first 
time, performed a detailed molecular epidemiological study, in which I utilized whole 
genome sequencing to assess the phylogenetics and populations structure of S. 
Paratyphi A and combined this highly resolved genetic information with individual 
GPS location to interrogate the spatiotemporal dynamics of S. Paratyphi A infections 
in Nepal. I additionally reconstructed a Nepalese S. Paratyphi A phylogeny in a global 
context to further investigate into the dynamics of this bacterial population. This was 
also the first study characterizing the genetic relationship between carrier and acute S. 
Paratyphi A isolates to provide new insights into the role of typhoid carriage in this 
setting.  
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4.2 Results 
4.2.1 Baseline characteristics 
Between 2005 and 2014, 223 S. Paratyphi A isolates were collected and whole-
genome sequenced, of which 92% (206/223) were from acutely infected patients and 
the remainder were from the gallbladder of carriers (8%, 17/223). The median age of 
acute S. Paratyphi A patients was 19 years (IQR: 13-24 years), while the median age 
of asymptomatically infected individuals was 37 years (IQR: 32-44 years) (p<0.001, 
Mann-Whitney U test).  Over the observed time period, the median age of acutely 
infected patients did not vary substantially (p=0.120, Mann-Whitney U test). 71% 
(146/206) of the acute S. Paratyphi A patients were male, this contrasted with 
asymptomatically infected individuals, of which only 25% (4/16) were male 
(p<0.001, Fisher’s exact test). There were no major differences in sex distribution 
between patients enrolled in acute studies (p=0.251, Fisher’s exact test). The spatial 
distribution demonstrated that most S. Paratyphi A patients lived in the central 
Kathmandu Valley, specifically within Lalitpur; the carriers were more likely to live 
further away from the centre of the city (Figure 4.1). This is likely due to a lack of 
cholecystectomy facilities available outside of central Kathmandu. 
 
A clinical history was collected for all acutely infected patients. The majority of 
patients reported a history of headache (93%) and anorexia (67%). Diarrhoea (13%) 
and constipation (12%) were rare. There were also no major differences between 
years were present for any symptom. Of 162 S. Paratyphi A patients with recorded 
water use information, only about half (52%, 85/162) reported using the municipal 
supply water as their main source. Other water sources included stone spout (14%, 
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23/162), sunken well (10%, 17/162), bottled water (12%, 19/162). Over a third (35%, 
57/161) of patients reported using untreated water for drinking, with an additional 
35% (57/161) reporting the use of a filter and 14% (23/161) reporting boiling as their 
primary treatment method. Additionally, a total of 52% (12/23) of patients reporting 
stone spout use did not treat the water prior to drinking, compared to 24% (20/85) of 
those using municipal supply water. 
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Figure 4.1 Locations of Salmonella Paratyphi A isolates in Kathmandu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Map shows the locations of S. Paratyphi A in Kathmandu between 2005 and 2014 
with carrier isolates shown in red and acute isolates in blue. Note: 4 additional 
carrier isolates are not shown on the map due to the fact that they are 70km from 
central Kathmandu 
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4.2.2 Antimicrobial resistance 
MICs of all S. Paratyphi A isolates were determined as described in section 2.2.3. 
Overall, S. Paratyphi A isolates were susceptible to all first-line antimicrobials 
including chloramphenicol, amoxicillin, and cotrimoxazole.  However, 93% 
(208/223) of these isolates displayed resistance to nalidixic acid. Additionally, of 
those tested, 8% (14/178) were resistant to ciprofloxacin (MIC ≥1 μg/ml) and 39% 
(69/178) were resistant to ofloxacin (MIC ≥ 2 μg/ml) according to the updated CLSI 
breakpoints.  None were resistant to ceftriaxone and gatifloxacin. As shown in Figure 
4.2, MICs against ciprofloxacin, ofloxacin and gatifloxacin did not change 
significantly over time. In contrast, MICs to other first-line antimicrobials remained 
largely constant over the study period. MICs to azithromycin declined between 2006-
2010 (Pearson correlation coefficient = -0.387, p<0.001). Additionally, the median 
MIC to azithromycin was significantly higher in organisms from acutely infected 
patients compared to carriers (p=0.004, Mann-Whitney U test). Nalidixic acid 
resistance was also more common in S. Paratyphi A isolates from acute patients 
(96%, 198/206) than the asymptomatic individuals (71%, 12/17) (Chi-square test, 
p<0.001). There were no significant differences in median MICs to ciprofloxacin and 
ofloxacin between these two groups. An in silico resistome analysis also found that 
none of S. Paratyphi A isolates in Nepal carried any plasmid or gene cassette 
associated with antimicrobial resistance. 
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Figure 4.2 Minimal inhibitory concentrations (MICs) of S. Paratyphi A isolates to 
various antimicrobials over time 
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4.2.3 The population structure and dynamics of S. Paratyphi A isolates in Nepal 
To investigate the population structure and dynamics of S. Paratyphi A in Nepal, I 
reconstructed the phylogeny of all Nepalese S. Paratyphi A isolates along with 111 
genomes from a global collection. These data showed that the majority of Nepalese 
isolates (94,2%, 210/223) fell within global lineage A, which contained organisms 
circulating mostly within South Asian countries such as India, Nepal, and Pakistan 
(Figure 4.3). A small proportion of Nepalese S. Paratyphi A (5.4%, 12/223) also 
belonged to global lineage C. Unlike lineage A, lineage C has successfully spread 
globally and contains organisms from a wide range of geographical areas including 
South Asia (India, Nepal, Pakistan, Sri Lanka), Southeast Asia (Cambodia, Vietnam, 
Thailand, Indonesia), Middle East (Turkey), East Asia (China) and Africa (Ghana, 
Chad, Senegal, Guinea, Mali, Morocco, Egypt). Only 1/223 (0.4%) S. Paratyphi A 
isolate in Nepal grouped within global lineage F, which included mostly historic 
isolates.  
 
Noticeably, between 2005 and 2011 I observed the phenomenon of clonal expansion 
of nalidixic resistant Nepalese S. Paratyphi A within global lineage A, which was 
designated as sub-lineage A1. This sub-lineage constituted 64% (135/210) of 
Nepalese isolates belonging to lineage A; 98.5% (133/135) had a mutation in codon 
83 of gyrA, changing serine to phenylalanine. These organisms were resistance to 
nalidixic acid.  From the global collection, there were one Indian and one Nepalese 
isolates recovered in 1999 and 2000, respectively also within sub-lineage A1; 
however, these two isolates were susceptible to nalidixic acid. As a result, this 
resistance associated mutation in gyrA likely developed and subsequently become 
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fixed in the bacterial population between 2000 and 2005. All acute S. Paratyphi A 
organisms isolated after 2005 had this mutation, suggesting a strong selective 
advantage for nalidixic acid resistance. Additionally, in comparison to the reference 
genome AKU_12601 (lineage C), isolates from sub-lineage A1 did not carry the 
SPA-2 sopE phage (SSPA2377 to SSPA2423) and the prophage region SPA-3 
(SSPA2424 to SSPA2446). Alternatively, these organisms had acquired a novel intact 
prophage inserted in the chromosome between CDSs SSPA3930 and SSPA3931. This 
prophage was 33.8 kb in size and mostly closely related to phage P88 (NC_026014) 
(Figure 4.4). This novel prophage carried approximately 50 proteins, including a 
variant of the sopE gene, which exhibited 220/240, 222/240 and 221/240 amino acid 
identity to the sopE gene present in SPA-2 phage of the S. Paratyphi A reference 
strain AUK_12601 (FM200053); prophage of S. Typhimurium SL1344 
(NC_016810.1) and SPI-7 in S. Typhi CT18 (AL513382), respectively. SopE is an 
effector protein secreted via a type III secretion system  (SPI-1) and plays an 
important role in bacterial invasion into non-phagocytic cells by activating the actin 
cytoskeleton rearrangements and stimulating membrane ruffling.  SopE-expressing S. 
Typhimurium has been shown to increase virulence and organisms carrying this 
additional gene have been associates with several epidemics 303.  It is unclear whether 
this novel sopE prophage modulates the virulence of these S. Paratyphi A. In addition 
to gaining resistance to nalidixic acid and a novel sopE prophage, there were also a 
number of non-synonymous mutations and gene disruptions associated with sub-
lineage A1 (Table 4.1).  
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Figure 4.3 Phylogenetics of Nepalese S. Paratyphi A isolates in a global context 
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Figure 4.4 Novel sopE prophage of sub-lineage A1 
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Table 4.1 Nonsynonymous mutations and indels associated with sub-lineage A1 
 
Position in 
FM200053 CDS Product Mutation Ref Alt 
253654 SSPA0212 
2,3,4,5-
tetrahydropyridine-2-
carboxylate N-
succinyltransferase 
Nonsynonymous C T 
860533 SSPA0723 dTDP-glucose 4,6-dehydratase Nonsynonymous C T 
2753956 SSPA2470 4-aminobutyrate aminotransferase Nonsynonymous G A 
1346343 SSPA1187 
putative NADP-
dependent 
oxidoreductase 
Nonsynonymous C T 
1690227 SSPA1517 ABC transporter ATP-binding subunit Nonsynonymous G A 
1881695 SSPA1689 30S ribosomal protein S1 Nonsynonymous T A 
2899096 SSPA2613 
sulfite reductase 
(NADPH) flavoprotein 
beta subunit 
Nonsynonymous A C 
3135049 SSPA2833 conserved hypothetical protein Nonsynonymous G A 
4441670 SSPA3972 putative innner membrane protein Nonsynonymous G A 
73777 SSPA0061 CitG protein Nonsynonymous C T 
482924 SSPA0385 ethanolamine ammonia-lyase light chain Nonsynonymous C T 
2311942 SSPA2069 conserved hypothetical protein Nonsynonymous G A 
2600568 SSPA2336 DNA polymerase III epsilon subunit Nonsynonymous C T 
2794835 SSPA2511 
putative sigma-54-
dependent transriptional 
regulator 
Nonsynonymous G A 
4023577 SSPA3609 putative lipoprotein Nonsynonymous C T 
4295443 SSPA3826 anaerobic C4-dicarboxylate transporter Nonsynonymous A C 
4332842 SSPA3866 putative amino acid permease Nonsynonymous C A 
679384 SSPA0561 outer membrane protein C Nonsynonymous A C 
4569233 SSPA4083 putative two-component response regulator (creB)  Nonsense C T 
3631814 SSPA3280 xylose operon regulatory protein  Insertion GT GGT 
2809585 SSPA2524 formate hydrogenlyase subunit 2 Deletion CGGGCGGCGC C 
 
Nonsynonymous mutations and indels in sub-lineage A1 were identified relative to the inferred most recent 
common ancestor of sub-lineage A1 and sub-lineage A2. 
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The genomics data suggested that, after clonal expansion, sub-lineage A1 gradually 
began to disappear from the population after 2011 and was replaced by the distantly 
related sub-lineage, A2 (Figure 4.3). The main branch of sub-lineage A2 differed by 
96 SNPs from sub-lineage A1 and contained 67/210 (32%) of the Nepalese isolates 
belonging to lineage A. Isolates belonging to sub-lineage A2 was first detected in 
2008 and initiated a clonal expansion, which replaced all other lineages from 2011. 
Sub-lineage A2 became the most dominant genotype accounting for 83-96% of 
isolates annually between 2012 and 2014. The median pairwise SNP distance of the 
Nepalese isolates within sub-lineage A2 was only 2 SNPs (IQR: 1-4 SNPs), which 
was lower than the median pairwise SNP distance of isolates belonging to sub-lineage 
A1 (5 SNPs, IQR: 4-7 SNPs), indicating a very recent clonal expansion of sub-lineage 
A2. All Nepalese isolates in sub-lineage A2 also had a Ser83Phe mutation in gyrA 
and were resistant to nalidixic acid. In comparison to the reference strain 
AKU_12601, isolates within sub-lineage A2 carried a comparable complement of 
prophage regions and there was no apparent difference in gene content between the 
first A2 isolate in 2008 and the remaining isolates in later years of this sub-lineage. 
As shown in Table 4.2, there were various non-synonymous mutations and gene 
disruptions associated with sub-lineage A2. Gene disruptions included SSPA0470, 
which encodes for a conserved hypothetical across Salmonella enterica and 
SSPA2905 (tdcD), encoding for propionate kinase. The Tdc operon (tdcABCDEFG) 
consists of seven genes which encode enzymes essential for the degradation of short-
chain fatty acids, which serve as an alternative carbon and energy source in the 
absence of a preferred nutrient in human gut. Additionally, a number of non-
synonymous mutations were located in genes involved in bacterial virulence, LPS and 
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gene regulation, such as secreted protein SifA, an effector protein of the SPI-2 Type 3 
secretion system, which plays an important role in Salmonella virulence 304, WaaP 
(SSPA3336) involved in lipopolysaccharide core biosynthesis, signal peptidase I 
(LepAB), sensor protein KdpD in the two-component KdpD/KdpE regulatory system 
305. Details regarding all nonsynonymous mutations and indels associated with sub-
lineage A2 are shown in Table 4.2.  
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Table 4.2 Nonsynonymous mutations and indels associated with sub-lineage A2 
Position in 
FM200053 CDS Product Mutation Ref Alt 
2176873 SSPA1948 rare lipoprotein A precursor Nonsynonymous A G 
2412607 SSPA2166 proline-specific permease ProY Nonsynonymous C T 
475620 SSPA0379 putative aldehyde dehydrogenase Nonsynonymous T C 
1671505 SSPA1500 putative MutT-family protein Nonsynonymous G A 
3035334 SSPA2730 conserved hypothetical protein Nonsynonymous G A 
1978639 SSPA1777 hypothetical ABC transporter ATP-binding protein Nonsynonymous A G 
3156617 SSPA2852 possible lipoprotein Nonsynonymous T A 
4160748 SSPA3728 
phosphoribosylaminoimidazolecarboxa
mide formyltransferase and IMP 
cyclohydrolase (bifunctional enzyme) 
Nonsynonymous C A 
320372 SSPA0268 signal peptidase I Nonsynonymous G A 
2118532 SSPA1899 membrane-associated protein kinase KdpD Nonsynonymous G C 
2118529 SSPA1899 membrane-associated protein kinase KdpD Nonsynonymous C T 
1035960 SSPA0902 aspartyl-tRNA synthetase Nonsynonymous C T 
1798103 SSPA1620 putative 4-hydroxyphenylacetate permease Nonsynonymous T C 
2936045 SSPA2640 L-serine dehydratase 2 (L-serine deaminase 2) Nonsynonymous G A 
825360 SSPA0698 conserved hypothetical protein Nonsynonymous C T 
3321069 SSPA3005 oxaloacetate decarboxylase beta chain Nonsynonymous C G 
3204223 SSPA2895 putative membrane protein Nonsynonymous T C 
999519 SSPA0865 putative glucose-6-phosphate dehydrogenase Nonsynonymous C T 
1684077 SSPA1511 putative virulence determinant Nonsynonymous G A 
3109130 SSPA2806 possible transferase Nonsynonymous G A 
1133549 SSPA1000 alanine racemase Nonsynonymous C T 
1106787 SSPA0973 PTS system, mannose-specific IIAB component Nonsynonymous T C 
3289612 SSPA2977 nitrogen regulatory IIA protein Nonsynonymous A G 
279714 SSPA0232 putative secreted chitinase Nonsynonymous A T 
1216127 SSPA1073 anthranilate synthase component I Nonsynonymous G A 
3210225 SSPA2900a conserved hypothetical transport protein (pseudogene) Nonsynonymous G A 
3700432 SSPA3336 lipopolysaccharide core biosynthesis protein Nonsynonymous C T 
578579 SSPA0470 conserved hypothetical protein Nonsense G T 
3215599 SSPA2905 propionate kinase  tdcD Deletion AT T 
 
Nonsynonymous mutations and indels in sub-lineage A2 were identified relative to the inferred most recent 
common ancestor of sub-lineage A1 and sub-lineage A2. 
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4.2.4 Genetic relatedness between acute and carriage S. Paratyphi A isolates in 
Nepal 
The majority of S. Paratyphi A carriage isolates belonged to sub-lineage A1 (53%, 
9/17) and clustered within the acute isolates, of which 8/9 were resistant to nalidixic 
acid and had the same mutation Ser83Phe in gyrA. These carriage isolates probably 
resulted from recent asymptomatic infections for the following reasons. First, as 
mentioned above, the resistance mutation Ser83Phe in gyrA likely occurred and 
subsequently become fixed in the bacterial population after 2005. Second, these 
carriage isolates were collected between 2007 and 2009. There was one nalidixic acid 
susceptible isolate from a carrier (GB624) that was collected in 2009 and clustered 
within the global nalidixic acid susceptible isolates. The duration of asymptomatic 
carriage by this isolate is at least 5 years considering the establishment of nalidixic 
resistant sub-lineage A1 from 2005. The median pairwise SNP distance between acute 
isolates within this sub-lineage A1 was 5 SNPs (IQR: 3-7 SNPs), which was 
significantly lower than the median pairwise SNP distance between carrier isolates (7 
SNPs, IQR: 5-7 SNPs) (Wilcoxon rank sum test, p= 0.003). My data demonstrated 
that the genetic diversity within the carriage isolates was higher compared to acute 
isolates in sub-lineage A1 considering the number of acute isolates was much higher.  
 
Additionally, there was one carrier isolate collected in 2009 (GB672) that clustered 
within sub-lineage A2. This isolate was resistant to nalidixic acid (mutation 
Ser83Phe) and was only 1 SNP different from the first acute isolate collected in 2008, 
therefore this organism likely originated from recent asymptomatic infection. Three 
other carriage isolates (GB193, GB640, and GB726) belonged to global lineage A, 
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but they were distantly related to Nepalese isolates and clustered tightly with Indian 
isolates. The remaining 4 carrier isolates belonged to global lineage C (3) and lineage 
F (1).   
 
Overall, my data demonstrated that the carriage isolates belonged to a wide range of 
genotypes; the most common genotype was sub-lineage A1. Additionally, the 
genotypic distribution of carrier isolates reflected the general genetic structure in the 
bacteria population. I found sufficient evidence to suggest that half of carrier isolates 
likely originated from recently asymptomatic carriage. Further, the fact that carriage 
isolates within sub-lineage A1 displayed higher diversity than acute isolates suggests 
that the carriage isolates may have been exposed to distinctive evolutionary process to 
induce adaptation for survival and replication in the gall bladder. Generally, the 
bacterial population of S. Paratyphi A in Kathmandu was highly diverse and dynamic 
with evidence of clonal expansion followed by clonal replacement. Sub-lineage A2 
replaced all other pre-existing lineages since 2011 suggesting that carrier isolates 
seemed to have limited role in maintaining the bacterial diversity or facilitating the 
transmission in this population.  
 
Most carriage and acute Nepalese isolates within lineage C clustered in proximity to 
other South Asia global isolates. These isolates were mostly detected in 2005 and 
gradually disappeared from this population in Kathmandu after 2011, this may be 
associated with the expansion and replacement of other successful genotypes. The 
only carriage strain in lineage F was distantly related and highly distinctive from the 
rest of the Nepalese isolates. 
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4.2.5 Spatial and spatiotemporal distribution of S. Paratyphi A genotypes 
4.2.5.1 Genotypic subgrouping 
To investigate the short-term evolution and dynamics of bacterial transmission in this 
setting, I firstly reconstructed the phylogeny for Nepalese isolates using a maximum-
likelihood method and further subdivided sub-lineage A1 and A2 into different 
monophyletic clusters (designated as A1.1-11 and A2.1) based on moderate-to-high 
supported bootstrap values (60-99%). Subsequently, a SNP alignment of organisms 
belonging to sub-lineage A1 and A2 was extracted and used to build a minimal 
spanning tree using the goeBURST algorithm. Subgroups identified using this method 
were identical to the monophyletic clusters within the maximum-likelihood 
phylogeny; the minimal spanning tree was displayed for better visualization (Figure 
4.5). I then combined this genotype information with individual GPS location data to 
investigate the spatiotemporal distribution and specific demographic and clinical 
characteristics associated with the common genotypes.  
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Figure 4.5 Minimal spanning tree showing different clonal clusters within sub-lineages A1 and A2 
Minimum spanning tree showing various clonal clusters within sub-lineage A1 (A1.1-A1.11) and sub-lineage A2 (A2.1). The 
different clonal clusters are color-coded for reference. The number on each of the branches indicates the number of SNPs 
between each cluster. 
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I identified a total of 16 different genotypes of S. Paratyphi A. Between 2005 and 
2009, sub-clade A1 was dominant and accounted for 91-96% (2005-2008) and 67% 
(2008-2009) of all S. Paratyphi A, respectively. During this period, this sub-lineage 
diversified and formed 11 distinct clonal clusters (A1.1-A1.11). There were 
substantial changes in the dominant cluster over time as well as the formation and 
extinction of minor clusters (Figure 4.6). For example, cluster A1.2 was the most 
common genotype in 2005, accounting for 27.9% of all isolates collected this year; 
however, this genotype subsequently disappeared and was replaced by another 
common cluster (A1.11) in the following years. Overall, the diversity of sub-lineage 
A1 decreased with time, declining from 9 different clusters in 2005 to only 3 in 2009. 
Between 2011-2014 there were dramatic changes in the bacterial population structure 
with the sudden increase of sub-lineage A2 in 2011 (62.7%, 32/51), which was 
concurrent with the disappearance of clonal clusters within sub-lineage A1. During 
this period (2011-2014), sub-lineage A2 predominated and a clonal cluster (A2.1) was 
represented at an almost constant rate annually (22-33%). Lineage C was constantly 
detected over the whole study period but represented only a small proportion of 
organisms.  
 
After comparing some characteristics between sub-lineage A1 and A2, I found that 
the median age of patients within sub-lineage A1 was significantly older (21 years 
(IQR: 15-25 years) versus 18 years (IQR: 11-23 years) (p=0.0498, Kruskal-Wallis 
test) (Table 4.3). Clinical symptoms at presentation between these two sub-lineages 
were comparable except that organisms within sub-lineage A1 were more likely to be 
associated with abdominal pain (p=0.044, Chi-squared test). Water use also differed 
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dramatically, with people infected with sub-lineage A2 more likely to report drinking 
bottled water (21%, 14/66) compared to those infected with sub-lineage A1 (5.7%, 
5/88) (p=0.0037, Chi-squared test). Additionally, a higher proportion of patients 
infected with sub-lineage A2 (60%, 40/66) organisms reported using municipal 
supply as the main water source compared to 47.7% (42/88) to those infected with 
sub-lineage A1 organisms (p=0.113, Chi-squared test) and were also more likely to 
filter water (42.4%, 28/66) compared to sub-lineage A1 (28.7%, 25/87) (p=0.078, 
Chi-squared test). Lastly, those infected with sub-lineage A2 organisms were 
significantly less likely to use well water as the main water source (3% compared to 
15.9%, p=0.015, Fisher’s exact test). There was no difference in the antimicrobial 
resistance profiles between sub-lineage A1 and A2.  
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Figure 4.6 Annual distribution of S. Paratyphi A genotypes in Nepal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The graph shows the annual percentage of each S. Paratyphi A genotype in Nepal between 
2005 and 2014. Different genotypes are color-coded for reference.   
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Table 4.3 Characteristics of two main sub-lineages A1 and A2 of S. Paratyphi A in 
Nepal 
 
             Sub-lineage   
Characteristic A1 A2 p_value 
Age (median(IQR) 21 (15-25) 18 (11-23) 0.0498 
Male sex 67% (89/135) 78% (52/67) 0.089 
Symptom    
 Anorexia 67.7 (86/127) 66.7 (44/66) 
 Nausea 37.8 (48/127) 36.4 (24/66) 
 Abdominal pain 37 (47/127) 22.7 (15/66) 0.044 
 Diarrhoea 12.6 (16/127) 12.1 (8/66)  
 Constipation 13.4 (17/127) 10.6 (7/66)  
 Headache 95.3 (121/127) 87.9 (58/66) 
Water source      
Municipal supply 47.7 (42/88) 60.6 (40/66) 0.113 
Bottled 5.7 (5/88) 21.2 (14/66) 0.0037 
Stone spout 14.8 (13/88) 10.6 (7/66) 0.446 
Tanker 1.1 (1/88) 1.5 (1/66)  
Well 15.9 (14/88) 3.0 (2/66) 0.015 
Mix 14.8 (13/88) 3.0 (2/66)  
Water treatment    
Boil 13.8 (12/87) 12.1 (8/66)  
Chlorine 6.9 (6/87) 0 (0/66)  
Filter 28.7 (25/87) 42.4 (28/66) 0.078 
Mix 10.3 (9/87) 7.6 (5/66)  
Other 4.6 (4/87) 0 (0/66)  
Untreated 35.6 (31/87) 37.9 (25/66) 
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4.2.5.2 Spatial and spatiotemporal mapping of S. Paratyphi A genotypes 
Overall, there were a number of genotypes that exhibited spatial clustering. For the 
organisms within sub-lineage A1, genotype A1.2 (11/17 cases) clustered within a 
radius of 747m (RR = 8.6, p=0.004), genotype A1.3 (9/10 cases) also exhibited 
significant clustering within a radius of 696m (RR = 37.7, p<0.0001). Genotypes 
A1.6 (3/3 cases) and A1.10 (3/5 cases) were associated with smaller clusters 
containing almost all identified patients with radii <150m (RR = ∞, p<0.001 and RR 
= 110.0, p=0.002, respectively). For sub-lineage A2, I detected a cluster of genotype 
A2.1 (10/21 cases) in the south of Lalitpur with a radius of 769m (RR=12.6, 
p<0.001). I also investigated the remaining isolates within sub-lineage A2 and 
identified one cluster in the North of Lalitpur (14/46 cases) with a radius of 1.2 km 
(RR=3.76, p=0.003) and another smaller cluster (6/46 cases) with a radius of 157m 
(RR=5.2, p=0.01) nested within the cluster of genotype A1.3. The location and the 
magnitude of significant clusters of different genotypes over the entire period of study 
is shown in Figure 4.7.  
 
I also found a number of genotypes that clustered spatiotemporally over the study 
period. Spatiotemporal clusters were far more common in the beginning of study 
period compared to later years. For example, I identified 4 distinct and significant 
spatiotemporal clusters of genotypes A1.2, A1.6, A1.8 and A1.10 in 2005; noticeably 
all clusters were concentrated between June and September. Similarly in 2006 there 
were two significant clusters of genotypes A1.3 and A1.11, which were also found 
during the same period between May and August. Sub-lineage A2 started to replace 
other genotypes and expand in the bacterial population from 2011 with one significant 
spatiotemporal cluster detected (genotype A2.1). This cluster incorporated the 
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majority of patients presenting between May and September in 2011. In later years, 
sub-lineage A2 disseminate throughout the geographical study area, but I identified a 
significant spatiotemporal cluster of sub-lineage A2 spanning 2011 to 2013 in the 
north of Lalitpur, suggesting this area was a hot spot of S. Paratyphi A infection in 
these years.   
 
The combination of evidence from both spatial and spatiotemporal clustering analyses 
suggests that localized clusters of a variety of genotypes within sub-lineage A1 were 
common early on in the study period (2005-2006) and declined in favor of setting-
wide dominance of sub-lineage A2 by 2011. Genotypes with overlapping spatial and 
spatiotemporal clusters (namely, A1.2, A1.3, A1.6, A1.0, A2.1) showed the strongest 
evidence of concentrated, localized outbreaks synced in time and space. Genotypes 
with only spatiotemporal clustering (A1.4 and A1.11) were diffuse over space, but 
more concentrated temporally. Sub-lineage A2 clustered spatiotemporally most 
obviously in 2011 when it started to replace the majority of other genotypes and 
subsequently dispersed over the study area.  
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Figure 4.7 Clustering of S. Paratyphi A genotypes over space between 2005 and 2014 
 
 
 
 
 
 
 
 
 
 
Clusters are shown in different colours, as indicated by the legend in the lower right. 
Significant clusters are highlighted by circles of various radii. The red star shows the 
location of Patan Hospital. 
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4.3 Discussion 
S. Paratyphi A has become an increasingly important agent of typhoid fever, 
particularly with respect to disease prevalence and antimicrobial resistance. However, 
research on this pathogen is lagging behind that of S. Typhi and even other 
Salmonella serovars as a result of lack of public attention and a challenge of robust 
methodology. Previous epidemiological investigations of S. Paratyphi A lack a 
detailed characterization of the pathogen population and therefore do not provide any 
information about the disease dynamics. Here, I utilized a combination of bacterial 
genomics and more conventional epidemiology to provide new insights into the 
structure and dynamics of S. Paratyphi A in Nepal, which is essential for 
understanding the pattern of disease transmission in this endemic setting. I found that 
the S. Paratyphi A population in Nepal was diverse and highly dynamic and I 
observed evidence of a clonal expansion in early of study period followed by the 
replacement and expansion of a distinct clone in later years. S. Paratyphi A spread 
very rapidly throughout the geographical area during the clonal expansions.  
 
From the global phylogeny, there were at least nine occasions where isolates from 
Nepal clustered with other South Asian isolates, mostly from India and Pakistan, 
suggesting that organism transfer between these neighbouring countries was common. 
Sub-lineages A1 and A2, which expanded in this location, shared common ancestors 
with Indian isolates. Therefore, it is unclear whether these expansions were due to 
successful clones locally or as a result of organism importation from neighbouring 
countries.  
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None of these Nepalese S. Paratyphi A in this study was resistant to any first-line 
drugs. Therefore, I propose that a mutation in gyrA and the acquisition of a novel 
sopE prophage were factors associated with the expansion of sub-lineage A1, which 
may indicate a strong selective pressure for fluoroquinolones in this setting. Previous 
surveillance between 1993-2003 in Nepal found that multi-drug resistant S. Paratyphi 
A were diminishing in this location population, this was occurring concurrently with 
decreased susceptibility against to fluoroquinolones 298. Such phenomenon was also 
observed in Nepal for S. Typhi and is concerning given that fluoroquinolones are 
widely used to treat typhoid fever and can be purchased without prescription 306. The 
replacement and rapid expansion of sub-lineage A2 throughout the study area from 
2011 warrants further investigations as such events are rarely observed for S. 
Paratyphi A. These data imply that organisms within sub-lineage A2 have entered into 
a population that was either naïve or had lower immunity. S. Paratyphi A has been 
endemic in Nepal for many years and sub-lineage A1was historically the dominant 
lineage, therefore this genotype shift may be associated with a subtle change in 
antigenicity of the organisms.   
 
Defining the population structure of S. Paratyphi A in Nepal allowed me to further 
classify these organisms into different genotypes for investigating their short-term 
spatiotemporal distribution, which could not be performed by conventional 
approaches. The spatiotemporal clustering analysis demonstrated that a substantial 
number of genotypes clustered by space and time, suggesting a high level of acute, 
person-to-person transmission of S. Paratyphi A in Kathmandu. Previous case-control 
studies in Indonesia and Nepal also found that person-to-person transmission plays an 
important role in S. Paratyphi A infection with risk factors also including flooding and 
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contaminated street food, whereas contaminated drinking water were more associated 
with S. Typhi infection 129,142.  Noticeably, all localized S. Paratyphi A outbreaks 
occurred during monsoon months between May and September, which corresponds 
with the seasonal distribution of typhoid fever in this setting 302. Previous study also 
demonstrated a high level of faecal contamination of the water supply, which 
correlated with increased rainfall 307. Given that only half of patients in this study 
access to the municipal water, the contamination of drinking water and water used in 
food preparation during that rainy season was likely the most important source of 
infection.   
 
Outbreaks of typhoid fever caused by S. Paratyphi A are not uncommon. Very 
recently, an outbreak of S. Paratyphi A infection caused by an identical organisms 
was reported in Cambodia, which spread to several provinces and sickened dozens of 
European, American, Japanese travellers returning home 308. Even though the source 
of this outbreak remains unknown, contaminated food is the most reasonable cause of 
this large-scale infection. Such outbreaks may go unobserved in Nepal, therefore 
improvements in food safety should be considered as an important primary control 
measure for S. Paratyphi A infection. While improvements in safe water, food safety 
and proper sanitation seems to be the most effective way to manage typhoid fever, it 
is unlikely that it would be an imminent solution for Nepal. As a result, there is an 
urgent need of S. Paratyphi A vaccine, or more ideally, a bivalent vaccine which can 
prevent both S. Typhi and S. Paratyphi A infections.  
 
The relative role of typhoid carriage in the disease transmission, as well as 
maintaining genetic diversity and generating novel genotypes, has been extensively 
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questioned. By whole-genome sequencing 17 carriage isolates and relating these 
genomic data with acute isolates, I have, for the first time, provided new insights into 
the genetic relatedness between acute and carriage S. Paratyphi A isolates and then 
assessed the potential role of carriage in this endemic setting. I found a high genetic 
diversity within the carriage isolates from this location; the genetic diversity 
suggested that the majority of these isolates (59%, 10/17) were likely associated with 
recent asymptomatic/acute infections. However, the exact duration of carriage of 
these individuals is unknown as the majority did not have recent history of typhoid. 
The remainders of the carriage isolates were generally distantly related to the acute 
isolates. However, the genetic diversity within the Nepalese S. Paratyphi A reduced 
substantially after 2011 with almost all isolates falling within sub-lineage A2. 
Furthermore, the carriage isolates appear to have accumulated a set of differing 
mutations during gall bladder carriage and have become genetically distinct from 
contemporary acute isolates. My limited data suggests that S. Paratyphi A carriers did 
not play an important role in maintaining the genetic diversity nor in the disease 
transmission in this endemic setting.   
 
In conclusion, this chapter represented a detailed molecular epidemiological 
investigation of S. Paratyphi A in Nepal. The structure and dynamics of the pathogen 
population was described and distinguishing by both clonal expansion and clonal 
replacement. I found a high rate of reduced fluoroquinolone susceptibility in S. 
Paratyphi A in this location, which likely contributed to the successful expansion of 
these organisms. The rapid dissemination within local population and diversification 
of dominant clones resulted in short-term spatiotemporal clusters of various 
genotypes, indicating the importance of human-to-human transmission for S. 
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Paratyphi A in this setting. My data also demonstrated that in a highly endemic 
setting, S. Paratyphi A carriage likely plays a limited contribution to the disease 
transmission and maintenance of the bacterial diversity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 
 
 
The molecular and spatial epidemiology of typhoid fever in rural 
Cambodia 
 
5.1 Introduction 
Typhoid fever is mainly contracted through the consumption of contaminated water or 
food. Therefore, the disease is largely preventable through the provision of safe water, 
food safety and adequate sanitation. However, such interventions are still challenging 
in many endemic locations given the huge economic costs and long timelines 309. 
Licensed typhoid vaccines have been proved to be an effective short-term strategy in 
reducing typhoid burden and are currently recommended by the World Health 
Organization (WHO) in areas with high disease burden and increasing antimicrobial 
resistance 33.  Despite this recommendation, the programmatic use of typhoid vaccines 
is very limited, largely due to insufficient data on the epidemiology of the disease and 
prevalence of antimicrobial resistant organisms for evidence generation and policy 
making 146. Additionally, identification of high-risk areas and vulnerable populations 
for targeted vaccination appears as a big challenge in resource-limited settings where 
usually lack of systemic disease surveillance. In such circumstances, case detection 
and appropriate antimicrobial therapy become crucial for typhoid management in 
endemic locations. However, the effectiveness of these strategies is diminished due to 
a lack of accurate and inexpensive rapid diagnostic tests for typhoid as well as the 
emergence of antimicrobial resistance organisms 109,310.  
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Most studies on typhoid have focused on urban slum populations, where high 
incidence rates have been reported 133,311,312. However, the epidemiological features of 
typhoid fever in different environmental settings remain unclear, especially in rural 
areas with poor access to healthcare. Investigation on the transmission patterns and 
risk factors of typhoid fever in both urban and rural areas is critical for effective 
disease control and prevention 309. Over the last decade, advances of molecular 
genotyping methods such as Single Nucleotide Polymorphisms (SNPs) typing and 
whole genome sequencing (WGS) have successfully provided unprecedented insights 
into the bacterial population structure and evolutionary relationships between isolates 
128,244. SNP-based typing and WGS have played a significant role in studying the 
molecular epidemiology of typhoid fever, discovering a diverse range of S. Typhi 
haplotypes that are commonly found co-circulating in different geographical settings 
131–134,246. These studies have outlined the importance of environment transmission 
within the localized human populations. Such molecular investigations are also 
critical for understanding the bacterial population dynamics and tracking the 
emergence of antimicrobial resistant organisms. The current population structure of S. 
Typhi has been primarily driven by series of clonal expansions and scattering of a 
specific haplotype (H58) in Asia and Africa. This globally dominant H58 haplotype 
mostly exhibits reduced susceptibility to fluoroquinolones and is commonly multidrug 
resistant against first-line agents (ampicillin, chloramphenicol, and trimethoprim-
sulphamethoxazole) 248. 
 
Typhoid fever is endemic in Cambodia but epidemiological data regarding to the 
mortality, morbidity and risk factors for the disease are limited. Between 2006 and 
2008, a community-based study was conducted near Phnom Penh (the capital city) 
 118 
 
and multidrug resistant S. Typhi with reduced susceptibility to ciprofloxacin was 
routinely detected from patients presenting with acute fever 313. Additionally, a 
hospital-based surveillance of pediatric bloodstream infections in Siem Reap 
(Northwest of Cambodia) from 2007 and 2011 reported that S. Typhi was the most 
common pathogen causing pediatric bloodstream infection and H58 S. Typhi 
exhibiting reduced susceptibility to ciprofloxacin was dominant (accounting for 96% 
of S. Typhi isolates) 247. In this investigation, I utilized whole genome sequencing to 
further characterize the H58 S. Typhi population in Siem Reap, Cambodia and 
combined the resulting phylogenetic information with additional epidemiological 
approaches to investigate the spatiotemporal distribution of S. Typhi and identify 
population-level risk factors associated with typhoid fever in this location. The data 
presented in this study was published in PLoS Negleted Tropical Diseases in June 
2016 (Appendix G).  
 
5.2 Results 
5.2.1 Baseline characteristics  
Between 2007 and 2014, there were 284 microbiologically confirmed cases of 
typhoid fever caused by S. Typhi at Angkor Hospital for Children (AHC) in Siem 
Reap (method section 2.4.3). S. Paratyphi A was uncommon, with only three cases in 
2008 followed by an isolated outbreak in 2013-2014 (38 cases). A total of 262/284 
(93%) of the confirmed S. Typhi cases lived within a 100 km radius of AHC and 
spanned 78 communes; these 78 communes were selected for a spatial investigation 
and to determine population level risk factors for typhoid fever. During this same 
period there were 19,877 admissions with an ICD-10 discharge diagnosis other than 
typhoid fever originating from the same geographic area. The baseline characteristics 
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of all communes and those with at least one case of typhoid fever are shown in Table 
5.1.  
 
Of the 262 cases of typhoid fever living within a 100 km radius of AHC, the median 
age was 8.2 years (interquartile range (IQR): 5.1-11.5 years). Additionally, 62/262 
(24%) of the cases were less than five years of age and 142/262 (54%) were female. 
As shown in Figure 5.1a, the absolute number of confirmed cases of typhoid fever 
increased dramatically (from 12 cases per year to 71 cases per year) between 2009 
and 2012, but then declined in 2013 and 2014 (28 and 45 cases in 2013 and 2014; 
respectively); data from my non-confirmed typhoid cases also reflected this trend. 
Over this same time period (2009 to 2014) the number of patients attending AHC for 
other conditions (control population) mirrored the distribution of the cases (Figure 
5.1b). There was seasonal variation in the number of typhoid cases, with the majority 
of the cases (178/262; 68%) occurring during the early monsoon months (April, May, 
June and July) (Figures 5.1c & 5.1d). In late monsoon months (August to October), 
the number of cases declined to less than two cases per month and generally remained 
below this threshold in the dry season (November to March) (Figures 5.1c & 5.1d). 
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Table 5.1 Baseline characteristics of all communes and those with at least one case of 
typhoid fever 
 
Characteristic All communes Typhoid communes 
median IQR median IQR 
n=243 n=78 
Population density/km2 105.7 53-210 119.4 60-214 
Elevation, m 17 12-28 18 11-35 
Distance to lake, km 45.3 24-63 30.0 14-49 
Average household size 4.8 4.6-5.0 5.0 4.8-5.1 
Percent of population <15 yr 36.4% 34-39% 36.9% 35-39% 
Median age of population, yr 19.5 18-21 19.4 18-20 
Adult literacy 72.8% 59-82% 69.3% 57-77% 
Female adult literacy 65.3% 50-75% 62.5% 49-71% 
Total attending school 28.6% 26-31% 28.0% 24-31% 
Female attending school 26.8% 24-29% 26.0% 23-28% 
Female education >25 years /1,000 population   
 Primary not completed 85.6 63-101 78.5 59-101 
 Primary/Lower secondary 27.8 16-55 22.0 16-39 
 Secondary or above 0.51 0.1-1.6 0.4 0.1-1.4 
Toilet, % of households    
 None 83.1% 63-92% 85.2% 68-92% 
 Sewage 5.3% 2-14% 4.6% 2-15% 
 Septic tank 3.9% 1-16% 2.8% 1-11% 
 Pit latrine 2.0% 1-5% 1.2% 1-5% 
Drinking water, % of households   
 Piped 1.5% 1-4% 2.1% 1-4% 
 Tube/pipe well 10.2% 3-28% 23.6% 8-63% 
 Dug well 26.9% 11-56% 23.6% 9-63% 
 Spring/river 23.9% 4-54% 4.7% 1-27% 
Drinking water location, % of households   
 Within premises 19.3% 10-35% 27.8% 18-56% 
 Near premises 31.1% 22-40% 28.0% 21-34% 
  Away premises 41.8% 23-56% 35.0% 11-52% 
IQR: interquartile range. 
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Figure 5.1 The annual and seasonal distribution of typhoid fever cases at Angkor 
Hospital for Children in Cambodia 
 
 
 
 
 
 
 
 
 
 
 
a) The annual number of culture confirmed (solid line) and non-confirmed (broken line) typhoid 
cases at AHC from 2007 to 2014. b) The annual number of total admissions at AHC from 2007 to 
2014. c) The mean monthly count of typhoid cases aggregated from 2007 to 2014. d) The average 
monthly rainfall (mm) per month over the study period. 
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5.2.2 Spatiotemporal clustering of typhoid fever cases 
The majority of S. Typhi cases (241/284; 85%) originated from communes located 
within Siem Reap province (Figure 5.2). The median population density in communes 
with at least once case of typhoid fever was 119 people/km2 (IQR: 60-212), and 70/78 
(90%) of communes with a typhoid fever case were classified as rural. Compared to 
typhoid cases, the non-typhoid fever population controls came from a larger area (243 
communes), the median population density of which was lower at 106 people/km2 
(IQR: 53-210); however, a similar proportion of these communes (220/243; 91%) was 
also classified as rural (Figure 5.2).  
 
The estimated median commune level minimum incidence of reported cases of 
typhoid fever over the study period was 0.62/1,000 children aged <15 years (IQR: 
0.37-1.02; range: 0.5-11.36). The reported incidence varied significantly across the 78 
communes. Kampong Kleang commune (Soutr Nikom district, Siem Reap) showed 
the highest incidence of typhoid fever over the study period with 11.36 cases of 
typhoid fever /1,000 population of children aged <15 years (Figure 5.2c). This area is 
renowned for its floating villages and is situated on the edge of Tonle Sap Lake, 
approximately 35 km southeast of Siem Reap City. The second highest incidence was 
identified in Kaoh Chiveang commune (Aek Phnum district, Battambang, 33 km 
southwest of Siem Reap City) with 4.1 cases/1000 people aged <15 years over the 
study period (Figure 5.2c). Both of these areas experience heavy flooding when the 
Tonle Sap Lake expands during the rainy season. 
 
Overall, there was some evidence of positive spatial autocorrelation (case clustering) 
across the 78 communes that had at least one case of typhoid fever between 2007 and 
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2014 (Moran’s I=0.11, p<0.056). The magnitude of this autocorrelation varied over 
time and was the most significant in 2013 (Moran’s I=0.19, p<0.019) but was non-
significant in other years. I was able to identify three significant spatiotemporal 
clusters associated with high rates of typhoid fever. The first occurred in 2008 toward 
the west of the study area and had a radius of 23.8 km; this cluster had 1.27 predicted 
cases and 10 observed cases (relative risk [RR]=8.17, p=0.002). The second cluster 
occurred in 2012 in the central northern area and had a radius of 10.8 km, with 1.67 
predicted cases and 12 observed cases (RR=7.47, p<0.001). The final cluster occurred 
in 2013 in the southeastern area and had a radius of 15.5 km, with 0.88 predicted 
cases and 14 observed cases (RR=16.8, p<0.0001) (Figure 5.2d). 
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 Figure 5.2 The spatial distribution of typhoid fever cases in Siem Reap province, 
Cambodia 
 
 
 
 
 
 
 
 
a) North oriented map of Cambodia, the black cross shows the location of AHC. b) Map 
showing the population density (people/km2, color-coding in key) of the 78 communes 
within the typhoid study area. AHC is shown by the black cross, the black border denotes 
Siem Reap province and the left and right asterisks are mark the locations of the communes 
with highest incidence of typhoid fever; Kaoh Chiveang and Kampong Kleang, 
respectively. c) Map of the study area showing the rate of reported typhoid cases per 1,000 
population under the age of 15 years (color-coding in key). d) Map of the study area 
showing significant spatiotemporal clusters of typhoid during the study period, the size of 
the grey circles corresponds to the radius of the cluster and the years of the clusters are 
denoted. 
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5.2.3 The population structure of Salmonella Typhi in Siem Reap province,  
Cambodia 
The resulting WGS data demonstrated that 97% (203/209) of the sequenced 
Cambodian isolates could be attributed to haplotype H58. The majority (199/203, 
98%) of the H58 isolates exhibited intermediate susceptibility against 
fluoroquinolones (0.12-0.5 μg/mL) via the common amino acid substitution of serine 
to phenylalanine at codon 83 (S83F) in the DNA gyrase protein encoded by gyrA. 
There was a strong association between haplotype H58 and an IncHI1 plasmid, which 
confers an MDR phenotype, with 89% (180/203) of the H58 isolates harboring the 
common IncHI1 plasmid and the corresponding antimicrobial resistance phenotype. 
For the six non-H58 isolates, no mutations were observed in the gyrA gene, while two 
(33%) carried the same IncHI1 plasmid as found in the H58 isolates. I identified 188 
SNPs across the H58 population and, from a SNP-based phylogeny, identified the 
circulation of at least four lineages of H58 circulating in the selected area of 
Cambodia between 2007 and 2012 (Fig 5.3a). These lineages, designated here as I-IV, 
differed from each other by as little as three to five SNPs and were phylogenetically 
well-supported (bootstrap values ≥ 87%). The majority of the H58 isolates fell into 
lineage IV (152/203, 75%) and lineage III (41/203, 20%).  
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Figure 5.3 The phylogenetic structure of the H58 lineage of Cambodian Salmonella Typhi
 
a) Maximum likelihood phylogenetic tree of the 203 H58 isolates identified during this project (scale bar denotes SNP differences). The sub-
lineages are shown on the major branches. Isolates exhibiting a multi-drug resistance (MDR) phenotype are indicated by black nodes. The 
tree is midpoint-rooted for the purpose of clarity.  Bootstrap values >85% are indicated by an asterisk. b) Minimum spanning tree subdividing 
H58 lineage III and IV into the various sublineages (IIIa, IIIb, IIIc, IV, IVa, IVb, IVc). The various sublineages are color-coded for reference 
and the number of each variant is indicated by the cluster size. The number on each of the branches signifies the number of SNPs between 
each cluster. 
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5.2.4 The spatiotemporal distribution of Salmonella Typhi genotypes 
To investigate short-term evolutionary traits within the identified lineages, I constructed 
a SNP-based minimum spanning tree (Figure 5.3b). Using these data, I was able to 
investigate the local population dynamics and detected several clonal clusters emerging 
from lineage III (IIIa-IIIc) and lineage IV (IVa-IVc). My data show a complex temporal 
distribution of S. Typhi H58 sublineages circulating in this location between 2007 and 
2012 (Figure 5.4a). The distribution of these various strains was highly dynamic, with 
strain replacements, potential extinctions and the specific microevolution and expansion 
of H58-IVc (Figure 5.4a). In 2011 and 2012, H58-IVc became the dominant genotype, 
accounting for 44% (18/42) and 85% (61/72) of all S. Typhi isolates in these years, 
respectively.  
 
I next aimed to identify spatiotemporal clustering of the various S. Typhi H58 
sublineages, and found that IIIc, IV, IVb and IVc all displayed significant evidence of 
clustering over space and time. Notably, the locations of these clusters were generally 
different between sublineages, signifying some degree of geographical variation of the 
circulating S. Typhi strains. For example, I identified significant clustering of H58-IIIc 
in the western part of the study area in 2011 (p<0.001, RR: 26.7, radius: 36km) (Figure 
5.4b) and clustering of the emergent H58-IVc strain in both 2011 (Kampong Khleang 
commune, p<0.001, RR: 39.4, radius: <1km) and in two locations in 2012 (smaller 
cluster, p=0.017, RR: 5.17, radius: 6.2km; larger cluster, p<0.001, RR: 5.87, radius: 
33.9km).  
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a) Bar chart shows the annual distribution of the various S. Typhi lineages/sublineages from 2007 to 
2012; sublineages are color-coded as in Figure 3b. b) Maps showing significant spatiotemporal 
clusters identified for sublineages IIIc, IV, IVb and IVc. The timing of each cluster is shown by the 
year in black text and the dotted circle represents the radius of the detected cluster. Background colors 
represent the rate of each sublineage per 1,000 population aged under 15 years. The incidence rates 
vary between sublineages, ranging from 0 to a maximum of 0.8 (IIIc), 3.12 (IV), 2.56 (IVb) and 5.84 
(IVc) 5.84 cases/1,000 population aged under 15 years.  
 
 
Figure 5.4 The spatiotemporal distribution of the various Salmonella Typhi 
lineages/sublineages in Siem Reap province, Cambodia 
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5.2.5 Population risk factors for typhoid fever 
I additionally investigated associations between rates of typhoid in children and 
demographic and sanitation variables at the commune level. I found a number of 
significant risk factors (e.g. low female education level and collection of drinking water 
near the household premises) and protective factors (e.g. higher population density, 
elevation, distance from lake and attendance at school) associated with the rate of 
typhoid hospitalizations in the univariate analysis (Table 5.2). However, after 
controlling for confounders, I found that the distance of the centroid of the commune to 
the perimeter of the lake was strongly and significantly associated with rate of typhoid 
cases (10km increase in distance from the lake, incidence rate ratio (IRR): 0.38, 95%CI 
0.26-0.55, p<0.001) (Table 5.2). Furthermore, the relative numbers of households 
within the commune connected to public sewage services and households using a 
sunken well were also strongly protective, however these associations were reversed 
through interaction with increasing number of households using wells and distance from 
the lake, respectively (Table 5.2). Finally, a high number of households reporting 
drinking water retrieval from ‘within the household premises’ were also associated with 
a significant protective effect (log households/1,000 households, IRR: 0.65, 95%CI: 
0.49-0.86, p=0.003).
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Table 5.2 Regression results of highlighting factors associated with typhoid cases 
 
Commune characteristic Univariable Multivariable 
IRR (95%CI) p IRR (95%CI) P 
Population density^ 0.81 (0.70-0.95) 0.008   
Elevation, 10m  0.89 (0.81-0.99) 0.026   
Distance to lake, 10km 0.81 (0.74-0.89) <0.001 0.38 (0.26-0.55) <0.001 
Average household size 1.54 (0.66-3.57) 0.317   
Total attending school/1,000^ 0.11 (0.04-0.33) <0.001   
Female education >25 years /1000 population^    
 Primary not completed 2.59 (1.53-4.38) <0.001   
 Primary/Lower secondary 0.94 (0.70-1.25) 0.654   
 Secondary or above 0.96 (0.80-1.17) 0.714   
Toilets per 1000 people^    
 None  1.24 (0.84-1.79) 0.246   
 Sewage 0.96 (0.81-1.15) 0.676 0.44 (0.25-0.80) 0.007 
  x households with wells  1.19 (1.07-1.32) 0.001 
 Septic tank 0.89 (0.78-1.02) 0.090   
 Pit latrine 0.95 (0.79-1.15) 0.621   
Drinking water, hh/1000 hh^    
 Piped  0.87 (0.74-1.03) 0.104   
 Tube/pipe well 0.82 (0.73-0.92) 0.001   
 Dug well 0.83 (0.64-0.83) <0.001 0.31 (0.19-0.50) <0.001 
  x distance to lake  1.16 (1.09-1.25) <0.001 
 Spring/river 1.15 (1.05-1.25) 0.003   
Drinking water location, hh/1000 hh^    
 Within premises 0.71 (0.55-0.93) 0.013 0.65 (0.49-0.86) 0.003 
 Near premises 3.38 (2.24-5.10) <0.001   
 Away premises 0.88 (0.73-1.06) 0.177   
^log of the variable was included ; hh: household 
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5.3 Discussion 
In this study I combined conventional epidemiological methods, current genome 
sequencing tools and geospatial mapping to add insight into the epidemiology of typhoid 
fever in atric patients attending a single healthcare facility in central Cambodia. The 
majority of recent typhoid fever studies originate from urban locations in low-income 
countries. This study provides a new perspective into this important community-acquired 
infection from a predominantly rural setting. The primary finding of this study is that 
there is a considerable and widespread burden of pediatric typhoid fever in rural 
Cambodia, thus questioning the dogma that typhoid fever is predominantly 
geographically restricted to urban populations with poor sanitation systems 133,314. My 
data are consistent with findings from a recent study conducted across sub-Saharan 
Africa 315. The Typhoid Surveillance in Africa Programme (TSAP) found a large burden 
of typhoid fever in younger children and almost equivalent population incidences 
between urban and rural settings. This distribution was most apparent in West Africa 
(Burkina Faso and Ghana) and was similarly restricted to children aged less than 15 years 
315. Therefore, I infer that the epidemiology of typhoid fever in Cambodia may be more 
similar to contemporary observations from sub-Saharan Africa, as opposed to the urban 
distribution that has commonly been observed across much of Asia 133,316.  
  
The impending availability of Vi-conjugate vaccine raises the question of who should be 
given this vaccine and when it should be given to obtain maximum benefit in the control 
of typhoid fever 317,318. This issue is complicated by a lack of population-based incidence 
data and a poor understanding of the burden of disease in school and preschool aged 
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children, for whom the conjugated form of the Vi polysaccharide vaccine would be 
particularly beneficial 319. My data indicate a substantial burden of typhoid fever in 
school and preschool aged children in this area, with a hospital-based incidence (i.e. a 
minimum population incidence) of 11.36 cases of typhoid fever /1,000 population in 
children aged <15 years over the study period. The overall burden of typhoid fever in this 
population is likely to be greater than I have estimated due to poor sensitivity of blood 
culture and restriction of the study to a single healthcare centre. Siem Reap province 
could be a suitable location in which to trial, or even introduce, the next generation 
typhoid vaccines in Cambodia that have been tested elsewhere 317. Further, I suggest that 
immunizing school-aged children in the period prior to the wet season may provide the 
most economic and prudent approach for vaccine introduction. 
 
Between 2007 and 2012, I observed a sharp increase in the number of typhoid cases 
concurrent with an increasing geographic expansion. I also observed that typhoid fever in 
this population followed a seasonal pattern, suggesting an association with rainfall and 
potentially with localized flooding and the contamination of water sources. The 
population-based risk factors support these hypotheses, as living further away from Tonle 
Sap Lake and access to water within the household were highly protective. Additionally, 
I found that two communes located next to the lake (Kaoh Chiveang and Kampong 
Kleang) had the highest incidence of typhoid fever and had large clusters of cases in 2008 
and 2013. This case clustering in specific locations warrants further investigation at the 
household level to understand specific sanitation-associated risk factors and likely 
exposures to S. Typhi in this setting 307. It appears that access to lake water in some of 
  133 
these communes, such as Kaoh Chiveang, is vital for the household water supply and I 
hypothesize that the lake water is more prone to localised fecal contamination at specific 
times throughout the year.  
 
Using targeted SNP-specific PCR, I have previously shown that MDR H58 S. Typhi 
strains dominate in this population 247. My WGS investigation confirmed these findings 
and identified additional diversification in this population. I was able to separate these 
H58 strains into seven (IIIa, IIIb, IIIc, IV, IVa, IVb, IVc) major sublineages. These 
discrete groups varied in size and were segregated by only limited numbers of SNPs. I 
did observe some evidence of expansion of sublineage IVc between 2009 and 2012; this 
correlated with several spatiotemporal clusters suggesting small disease outbreaks. I 
currently cannot explain the expansion of this group and my strain selection for 
sequencing was limited by the availability of strains isolated only up to 2012. Despite 
some clustering of closely related strains, the overall temporal and spatial distribution of 
strains was random, with a range of S. Typhi H58 sublineages circulating throughout the 
study period, which is similar to patterns described in urban settings in Asia 132,289.   
 
This study has some limitations. First the data originated from patients attending a single 
healthcare facility, without the added support of healthcare utilization data. This 
approach, while cost-effective, induces bias in the spatial and risk factor analyses. 
Furthermore, while the associations identified in the regression analysis are plausible and 
provide direction for future investigations, they should be viewed with caution. The 
population level census data does not allow examination of exposures at an individual or 
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household-level and provides only broad epidemiological evidence. However, the 
association with distance to the lake and water and sanitation variables suggests these 
factors should be examined more rigorously in the future with respect to the dynamics of 
typhoid fever outbreaks. Similarly, the identification and location of the spatiotemporal 
clusters should be interpreted with some degree of caution. Communes without cases 
were not included in the cluster analyses due to a lack of data as to whether these regions 
truly lacked typhoid cases. A dataset with more complete spatial information on presence 
and absence of typhoid would permit a more reliable analysis.  
 
In summary, I found a large burden of typhoid fever in children in rural Cambodia. My 
conventional population-based risk factor analysis identified access to water in the 
household and increasing distance from Tonle Sap Lake as protective against typhoid 
fever in communes. Spatial mapping and WGS provided additional resolution to 
investigate these findings and confirmed that proximity to that lake was associated with 
discrete disease clusters. I confirmed the dominance of MDR H58 S. Typhi in this 
location and found a substantial amount of diversification within this lineage. My data 
provide a platform for additional studies in the Cambodian population and suggest that 
this is a suitable location in which to introduce Vi conjugate vaccines for school children.  
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Genetic traits of Salmonella Typhi gallbladder carriage isolates and 
their role in disease transmission in Kathmandu, Nepal 
 
6.1 Introduction 
Typhoid carriage has been recognized as an important public health problem for over a 
century. Mary Mallon (better known as Typhoid Mary), a cook in New York, and Mr N, 
a milker in England, were associated with the first true epidemiological investigations of 
infections and typhoid outbreaks caused by asymptomatic carriers in the early 1900s 
119,320. Typhoid carriage is typically thought to occur in patients who fail to fully clear the 
organisms after recovering from their acute phase of illness. These people become 
asymptomatic carriers and can shed the bacteria for up to three months. A subset of these 
individuals (~2- 5 percent) may develop into a chronic carrier state, whereby they 
intermittently shed the bacteria via stool and urine for more than a year 34. Chronic 
carriage may provide an ecological niche that facilitates the transmission and persistence 
of the bacteria in human populations, potentially posing a major public health threat 321. 
As a result, to prevent disease transmission and eventually eradicate the causative 
pathogens, it is essential to detect and provide treatment for the chronic carriers. 
However, this remains a huge challenge due to several impeding factors exist such as a 
lack of epidemiological data on the long-term follow-up of typhoid patients, intermittent 
fecal shedding, sup-optimal diagnostic methods with poor sensitivity to detect Salmonella 
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carriage, and a lack of scientific data on effectiveness of antimicrobial treatment for 
chronic carriage 322,323. The situation is further exacerbated given the fact that infections 
can be symptomless and up to 25 percent of carriers have no history of acute typhoid 
34,119.  
 
Some understanding of typhoid carriage has only been gleaned in recent decades. 
Evidence from mouse models of Salmonella infection and clinical investigations have 
demonstrated that the gallbladder is the primary permissive niche for long-term bacterial 
persistence 122–126,130,324. Various epidemiological investigations have shown an 
association between typhoid carriers and individuals with gallstones in their gallbladder 
120,122,130,325–327. Salmonella can form dense biofilms on the gallstone surface and 
specifically bind to cholesterol gallstones, which is considered as a hallmark of typhoid 
carriage 124,130,324,328,329. Moreover, recent studies have suggested that biofilms form on 
the gallbladder epithelium and it has been suggested that intracellular invasion of 
epithelial cells lining the gallbladder may be another possible mechanism for persistence 
125,330. Despite these advances, there are still unresolved questions regarding the 
development of a chronic carrier state such as host responses to long-term colonization of 
S. Typhi, bacterial adaptive mechanisms for surviving within the gallbladder 
environment, the role of chronic carriers in disease transmission in endemic areas, 
regulatory mechanisms of biofilm formation, and the interaction between S. Typhi and 
the human gallbladder. Genomic characterization of individual carriage isolates as well as 
genomic comparison between acute and carrier isolates have been performed to 
investigate the genetic signatures associated with typhoid carriage 331–334. However, these 
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studies provided limited information because of the limited number of isolates, making 
the population structure and genetic background of the acute and chronic isolates difficult 
to resolve. In this chapter, I performed the genome sequencing and analyses of 24 isolates 
from typhoid carriers and 96 isolates from acute patients collected during the time same 
period in Kathmandu, Nepal to describe the population structure and characterize the 
genetic relatedness between acute and carrier S. Typhi isolates. This investigation also 
aimed to decipher potential genetic traits associated with carrier isolates and estimate the 
role of carriage in the disease transmission in an area that is highly endemic for typhoid 
fever.  
 
6.2 Results 
6.2.1 The phylogenetic structure of Nepalese acute and carrier Salmonella Typhi 
isolates between 2007 and 2010 
My genomic and phylogenetic analyses of 120 S. Typhi isolates (24 from typhoid carriers 
and 96 from acute patients) demonstrated that genotype 4.3.1 (H58) was the most 
dominant genotype isolated during this study period, constituting 65.6% (63/96) of all 
acute isolates and 62.5% (15/24) of all carriage isolates. The second most common 
genotype was 3.3.0 (H1), accounting for 14.6% (14/96) and 12.5% (3/24) of all acute and 
carrier isolates, respectively. Additionally, there was high genetic diversity within this 
bacterial population with various minor genotypes co-circulating, including the subclades 
3.2.2; 3.0.1; 2.2.2; 2.2.1; clades 4.1; 3.1; 2.2 and primary cluster 2 (Figure 6.1). Of these 
minor genotypes, the carriage isolates fell within subclade 3.2.2 (8.3%; 2/24), 2.2.2 
(4.2%; 1/24), clade 2.2 (8.3%; 2/24) and primary cluster 2 (4.2%; 1/24). Overall, the 
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carriage isolates were not significantly more likely to be H58 in comparison to non-H58 
organisms (p=0.774, Chi-squared test). These data suggest that S. Typhi carriage isolates 
were not restricted to any particular bacterial genotype; instead, the genotype distribution 
among carrier isolates mirrored the general genetic structure of the sampled bacterial 
population.  
 
I hypothesized that carriage isolates may be more resistant to antimicrobials, therefore I 
firstly selected to investigate the presence of fluoroquinolone-resistance mutations. The 
genome sequence data showed that mutations conferring non-susceptiblity to 
fluoroquinolones were predominately found within the H58 organisms (64/78, 82.1%), 
rather than the non-H58 organisms (1/42, 2.4%). The majority of the mutations occurred 
at codon 83 of the DNA gyrase gene gyrA, changing serine to phenylalanine (S83F) in 
the protein. Comparing gyrA mutations between the acute and carriage isolates, 
respectively, within the H58 organisms, I found that 76.2% (48/63) and 60% (9/15) 
contained the S83F mutation; 7.9% (5/63) and 13.3% (2/15) had a S83Y mutation and 
15.9% (10/63) and 26.7% (4/15) had no mutation. There was no significant difference 
(p=0.327, Chi-squared test) in the presence of fluoroquinolone resistance-associated 
mutations between acute and carrier isolates in this group.   
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Mid-point rooted maximum likelihood tree based on core-genome SNPs of 120 Salmonella Typhi isolates including 24 from typhoid carriers 
and 96 from acute patients with the corresponding metadata: genotype, gyrA mutations and a heat map of functional distribution of 
nonsynonymous SNPs that were specific to chronic and acute isolates. The heat map is based on the number of nonsynonymous SNPs specific 
to chronic (represented as red bars) and acute isolates (represented as blue bars) in each functional class, with an emphasis on functions related 
to bacterial regulation, surface structures, pathogenicity and virulence. Chronic and acute isolates are shown as red and dark circles at the 
terminal nodes, respectively. Terminal branches leading to chronic isolates are highlighted in red.  
 
 
Figure 6.1 The phylogenetic structure of carriage and acute S. Typhi isolates collected between 2007 and 2010 
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6.2.2 Dissecting the genetic traits of Salmonella Typhi carriage isolates 
There was a total of 2186 SNPs (in comparison with reference genome CT18) identified 
across this collection of 120 genomes from acute and carriage S. Typhi carriage isolates. 
1038/2186 (47.5%) of these SNPs were nonsynonymous (44.7% (977/2186) missense 
and 2.8% (61/2186) were nonsense); 32.4% (708/2186) were synonymous and 20% 
(440/2186) were in the intergenic regions and pseudogenes. The mean dN/dS for acute 
isolates was slightly less than the mean dN/dS for carrier isolates (0.478 vs 0.495, 
respectively), although both of these figures suggest that most of the mutations were 
neutral. In order to better understand the adaptive point mutations associated with typhoid 
carriage, all nonsynonymous SNPs (NSs) occurring exclusively within carrier S. Typhi 
genomes were identified. Genes containing these SNPs were further grouped by their 
predicted functions according to the S. Typhi functional classification scheme generated 
by the Sanger Institute. A comparable analysis was performed for all NSs in the acute S. 
Typhi isolates. There were a total of 228 carriage-specific NSs (212 missense and 16 
nonsense mutations, appendix E) and 469 acute-specific NSs (437 missense and 32 
nonsense mutations, appendix F). There was no significant difference (p=0.924, Chi-
square test) in the proportion of nonsense mutations out of total specific NSs in the acute 
versus the carriage isolates across the whole phylogenetic structure. However, for 
genotype 4.3.1 (H58), the proportion of nonsense mutations out of total specific NSs for 
carrier isolates was significantly higher than that of acute isolates (10/60 compared to 
2/67, Fisher exact test, p=0.009). These data suggested that gene degradation by nonsense 
mutations was more common in carriage isolates in comparison to the acute isolates 
within genotype 4.3.1. The inactivated genes among the carriage isolates included genes 
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involved in the synthesis of peptidoglycan (pbpC), vitamin B12 receptor (btuB), general 
stress response regulator (rpoS), laterally acquired protein in SPI-7 (STY4562), 
membrane transport protein (STY3932), central metabolism (STY0230, ggt), 
hypothetical proteins (STY0929, STY4178) and osmotically inducible lipoprotein E 
precursor (osmE).  
 
Overall, the NSs associated with acute versus carrier S. Typhi isolates could be grouped 
into 78 functions. The highest prevalence of NSs was found in gene functions related to 
hypothetical proteins, membranes lipoproteins, unknown function, transport/binding 
proteins, SPI-7, general regulatory function, surface polysaccharides and antigens, 
carbohydrate degradation, and DNA replication/modification (Figure 6.2). There was no 
statistically significant difference found in the prevalence of these NSs across all gene 
functions between acute and carrier isolates. However, the data showed that the 
proportion of NSs in the viaB operon was significantly higher in carriage isolates in 
comparison to the acute isolates (9/228 compared to 7/469, Chi squared test, p=0.04). 
This finding was also reflected for S. Typhi isolates belonging to genotype 4.3.1, with 
carriage isolates having more specific NSs in the viaB operon than the acute isolates 
(5/60 compared to 1/67, Fisher’s exact test, p=0.08). Additionally, there were two 
carriage isolates (GB428 and GB003) that had lost the Vi capsular polysaccharide due to 
the deletion of the entire SPI-7 region (134kb). Their loss of Vi expression was 
confirmed by agglutination test using Vi antisera under different osmolarity conditions 
(method section 2.3). The viaB operon is a ~14 kb region located within SPI-7 in the S. 
Typhi chromosome containing five genes responsible for Vi polysaccharide synthesis 
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(tviABCDE) and a further five genes (vexABCDE) involved in transportation of the Vi 
capsule to the cell surface. The Vi capsular polysaccharide is an important virulence 
factor enhancing bacterial resistance to complement and phagocytic killing 335. Anti-Vi 
antibody titers have been found to be abnormally high in the blood of typhoid carriers 
and have been used as a serological marker for the detection of typhoid carriage 336,337. 
Here, I show that multiple S. Typhi carriage isolates had lost the ability to express Vi. 
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Figure 6.2 Top ten functional classes with highest prevalence of acute-specific nonsynonymous SNPs versus carrier-specific 
nonsynonymous SNPs
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6.2.3 Positive selection associated with typhoid carriage 
Next, I investigated signatures of positive selection by trying to identify similar genetic 
changes within different carrier isolates. Among the carrier-specific NSs identified, there 
were a number of different mutations occurring in the same gene or the same biological 
pathways in at least two phylogenetically unlinked carrier isolates. For example, within 
the viaB operon as mentioned above, there were two NSs at codon 137 and 462 in the 
tviE gene (isolates GB580 and GB026) and six NSs in codons 166, 504, 506, 508, 665, 
752 in the tviD gene (isolates GB005, GB026, GB076, GB125 and GB281). Both genes 
are known to be involved in the polymerization and translocation of the Vi capsule 338.  
Convergent NSs also occurred the rpoS gene of isolates GB125 (nonsense mutation at 
codon 247) and GB705 (NSs at codon 94 and 250). The rpoS gene encodes the sigma 
factor sigma-38, a central regulatory protein of the general stress responses (temperature, 
pH, osmolarity, redox state, antimicrobial peptide) and nutrient starvation. RpoS has been 
showed to down-regulate Vi expression and RpoS-negative strains of S. Typhi 
overexpressed Vi polysaccharide at low and medium osmolarities, which can affect their 
invasiveness and macrophage resistance 339,340. A further example was NSs at codon 59 
and 230 in the degS gene (serine protease) (isolates GB005 and GB169). DegS is a 
component of DegS-DegU two-component system, which is involved in expression of 
several degradative enzymes for salt stress responses and growth-limiting conditions in 
Gram-positive bacteria, suggesting it might have an important role for bacterial survival 
in the high salt concentration within the gall bladder. Additionally, three isolates (GB005, 
GB026, and GB705) had different NSs in codons 335, 406, 946, respectively, in 
STY1242 (ptsG - glucose-specific PTS system IIBC component). The PtsG enzyme is a 
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component of the glucose-specific phosphotransferase system, plays a role in 
phosphorylation and translocation of glucose across the bacterial membrane, and is 
induced in carbon-limited conditions 341. None of the acute isolates had mutations in this 
gene. There were also several other genes containing NSs in more than two carriage 
isolates, such as STY0429 (SbcC - exonuclease), STY0661 (dmsC -  molybdopterin 
containing oxidoreductase membrane anchor subunit), STY1447 (putative ribulose-5-
phosphate 3-epimerase) and STY2760 (ratA - putative exported protein).  
 
With respect to convergent mutations within the same biological pathways, there were a 
number of carriage-specific NSs involved in LPS O-antigen synthesis and modification. 
For example, a NS in the rfc gene (regulator of O-antigen polymerization) in isolate 
GB441; a NS in the STY2629 gene (LPS modification acyltransferase) of isolate GB335; 
two NSs in the rfbE (CDP-tyvelose-2-epimerase) and rfaG genes (lipopolysaccharide 
core biosynthesis protein) in isolate GB281 and three NSs in the rfbK 
(phosphomannomutase), manB (phosphomannomutase) and rfaD genes (ADP-L-
Glycero-D-mannoheptose-6-epimease) in isolate GB026. RfbK and manB are both related 
to GDP-mannose synthesis for the LPS and rfaD is an enzyme that catalyzes the 
conversion of ADP-D-glycerol-D-mannoheptose to ADP-L-glycerol-D-mannoheptose, a 
precursor for the synthesis of inner-core LPS. The enrichment of NSs related to LPS 
structure suggests that LPS has an important role for the long-term colonization of these 
carrier isolates.  
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6.2.4 Estimating the role of typhoid carriage in disease transmission in Kathmandu, 
Nepal 
Although the majority of acute and carriage isolates generally clustered together within 
the same genotypes across the phylogenetic tree of Nepalese S. Typhi, many carriage 
isolates were associated with atypically long terminal branches, suggesting they exhibited 
a greater degree of genetic variation from the acute isolates (Figure 6.1). One rational 
explanation for this phenomenon was that many of the S. Typhi isolates from typhoid 
carriers have been colonizing the gallbladder for a prolonged period and have undergone 
distinct mutational accumulation for adaptation, whereby they have gradually become 
distantly related to contemporary acute isolates. Additionally, there were very few cases 
where contemporary acute isolates were directly linked to carriage isolates within the 
phylogenetic structure. Taken together, these results potentially indicate that these 
typhoid carriers had limited contribution to the transmission of disease in Kathmandu.  
 
Alternatively, there may be other explanations for the presence of long terminal branches 
in the phylogenetic tree of carriage isolates. For example, carriers may have been 
colonized by imported variants with a different genetic background, or more simply, the 
S. Typhi isolates from acute patients may have been under-sampled or not representative 
of the diversity circulating in the environment. I therefore aimed to identify the most 
probable molecular mechanisms contributing to the variation in branch lengths. The 
number of S. Typhi isolates was not evenly distributed among different genotypes, 
therefore, for this sub-analysis I selected the acute and carrier isolates belonging to only 
genotype 4.3.1 (H58), which is also the most successful and globally dominant genotype.  
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First, I reconstructed a global phylogeny of 4.3.1 S. Typhi isolates including 78 isolates 
from this study (63 from acute patients and 15 from typhoid carriers) and a global 
collection of 798 published previously isolates 248. The phylogenetic reconstruction 
showed that the majority of Nepalese 4.3.1 isolates belonged to a dominant group 
comprising of 9/15 carrier isolates and 45/63 acute isolates (Figure 6.3). For the 
remaining isolates, two carrier isolates (GB003 and GB044) clustered together with 
Indian isolates; the other four carrier isolates (GB076, GB441, GB266, and GB387) were 
distantly related with respect to the rest of the 4.3.1 isolates and consistently associated 
with long terminal branch lengths; the acute isolates were found to cluster with Indian 
(n=6) and Southeast Asian isolates (n=6) and other minor groups within the Nepalese 
4.3.1 population. This finding suggested that there has been a clonal expansion of 4.3.1 S. 
Typhi in Kathmandu, with some evidence of inter-country typhoid transmission. 
However, it was difficult to determine the direction of transmission without 
accompanying epidemiological information. Furthermore, there were little data to support 
that long terminal branches associated with carrier isolates were driven by colonization of 
imported strains.  
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Figure 6.3 Phylogenetic structure of acute and carrier 4.3.1 Salmonella Typhi isolates 
from Nepal in the global context
Maximum likelihood phylogenetic tree of Nepalese H58 S. Typhi isolates (63 from acute 
patients and 15 from typhoid carriers) in the global context. H58 S. Typhi isolates from this 
study are highlighted in red circles at the terminal nodes. Terminal branches associated with 
carriage isolates are shown in red color. The outer ring exhibits the location of the isolates 
from Nepal and its neighboring countries as well as other regions in the world.  
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I next extracted and compared the branch lengths from the most recent common ancestor 
(tMRCA) for acute versus carriage isolates belonging to genotype 4.3.1. My data showed 
that the mean branch length from the tMRCA for the acute isolates was 0.00447 
substitutions/site (range: 0.00196-0.0083) equivalent to 12 SNPs (range: 5-21 SNPs). The 
mean branch length from the tMRCA for the carriage isolates was 0.0052 
substitutions/site (range: 0.00276-0.01108) equivalent to 14 SNPs (range: 7-28 SNPs). 
Therefore, although some carriage isolates within genotype 4.3.1 were associated with 
longer branch lengths in comparison to acute isolates, this difference was not significant. 
One explanation for this may be a variable duration of S. Typhi carriage.  
 
Lastly, I estimated and compared the pairwise genetic distances within the acute isolates 
versus the pairwise genetic distances within carriage isolates. The rationale for this was 
that the number of acute isolates (n=63) was higher than chronic isolates (n=15), 
therefore the genetic diversity within acute isolates should be higher if there was no 
selection and the mutation rates were comparable. However, the median pairwise SNP 
distance within the acute isolates was 13 SNPs (IQR: 8-19 SNPs), which was 
significantly lower than the median pairwise SNP distance within the carriage isolates: 21 
SNPs (IQR: 12-24) (Wilcoxon rank sum test, p=2.8x10-9) (Figure 6.4). Additionally, the 
median pairwise SNP difference between the acute and the carriage isolates was 17 
SNPs, suggesting some degree of overlap in SNP content between these two groups. 
These findings demonstrate that there was more genetic diversity among carriage isolates 
than acute isolates, which may result from an accumulation of adaptive point mutations in 
  150 
response to alternative selective pressures within the gallbladder.  
 
These data suggest that carriage isolates likely follow different evolutionary pathways 
from acute isolates. During carriage S. Typhi consistently accumulates potentially 
adaptive point mutations, which may assist long-term survival within human gallbladder. 
My data proposes that the longer carrier isolates reside within the gallbladder, the more 
genetically distinct they are from acute isolates. Furthermore, it suggests that typhoid 
carriage may not be an important source of disease transmission in Kathmandu. 
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Figure 6.4 Distribution of pairwise SNP distances within and between acute and carrier 
isolates 
 
 
 
 
 
 
 
 
 
Acute-Acute 
n=1953 
Acute-Carrier 
n=945 
Carrier-Carrier 
n=105 
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6.3 Discussion 
Understanding the molecular mechanisms associated with chronic typhoid carriage 
represents a challenging research area given that this population is difficult to identify 
prospectively. Additionally, there has been as a lack of robust genetic methodology to 
investigate these questions due to the genetic conservation of S. Typhi. The 
environmental factors driving the evolution of S. Typhi within the gallbladder are poorly 
understood and little is known about the adaptive mechanisms that promote long-term 
survival. Previous genomic comparisons between S. Typhi isolates recovered from acute 
patients and typhoid carriers have failed to take into consideration the heterogeneity of 
the bacterial population, which may have a large effect on determining genetic variation 
between acute and carrier isolates. An ideal approach for genomic comparison should 
include a characterization of the bacterial population structure in the context of typhoid 
endemicity. In this study, my data demonstrated that typhoid carriage was induced by a 
diverse range of bacterial genotypes. Further, the development of a carrier state was 
neither restricted to any particular genotype nor to a fluoroquinolone-resistant phenotype. 
My study thus rejects the notions that typhoid carriage may be associated with one 
particular genotype or that a shift towards fluoroquinolone therapy has reduced carriage. 
In fact, the genetic distribution of carriage isolates largely reflected the overall genetic 
structure in the bacterial population, with the most dominant genotype being 4.3.1. 
Genotype 4.3.1 (H58) started to emerge and disseminate across South Asia in the early 
1990s 176. Until now, 4.3.1 has been replacing other older preexisting genotypes to 
become the dominant genotype circulating in South Asia, Southeast Asia and Africa. 
According to my data, it is likely that the continued spread of 4.3.1 S. Typhi will 
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dominate over other minor genotypes in Kathmandu. This may also increase the detection 
of 4.3.1 S. Typhi in typhoid carriers over time, compromising the potential role that 
typhoid carriers play in maintaining bacterial diversity.    
 
Assessing the role of chronic carriage in disease transmission represents one of the most 
important public health issues in typhoid control. Typhoid carriers have been widely 
considered as an important source of infection; however, their exact contribution to 
newly infected cases in endemic areas like Kathmandu remains questionable. Previous 
molecular epidemiological studies in endemic regions in Nepal, Vietnam, and Indonesia 
have shown the abundance of environmental transmission in these areas, with a wide 
diversity of co-circulating bacterial genotypes identified among acute typhoid patients 
131–134. These studies have also implied a minimal contribution of person-to-person 
transmission to new typhoid cases in endemic settings. Here, a phylogenetic 
reconstruction for non-recombinant non-repetitive core genomes demonstrated a high 
level of genetic diversity of S. Typhi genotypes circulating in Kathmandu. More 
importantly, the phylogenetic structure of the acute and chronic isolates collected during 
the same period in a single location provided a unique opportunity to investigate the 
phylogenetic relationship between these isolates and assess the role of carriage in disease 
transmission. There were very few examples in the phylogenetic tree where the carriage 
isolates clustered in close proximity or directly gave rise to acute isolates. Further, many 
carriage isolates were associated with atypically long terminal branches. While there 
might be several factors that may lead to this phenomenon, my investigations suggested 
that the accumulation of adaptive point mutations in the carriage isolates was the most 
  154 
likely molecular mechanism. Considering acute and carrier isolates are circulating in 
different ecological niches, long-term exposure to different selective pressures exerted by 
these environments may result in a difference in their accumulated adaptive mutations 
over time. This also means that the longer the duration of carriage in the gallbladder, the 
more genetically distantly related they are in comparison to contemporary acute isolates. 
This speculation is supported by the fact that genotype 4.3.1 carrier isolates exhibited a 
significantly higher level of genetic diversity in comparison to the acute isolates. Taken 
together, my analysis strongly advocates that S. Typhi have undergone a distinctive 
evolutionary pathway during the carrier state and play a limited role in disease 
transmission in Kathmandu. 
 
I additionally aimed to investigate the genetic signatures associated with typhoid carriage 
with a focus on genetic function, particularly at the single nucleotide level. As typhoid 
carriage is not restricted to any bacterial genotype, gene acquisition is unlikely to 
contribute to the development of a carrier state. By identifying NS mutations occurring 
specifically in carrier isolates and classifying them into predicted functional classes for 
comparisons with those of acute isolates, I found that gene degradation by nonsense 
mutations was significantly higher in carriage than acute isolates within genotype 4.3.1. 
The phenotypic effect of gene inactivation on the bacterial phenotype and carriage is 
unknown. However, it is an intriguing phenomenon and worthy of further investigation, 
as gene inactivation has been shown to be an important evolutionary mechanism in the 
adaptation of S. Typhi 231,240. There was also evidence regarding the enrichment of NS 
mutations related to the Vi polysaccharide capsule in the carrier isolates. Vi antigen is 
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immunogenic and anti-Vi antibody gradually wanes in acute typhoid patients after 
recovery, but is persistent in the blood of chronic carriers 337,342. Despite the fact that anti-
Vi antibody is not a reliable serological marker for the detection of typhoid carriers in 
endemic areas, data from sero-surveillance studies for chronic carriage in these areas 
have commonly reported a high prevalence of elevated levels of anti-Vi antibodies in 
healthy individuals, which may be associated with both carriers and repeatedly infected 
persons 343,344. Immunofluorescent staining of biofilms produced by S. Typhi on the 
surface of human gallstones has shown the abundance of Vi capsule in the biofilm 
extracellular matrix, suggesting that S. Typhi consistently express Vi antigen during the 
carrier state 329. The increased frequency of nonsynonymous mutations in the viaB 
operon (tviB, tviD and tviE gene) of carrier isolates in this study together with their high 
level of anti-Vi antibodies in the blood (unpublished data) suggest that S. Typhi residing 
in the gallbladder are under consistent selection pressure imposed by the human immune 
response.  
 
Identifying genes that may be under positive selection among carriage isolates is crucial 
for understanding the evolutionary forces and bacterial adaptation to the gallbladder 
environment during the carrier state. Signatures of positive selection were detected in a 
number of genes containing differing carriage-specific NS mutations in at least two 
phylogenetically unlinked carriage isolates. Many of these genes were associated with 
gene regulation under stress conditions and the expression of virulence genes. For 
example, the global regulatory gene rpoS is not only responsible for general stress 
responses and nutrient starvation but also regulates genes involved in biofilm formation, 
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the colonization of Peyer’s patches, persistence of S. Typhimurium in the spleen, and 
virulence and Vi polysaccharide synthesis of S. Typhi 345–347. Furthermore, the degS gene 
is involved in salt stress responses and growth-limiting conditions in Gram-positive 
bacteria; STY1242 (ptsG - glucose-specific PTS system IIBC component) is activated 
under the stress of carbon starvation. These findings suggest that S. Typhi is exposed to a 
range of differing stresses within the human gallbladder. Furthermore, the genes 
responsible for LPS biosynthesis and modification also displayed a marked accumulation 
of NS mutations in the carriage isolates. LPS is a major component of the outer 
membrane of all Gram-negative bacteria and represents one of the main factors 
contributing to the resistance for high concentrations of bile salt in the gallbladder 348,349. 
LPS is also a key structural component of the biofilm extracellular matrix which forms on 
human gallstones 329. The disruption of genes involved in LPS biosynthesis of S. 
Typhimurium may have a negative effect on the production of biofilms and the 
attachment of bacteria on contact surfaces 350. The enrichment of NS mutations in genes 
involved in LPS biosynthesis and modification can lead to structural changes of the LPS 
and thereby might enhance bile resistance or affect biofilm formation. There were also 
several other genes potentially under positive selection which could have unknown 
effects on carriage, including STY0429 (SbcC - exonuclease), STY0661 (dmsC - 
molybdopterin containing oxidoreductase membrane anchor subunit), STY1447 (putative 
ribulose-5-phosphate 3-epimerase), and STY2760 (ratA - putative exported protein).  
 
This study has some limitations. First, the number of carrier and acute isolates was 
relatively small and thus might not truly reflect the actual genetic structure in the 
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bacterial population. This sample size may also affect the interpretation of the 
phylogenetic distances between acute and carrier isolates and the functional analyses of 
the specific NS mutations in these isolates. Second, the duration of carriage is impossible 
to assess as most typhoid carriers do not recall a history of typhoid. My data suggested 
that the duration of carriage was likely to be highly variable, which consequently led to 
variable terminal branch lengths. It was not possible to measure the evolutionary rate of 
S. Typhi during the carriage state without knowing the duration of carriage in the 
gallbladder. Therefore, it is necessary for all future epidemiological investigations of 
typhoid fever to include a follow-up period of at least one year. This is essential not only 
to provide better estimate of the evolutionary rate of S. Typhi in different ecological 
niches but also to understand bacterial adaptation during carriage. Despite these obvious 
limitations, this was the first ever genomic investigation of the genetic characteristics of 
S. Typhi carriage isolates and the phylogenetic relatedness between carrier and acute 
isolates circulating over the same time period in a typhoid-endemic area. This study also 
provided valuable evidence for assessing the role of typhoid carriers in disease 
transmission in Kathmandu, Nepal. 
 
In conclusion, typhoid carriage is not associated with any particular genotype nor driven 
by fluoroquinolone resistance. Additionally, I found strong evidence that typhoid carriers 
are likely not an important source of new infections in endemic settings such as 
Kathmandu. As a result, public health control measures should focus on providing people 
with safe water, food safety and vaccination for disease prevention. S. Typhi is exposed 
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to a variety of stressful conditions within the gallbladder and undergoes distinctive 
evolutionary processes for better adaptation.  
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General discussion 
 
The emergence and spread of a novel subclade of ciprofloxacin-resistant H58 S. Typhi in 
Nepal and a neighboring country demonstrates that fluoroquinolone resistance in this 
pathogen has become a serious problem across South Asia. More importantly, such 
organisms were found to be associated with fluoroquinolone treatment failure. My data 
strongly advocate that fluoroquinolones should no longer be used as empirical therapy for 
typhoid in this region; therefore, more clinical studies should be conducted to evaluate 
the effectiveness of alternative treatment options. Additionally, with the first typhoid 
conjugate vaccine Typbar-TCV that can be used for children aged less than two years and 
has been prequalified by WHO, it is necessary to conduct vaccine trials to measure the 
efficacy and immunogenicity of this new vaccine in Nepal and to develop a sustainable 
vaccine procurement and financing mechanisms. Programmatic use of the new typhoid 
vaccine targeting high-risk populations may not only reduce the disease burden but also 
minimize the antimicrobial use and selective pressure in the bacterial population. 
Meanwhile, molecular typing and phenotypic characterization of S. Typhi needs to be 
performed routinely in South Asian countries and other reference laboratories outside this 
region to keep track of the spread of this novel H58 subclade to provide early warning for 
public health authorities and healthcare providers. These potentially dangerous organisms 
are likely to be widespread across the Indian subcontinent and may become a global 
health threat if they reach other vulnerable populations in Asia and Africa, as we have 
seen previously with the other H58 S. Typhi.  
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Despite the progress in S. Typhi vaccine development, there is still no vaccine against S. 
Paratyphi A. Further, the epidemiological characteristics and burden of disease caused by 
S. Paratyphi A are not well described, and the dynamics of bacterial populations in 
endemic areas are often overlooked. Using a genomic approach combined with 
conventional epidemiological tools, my study provided a detailed characterization of the 
phylogenetic structure and spatiotemporal distribution of S. Paratyphi A isolates from 
Kathmandu. This Nepalese S. Paratyphi A population was highly dynamic with evidence 
of regular bacterial transmission between Nepal and neighboring countries, resulting in 
clonal expansions of distinct genotypes at different time periods. Lineage A was the most 
common genotype found in this collection of S. Paratyphi A, which consisted of two 
dominant sub-lineages (A1 and A2), whereby a single sub-lineage (A2) has rapidly 
replaced all other preexisting genotypes from 2011. The emergence and rapid lineage 
replacement of sublineage A2 in Nepal is an intriguing phenomenon and requires further 
research into its virulence and antigenicity. For example, in my laboratory we are 
working on the characterization of LPS structure, epithelial cellular invasion and 
macrophage killing of S. Paratyphi A isolates belonging to different genotypes. Further, 
human protective immunity against differing S. Paratyphi A genotypes as well as the 
clinical and epidemiological features associated with infections caused by sub-lineage A2 
need to be further investigated. The introduction of the new typhoid conjugate vaccine 
against S. Typhi in areas where S. Typhi and S. Paratyphi A are co-circulating may 
additionally lead to an increase in S. Paratyphi A infections. While S. Paratyphi A 
infections have become a growing problem in many parts of Asia, vaccines against this 
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pathogen are lagging far behind. Therefore, routine surveillance and improved public 
health practices in endemic areas can be an immediate solution for disease control and 
management. 
 
Most previous typhoid studies have primarily focused on urban slums in low and middle-
income countries where high rates of typhoid fever have often been reported. There is a 
general lack of epidemiological data about the disease burden and antimicrobial 
resistance of S. Typhi in rural settings with limited access to healthcare. My study 
provided unprecedented insights into the S. Typhi population structure and 
epidemiological features of typhoid fever in rural areas in Siem Reap province, 
Cambodia. Typhoid fever is widespread in rural areas of Cambodia, causing a significant 
disease burden in children aged less than 15 years. Several spatiotemporal outbreaks were 
identified in communes located near Tonle Sap Lake and proximity to the lake was 
associated with increased risk of infection. There was also a wide geographic distribution 
and high prevalence of MDR H58 S. Typhi with reduced susceptibility to 
fluoroquinolone in this setting. Despite these novel findings, the study was based on 
hospital surveillance data, which was limited to a single healthcare setting and lacked 
complete geospatial data. Therefore, community surveillance at individual or household-
level in communes with high typhoid fever incidence (such as Kaoh Chiveang and 
Kampong Kleang) is necessary to identify specific risk behaviors and spatiotemporal case 
clusters. Furthermore, the level of fecal contamination and the presence of S. Typhi in 
water resources in these areas should also be examined. Such valuable information would 
be essential for guiding public health interventions as well as identifying high-risk 
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populations for typhoid vaccine introduction, given the fact that the new typhoid 
conjugate vaccine has been prequalified and registered in Cambodia.  
 
The scope of my study also aimed to address one of the most important typhoid research 
questions regarding to role of typhoid carriage in disease transmission in endemic 
settings. My genomic and phylogenetic analyses of S. Typhi and S. Paratyphi A isolates 
recovered from asymptomatic carriers and acute patients suggested that typhoid carriers 
are not likely to contribute significantly to new infections in endemic area or the 
maintenance of bacterial genetic diversity. S. Typhi is likely to be under stress within the 
gallbladder and forge a distinct evolutionary pathway for better adaptation within the 
gallbladder. One of the important limitations of my study was a lack of information on 
the duration of carriage, which is crucial to estimate the mutation rate of S. Typhi during 
the carrier state and to better understand the phylogenetic relationships between carriage 
and acute isolates. However, it is very difficult to identify chronic typhoid carriers 
prospectively considering the very low rate of chronic carriage, intermittent fecal 
shedding, and a lack of a robust detection method. To follow up on the findings described 
in my thesis, studies are currently being performed in my laboratory to further 
characterize and compare the capacity to invade epithelial cells, kill macrophages and 
form biofilms between the acute and carrier isolates belonging to the same lineages. Such 
experiments are necessary to better understand how S. Typhi behave within the 
gallbladder environment during the carrier state. Additional research is also being 
conducted to identify specific biological markers associated with chronic carriage that 
can be used to develop a diagnostic test.  
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In conclusion, the advance of next-generation sequencing has revolutionized 
epidemiological research and bacterial genomics has become an essential tool for 
understanding the circulation of pathogens and the impact of antimicrobial resistant 
organisms on disease outcomes. Using genomic approaches combined with other clinical 
and epidemiological data, my research contributed significantly to a better understanding 
of the emergence of antimicrobial resistance and epidemiological features of typhoid 
fever in both rural and urban settings. For the first time, I measured an effect of AMR and 
bacterial genotype on the treatment outcome of typhoid fever, which is likely to have a 
substantial impact on clinical and public health practices.  
 
In conclusion, my thesis strongly advocates the discontinued use of fluoroquinolones as 
empirical treatment for typhoid fever in South Asia and highlights the necessity for 
alternative antimicrobial therapies, as well as the introduction of new conjugate typhoid 
vaccines in this region. Further molecular investigations on disease transmission and 
AMR surveillance are required to routinely monitor the emergence and spread of these 
clinically important pathogens. The research methods described in my thesis have proven 
to be powerful, adaptable, robust and should be applied for similar studies on alternative 
pathogens in the future. Only by understanding the interaction of antimicrobial treatment 
and the infecting organism can we begin to curtail the current antimicrobial resistance 
crisis. 
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Appendices 
Appendix A Salmonella Typhi isolates and their corresponding sequencing metadata in chapter 3 
Name Tree ID Accession number Trial Year Country 
gyrA gyrA gyrA gyrB gyrB parC parE parE parE 
H58 
MIC MIC 
group* S83F D87N D87V S464Y A574V S80I A353V A364V E460K Cipro 
02TY_001 STY1_AL513382 ERR1079230 1 2011 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
02TY_006 STY6_AL513382 ERR1079231 1 2011 Nepal 1  0 0 0 0 0 0 0 1 0.38 2 
02TY_007 STY7_AL513382 ERR1079232 1 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_009 13STY9_AL513382 ERR1079233 1 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_015 STY15_MERGE_AL513382 ERR1079234 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_016 STY16_AL513382 ERR1079235 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_018 STY18_AL513382 ERR1079236 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_027 STY27_MERGE_AL513382 ERR1079237 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_028 STY28_MERGE_AL513382 ERR1079238 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_030 STY30_AL513382 ERR1079239 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_031 STY31_AL513382 ERR1079240 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_032 STY32_AL513382 ERR1079241 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_034 STY34_AL513382 ERR1079242 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.5 2 
02TY_037 STY37_AL513382 ERR1079243 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_038 STY38_AL513382 ERR1079244 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_045 STY45_MERGE_AL513382 ERR1079245 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_047 STY47_AL513382 ERR1079246 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
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02TY_048 STY48_AL513382 ERR1079247 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.125 2 
02TY_051 STY51_AL513382 ERR1079248 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_055 STY55_AL513382 ERR1079249 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_057 STY57_AL513382 ERR1079250 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_058 4STY58D1_AL513382 ERR1079251 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_059 STY59_AL513382 ERR1079253 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_060 STY60_AL513382 ERR1079254 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
02TY_061 STY61_AL513382 ERR1079255 1 2012 Nepal 0 0 0 0 0 0 0 1 0 0 0.012 1 
02TY_078 14STY78_AL513382 ERR1079256 1 2012 Nepal 0 0 0 0 0 0 0 0 0 0 0.016 1 
02TY_080 STY80_AL513382 ERR1079257 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
02TY_083 STY83_AL513382 ERR1079258 1 2012 Nepal 1 0 0 0 0 0 0 0 0 1 0.5 2 
02TY_119 15STY119D1_AL513382 ERR1079279 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_125 STY125_MERGE_AL513382 ERR1079260 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_126 6STY126_AL513382 ERR1079261 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_127 7STY127_AL513382 ERR1079262 1 2013 Nepal 0 1 0 0 0 0 0 0 0 0 0.125 2 
02TY_132 15STY132_AL513382 ERR1079263 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_135 16STY135_AL513382 ERR1079264 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_136 STY136_MERGE_AL513382 ERR1079265 1 2013 Nepal 0 0 0 0 0 0 0 0 0 1 0.023 1 
02TY_140 16STY140_AL513382 ERR1079266 1 2013 Nepal 0 0 0 0 0 0 0 0 0 1 0.023 1 
02TY_143 9STY143D26_AL513382 ERR1079267 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_144 10STY144_AL513382 ERR1079268 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
02TY_146 11STY146_AL513382 ERR1079269 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_147 17STY147_AL513382 ERR1079270 1 2013 Nepal 1 0 0 0 1 0 0 1 0 0 1 3 
02TY_148 17STY148_AL513382 ERR1079271 1 2013 Nepal 1 0 0 0 1 0 0 1 0 0 0.38 2 
02TY_149 12STY149_AL513382 ERR1079272 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_150 13STY150_AL513382 ERR1079273 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_156 14STY156_AL513382 ERR1079274 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_157 18STY157_AL513382 ERR1079275 1 2013 Nepal 0 0 0 0 0 0 1 1 0 0 0.008 1 
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02TY_158 15STY158_AL513382 ERR1079276 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_159 16STY159_AL513382 ERR1079277 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 1 3 
02TY_160 17STY160_AL513382 ERR1079278 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_163 18STY163_AL513382 ERR1079279 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_164 19STY164_AL513382 ERR1079280 1 2013 Nepal 0 0 0 0 0 0 0 0 0 0 0.016 1 
02TY_169 STY169_MERGE_AL513382 ERR1079281 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 24 3 
02TY_173 STY173_MERGE_AL513382 ERR1079282 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_174 19STY174_AL513382 ERR1079283 1 2013 Nepal 1 0 1 0 0 1 0 1 0 0 32 3 
02TY_176 22STY176D1_AL513382 ERR1079284 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_178 24STY178_AL513382 ERR1079286 1 2013 Nepal 1 0 1 0 0 1 0 1 0 0 32 3 
02TY_183 13254_5#37 ERR586912 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_185 25STY185_AL513382 ERR1079287 1 2013 Nepal 0 0 0 1 0 0 0 0 0 0 0.15 2 
02TY_186 26STY186_AL513382 ERR1079288 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_188 STY188_MERGE_AL513382 ERR1079289 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_190 13254_5#39 ERR586914 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 24 3 
02TY_195 STY195_MERGE_AL513382 ERR1079290 1 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
02TY_196 29STY196_AL513382 ERR1079291 1 2013 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
02TY_200 30STY200_AL513382 ERR1079292 1 2013 Nepal 0 0 0 0 0 0 0 0 0 0 0.016 1 
02TY_202 20STY202_AL513382 ERR1079293 1 2013 Nepal 1 0 0 0 0 0 0 1 0 0 0.25 2 
02TY_210 18STY210_AL513382 ERR1079294 1 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_213 24STY213_AL513382 ERR1079295 1 2014 Nepal 0 0 0 0 0 0 0 1 0 0 0.016 1 
02TY_216 31STY216_AL513382 ERR1079296 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_219 21STY219D1_AL513382 ERR1079297 1 2014 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_222 23STY222_AL513382 ERR1079299 1 2014 Nepal 1 0 0 0 0 0 0 0 1 1 0.38 2 
02TY_226 32STY226_AL513382 ERR1079300 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_229 20STY229_AL513382 ERR1079301 1 2014 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_232 STY232_MERGE_AL513382 ERR1079302 1 2014 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
02TY_235 24STY235D1_AL513382 ERR1079303 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
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02TY_236 STY236_MERGE_AL513382 ERR1079305 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
02TY_239 28STY239_AL513382 ERR1079306 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_240 29STY240_AL513382 ERR1079307 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
02TY_241 30STY241_AL513382 ERR1079308 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.5 2 
02TY_244 12STY244_AL513382 ERR1079309 1 2014 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
01TY072 5886_3#1 ERR119817 0 2008 Nepal 0 0 0 0 0 0 0 0 0 0 0.016 1 
01TY075 5886_3#2 ERR119818 0 2008 Nepal 0 0 0 0 0 0 0 0 0 0 0.016 1 
01TY090 5886_3#4 ERR119820 0 2009 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
01TY098 5886_3#5 ERR119821 0 2009 Nepal 0 0 0 0 0 0 0 0 0 0 0.016 1 
01TY101 5886_3#6 ERR119822 0 2009 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
01TY103 5886_3#3 ERR119819 0 2009 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
01TY104 5886_3#7 ERR119823 0 2009 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
01TY112 5886_3#8 ERR119824 0 2009 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
01TY122 5886_3#9 ERR119825 0 2009 Nepal 0 0 0 0 0 0 0 0 0 1 0.016 1 
CC_04 10561_2#1 ERR357576 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_05 10561_2#8 ERR357583 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_08 10561_2#12 ERR357587 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_11 10561_2#19 ERR357594 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_12 10561_2#25 ERR357600 0 2011 Nepal 0 0 0 0 0 0 0 1 0 0 0.004 1 
CC_13 10561_2#31 ERR357606 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_16 10561_2#37 ERR357612 0 2011 Nepal 0 0 0 0 0 0 0 1 0 0 0.004 1 
CC_22 10561_2#44 ERR357619 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_27 10425_1#9 ERR349339 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
CC_31 10561_2#53 ERR357628 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_39 10561_2#57 ERR357632 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_40 10561_2#62 ERR357637 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
CC_41 10561_2#2 ERR357577 0 2011 Nepal 1 0 0 0 0 0 0 1 0 0 0.125 2 
CC_43 10561_2#9 ERR357584 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
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CC_44 10561_2#13 ERR357588 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_45 10425_1#5 ERR349335 0 2011 Nepal 0 0 0 0 0 0 0 1 0 0 0.008 1 
CC_49 10561_2#26 ERR357601 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_50 10561_2#32 ERR357607 0 2011 Nepal 0 1 0 0 0 0 0 0 0 0 0.125 2 
CC_51 10561_2#38 ERR357613 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
CC_57 10561_2#45 ERR357620 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
CC_60 10561_2#50 ERR357625 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_61 10426_1#6 ERR349528 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_65 10561_2#58 ERR357633 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.125 2 
CC_67 10561_2#63 ERR357638 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_69 10425_1#2 ERR349332 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.125 2 
CC_74 10425_1#3 ERR349333 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_75 10561_2#14 ERR357589 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_80 10425_1#6 ERR349336 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_81 10561_2#27 ERR357602 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_83 10561_2#33 ERR357608 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_87 10561_2#39 ERR357614 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.25 2 
CC_88 10561_2#46 ERR357621 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_89 10561_2#51 ERR357626 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_90 10561_2#54 ERR357629 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_92 10561_2#59 ERR357634 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_93 10561_2#64 ERR357639 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_94 10561_2#3 ERR357578 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_95 10561_2#10 ERR357585 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_97 10561_2#15 ERR357590 0 2011 Nepal 1 0 0 0 0 0 0 0 0 1 0.19 2 
CC_99 10561_2#20 ERR357595 0 2011 Nepal 1 0 0 0 0 0 0 1 0 0 0.094 2 
Ind082356_2008 10349_1#34 ERR343282 0 2008 India 1 1 0 0 0 1 0 0 0 1 32 3 
Ind101104_2010 10349_1#52 ERR343300 0 2010 India 1 1 0 0 0 1 0 0 0 1 32 3 
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IndBCR175_2011 8616_4#48 ERR420424 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndBCR191_2011 8616_4#50 ERR420426 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndBCR211_2011 8616_4#51 ERR420427 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndBCR62_2009 8616_4#41 ERR420417 0 2009 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST127_2011 10492_1#6 ERR352259 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST128_2011 10493_1#9 ERR352434 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST147_2012 10492_1#13 ERR352266 0 2012 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST167_2011 10562_2#13 ERR357768 0 2011 India 1 1 0 0 0 1 0 0 0 1 24 3 
IndMDUST197_2010 10492_1#25 ERR352278 0 2010 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST216_2011 10492_1#31 ERR352284 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST247_2011 10562_2#32 ERR357787 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST248_2011 10492_1#43 ERR352296 0 2011 India 1 1 0 0 0 1 0 0 0 1 24 3 
IndMDUST254_2010 10562_2#34 ERR357789 0 2010 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndMDUST400_2012 10562_2#79 ERR357834 0 2012 India 1 1 0 0 0 1 0 0 0 1 24 3 
IndMDUST408_2012 10492_1#82 ERR352335 0 2012 India 1 1 0 0 0 1 0 0 0 1 32 3 
IndSP80_2011 8616_4#58 ERR420434 0 2011 India 1 1 0 0 0 1 0 0 0 1 32 3 
NEN_2512 13254_5#40 ERR586915 0 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
NEN_2533 2533_AL513382 ERR1079310 0 2013 Nepal 1 0 0 0 0 0 0 0 0 1 0.38 2 
NEN_2546 2546_AL513382 ERR1079311 0 2013 Nepal 1 0 1 0 0 1 0 1 0 0 6 3 
OTHERS_510 13254_5#42 ERR586917 0 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
OTHERS_514 13254_5#43 ERR586918 0 2013 Nepal 1 0 1 0 0 1 0 1 0 0 8 3 
OTHERS_515 13254_5#44 ERR586919 0 2013 Nepal 1 1 0 0 0 1 0 0 0 1 32 3 
OTHERS_516 13254_5#45 ERR586920 0 2013 Nepal 1 0 1 0 0 1 0 1 0 0 8 3 
OTHERS_521 13254_5#46 ERR586921 0 2013 Nepal 1 1 0 0 0 1 0 0 0 1 8 3 
OTHERS_535 535_AL513382 ERR1079312 0 2013 Nepal 1 0 1 0 0 1 0 1 0 0 32 3 
UnkMDUST146_2012 10562_2#10 ERR357765 0 2012 Unknown 1 1 0 0 0 1 0 0 0 1 32 3 
  
* ciprofloxacin MIC group: 1; susceptible, 2; intermediate, 3; resistan 
  200 
Appendix B Salmonella Paratyphi A isolates and their corresponding metadata in chapter 4 
Strain Acute/Carrier Lineage Genotype Lat Long GyrA Date Age Sex Main_water Treat_water Anorexia Nausea Abdominal pain Diarrhoea Constipation Headache 
DM035 Acute A A1.6 27.69116 85.34435 S83F 17-Jun-05 23 F   Yes Yes Yes No Yes Yes 
DM038 Acute A A1 27.65838 85.32773 S83F 19-Jun-05 25 M   Yes Yes Yes Yes No Yes 
DM042 Acute A A1.6 27.6898 85.34475 S83F 20-Jun-05 30 M   Yes No No No No Yes 
DM049 Acute A A1 27.68463 85.32151 WT 21-Jun-05 22 M   Yes No No No No Yes 
DM056 Acute A A1.1 27.69708 85.33345 S83F 25-Jun-05 11 M   Yes No No No No Yes 
DM067 Acute A A1.2 27.6692 85.32035 S83F 27-Jun-05 16 M   Yes Yes Yes No No Yes 
DM072 Acute A A1.7 27.67321 85.32898 S83F 28-Jun-05 31 M   Yes Yes No No No Yes 
DM080 Acute A A1 27.67098 85.3219 S83F 29-Jun-05 6 M   No No Yes No No Yes 
DM082 Acute A A1.2 27.67166 85.32711 S83F 29-Jun-05 50 F   Yes No No No Yes Yes 
DM089 Acute A A1 27.67448 85.31856 S83F 30-Jun-05 13 M   Yes No No Yes No Yes 
DM093 Acute C C 27.676 85.33893 WT 30-Jun-05 21 F   Yes Yes Yes No No Yes 
DM098 Acute A A1.8 27.67525 85.33198 S83F 3-Jul-05 18 M   Yes No Yes No No Yes 
DM111 Acute A A1.9 27.65938 85.32823 S83F 6-Jul-05 21 M   Yes No No No No Yes 
DM116 Acute A A1.7 27.6421 85.32248 S83F 8-Jul-05 32 M   Yes No Yes No No Yes 
DM118 Acute A A1.9 27.69901 85.35241 S83F 8-Jul-05 30 M   Yes No No Yes No Yes 
DM158 Acute A A1.6 27.68921 85.34438 S83F 16-Jul-05 29 M   Yes No No No No Yes 
DM175 Acute A A1.10 27.67495 85.30568 S83F 17-Jul-05 13 F   No No No No No Yes 
DM178 Acute A A1.2 27.66806 85.3289 S83F 19-Jul-05 8 F   No No No No No Yes 
DM183 Acute A A1 27.67451 85.31931 S83F 19-Jul-05 22 F   No No Yes No No Yes 
DM186 Acute A A1.7 27.67746 85.33521 S83F 20-Jul-05 15 M   Yes No No Yes No Yes 
DM188 Acute C C 27.66326 85.32745 D87Y 20-Jul-05 28 M   No Yes No No No Yes 
DM192 Acute A A1.10 27.65668 85.3298 S83F 21-Jul-05 14 F   Yes No Yes No No Yes 
DM210 Acute A A1.10 27.6751 85.30683 S83F 26-Jul-05 20 M   No No No No No Yes 
DM211 Acute A A1.7 27.67746 85.33521 S83F 26-Jul-05 16 M   Yes No Yes No No Yes 
DM219 Acute A A1.2 27.66865 85.32715 S83F 28-Jul-05 10 M   No No No No Yes Yes 
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DM227 Acute A A1.2 27.66311 85.31691 S83F 31-Jul-05 14 M   No No No No No Yes 
DM233 Acute A A1.7 27.66948 85.32518 S83F 31-Jul-05 4 F   Yes Yes Yes Yes No Yes 
DM247 Acute A A1.8 27.67205 85.32166 S83F 2-Aug-05 20 M   Yes No No No No Yes 
DM253 Acute A A1 27.66886 85.32515 S83F 4-Aug-05 21 M   Yes Yes No No No Yes 
DM254 Acute A A1.2 27.66913 85.32666 S83F 4-Aug-05 12 F   No No No No No Yes 
DM256 Acute A A1.2 27.67683 85.3219 S83F 4-Aug-05 17 M   No No No No No Yes 
DM265 Acute A A1.2 27.66198 85.32601 S83F 5-Aug-05 14 M   No No No No No Yes 
DM274 Acute A A1.2 27.68061 85.32708 S83F 8-Aug-05 23 M   Yes No No No No Yes 
DM295 Acute A A1.8 27.68211 85.3234 S83F 12-Aug-05 23 M   Yes No No No No Yes 
DM305 Acute A A1.3 27.67885 85.32426 S83F 17-Aug-05 20 M   Yes Yes Yes No No Yes 
DM313 Acute C C 27.67413 85.30495 WT 19-Aug-05 17 M   Yes No No No No Yes 
DM323 Acute A A1.2 27.67336 85.32105 S83F 22-Aug-05 30 M   Yes Yes Yes Yes No Yes 
DM329 Acute A A1.10 27.67471 85.30631 S83F 25-Aug-05 30 M   Yes No No No No No 
DM356 Acute A A1.2 27.67951 85.32698 S83F 30-Aug-05 24 M   No Yes Yes No No Yes 
DM358 Acute A A1.2 27.64466 85.3157 S83F 31-Aug-05 15 M   No No Yes No No Yes 
DM363 Acute C C 27.67413 85.30495 WT 1-Sep-05 16 M   Yes No No No No Yes 
DM387 Acute A A1 27.68 85.3272 S83F 7-Sep-05 19 M   Yes No No No No Yes 
DM390 Acute A A1.8 27.67256 85.3215 S83F 8-Sep-05 25 M   No No No No No Yes 
ED027 Acute A A1.5 27.66598 85.31043 S83F 20-May-06 22 M Mix Untreated Yes No No No No Yes 
ED034 Acute A A1.11 27.6673 85.33213 S83F 22-May-06 21 M Municipal  Untreated No No No No No Yes 
ED035 Acute A A1.3 27.67546 85.3212 S83F 22-May-06 10 F Municipal  Boil Yes No Yes No No Yes 
ED037 Acute A A1.3 27.6748 85.32711 S83F 23-May-06 12 M Well Untreated No No No No No No 
ED039 Acute A A1.11 27.67965 85.30196 S83F 23-May-06 26 M Municipal  Boil Yes Yes No No No Yes 
ED043 Acute A A1.11 27.67363 85.32805 S83F 24-May-06 8 M Well Untreated Yes Yes Yes Yes No Yes 
ED044 Acute A A1.1 27.67761 85.34775 S83F 24-May-06 21 M Mix Boil No No Yes No No Yes 
ED051 Acute A A1.9 27.67986 85.32321 S83F 28-May-06 39 M Municipal  Other No No No No No Yes 
ED053 Acute A A1.9 27.67731 85.33545 S83F 28-May-06 19 M Well Chlorine Yes Yes Yes No Yes Yes 
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ED065 Acute A A1.4 27.67181 85.30208 S83F 1-Jun-06 17 M Municipal  Filter Yes No Yes No No Yes 
ED068 Acute A A1.11 27.66946 85.31273 S83F 4-Jun-06 35 M Municipal  Boil No No No No No Yes 
ED070 Acute A A1.11 27.6352 85.31878 S83F 5-Jun-06 7 F Municipal  Untreated No No Yes No No Yes 
ED071 Acute A A1.7 27.68526 85.31778 S83F 5-Jun-06 16 M Municipal  Untreated Yes No No No No Yes 
ED074 Acute C C 27.68463 85.32151 WT 6-Jun-06 4 F Stone spout Untreated No No Yes No No No 
ED079 Acute A A1.11 27.67256 85.3323 S83F 6-Jun-06 21 M Stone spout Untreated No No Yes No No Yes 
ED099 Acute A A1 27.66573 85.33275 WT 10-Jun-06 28 M Municipal  Filter No No No No No Yes 
ED161 Acute A A1.11 27.65751 85.31991 S83F 25-Jun-06 23 F Well Mix No Yes No No No Yes 
ED164 Acute A A1.11 27.67776 85.32176 S83F 26-Jun-06 34 M Municipal  Yes Yes No No Yes Yes 
ED168 Acute A A1.3 27.67761 85.32058 S83F 27-Jun-06 13 F Mix Boil Yes No No No No Yes 
ED179 Acute A A1.3 27.67891 85.32911 S83F 2-Jul-06 21 F Stone spout Boil Yes No No No No Yes 
ED182 Acute A A1.7 27.67718 85.32768 S83F 3-Jul-06 24 M Stone spout Untreated Yes No No No No Yes 
ED191 Acute A A1.5 27.67318 85.32173 S83F 5-Jul-06 13 M Well Filter Yes No No Yes No Yes 
ED192 Acute A A1.3 27.67595 85.32538 S83F 5-Jul-06 8 M Mix Untreated No No Yes No No Yes 
ED193 Acute A A1.11 27.68211 85.3234 S83F 5-Jul-06 20 M Mix Other Yes No No No No Yes 
ED194 Acute A A1.3 27.67546 85.3212 S83F 5-Jul-06 19 F   Yes Yes Yes No No Yes 
ED199 Acute C C 27.66366 85.32826 WT 6-Jul-06 35 F Stone spout Boil Yes No Yes No No Yes 
ED260 Acute A A1 27.41299 85.187 S83F 23-Jul-06 7 F Municipal  Chlorine Yes No No No No Yes 
ED261 Acute A A1.4 27.66781 85.32068 S83F 23-Jul-06 26 M Tanker Untreated No Yes No No No Yes 
ED262 Acute A A1.11 27.66475 85.32506 S83F 24-Jul-06 9 M Well Untreated Yes No Yes Yes No Yes 
ED267 Acute A A1.11 27.68061 85.32708 S83F 25-Jul-06 18 M Stone spout Chlorine No No No No Yes Yes 
ED272 Acute A A1.5 27.673 85.3224 S83F 26-Jul-06 27 F Well Filter Yes Yes No No No Yes 
ED274 Acute A A1.9 27.67776 85.32176 S83F 26-Jul-06 8 F Municipal  Untreated Yes No No No No No 
ED275 Acute A A1.11 27.68531 85.31443 S83F 26-Jul-06 17 F Municipal  Boil No Yes No No No Yes 
ED286 Acute A A1.5 27.66928 85.32481 S83F 28-Jul-06 26 M Municipal  Mix Yes Yes Yes No Yes Yes 
ED293 Acute A A1.3 27.67653 85.32718 S83F 30-Jul-06 24 M Stone spout Untreated No No No No No No 
ED317 Acute A A1.9 27.66355 85.31371 S83F 6-Aug-06 33 F Mix Filter Yes Yes Yes No No Yes 
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ED318 Acute A A1.5 27.67208 85.34118 S83F 6-Aug-06 24 M Stone spout Untreated Yes No Yes Yes No Yes 
ED320 Acute A A1.1 27.65438 85.32065 S83F 6-Aug-06 20 M Mix Chlorine Yes No No No No Yes 
ED321 Acute A A1.11 27.67246 85.32088 S83F 7-Aug-06 26 F Municipal  Mix No Yes No Yes No Yes 
ED327 Acute A A1.9 27.67821 85.31538 S83F 9-Aug-06 12 M Municipal  Untreated Yes Yes Yes No Yes Yes 
ED330 Acute A A1.11 27.66311 85.31691 S83F 10-Aug-06 17 F Bottled Other Yes Yes No No No Yes 
ED335 Acute A A1.5 27.67105 85.32501 S83F 13-Aug-06 24 F Well Untreated Yes No No No No Yes 
ED338 Acute A A1.1 27.67106 85.3047 S83F 15-Aug-06 33 F Municipal  Filter Yes Yes Yes No No Yes 
ED340 Acute A A1.5 27.67303 85.32156 S83F 16-Aug-06 11 M Municipal  Filter Yes No No No Yes Yes 
ED345 Acute A A1.4 27.68505 85.30958 S83F 17-Aug-06 25 M Municipal  Mix No No No No No Yes 
ED347 Acute A A1.5 27.6657 85.32391 S83F 17-Aug-06 16 M Mix Untreated No No No No No Yes 
ED348 Acute A A1.11 27.66415 85.31873 S83F 18-Aug-06 23 F Well Other Yes Yes No No No Yes 
ED356 Acute A A1.11 27.66821 85.3221 S83F 21-Aug-06 25 M Stone spout Untreated Yes No No Yes No Yes 
ED361 Acute A A1.11 27.67396 85.31955 S83F 22-Aug-06 9 F Municipal  Untreated Yes Yes Yes No Yes Yes 
ED362 Acute A A1.11 27.66913 85.32336 S83F 23-Aug-06 15 M Municipal  Filter Yes Yes No Yes No Yes 
ED363 Acute A A1.1 27.67048 85.31215 S83F 23-Aug-06 25 M Mix Untreated Yes Yes Yes No No Yes 
ED366 Acute A A1.11 27.67031 85.3251 S83F 23-Aug-06 24 F Well Boil No No No No No No 
ED375 Acute A A1.5 27.6799 85.31151 S83F 28-Aug-06 22 M Municipal  Chlorine Yes Yes Yes No No Yes 
ED383 Acute A A1.11 27.66998 85.32285 S83F 31-Aug-06 3 M Well Untreated No No Yes Yes Yes Yes 
ED408 Acute A A1.11 27.65583 85.33271 S83F 17-Dec-06 26 M Stone spout Boil Yes Yes Yes No No Yes 
ED416 Acute C C 27.67343 85.3222 WT 4-Jan-07 19 F Well Boil Yes Yes No No No Yes 
ED417 Acute A A1 27.68121 85.32736 S83F 5-Jan-07 19 F Stone spout Mix Yes No Yes No Yes Yes 
ED432 Acute A A1.9 27.67593 85.31933 S83F 2-Mar-07 25 F Municipal  Mix Yes Yes No No No Yes 
ED443 Acute A A1 27.68886 85.31315 S83F 16-Mar-07 24 M Bottled Untreated Yes No No Yes No Yes 
ED446 Acute A A2 27.68018 85.32763 D87Y 19-Mar-07 25 M Stone spout Boil No No No No No Yes 
ED459 Acute A A1.1 27.67735 85.32795 S83F 4-Apr-07 23 M Mix Untreated Yes Yes No No No Yes 
ED494 Acute A A1.11 27.66525 85.33801 S83F 6-May-07 22 F Municipal  Untreated Yes Yes Yes No No Yes 
ED503 Acute A A1.9 27.68463 85.32151 S83F 16-May-07 23 M Stone spout Untreated Yes No No No No No 
  204 
ED523 Acute A A1.11 27.669 85.32908 S83F 1-Jun-07 17 F Mix Filter Yes No No No No Yes 
ED579 Acute A A1.11 27.6729 85.3215 S83F 11-Jul-07 16 M Well Filter Yes No No No No Yes 
ED624 Acute A A1.11 27.68061 85.32708 S83F 10-Aug-07 20 M Municipal  Chlorine Yes Yes Yes Yes No Yes 
ED632 Acute A A1 27.67006 85.32481 S83F 20-Aug-07 33 M Municipal  Filter Yes Yes No No No Yes 
ED646 Acute A A1.1 27.6724 85.32131 S83F 5-Sep-07 11 M Well Boil Yes No No No No Yes 
ED805 Acute A A1.11 27.66795 85.29868 S83F 2-Jun-08 20 F Municipal  Untreated Yes No No No No Yes 
ED849 Acute A A1.4 27.67208 85.30555 S83F 22-Jul-08 15 F Stone spout Mix Yes No Yes No No Yes 
GB113 Carrier C C 27.13393 85.15166 WT 17-Jan-08 45 F         
GB193 Carrier A A2 27.699308 85.290304 WT 10-Mar-08 43 F         
GB214 Carrier F F 27.67391 85.3218 WT 24-Mar-08 38 F         
GB224 Carrier C C 27.67391 85.3218 WT 27-Mar-08 42 F         
GB245 Carrier A A1.11 27.13733 85.00836 S83F 11-Apr-08 33 F         
GB280 Carrier A A1 27.15806 85.15575 S83F 4-May-08 34 F         
GB493 Carrier A A1 27.670389 85.437631 S83F 3-Oct-08           
GB58 Carrier A A1.10 27.672926 85.428279 S83F 20-Dec-07 28 M         
GB624 Carrier A A1 27.69179 85.342969 WT 9-Jan-09 33 F         
GB625 Carrier A A1.3 27.678325 85.316358 S83F 16-Jan-09 57 M         
GB63 Carrier A A1.7 27.693811 85.218566 S83F 21-Dec-07 35 F         
GB637 Carrier C C 27.693335 85.281691 S83F 23-Jan-09 24 F         
GB640 Carrier A A2 27.720193 85.329767 S83F 30-Jan-09 18 M         
GB672 Carrier A A2 27.621328 85.302213 N/A 25-Mar-09 31 F         
GB726 Carrier A A2 27.67076 85.32031 S83Y 9-Apr-09 44 F         
GB20 Carrier A A1 27.665874 85.328512 S83F 12-Jun-09 40 F         
GB75 Carrier A A1.7 27.00845 85.13981 S83F 19-Jun-09 49 M         
SPA010 Acute A A1.11 27.6779 85.31366 S83F 4-Oct-11 22 F Municipal  Untreated Yes Yes No No No Yes 
SPA014 Acute A A1.1 27.67681 85.31805 S83F 4-Nov-11 28 F Municipal  Mix Yes Yes No No No Yes 
SPA015 Acute A A1.11 27.66745 85.30191 S83F 13-Apr-11 15 F Municipal  Mix No No Yes No No Yes 
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SPA017 Acute A A2.1 27.67895 85.32656 S83F 15-Apr-11 19 M Stone spout Mix Yes No No No No Yes 
SPA018 Acute A A1.1 27.6671 85.3055 S83F 20-Apr-11 9 M Municipal  Untreated Yes Yes Yes No No Yes 
SPA019 Acute A A1.11 27.66545 85.32481 S83F 28-Apr-11 25 M Municipal  Filter No Yes No No No Yes 
SPA02 Acute A A2 27.66033 85.31735 S83F 21-Mar-11 17 M Municipal  Filter No No Yes No No Yes 
SPA020 Acute A A2 27.67618 85.34698 S83F 28-Apr-11 18 M Bottled Filter No No No No No Yes 
SPA021 Acute A A2 27.65503 85.3199 S83F 5-May-11 24 F Bottled Mix No Yes No No No Yes 
SPA023 Acute A A1.1 27.69058 85.31155 S83F 5-Mar-11 20 M Bottled Filter Yes No No No No Yes 
SPA024 Acute A A2 27.67995 85.3481 S83F 5-May-11 15 M Well Filter Yes No No No No Yes 
SPA025 Acute A A1.11 27.6573 85.3115 S83F 5-Aug-11 9 F Bottled Filter No Yes No No No Yes 
SPA026 Acute A A2 27.66845 85.34206 S83F 15-May-11 22 M Bottled Untreated No No No No No Yes 
SPA028 Acute A A1.2 27.6661 85.3171 S83F 22-May-11 10 M Municipal  Filter No Yes Yes No Yes Yes 
SPA029 Acute A A2 27.67298 85.31961 S83F 20-May-11 18 M Municipal  Filter Yes Yes Yes No No Yes 
SPA030 Acute A A1.2 27.66778 85.3242 S83F 22-May-11 20 M Municipal  Boil No Yes Yes No No Yes 
SPA032 Acute A A1.11 27.69856 85.31235 S83F 26-May-11 23 F Municipal  Filter Yes No No No No Yes 
SPA033 Acute A A1.11 27.67223 85.03216 S83F 24-May-11 20 M Municipal  Filter No No No No No Yes 
SPA034 Acute A A2 27.67246 85.322 S83F 26-May-11 22 M Municipal  Filter Yes No No No No Yes 
SPA037 Acute A A2 27.67661 85.32435 S83F 30-May-11 8 M Stone spout Untreated No No No No No No 
SPA038 Acute A A2 27.67661 85.32435 S83F 30-May-11 5 M Stone spout Untreated Yes No Yes No No Yes 
SPA042 Acute A A1.2 27.67038 85.32515 S83F 6-Jun-11 16 M Municipal  Filter Yes No No No No Yes 
SPA046 Acute A A2 27.67661 85.32435 S83F 14-Jun-11 6 F Stone spout Untreated Yes No No No No No 
SPA047 Acute A A2 27.67758 85.32498 S83F 19-Jun-11 21 M Municipal  Filter Yes Yes Yes Yes No Yes 
SPA048 Acute A A1.11 27.67373 85.31835 S83F 20-Jun-11 25 M Municipal  Filter No No Yes No No Yes 
SPA052 Acute A A2 27.67781 85.32286 S83F 7-Oct-11 7 M Municipal  Boil No No No No No No 
SPA053 Acute A A1.1 27.68108 85.32763 S83F 14-Jul-11 25 M Mix Untreated Yes Yes No No Yes Yes 
SPA055 Acute A A2 27.67088 85.33695 S83F 18-Jul-11 8 M Municipal  Filter Yes No No No No Yes 
SPA056 Acute A A2 27.66813 85.30933 S83F 17-Jul-11 8 F Municipal  Untreated Yes Yes Yes No No Yes 
SPA057 Acute A A2.1 27.67536 85.34578 S83F 22-Jul-11 55 M Mix Filter Yes Yes No Yes No Yes 
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SPA058 Acute A A1.1 27.6792 85.34925 S83F 22-Jul-11 24 F Mix Untreated Yes Yes No No No Yes 
SPA06 Acute A A1.2 27.68125 85.30543 S83F 3-Mar-11 20 F Well Filter Yes No No No No Yes 
SPA062 Acute A A2.1 27.65415 85.32045 S83F 24-Jul-11 10 M Municipal  Boil Yes No No Yes No No 
SPA063 Acute A A2 27.66641 85.34001 S83F 24-Jul-11 18 M Bottled Filter Yes No No No No Yes 
SPA064 Acute A A2.1 27.65408 85.32073 S83F 25-Jul-11 25 M Mix Untreated Yes Yes No No No Yes 
SPA07 Acute A A2 27.68031 85.3365 S83F 3-Mar-11 18 M Bottled Filter Yes No No No No Yes 
SPA072 Acute A A2.1 27.65323 85.3214 S83F 8-Feb-11 19 M Municipal  Untreated No No No No No Yes 
SPA076 Acute A A2 27.65968 85.31146 S83F 8-Jul-11 6 M Municipal  Filter No No Yes Yes No Yes 
SPA077 Acute A A1.5 27.66098 85.30935 S83F 14-Aug-11 7 M Municipal  Filter Yes Yes Yes No No Yes 
SPA078 Acute A A2.1 27.65855 85.32275 S83F 14-Aug-11 10 M Municipal  Filter Yes No No No No Yes 
SPA079 Acute C C 27.64206 85.33405 S83F 15-Aug-11 33 M Municipal  Filter Yes Yes Yes Yes No Yes 
SPA082 Acute A A2 27.66486 85.33193 S83F 17-Aug-11 21 M Bottled Filter No No No No No Yes 
SPA085 Acute A A2.1 27.65855 85.32275 S83F 15-Aug-11 21 F Municipal  Untreated Yes Yes No No No Yes 
SPA086 Acute A A2.1 27.65051 85.32133 S83F 25-Aug-11 10 M Municipal  Mix Yes No No No No Yes 
SPA09 Acute A A1.2 27.6666 85.3295 S83F 4-Nov-11 9 M Municipal  Filter Yes Yes No No No Yes 
SPA096 Acute A A2.1 27.65415 85.31986 S83F 9-Sep-11 12 F Municipal  Mix Yes Yes Yes No No Yes 
SPA098 Acute A A2.1 27.65886 85.3134 S83F 13-Sep-11 25 F Municipal  Filter Yes Yes Yes No No Yes 
SPA100 Acute A A2 27.67816 85.32581 S83F 15-Sep-11 25 F Municipal  Untreated No Yes Yes No No Yes 
SPA102 Acute A A2 27.68808 85.31613 S83F 23-Sep-11 11 F Municipal  Mix Yes Yes No No No Yes 
TY018 Acute A A2 27.6762 85.32461 S83F 6-Aug-08 18 M Stone spout Untreated No Yes No No No Yes 
TY035 Acute A A1.3 27.66776 85.3051 S83F 4-Sep-08 17 M Stone spout Untreated Yes Yes Yes No Yes Yes 
TY037 Acute A A1.11 27.66083 85.32318 S83F 7-Sep-08 5 M Municipal  Filter Yes No Yes No Yes Yes 
TY051 Acute A A1.11 27.67546 85.29706 S83F 31-Oct-08 14 F Municipal  Filter Yes Yes No No No Yes 
02TY004 Acute A A2 27.68808 85.31613 S83F 23/9/2011 11 F Municipal  Boil Yes Yes Yes No No Yes 
02TY013 Acute A A2.1 27.66751 85.32836 S83F 25/12/2011 22 M Stone sprout Filter No No No No No Yes 
02TY036 Acute A A2.1 27.66438 85.30686 S83F 22/4/2012 30 M Municipal  Untreated Yes Yes No Yes No Yes 
02TY041 Acute A A2 27.68046 85.33966 S83F 29/4/2012 23 F Municipal  Filter Yes Yes No Yes No Yes 
  207 
02TY044 Acute A A2 27.68915 85.32486 S83F 8/5/12 4 M Municipal  Filter Yes No Yes No No No 
02TY046 Acute A A2 27.68053 85.33798 S83F 9/5/12 32 M Municipal  Boil No No No No Yes Yes 
02TY049 Acute A A2.1 27.67411 85.32641 S83F 15/5/2012 16 M Bottled Untreated YesYes No YesYes No No Yes 
02TY052 Acute A A2.1 27.66096 85.31985 S83F 17/5/2012 21 M Municipal  Filter Yes Yes No Yes No Yes 
02TY053 Acute A A2 27.66735 85.31911 S83F 22/5/2012 12 M Municipal  Boil Yes No No No No No 
02TY062 Acute A A2 27.68858 85.32641 S83F 10/6/12 22 M Bottled Untreated No Yes No No No Yes 
02TY063 Acute A A2 27.68858 85.32641 S83F 10/6/12 19 M Bottled Untreated Yes Yes No No No No 
02TY067 Acute A A1.9 27.68263 85.3381 S83F 14/6/2012 24 M Bottled Boil No No Yes No Yes Yes 
02TY068 Acute A A2 27.693 85.34703 S83F 15/6/2012 24 M Bottled Untreated Yes No No No No Yes 
02TY072 Acute A A2.1 27.67253 85.3352 S83F 18/6/2012 21 M Bottled Untreated No No No No No Yes 
02TY074 Acute A A2 27.68193 85.32373 S83F 18/6/2012 22 M Municipal  Filter Yes No No No No Yes 
02TY075 Acute A A2 27.67121 85.3166 S83F 11/7/12 24 M Municipal  Boil Yes Yes No No Yes Yes 
02TY076 Acute A A2.1 27.66033 85.33945 S83F 12/7/12 12 F Municipal  Filter Yes No No No No No 
02TY077 Acute A A2 27.6673 85.34081 S83F 13/7/2012 12 F Municipal  Filter Yes No No No No Yes 
02TY081 Acute A A2 27.67988 85.33608 S83F 22/7/2012 22 M Well Boil No Yes No No No Yes 
02TY084 Acute A A2 27.68456 85.34125 S83F 30/7/2012 15 F Municipal  Filter Yes No Yes No No Yes 
02TY085 Acute A A2 27.67305 85.33271 S83F 2/8/12 13 M Tanker Untreated Yes Yes Yes No No Yes 
02TY086 Acute A A2 27.6698 85.3161 S83F 5/8/12 10 M Municipal  Untreated Yes No No No No Yes 
02TY091 Acute A A2 27.67656 85.32735 S83F 19/8/2012 27 M Stone sprout Filter Yes No No No No Yes 
02TY094 Acute A A2 27.68203 85.34038 S83F 21/8/2012 19 M Bottled Untreated Yes  No No Yes Yes 
02TY100 Acute A A2 27.68236 85.31561 S83F 5/9/12 9 M Tanker Filter Yes Yes Yes No Yes Yes 
02TY101 Acute A A2.1 27.67696 85.32135 S83F 1/11/12 14 M Municipal  Filter No No No No No Yes 
02TY109 Acute A A2 27.66198 85.30661 S83F 8/9/12 10 M Municipal  Filter Yes Yes No No Yes Yes 
02TY129 Acute A A2.1 27.65771 85.31621 S83F 16/04/2013 6 M Municipal  Untreated Yes No No No No Yes 
02TY152 Acute A A2 27.69551 85.33811 S83F 4/6/13 35 M Municipal  Boil No No No No Yes Yes 
02TY153 Acute A A2 27.69343 85.34256 S83F 4/6/13 20 M Municipal  Untreated Yes No No No No Yes 
02TY155 Acute A A2 27.69343 85.34256 S83F 16/06/2013 18 M Municipal  Untreated Yes Yes Yes Yes No Yes 
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02TY180 Acute C C 27.66913 85.32658 S83F 14/08/2013 10 F Municipal  Filter No No No Yes No Yes 
02TY187 Acute A A2.1 27.68955 85.33551 S83F 28/88/2013 25 M Bottled Untreated Yes No No No No Yes 
02TY212 Acute A A2 27.68063 85.31225 S83F 12/1/14 34 M Municipal  Untreated No No No No No Yes 
02TY215 Acute A A2.1 27.66568 85.32441 S83F 29/01/2014 32 M Municipal  Filter No Yes No No Yes Yes 
02TY221 Acute A A2 27.67211 85.31981 S83F 31/03/2014 24 M Municipal  Filter Yes Yes No No No Yes 
02TY223 Acute A A2 27.69096 85.33345 S83F 4/3/14 17 M Municipal  Filter No No No Yes No Yes 
02TY224 Acute A A1.1 27.69075 85.3488 S83F 17/03/2014 27 M Stone sprout Filter No No No No No Yes 
02TY231 Acute A A2 27.66741 85.35096 S83F 1/5/14 18 M Bottled Untreated Yes No Yes No Yes Yes 
02TY242 Acute A A2.1 27.68543 85.3415 S83F 16/06/2014 15 F Municipal  Filter No No No No No Yes 
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Appendix C Salmonella Typhi isolates and their corresponding metadata in chapter 5  
 
ID 
 
Age_
years Sex Year Province District Commune Longtitude Latitude Lineages Sublineages 
IncH1 
plasmid AMP CHL SXT Na 
AZI_MI
C 
CIP_
MIC Acc No 
1 9.3 F 2007 Siem Reap Siem Reab Sala Kamraeuk 103.867133 13.345557 I I 0 S S S I 8 0.094 ERR340759 
2 13.6 F 2010 Siem Reap Angkor Chum 
Nokor 
Pheas 103.719479 13.624206 II II 1 R R R S 12 0.016 ERR360845 
3 14.8 M 2007 Siem Reap Angkor Chum Ta Saom 103.677526 13.671199 II II 1 R R R S 8 0.012 ERR340758 
4 12.0 F 2007 Siem Reap Siem Reab Sala Kamraeuk 103.867133 13.345557 II II 0 S S S R 16 0.19 ERR340774 
5 7.1 F 2007 Banteaymeanchey O Chrauv Poipet 102.659645 13.642996 III IIIa 1 R R R R 8 0.19 ERR340760 
6 1.5 F 2011 Battambang Samlaut Chamlorng Kuoy 102.859385 12.583148 III IIIa 1 R R R 0 0 0 ERR360770 
7 14.7 F 2012 Kampong Cham Cheung Prey 
Khnaor 
Dambang 105.014179 12.018816 III IIIa 1 R R R 0 0 0 ERR319473 
8 3.8 F 2011 Kampong Chhnang 
Kampong 
Chhnan Khsam 104.660713 12.279773 III IIIa 1 R R R 0 12 0.25 ERR319445 
9 12.7 M 2011 Kampong Thom Stoeng Sen Ou Kanthor 104.816132 12.667063 III IIIa 1 R R R 0 0 0 ERR360773 
10 13.7 M 2010 Kampong Thom Stoeng Sen Srayov 104.858972 12.59656 III IIIa 1 R R R R 12 0.25 ERR360952 
11 4.2 F 2009 Siem Reap Siem Reab Siem Reab 103.843962 13.277306 III IIIa 0 S S S R 12 0.25 ERR319416 
12 13.2 F 2011 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 III IIIa 0 S S S S 8 0.008 ERR319459 
13 #N/A #N/A 2010 
Banteaymea
nchey 
Preah Netr 
Preah Prasat 103.365501 13.457949 III IIIb 1 R R R R 12 0.38 ERR360754 
14 5.9 F 2010 Banteaymeanchey 
Preah Netr 
Preah Rohal 103.237876 13.593116 III IIIb 1 R R R R 16 0.38 ERR319425 
15 9.8 F 2010 Banteaymeanchey 
Preah Netr 
Preah Tuek Chour 103.369654 13.620483 III IIIb 1 R R R R 12 0.25 ERR360956 
16 11.7 F 2010 Siem Reap Angkor Chum 
Kouk 
Doung 103.792493 13.701174 III IIIb 1 R R R R 8 0.25 ERR319439 
17 8.1 M 2010 Siem Reap Banteay Srei Tbaeng 104.038638 13.552495 III IIIb 1 R R R R 12 0.25 ERR360846 
18 14.1 F 2010 Siem Reap Banteay Srei Tbaeng 104.038638 13.552495 III IIIb 1 R R R R 12 0.25 ERR319434 
19 4.6 M 2010 Siem Reap Kralanh Krouch Kor 103.587557 13.703525 III IIIb 1 R R R R 8 0.25 ERR319437 
20 13.3 F 2010 Siem Reap Kralanh Krouch Kor 103.587557 13.703525 III IIIb 1 R R R R 12 0.25 ERR319441 
21 12.2 F 2010 Siem Reap Prasat Bakong Bakong 103.991452 13.355008 III IIIb 1 R R R R 12 0.25 ERR319429 
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22 1.6 F 2012 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 III IIIb 0 S S S R 12 0.5 ERR360792 
23 1.3 F 2010 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 III IIIb 0 S S S R 0 0.5 ERR319423 
24 12.5 F 2010 Siem Reap Siem Reab Nokor Thum 103.889397 13.423837 III IIIb 1 R R R R 8 0.25 ERR319422 
25 10.2 M 2010 Siem Reap Siem Reab Siem Reab 103.843962 13.277306 III IIIb 1 R R R R 16 0.25 ERR319427 
26 7.8 M 2010 Siem Reap Siem Reab Siem Reab 103.843962 13.277306 III IIIb 0 S S S R 12 0.38 ERR319432 
27 7.4 M 2010 Siem Reap Svay Leu Boeng Mealea 104.280929 13.45211 III IIIb 0 R R R R 12 0.19 ERR319438 
28 10.7 M 2011 Banteaymeanchey 
Mongkol 
Borei Koy Maeng 103.101314 13.550598 III IIIc 1 R R R 0 0 0 ERR319463 
29 11.8 M 2011 Banteaymeanchey 
Preah Netr 
Preah Chob Veari 103.167669 13.66311 III IIIc 1 R R R 0 0 0 ERR319454 
30 7.9 F 2011 Banteaymeanchey 
Preah Netr 
Preah 
Phnum 
Lieb 103.297435 13.520053 III IIIc 1 R R R 0 0 0 ERR319466 
31 1.9 M 2011 Banteaymeanchey 
Preah Netr 
Preah 
Phnum 
Lieb 103.297435 13.520053 III IIIc 1 R R R 0 0 0 ERR319470 
32 7.1 M 2011 Battambang Phnom Preuk Pech Chenda 102.538466 13.268541 III IIIc 1 R R R 0 0 0 ERR360758 
33 12.3 F 2011 Siem Reap Angkor Chum 
Char 
Chhuk 103.623954 13.663726 III IIIc 0 S S S S 6 0.006 ERR319457 
34 5.1 F 2012 Siem Reap Chi Kreng Anlong Samnar 104.229051 12.94545 III IIIc 1 R R R R 12 0.38 ERR361000 
35 9.1 F 2011 Siem Reap Kralanh Chonloas Dai 103.46967 13.641287 III IIIc 1 R R R 0 0 0 ERR319458 
36 16.2 M 2011 Siem Reap Kralanh Kralanh 103.432035 13.55668 III IIIc 1 R R R 0 0 0 ERR319452 
37 7.7 M 2011 Siem Reap Puok Doun Kaev 103.774015 13.478241 III IIIc 1 R R R 0 0 0 ERR360766 
38 6.9 M 2011 Siem Reap Puok Kaev Poar 103.716096 13.321008 III IIIc 1 R R R R 12 0.38 ERR319460 
39 14.2 M 2011 Siem Reap Puok Prey Chruk 103.542856 13.503103 III IIIc 1 R R R 0 0 0 ERR319471 
40 5.6 M 2011 Siem Reap Puok Trei Nhoar 103.706054 13.574489 III IIIc 1 R R R 0 0 0 ERR360962 
41 11.2 F 2011 Siem Reap Puok Tuek Vil 103.807153 13.413196 III IIIc 1 R R R 0 12 0.38 ERR319446 
42 5.5 M 2011 Siem Reap Puok Yeang 103.624304 13.563253 III IIIc 1 R R R 0 12 0.38 ERR319448 
43 7.0 F 2012 Siem Reap Siem Reab Chong Khnies 103.829966 13.175937 III IIIc 1 R R R R 6 0.38 ERR360988 
44 8.7 F 2011 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 III IIIc 1 R R R R 12 0.5 ERR319447 
45 11.1 F 2009 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 III IIIc 0 S S S R 12 0.38 ERR360746 
46 5.7 M 2011 Siem Reap Sotr Nikom Popel 104.163519 13.39285 III IIIc 1 R R R 0 0 0 ERR319455 
47 5.1 F 2008 Banteaymeanchey O Chrauv Nimitt 102.659645 13.642996 IV IVa 0 S S S R 16 0.5 ERR360741 
  211 
48 14.1 F 2008 Oddar Meanchey Anlong Veng 
Anlong 
Veng 104.153127 14.240485 IV IVa 0 S S S R 12 0.38 ERR319410 
49 12.2 F 2008 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 IV IVa 0 S S S R 12 0.25 ERR340767 
50 9.1 F 2008 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 IV IVa 0 S S S S 8 0.008 ERR319411 
51 5.7 M 2008 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVa 1 R R R R 12 0.19 ERR360890 
52 8.5 M 2008 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVa 0 S R S R 16 0.5 ERR319406 
53 10.4 M 2010 Banteaymeanchey O Chrauv Changha 102.892727 13.647435 IV IV 1 R R R R 12 0.38 ERR360955 
54 13.2 M 2008 Banteaymeanchey 
Preah Netr 
Preah Prasat 103.365501 13.457949 IV IV 1 R R R R 12 0.38 ERR360742 
55 1.8 M 2008 Banteaymeanchey 
Preah Netr 
Preah Prasat 103.365501 13.457949 IV IV 1 R R R R 12 0.38 ERR360889 
56 5.5 F 2008 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IV 1 R R R R 16 0.25 ERR360743 
57 11.7 F 2009 Kampong Cham Chamkar Leu Bos Khnaor 105.335766 12.170203 IV IV 1 R R R R 16 0.5 ERR319415 
58 2.0 M 2007 Kampong Thom Stoung 
Banteay 
Stoung 104.6337 12.943935 IV IV 1 R R R R 12 0.5 ERR340757 
59 12.2 M 2008 Kampong Thom Stoeng Sen Achar Leak 104.903907 12.727871 IV IV 1 R R R R 12 0.5 ERR360950 
60 5.0 F 2007 Pursat Bakan Me Tuek 103.782131 12.803292 IV IV 1 R R R R 16 0.38 ERR340770 
61 4.5 M 2012 Pursat Bakan Me Tuek 103.782131 12.803292 IV IV 1 R R R R 0 0.38 ERR360999 
62 12.8 M 2008 Siem Reap Angkor Chum Srae Khvav 103.672335 13.793712 IV IV 1 R R R R 12 0.5 ERR360739 
63 6.0 F 2007 Siem Reap Chi Kreng Anlong Samnar 104.229051 12.94545 IV IV 1 R R R R 12 0.38 ERR340766 
64 13.0 F 2007 Siem Reap Chi Kreng Anlong Samnar 104.229051 12.94545 IV IV 1 R R R R 12 0.38 ERR340761 
65 11.9 M 2009 Siem Reap Chi Kreng Anlong Samnar 104.229051 12.94545 IV IV 1 R R R R 12 0.5 ERR319419 
66 14.8 M 2010 Siem Reap Chi Kreng Chi Kraeng 104.254404 13.074933 IV IV 0 S S S 0 12 0.5 ERR319431 
67 6.0 F 2007 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 12 0.38 ERR340772 
68 4.9 M 2008 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 12 0.38 ERR360738 
69 2.4 M 2008 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 12 0.38 ERR360740 
70 8.0 M 2008 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 16 0.38 ERR319405 
71 10.0 F 2008 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 16 0.5 ERR319409 
72 4.3 M 2009 Siem Reap Siem Reab Chong Khnies 103.829966 13.175937 IV IV 1 R R R R 0 0.25 ERR360744 
73 5.1 F 2008 Siem Reap Siem Reab Sambuor 103.7935 13.30069 IV IV 1 R R R R 12 0.38 ERR319403 
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74 15.2 F 2010 Siem Reap Siem Reab Srangae 103.776959 13.303244 IV IV 1 R R R R 8 0.38 ERR319428 
75 12.0 M 2007 Siem Reap Sotr Nikom Dan Run 104.087793 13.182907 IV IV 1 R R R R 12 0.38 ERR340768 
76 15.1 F 2008 Siem Reap Sotr Nikom Dan Run 104.087793 13.182907 IV IV 1 R R R R 12 0.38 ERR360948 
77 2.4 F 2007 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IV 1 R R R R 16 0.38 ERR340771 
78 4.5 F 2007 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IV 1 R R R R 12 0.38 ERR340773 
79 #N/A #N/A 2007 Siem Reap Sotr Nikom 
Kampong 
Khleang 104.142061 13.046753 IV IV 1 R R R R 12 0.5 ERR340775 
80 0.6 M 2007 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IV 1 R R R R 12 0.38 ERR340763 
81 3.2 F 2008 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IV 1 R R R R 16 0.38 ERR360891 
82 3.2 M 2008 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IV 1 R R R R 12 0.5 ERR319402 
83 6.1 M 2008 Banteaymeanchey 
Preah Netr 
Preah Prasat 103.365501 13.457949 IV IV 1 R R R R 16 0.38 ERR319404 
84 5.2 F 2010 Banteaymeanchey 
Preah Netr 
Preah Prasat 103.365501 13.457949 IV IV 1 NA NA NA NA NA NA ERR319433 
85 4.1 M 2009 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 16 0.38 ERR319412 
86 6.6 F 2009 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IV 1 R R R R 16 0.38 ERR319413 
87 14.7 M 2010 Banteaymeanchey 
Preah Netr 
Preah Tuek Chour 103.369654 13.620483 IV IVb 1 R R R R 16 0.5 ERR319426 
88 3.3 F 2010 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R R 8 0.38 ERR360748 
89 2.6 F 2011 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R 0 0 0 ERR360761 
90 5.6 F 2011 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R 0 0 0 ERR360772 
91 6.8 F 2008 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R R 16 0.38 ERR360949 
92 1.9 F 2009 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 0 S S S R 16 0.38 ERR319420 
93 1.2 M 2010 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R R 8 0.38 ERR319436 
94 4.1 M 2011 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R 0 0 0 ERR319469 
95 5.7 M 2008 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R R 12 0.5 ERR319408 
96 #N/A #N/A 2012 Battambang ek Phnum 
Kaoh 
Chiveang 103.610762 13.21135 IV IVb 1 NA NA NA NA NA NA ERR319476 
97 11.6 F 2012 Battambang ek Phnum Kaoh Chiveang 103.610762 13.21135 IV IVb 1 R R R R 0 0 ERR319484 
98 5.9 M 2011 Battambang ek Phnum Prey Chas 103.39292 13.304805 IV IVb 0 R R R 0 0 0 ERR360771 
99 12.1 M 2012 Preah Vihear Kulen Srayang 104.511339 13.76033 IV IVb 1 R R R 0 0 0 ERR319475 
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100 6.6 F 2012 Siem Reap Angkor Chum 
Nokor 
Pheas 103.719479 13.624206 IV IVb 0 S S S 0 0 0 ERR360964 
101 12.7 M 2012 Siem Reap Chi Kreng Chi Kraeng 104.254404 13.074933 IV IVb 1 R R R R 0 0.38 ERR360993 
102 5.3 M 2009 Siem Reap Kralanh Sambuor 103.445813 13.433224 IV IVb 1 R R R R 12 0.38 ERR319417 
103 4.1 M 2011 Siem Reap Prasat Bakong 
Kampong 
Phluk 103.986709 13.235758 IV IVb 1 R R R 0 0 0 ERR360769 
104 4.6 M 2011 Siem Reap Prasat Bakong 
Kampong 
Phluk 103.986709 13.235758 IV IVb 1 R R R 0 0 0 ERR319467 
105 5.2 M 2009 Siem Reap Puok Kaev Poar 103.716096 13.321008 IV IVb 1 R R R R 8 0.38 ERR319421 
106 14.2 F 2010 Siem Reap Puok Kaev Poar 103.716096 13.321008 IV IVb 1 R R R 0 0 0 ERR319440 
107 12.2 M 2010 Siem Reap Puok Lvea 103.659697 13.416587 IV IVb 1 R R R R 12 0.38 ERR319424 
108 13.0 M 2012 Siem Reap Puok Pou Treay 103.53096 13.374667 IV IVb 1 R R R R 0 0.38 ERR360997 
109 8.1 M 2011 Banteaymeanchey 
Serei 
Saophonj Mkak 102.965143 13.674269 IV IVc 1 R R R 0 0 0 ERR360760 
110 8.5 M 2012 Banteaymeanchey 
Serei 
Saophonj 
Preah 
Ponlea 102.990584 13.579188 IV IVc 1 R R R R 0 0.38 ERR360787 
111 10.3 M 2012 Kampong Thom 
Kampong 
Svay 
Kampong 
Svay 104.980724 12.761543 IV IVc 1 R R R 0 0 0 ERR319472 
112 4.0 M 2012 Oddar Meanchey Chong Kal Pongro 103.611356 14.057113 IV IVc 1 R R R R 0 0.38 ERR360782 
113 7.9 M 2012 Oddar Meanchey Samraong Osmach 103.662372 14.270904 IV IVc 1 R R R R 0 0.38 ERR360972 
114 8.3 F 2012 Oddar Meanchey Samraong Osmach 103.662372 14.270904 IV IVc 0 R R R R 0 0.38 ERR360987 
115 10.1 M 2012 Oddar Meanchey Samraong Osmach 103.662372 14.270904 IV IVc 1 R R R R 0 0.25 ERR319495 
116 8.5 F 2011 Oddar Meanchey Samraong Samraong 103.543846 14.154499 IV IVc 1 R R R 0 0 0 ERR360765 
117 5.3 M 2011 Preah Vihear Choam Ksant Kantuot 104.6417 14.280355 IV IVc 1 R R R 0 0 0 ERR360756 
118 12.2 F 2012 Preah Vihear Kulen Srayang 104.511339 13.76033 IV IVc 1 R R R R 0 0.25 ERR360986 
119 9.9 F 2012 Siem Reap Angkor Chum 
Char 
Chhuk 103.623954 13.663726 IV IVc 1 R R R 0 0 0 ERR360779 
120 13.0 F 2012 Siem Reap Angkor Chum 
Char 
Chhuk 103.623954 13.663726 IV IVc 1 R R R R 0 0.38 ERR360981 
121 9.6 F 2011 Siem Reap Angkor Chum 
Char 
Chhuk 103.623954 13.663726 IV IVc 1 R R R 0 0 0 ERR319465 
122 9.1 F 2011 Siem Reap Angkor Chum 
Kouk 
Doung 103.792493 13.701174 IV IVc 1 R R R 0 0 0 ERR319464 
123 10.3 M 2011 Siem Reap Angkor Chum 
Nokor 
Pheas 103.719479 13.624206 IV IVc 1 R R R R 0 0.38 ERR360762 
124 6.8 F 2012 Siem Reap Angkor Chum Ta Saom 103.677526 13.671199 IV IVc 1 R R R R 0 0 ERR360973 
125 1.5 M 2012 Siem Reap Angkor Chum Ta Saom 103.677526 13.671199 IV IVc 1 R R R R 0 0 ERR360977 
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126 6.7 M 2012 Siem Reap Angkor Chum Ta Saom 103.677526 13.671199 IV IVc 1 R R R R 0 0.38 ERR319486 
127 12.3 M 2012 Siem Reap Angkor Chum Ta Saom 103.677526 13.671199 IV IVc 1 R R R R 0 0.38 ERR319487 
128 12.3 M 2012 Siem Reap Angkor Thum Leang Dai 103.876266 13.502826 IV IVc 1 R R R R 0 0.25 ERR360775 
129 12.9 F 2012 Siem Reap Angkor Thum Leang Dai 103.876266 13.502826 IV IVc 1 R R R R 0 0.38 ERR360979 
130 1.8 M 2010 Siem Reap Angkor Thum 
Peak 
Snaeng 103.885243 13.610438 IV IVc 1 R R R R 8 0.25 ERR319435 
131 4.7 M 2012 Siem Reap Banteay Srei Khnar Sanday 103.952295 13.569677 IV IVc 1 R R R R 0 0.38 ERR360966 
132 3.9 M 2012 Siem Reap Banteay Srei Khun Ream 104.032137 13.668959 IV IVc 1 R R R R 0 0.25 ERR360778 
133 9.3 F 2012 Siem Reap Banteay Srei Khun Ream 104.032137 13.668959 IV IVc 1 R R R R 0 0 ERR360982 
134 11.3 M 2012 Siem Reap Banteay Srei Khun Ream 104.032137 13.668959 IV IVc 1 R R R R 0 0.25 ERR319494 
135 2.0 F 2012 Siem Reap Banteay Srei Rumchek 103.981952 13.508645 IV IVc 1 R R R R 0 0.38 ERR360783 
136 13.1 M 2011 Siem Reap Banteay Srei Run Ta Aek 104.039073 13.465833 IV IVc 1 R R R 0 12 0.38 ERR319444 
137 13.0 F 2012 Siem Reap Banteay Srei Run Ta Aek 104.039073 13.465833 IV IVc 1 R R R R 0 0 ERR319479 
138 10.0 F 2012 Siem Reap Banteay Srei Tbaeng 104.038638 13.552495 IV IVc 1 R R R R 0 0.38 ERR360992 
139 3.8 F 2010 Siem Reap Chi Kreng Anlong Samnar 104.229051 12.94545 IV IVc 1 R R R R 0 0.25 ERR360959 
140 15.4 M 2012 Siem Reap Chi Kreng Ruessei Lok 104.227712 13.251327 IV IVc 1 R R R R 0 0 ERR319482 
141 14.2 F 2012 Siem Reap Kralanh Chonloas Dai 103.46967 13.641287 IV IVc 1 R R R R 0 0.38 ERR360965 
142 #N/A #N/A 2009 Siem Reap 
Prasat 
Bakong Kandaek 103.931669 13.299934 IV IVc 1 R R R R 0 0.38 ERR360745 
143 7.8 F 2012 Siem Reap Prasat Bakong Kandaek 103.931669 13.299934 IV IVc 1 R R R R 0 0 ERR360781 
144 6.6 F 2012 Siem Reap Prasat Bakong Kandaek 103.931669 13.299934 IV IVc 1 NA NA NA NA NA NA ERR360968 
145 7.0 F 2012 Siem Reap Prasat Bakong Kandaek 103.931669 13.299934 IV IVc 1 R R R R 0 0.19 ERR319485 
146 13.4 M 2012 Siem Reap Prasat Bakong Kantreang 104.03968 13.347416 IV IVc 1 R R R R 0 0.25 ERR360990 
147 9.0 F 2011 Siem Reap Prasat Bakong Roluos 103.98127 13.310897 IV IVc 1 R R R 0 0 0 ERR360759 
148 5.8 F 2011 Siem Reap Puok Reul 103.73586 13.536268 IV IVc 1 R R R 0 0 0 ERR319453 
149 3.0 F 2012 Siem Reap Puok Samraong Yea 103.69054 13.361494 IV IVc 1 R R R R 0 0.38 ERR360984 
150 11.8 F 2009 Siem Reap Puok Sasar Sdam 103.630882 13.509808 IV IVc 1 R R R R 12 0.38 ERR319414 
151 10.9 M 2012 Siem Reap Puok Trei Nhoar 103.706054 13.574489 IV IVc 1 R R R R 0 0.25 ERR331208 
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152 10.9 F 2012 Siem Reap Puok Trei Nhoar 103.706054 13.574489 IV IVc 1 R R R R 0 0.25 ERR360788 
153 5.9 F 2012 Siem Reap Puok Trei Nhoar 103.706054 13.574489 IV IVc 1 R R R R 0 0.38 ERR360776 
154 11.5 M 2012 Siem Reap Puok Trei Nhoar 103.706054 13.574489 IV IVc 1 R R R R 0 0.38 ERR360998 
155 9.3 F 2012 Siem Reap Siem Reab Chreav 103.888751 13.283577 IV IVc 1 R R R R 0 0.38 ERR360777 
156 8.2 F 2011 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 IV IVc 1 R R R 0 0 0 ERR360763 
157 1.6 M 2012 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 IV IVc 1 R R R R 0 0 ERR360971 
158 6.7 M 2012 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 IV IVc 1 R R R R 0 0.38 ERR319483 
159 9.0 M 2012 Siem Reap Siem Reab Nokor Thum 103.889397 13.423837 IV IVc 1 R R R R 0 0.38 ERR360976 
160 7.2 F 2012 Siem Reap Siem Reab Sala Kamraeuk 103.867133 13.345557 IV IVc 0 R R R R 0 0.38 ERR360791 
161 9.8 F 2012 Siem Reap Siem Reab Sambuor 103.7935 13.30069 IV IVc 1 R R R R 0 0.25 ERR360963 
162 10.4 F 2011 Siem Reap Siem Reab Sambuor 103.7935 13.30069 IV IVc 1 R R R 0 0 0 ERR319461 
163 11.0 M 2012 Siem Reap Siem Reab Siem Reab 103.843962 13.277306 IV IVc 1 R R R R 0 0.25 ERR360991 
164 15.7 F 2012 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 IV IVc 1 R R R R 0 0.38 ERR360789 
165 3.7 F 2010 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 IV IVc 1 R R R R 12 0.25 ERR360847 
166 1.7 F 2010 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 IV IVc 1 R R R R 12 0.38 ERR360848 
167 6.3 M 2010 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 IV IVc 1 R R R 0 12 0.25 ERR360960 
168 11.4 M 2012 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 IV IVc 0 S S S 0 0 0 ERR360970 
169 6.4 F 2012 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVc 1 R R R R 0 0.25 ERR331205 
170 2.9 F 2012 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVc 1 R R R R 0 0 ERR360780 
171 14.1 M 2012 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVc 1 R R R R 0 0.25 ERR360785 
172 6.2 F 2012 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVc 1 R R R R 0 0.38 ERR360983 
173 14.1 M 2012 Siem Reap Siem Reab Svay Dangkum 103.822374 13.311014 IV IVc 1 R R R R 0 0.25 ERR319489 
174 13.2 F 2012 Siem Reap Soth Nikom Dam Daek 104.120345 13.255388 IV IVc 1 R R R R 0 0.19 ERR360967 
175 11.6 F 2012 Siem Reap Soth Nikom Dam Daek 104.120345 13.255388 IV IVc 1 R R R R 0 0.25 ERR360975 
176 15.1 F 2012 Siem Reap Soth Nikom Dan Run 104.087793 13.182907 IV IVc 1 R R R R 0 0.25 ERR331206 
177 3.8 F 2012 Siem Reap Soth Nikom Dan Run 104.087793 13.182907 IV IVc 1 R R R R 0 0.38 ERR360786 
178 6.4 M 2010 Siem Reap Sotr Nikom Dan Run 104.087793 13.182907 IV IVc 1 S R S R 12 0.25 ERR360954 
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179 10.0 M 2011 Siem Reap Soth Nikom Dan Run 104.087793 13.182907 IV IVc 1 R R R 0 0 0 ERR319456 
180 4.0 M 2011 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 0 0 ERR360755 
181 7.6 M 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0.38 ERR360774 
182 8.6 F 2010 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 0 0 ERR360958 
183 2.2 F 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 0 0 ERR360961 
184 3.0 F 2012 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 0 0 ERR360980 
185 #N/A #N/A 2012 Siem Reap Soth Nikom 
Kampong 
Khleang 104.142061 13.046753 IV IVc 1 NA NA NA NA NA NA ERR360985 
186 4.8 F 2012 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 NA NA NA NA NA NA ERR360994 
187 9.3 M 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 0 0 ERR319442 
188 5.1 F 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 12 0.38 ERR319443 
189 2.0 F 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0 ERR319449 
190 5.7 M 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 12 0.38 ERR319450 
191 7.0 M 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 12 0.38 ERR319451 
192 7.4 M 2011 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R 0 0 0 ERR319468 
193 11.8 F 2012 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0.38 ERR319474 
194 7.7 M 2012 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0 ERR319477 
195 3.8 M 2012 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0 ERR319480 
196 10.4 M 2012 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0 ERR319481 
197 12.9 F 2012 Siem Reap Soth Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0 ERR319490 
198 6.5 M 2012 Siem Reap Sotr Nikom Kampong Khleang 104.142061 13.046753 IV IVc 1 R R R R 0 0 ERR319492 
199 9.5 M 2012 Siem Reap Sotr Nikom Khchas 104.06283 13.254239 IV IVc 1 R R R R 0 0.38 ERR360996 
200 4.8 F 2012 Siem Reap Sotr Nikom Khnar Pou 104.089546 13.423928 IV IVc 1 R R R R 0 0.38 ERR331207 
201 7.0 M 2012 Siem Reap Soth Nikom Khnar Pou 104.089546 13.423928 IV IVc 0 R R R R 0 0 ERR319488 
202 3.1 F 2012 Siem Reap Soth Nikom Kien Sangkae 104.160906 13.208966 IV IVc 1 R R R R 0 0.25 ERR360978 
203 10.8 F 2012 Siem Reap Varin Lvea Krang 103.912669 13.900364 IV IVc 1 R R R R 0 0 ERR319478 
204 8.7 F 2010 Banteaymeanchey O Chrauv Nimitt 102.659645 13.642996 
non_H5
8 non_H58 0 S S S S 6 0.006 ERR360747 
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205 11.1 F 2007 Siem Reap Angkor Chum 
Char 
Chhuk 103.623954 13.663726 
non_H5
8 non_H58 1 R R R R 0 0.25 ERR340765 
206 7.7 F 2012 Siem Reap Angkor Chum 
Doun 
Peaeng 103.705808 13.728858 
non_H5
8 non_H58 0 S S S S 0 0.006 ERR360995 
207 7.6 F 2011 Siem Reap Puok Sasar Sdam 103.630882 13.509808 non_H58 non_H58 0 S S S 0 0 0 ERR319462 
208 3.8 M 2009 Siem Reap Siem Reab Kouk Chak 103.841705 13.429301 non_H58 non_H58 0 S S S R 0 0.25 ERR319418 
209 8.4 F 2007 Siem Reap Siem Reab Sla Kram 103.885703 13.367605 non_H58 non_H58 1 R R R R 0 0.38 ERR340769 
210 12.3 F 2014 Siem Reap Prasat Bak™ng Ampil 103.9468022 13.39642561           
211 9.4 F 2013 Siem Reap Chi Kr病ng Anlong Samnar 104.2274314 12.94743614           
212 5.2 F 2013 Siem Reap Chi Kr病ng Anlong Samnar 104.2274314 12.94743614           
213 6.2 M 2013 Siem Reap Chi Kr病ng Anlong Samnar 104.2274314 12.94743614           
214 2.2 M 2013 Siem Reap Chi Kr病ng Anlong Samnar 104.2274314 12.94743614           
215 4.8 M 2013 Siem Reap Chi Kr病ng Anlong Samnar 104.2274314 12.94743614           
216 9.6 M 2014 Siem Reap Prasat Bak™ng Bakong 103.9894232 13.35739817           
217 11.0 M 2014 Siem Reap Sotr Nik™m Chan Sar 104.1103659 13.37891805           
218 0.3 F 2014 Banteay Meanchey 
Preah NŽtr 
Preah Chob Veari 103.1649315 13.66601257           
219 6.6 M 2013 Siem Reap Siem RŽab Chong Knies 103.8401794 13.25630554           
220 1.3 F 2014 Siem Reap Siem RŽab Chong Knies 103.8401794 13.25630554           
221 12.3 M 2013 Siem Reap Srei Sn‰m 
Chrouy 
Neang 
Nguon 
103.5517513 13.8336277           
222 8.3 M 2014 Siem Reap Soth Nikom Dam Daek 104.1184591 13.25764664           
223 10.3 M 2013 Siem Reap Soth Nikom Dan Run 104.0859347 13.18512897           
224 10.7 F 2014 Siem Reap Soth Nikom Dan Run 104.0859347 13.18512897           
225 10.0 F 2014 Siem Reap Soth Nikom Dan Run 104.0859347 13.18512897           
226 10.7 M 2014 Kampong Thom Stoung 
Kampong 
Chen 
Tboung 
104.5560628 12.93187723           
227 1.2 M 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
228 7.2 F 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
229 1.4 M 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
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230 2.7 M 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
231 4.7 F 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
232 6.9 F 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
233 1.9 F 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
234 6.5 F 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
235 7.9 F 2013 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
236 2.6 F 2014 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
237 8.4 M 2014 Siem Reap Soth Nikom Kampong Khleang 104.1403332 13.04884688           
238 11.9 F 2014 Siem Reap Sotr Nik™m Kampong Khleang 104.1403332 13.04884688           
239 14.1 M 2014 Siem Reap Prasat Bak™ng Kandaek 103.9296375 13.30229341           
240 10.4 M 2014 Siem Reap Prasat Bak™ng Kandaek 103.9296375 13.30229341           
241 7.7 F 2014 Siem Reap Prasat Bak™ng Kandaek 103.9296375 13.30229341           
242 9.1 F 2013 Battambang æk Phnum Kaoh Chiveang 103.5919063 13.21889273           
243 1.7 F 2013 Battambang æk Phnum Kaoh Chiveang 103.5919063 13.21889273           
244 12.3 F 2013 Battambang æk Phnum Kaoh Chiveang 103.5919063 13.21889273           
245 1.7 F 2013 Battambang æk Phnum Kaoh Chiveang 103.5919063 13.21889273           
246 3.0 F 2014 Battambang æk Phnum Kaoh Chiveang 103.5919063 13.21889273           
247 7.7 M 2014 Siem Reap Sotr Nik™m Khchas 104.0609096 13.25652359           
248 12.0 F 2014 Siem Reap Sotr Nik™m Khchas 104.0609096 13.25652359           
249 11.4 F 2014 Siem Reap Svay Leu Khnang Phnum 104.1521159 13.55969797           
250 6.2 M 2014 Siem Reap Sotr Nik™m Kien Sangkae 104.1590757 13.21118358           
251 8.6 F 2014 Siem Reap Siem RŽab Kouk Chak 103.8395359 13.43179055           
252 4.2 M 2014 Siem Reap Siem RŽab Kouk Chak 103.8395359 13.43179055           
253 12.4 F 2014 Siem Reap Siem RŽab Kouk Chak 103.8395359 13.43179055           
254 13.0 M 2014 Siem Reap ångk™r Chum 
Kouk 
Doung 103.790108 13.7038741           
255 12.0 F 2014 Siem Reap Puok Lvea 103.6574108 13.41912907           
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256 9.0 M 2014 Banteay Meanchey O Chrauv Poipet 102.659645 13.642996           
257 13.0 F 2013 Siem Reap Sotr Nik™m Popel 104.1615677 13.3951848           
258 14.3 M 2014 Siem Reap Sotr Nik™m Popel 104.1615677 13.3951848           
259 5.5 F 2014 Siem Reap Puok Pou Treay 103.5286413 13.37723486           
260 7.8 F 2014 Battambang Battambang 
Preaek 
Preah 
Sdach 
103.2117684 13.08410463           
261 0.0 F 2014 Preah Vihear R™vieng Robieb 105.0841422 13.38869225           
262 11.2 M 2013 Battambang Battambang Rotanak 103.2150136 13.09952554           
263 6.6 F 2013 Siem Reap Chi Kr病ng Ruessei Lok 104.2258928 13.25354713           
264 3.1 M 2014 Siem Reap Chi Kr病ng Ruessei Lok 104.2258928 13.25354713           
265 6.7 F 2013 Siem Reap Siem RŽab Sala Kamraeuk 103.8650309 13.347982           
266 4.4 F 2014 Siem Reap Siem RŽab Sala Kamraeuk 103.8650309 13.347982           
267 6.8 M 2014 Siem Reap Siem RŽab Sala Kamraeuk 103.8650309 13.347982           
268 11.3 F 2014 Siem Reap Siem RŽab Siem Reab 103.8437332 13.30476315           
269 11.5 F 2014 Siem Reap Siem RŽab Siem Reab 103.8437332 13.30476315           
270 10.5 F 2014 Siem Reap Siem RŽab Siem Reab 103.8437332 13.30476315           
271 11.1 M 2013 Siem Reap Siem RŽab Sla Kram 103.8836083 13.37003502           
272 11.7 M 2014 Siem Reap Siem RŽab Sla Kram 103.8836083 13.37003502           
273 8.1 F 2014 Siem Reap Siem RŽab Sla Kram 103.8836083 13.37003502           
274 13.3 F 2014 Siem Reap Siem RŽab Sla Kram 103.8836083 13.37003502           
275 5.5 M 2014 Siem Reap Siem RŽab Sla Kram 103.8836083 13.37003502           
276 10.0 F 2014 Siem Reap Varin Srae Nouy 104.0130835 13.83855219           
277 11.0 M 2013 Siem Reap Siem RŽab Svay Dangkum 103.8202681 13.313428           
278 10.0 F 2014 Siem Reap Siem RŽab Svay Dangkum 103.8202681 13.313428           
279 9.6 F 2014 Siem Reap Siem RŽab Svay Dangkum 103.8202681 13.313428           
280 9.5 M 2014 Siem Reap Siem RŽab Svay Dangkum 103.8202681 13.313428           
281 6.1 M 2014 Siem Reap Siem RŽab Svay Dangkum 103.8202681 13.313428           
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282 9.4 F 2014 Siem Reap Sotr Nik™m Ta Yaek 104.1847881 13.30881913           
283 15.3 M 2013 Siem Reap Prasat Bak™ng 
Trapeang 
Thum 104.0448328 13.30570753           
284 7.5 F 2014 Siem Reap Puok Tuek Vil 103.8049637 13.41569467           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  221 
 
Appendix D          Salmonella Typhi isolates and their corresponding metadata in chapter 6 
ID Study_code Date Sex Age_year Year Acute/Carrier Genotype H58 status gyrA_mutation 
01TY052 01TY 4-Nov-08 Male 4 2008 Acute 4.3.1 H58 WT 
01TY061 01TY 30-Nov-08 Male 16 2008 Acute 4.3.1 H58 S83F 
01TY065 01TY 2-Dec-08 Female 23 2008 Acute 4.3.1 H58 S83F 
01TY066 01TY 9-Dec-08 Female 11 2008 Acute 4.3.1 H58 WT 
01TY069 01TY 11-Dec-08 Male 24 2008 Acute 4.3.1 H58 S83F 
01TY072 01TY 8-Dec Male 18 2008 Acute 4.1 non-H58 WT 
01TY073 01TY 16-Dec-08 Female 24 2008 Acute 4.3.1 H58 S83F 
01TY075 01TY 8-Dec Male 14 2008 Acute 3.2.1 non-H58 WT 
01TY077 01TY 26-Dec-08 Female 6 2008 Acute 4.3.1 H58 S83F 
01TY080 01TY 9-Jan-09 Male 0 2009 Acute 2.2 non-H58 WT 
01TY083 01TY 14-Jan-09 Male 6 2009 Acute 4.3.1 H58 WT 
01TY086 01TY 30-Jan-09 Male 13 2009 Acute 3.3 non-H58 WT 
01TY088 01TY 9-Feb-09 Male 19 2009 Acute 4.3.1 H58 S83F 
01TY090 01TY 9-Feb Female 29 2009 Acute 4.3.1 H58 WT 
01TY095 01TY 19-Feb-09 Male 16 2009 Acute 4.3.1 H58 S83F 
01TY096 01TY 20-Feb-09 Male 15 2009 Acute 4.3.1 H58 S83F 
01TY098 01TY 9-Feb Female 21 2009 Acute 3.2.1 non-H58 WT 
01TY099 01TY 24-Feb-09 Female 19 2009 Acute 2.2 non-H58 WT 
01TY101 01TY 9-Feb Male 24 2009 Acute 4.3.1 H58 WT 
01TY102 01TY 2-Mar-09 Male 18 2009 Acute 4.3.1 H58 S83F 
01TY103 01TY 9-Mar Female 14 2009 Acute 4.3.1 H58 WT 
01TY104 01TY 9-Mar Male 15 2009 Acute 4.3.1 H58 WT 
01TY105 01TY 9-Mar-09 Male 22 2009 Acute 3.3 non-H58 WT 
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01TY107 01TY 11-Mar-09 Male 21 2009 Acute 4.3.1 H58 S83F 
01TY112 01TY 9-Mar Female 15 2009 Acute 4.3.1 H58 WT 
01TY122 01TY 9-Apr Female 11 2009 Acute 4.3.1 H58 WT 
01TY128 01TY 3-May-09 Male 21 2009 Acute 4.3.1 H58 S83F 
01TY132 01TY 17-May-09 Female 28 2009 Acute 4.3.1 H58 S83F 
01TY134 01TY 18-May-09 Female 14 2009 Acute 3.0.1 non-H58 WT 
01TY139 01TY 14-Jun-09 Male 19 2009 Acute 2.2 non-H58 WT 
01TY142 01TY 19-Jun-09 Male 15 2009 Acute 4.3.1 H58 S83F 
01TY150 01TY 25-Jun-09 Female 29 2009 Acute 2.2.1 non-H58 WT 
01TY151 01TY 25-Jun-09 Female 6 2009 Acute 3.3 non-H58 WT 
01TY152 01TY 25-Jun-09 Male 28 2009 Acute 4.3.1 H58 S83F 
01TY154 01TY 8-Jul-09 Female 17 2009 Acute 3.3 non-H58 WT 
01TY157 01TY 12-Jul-09 Female 24 2009 Acute 4.3.1 H58 S83F 
01TY163 01TY 17-Jul-09 Female 27 2009 Acute 3.0.1 non-H58 WT 
01TY170 01TY 24-Jul-09 Female 17 2009 Acute 4.3.1 H58 S83F 
01TY172 01TY 26-Jul-09 Male 10 2009 Acute 4.3.1 H58 S83F 
01TY191 01TY 11-Aug-09 Male 18 2009 Acute 4.3.1 H58 S83F 
01TY205 01TY 28-Aug-09 Male 6 2009 Acute 4.3.1 H58 S83F 
01TY208 01TY 30-Aug-09 Female 28 2009 Acute 4.3.1 H58 S83F 
01TY211 01TY 30-Aug-09 Female 4 2009 Acute 4.3.1 H58 S83F 
01TY216 01TY 1-Sep-09 Male 25 2009 Acute 4.3.1 H58 S83F 
01TY218 01TY 3-Sep-09 Male 11 2009 Acute 4.3.1 H58 S83F 
01TY226 01TY 10-Sep-09 Female 7 2009 Acute 4.3.1 H58 S83F 
01TY230 01TY 1-Oct-09 Female 11 2009 Acute 4.3.1 H58 S83F 
01TY233 01TY 4-Oct-09 Male 7 2009 Acute 4.3.1 H58 S83F 
01TY242 01TY 22-Oct-09 Male 3 2009 Acute 4.3.1 H58 S83F 
01TY256 01TY 26-Nov-09 Male 8 2009 Acute 4.3.1 H58 S83F 
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01TY257 01TY 30-Nov-09 Male 19 2009 Acute 3.3 non-H58 WT 
01TY258 01TY 2-Dec-09 Male 19 2009 Acute 3.3 non-H58 WT 
01TY261 01TY 6-Dec-09 Male 7 2009 Acute 3.3 non-H58 WT 
01TY264 01TY 10-Dec-09 Male 21 2009 Acute 3.3 non-H58 WT 
01TY267 01TY 14-Dec-09 Female 4 2009 Acute 3.3 non-H58 WT 
01TY274 01TY 18-Jan-10 Male 9 2010 Acute 4.3.1 H58 S83F 
01TY283 01TY 5-Mar-10 Male 17 2010 Acute 3.3 non-H58 WT 
01TY286 01TY 14-Mar-10 Male 16 2010 Acute 3.3 non-H58 WT 
01TY301 01TY 5-Apr-10 Male 16 2010 Acute 4.3.1 H58 S83F 
01TY305 01TY 11-Apr-10 Female 22 2010 Acute 4.3.1 H58 S83F 
01TY311 01TY 18-Apr-10 Female 9 2010 Acute 3.3 non-H58 WT 
01TY312 01TY 18-Apr-10 Male 18 2010 Acute 2.2 non-H58 WT 
01TY313 01TY 18-Apr-10 Male 13 2010 Acute 2.2 non-H58 WT 
01TY315 01TY 20-Apr-10 Female 11 2010 Acute 2.2 non-H58 WT 
01TY327 01TY 4-May-10 Male 0 2010 Acute 4.3.1 H58 S83F 
01TY332 01TY 16-May-10 Female 14 2010 Acute 2.2 non-H58 WT 
01TY337 01TY 21-May-10 Male 17 2010 Acute 2.2 non-H58 WT 
01TY342 01TY 2-Jun-10 Male 0 2010 Acute 4.3.1 H58 S83F 
01TY347 01TY 10-Jun-10 Female 20 2010 Acute 4.3.1 H58 S83F 
01TY349 01TY 14-Jun-10 Male 14 2010 Acute 2.2 non-H58 WT 
01TY366 01TY 6-Jul-10 Female 9 2010 Acute 3.2.2 non-H58 WT 
01TY370 01TY 8-Jul-10 Male 18 2010 Acute 4.3.1 H58 S83F 
01TY371 01TY 8-Jul-10 Male 12 2010 Acute 4.3.1 H58 S83F 
01TY374 01TY 11-Jul-10 Female 8 2010 Acute 4.3.1 H58 S83Y 
01TY375 01TY 12-Jul-10 Male 8 2010 Acute 4.3.1 H58 S83Y 
01TY391 01TY 21-Jul-10 Male 13 2010 Acute 3.1 non-H58 WT 
01TY394 01TY 23-Jul-10 Male 8 2010 Acute 4.3.1 H58 S83F 
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01TY397 01TY 23-Jul-10 Male 20 2010 Acute 4.3.1 H58 S83Y 
01TY405 01TY 1-Aug-10 Female 4 2010 Acute 3.3 non-H58 WT 
01TY408 01TY 2-Aug-10 Male 9 2010 Acute 2.2 non-H58 WT 
01TY410 01TY 3-Aug-10 Female 31 2010 Acute 4.3.1 H58 WT 
01TY421 01TY 9-Aug-10 Male 17 2010 Acute 4.3.1 H58 S83F 
01TY426 01TY 10-Aug-10 Male 17 2010 Acute 4.3.1 H58 S83Y 
01TY432 01TY 13-Aug-10 Male 19 2010 Acute 4.3.1 H58 S83F 
01TY433 01TY 15-Aug-10 Male 19 2010 Acute 4.3.1 H58 S83F 
01TY441 01TY 18-Aug-10 Male 28 2010 Acute 4.3.1 H58 S83F 
01TY443 01TY 19-Aug-10 Male 18 2010 Acute 4.3.1 H58 S83F 
01TY444 01TY 20-Aug-10 Female 17 2010 Acute 4.3.1 H58 S83F 
01TY445 01TY 20-Aug-10 Male 18 2010 Acute 4.3.1 H58 S83F 
01TY447 01TY 22-Aug-10 Female 8 2010 Acute 4.3.1 H58 S83F 
01TY448 01TY 22-Aug-10 Female 13 2010 Acute 3.2.2 non-H58 WT 
01TY472 01TY 9-Sep-10 Male 13 2010 Acute 4.3.1 H58 S83Y 
01TY476 01TY 13-Sep-10 Male 22 2010 Acute 4.3.1 H58 S83F 
01TY481 01TY 19-Sep-10 Male 17 2010 Acute 4.3.1 H58 S83F 
01TY484 01TY 22-Sep-10 Male 16 2010 Acute 3.3 non-H58 WT 
01TY492 01TY 3-Oct-10 Male 13 2010 Acute 4.3.1 H58 S83F 
GB003 GB 12-Jun-09 Female 40 2009 Carrier 4.3.1 H58 S83Y 
GB005 GB 5-Nov-07 Female 34 2007 Carrier 3.2.2 non-H58 D87N 
GB026 GB 23-Dec-07 Female 27 2007 Carrier 2 non-H58 WT 
GB031 GB 26-Jun-09 Female 53 2009 Carrier 4.3.1 H58 S83F 
GB044 GB 6-Dec-07 Female 30 2007 Carrier 4.3.1 H58 S83Y 
GB071 GB 22-Mar-08 Female 42 2008 Carrier 4.3.1 H58 S83F 
GB076 GB 17-Jul-09 Female 35 2009 Carrier 4.3.1 H58 WT 
GB125 GB 21-Aug-09 Female 25 2009 Carrier 4.3.1 H58 S83F 
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GB169 GB 14-Sep-09 Female 27 2009 Carrier 4.3.1 H58 S83F 
GB199 GB 29-Sep-07 Female 15 2007 Carrier 4.3.1 H58 S83F 
GB266 GB 14-Mar-08 Male 50 2008 Carrier 4.3.1 H58 WT 
GB276 GB 1-May-08 Female 27 2008 Carrier 3.3 non-H58 WT 
GB281 GB 4-May-08 Female 27 2008 Carrier 2.2.2 non-H58 WT 
GB335 GB 6-Jun-08 Female 33 2008 Carrier 3.3 non-H58 WT 
GB336 GB 10-Jun-08 Female 30 2008 Carrier 3.3 non-H58 WT 
GB368 GB 30-Jun-08 Female 30 2008 Carrier 4.3.1 H58 S83F 
GB387 GB 8-Feb-10 Female 60 2010 Carrier 4.3.1 H58 WT 
GB428 GB 11-Mar-10 Female 34 2010 Carrier 2.2 non-H58 WT 
GB441 GB 19-Mar-10 Male 38 2010 Carrier 4.3.1 H58 WT 
GB496 GB 22-Apr-10 Female 20 2010 Carrier 4.3.1 H58 S83F 
GB580 GB 12-Dec-08 Female 54 2008 Carrier 2.2 non-H58 WT 
GB650 GB 6-Aug-10 Female 34 2010 Carrier 4.3.1 H58 S83F 
GB705 GB 16-Sep-10 Male 23 2010 Carrier 3.2.2 non-H58 WT 
GB710 GB 20-Sep-10 Female 67 2010 Carrier 4.3.1 H58 S83F 
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Appendix E          Acute-specific nonsynonymous mutations and their functional classes 
SNP_Site S/NS Ref_base 
SNP
_base 
ancestral 
Codon 
derived 
Codon 
Ancestral 
AA 
Derived 
AA CDS_name product functional_classes 
Number_acu
te_isolate Frequency 
2952 N G T CGA CTA R L STY0003 homoserine kinase 1.D.2 Aspartate Family 2 2.083333333 
25425 N G A GAT AAT D N bcfB fimbrial chaperone 3.C.3 Surface structures 2 2.083333333 
47769 N T C GTG GCG V A STY0048 transcriptional activator protein NhaR 2 Broad regulatory function 1 1.041666667 
50775 N A G ATG ACG M T STY0050 putative transport protein 4.A Transport/binding proteins 2 2.083333333 
54513 N C T GCG GTG A V STY0055 isoleucyl-tRNA synthetase 3.A.5 Aminoacyl tRNA synthetase 1 1.041666667 
58654 N G A GGC AGC G S STY0058 LytB protein 2 Broad regulatory function 2 2.083333333 
62410 N C T CGG CAG R Q citA sensor kinase cita 2 Broad regulatory function 1 1.041666667 
63682 N G T CGC AGC R S oadB oxaloacetate decarboxylase beta chain 
4.A Transport/binding 
proteins 1 1.041666667 
71918 N C T GCG GTG A V citF2 citrate lyase alpha chain 1.C Central Intermediary metabolism 1 1.041666667 
83223 N A G TCC CCC S P STY0081 
probable 
crotonobetaine/carnitine-
CoA ligase 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
92753 N G A AGC AAC S N STY0089 putative metabolite transport protein 
4.A Transport/binding 
proteins 1 1.041666667 
101269 N G A CGC TGC R C STY0103 bis(5'-nucleosyl)-tetraphosphatase 
1.F.4 Salvage of 
nucleosides and nucleotides 1 1.041666667 
103365 N C T GCG ACG A T STY0106 pyridoxal phosphate biosynthetic protein PdxA 1.G.6 Pyridoxine 3 3.125 
103932 N C T GCG ACG A T STY0106 pyridoxal phosphate biosynthetic protein PdxA 1.G.6 Pyridoxine 1 1.041666667 
113304 N G A CCG CTG P L STY0112 DNA polymerase II 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
5 5.208333333 
118304 N C T CCT CTT P L STY0117 hypothetical protein 5.I Unknown 1 1.041666667 
144484 N G A GTT ATT V I STY0142 penicillin-binding protein 3 precursor 
3.C.4 Murein sacculus, 
peptidoglycan 1 1.041666667 
151468 N G A GGC GAC G D STY0148 
UDP-N-
acetylglucosamine:N-
acetylmuramyl-
(pentapeptide) 
pyrophosphoryl-
undecaprenol N-
acetylglucosamine 
transferase 
3.C.4 Murein sacculus, 
peptidoglycan 1 1.041666667 
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162346 N A G TAT TGT Y C STY0156 preprotein translocase SecA subunit 4.A.6 Transport Other 1 1.041666667 
176718 N T G ACC CCC T P STY0173 aromatic amino acid transport protein AroP 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
204893 N G T ATG ATT M I STY0194 
hypothetical ABC 
transporter ATP-binding 
protein 
4.A Transport/binding 
proteins 1 1.041666667 
237022 N A G ACT GCT T A STY0225 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
249957 N T G ATC CTC I L STY0238 methionine aminopeptidase 3.A.8 Protein translation and modification 5 5.208333333 
256630 N G A GCC ACC A T STY0244 undecaprenyl pyrophosphate synthetase 
1.C.3 Sugar-nucleotide 
biosynthesis, conversions 6 6.25 
268918 N A G GAG GGG E G STY0254 DNA polymerase III, alpha chain 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
2 2.083333333 
272059 N T C TGG CGG W R STY0257 putative secreted chitinase 3.B.4 Degradations of polysaccharides 1 1.041666667 
274703 N C T TCC TTC S F STY0259 lysine decarboxylase 1.B.2 Pyruvate dehydrogenase 1 1.041666667 
304517 N G A GCC GTC A V STY0288 hypothetical protein SPI-6 1 1.041666667 
306763 N C T GGT GAT G D STY0290 conserved hypothetical protein SPI-6 1 1.041666667 
314369 N G A GGG AGG G R STY0300 hypothetical protein SPI-6 1 1.041666667 
320218 N C T CCG CTG P L STY0307 hypothetical protein SPI-6 2 2.083333333 
330250 N G A GGC AGC G S STY0319 Rhs-family protein SPI-6 2 2.083333333 
337459 N G A GGC AGC G S STY0324 Rhs-family protein SPI-6 1 1.041666667 
340105 N C T GTT ATT V I STY0328 hypothetical protein SPI-6 1 1.041666667 
343912 N C T CGC TGC R C safC outer-membrane fimbrial usher protein SPI-6 2 2.083333333 
365122 N G A GGT AGT G S STY0355 phosphoheptose isomerase 3.C.2 Surface polysaccharides & antigens 1 1.041666667 
396216 N G A GGG AGG G R mod 
type III restriction-
modification system StyLTI 
enzyme mod 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
406182 N G A ATG ATA M I STY0396 ferrioxamine B receptor precursor 4.A.6 Transport Other 1 1.041666667 
406738 2 G A CAG TAG Q * STY0397 RhtC-like transporter 4.A Transport/binding proteins 1 1.041666667 
439088 N T G GAA GAC E D STY0429 exonuclease SbcC 3.B.2 Degradation of DNA 1 1.041666667 
472038 N G A GCG GTG A V phnV 
probable membrane 
component of 2-
aminoethylphosphonate 
transporter 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
485521 N A G CTG CCG L P STY0481 cytochrome o ubiquinol oxidase C subunit 1.B.7.a Aerobic Respiration 2 2.083333333 
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490825 N C T GTA ATA V I STY0486 AmpG protein 4.A Transport/binding proteins 1 1.041666667 
490875 N G A GCG GTG A V STY0486 AmpG protein 4.A Transport/binding proteins 1 1.041666667 
502112 N G A GTA ATA V I ppiD peptidyl-prolyl cis-trans isomerase D 
3.A.8 Protein translation 
and modification 1 1.041666667 
518336 N G A CCC CTC P L ylaB 
hypothetical 58.9 kDa 
protein in tesb-hha 
intergenic region. Contains 
probable N-terminal signal 
sequence 
3.C.1 Membranes 
lipoprotein 2 2.083333333 
520037 N C A GGG TGG G W STY0514 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
540170 N G A ATG ATA M I STY0533 ferrochelatase 1.G.12 Heme and porphyrin 1 1.041666667 
554496 N C T GGC AGC G S STY0546 putative membrane protein 3.C.1 Membranes lipoprotein 7 7.291666667 
554650 N G A GCA GTA A V STY0547 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
556290 N T G GTA GGA V G STY0548 putative ABC transporter ATP-binding protein 
3.A.8 Protein translation 
and modification 2 2.083333333 
557966 N G A CCA CTA P L ybbN thioredoxin-like protein 5.I Unknown 1 1.041666667 
589822 N C A GCT TCT A S STY0581 
phosphoribosylaminoimidaz
ole carboxylase ATPase 
subunit 
1.F.1 Purine ribonucleotide 
biosynthesis 2 2.083333333 
596512 N A C AAG CAG K Q fimA type-1 fimbrial protein, a chain precursor 3.C.3 Surface structures 1 1.041666667 
608472 N C T GGG GAG G E gtrB bactoprenol glucosyl transferase 
3.C.2 Surface 
polysaccharides & antigens 1 1.041666667 
617891 2 C T TGG TAG W * STY0618 putative membrane protein 3.C.1 Membranes lipoprotein 6 6.25 
618849 N A G TAC TGC Y C apeE outer membrane esterase 4.I Pathogenicity 1 1.041666667 
621564 N G A TCC TTC S F STY0620 oxygen-insensitive NAD(P)H nitroreductase 
5.D Drug/Analogue 
sensitivity 1 1.041666667 
624836 N C T GGC AGC G S STY0626 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
625772 N C T GAT AAT D N STY0628 ferrienterobactin receptor precursor 4.A.6 Transport Other 1 1.041666667 
639491 N T C CAG CGG Q R STY0638 
ferrienterobactin-binding 
periplasmic protein 
precursor 
4.A.6 Transport Other 2 2.083333333 
641681 N G A GTC ATC V I STY0640 2,3-dihydroxybenzoate-AMP ligase 
1.G.14 Iron uptake and 
storage 5 5.208333333 
643446 N G T GCG TCG A S STY0641 isochorismatase 1.G.14 Iron uptake and storage 2 2.083333333 
648137 N C T CGC CAC R H STY0646 putative oxidoreductase 5.I Unknown 1 1.041666667 
664501 N A G CTG CCG L P STY0664 regulator of nucleoside diphosphate kinase 1.F.5 Miscellaneous 1 1.041666667 
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670557 N A G CTG CCG L P citE citrate lyase beta chain 1.C Central Intermediary metabolism 7 7.291666667 
676249 N C T GCA ACA A T dcuC C4-dicarboxylate anaerobic carrier 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
678229 N G A CCC CTC P L crcB putative membrane protein 3.C.1 Membranes lipoprotein 2 2.083333333 
691764 N G A CCA CTA P L STY0696 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
692954 N C T GAC AAC D N STY0697 DNA polymerase III, delta subunit 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
698331 N T A ATC AAC I N STY0702 probable permease 4.A Transport/binding proteins 1 1.041666667 
715716 N G A CAC TAC H Y STY0718 asparagine synthetase B 1.D.2 Aspartate Family 1 1.041666667 
722451 N A G AAC AGC N S STY0723 
pts system, N-
acetylglucosamine-specific 
IIABC component 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
724837 N C A AGC AGA S R STY0724 glutaminyl-tRNA synthetase 3.A.5 Aminoacyl tRNA synthetase 1 1.041666667 
725967 N G A GGT AGT G S ybfM putative outer membrane protein 3.C Cell envelope 1 1.041666667 
737776 N G A CCG CTG P L STY0737 possible 5-nitroimidazole antibiotic resistance 
5.D Drug/Analogue 
sensitivity 1 1.041666667 
750451 N C T CAT TAT H Y STY0749 deoxyribodipyrimidine photolyase 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
752359 N C A CGC CTC R L STY0750 PTR2-family transport protein 
4.A Transport/binding 
proteins 1 1.041666667 
752996 N C T GGT AGT G S STY0750 PTR2-family transport protein 
4.A Transport/binding 
proteins 1 1.041666667 
761027 N T C GTA GCA V A STY0760 putative glycosyl transferase 3.C.2 Surface polysaccharides & antigens 1 1.041666667 
761098 N T G TGT GGT C G STY0760 putative glycosyl transferase 3.C.2 Surface polysaccharides & antigens 1 1.041666667 
770444 N C T GGT AGT G S STY0772 putative membrane protein 3.C.1 Membranes lipoprotein 2 2.083333333 
771204 N C T GCG ACG A T STY0773 citrate synthase 1.B.3 Tricarboxylic acid cycle 5 5.208333333 
848432 N A G GTG GCG V A STY0853 HlyD-family secretion protein 
4.A Transport/binding 
proteins 1 1.041666667 
862862 N C T GCG ACG A T STY0871 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
883410 N A G AGC GGC S G yliB putative ABC transporter periplasmic binding protein 
4.A Transport/binding 
proteins 2 2.083333333 
884918 N C A CCC ACC P T yliD hypothetical ABC transporter permease protein 
4.A Transport/binding 
proteins 2 2.083333333 
888699 N A G AAC AGC N S yliI putative oxidoreductase 5.I Unknown 1 1.041666667 
901044 N G A CGG CAG R Q STY0908 ribosomal protein S6 modification protein 
3.A.2 Ribosomal proteins - 
synthesis, modification 1 1.041666667 
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903783 N T C GTG GCG V A STY0910 
putrescine-binding 
periplasmic protein 
precursor 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
905124 N C T ACG ATG T M STY0911 putrescine transport ATP-binding protein PotG 
4.A.1 Transport amino acid 
and amines 2 2.083333333 
913871 N G A CCG CTG P L STY0921 arginine transport system permease protein ArtM 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
923357 N C T GCC ACC A T STY0931 pyruvate dehydrogenase 1.A.1 Degradation of carbohydrates 2 2.083333333 
942558 N C T GAC AAC D N STY0954 transport ATP-binding protein CydC 
4.A Transport/binding 
proteins 1 1.041666667 
949130 N G A GCC ACC A T STY0958 cell division protein FtsK 4.C Cell division 1 1.041666667 
960373 N G A GGT AGT G S ycaD probable transport protein 4.A Transport/binding proteins 1 1.041666667 
974754 N A G AAT GAT N D STY0979 putative lipoprotein 3.C.1 Membranes lipoprotein 1 1.041666667 
982823 N C T CCG TCG P S lpxK tetraacyldisaccharide 4'-kinase 
3.C.2 Surface 
polysaccharides & antigens 1 1.041666667 
1000363 N C T GAC AAC D N STY1002 outer membrane protein F precursor 3.C Cell envelope 1 1.041666667 
1054897 N G A GCC ACC A T STY1078 aminopeptidase N 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
6 6.25 
1086577 N T G AAC ACC N T pipA conserved hypothetical protein SPI-5 1 1.041666667 
1092031 2 C T TGG TAG W * pipD putative secreted peptidase SPI-5 1 1.041666667 
1106048 N C T CAT TAT H Y hpaA 
4-hydroxyphenylacetate 3-
monooxygenase operon 
regulatory protein 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
1130628 N G A GGT AGT G S STY1167 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
1133453 N T C GTT GCT V A STY1170 putative oxidoreductase 5.I Unknown 1 1.041666667 
1135518 N G A GTC ATC V I STY1172 
putative 2-hydroxyacid 
dehydrogenase in phoh-csgg 
intergenic region 
5.I Unknown 1 1.041666667 
1137867 N T C TGG CGG W R STY1175 putative membrane protein 3.C.1 Membranes lipoprotein 2 2.083333333 
1139129 N G A CCG CTG P L STY1176 
assembly/transport 
component in curli 
production 
3.C.3 Surface structures 2 2.083333333 
1145923 N C T AGC AAC S N STY1186 glucans biosynthesis protein 5.F Adaptions and atypical conditions 1 1.041666667 
1157933 N G A CAT TAT H Y STY1199 conserved hypothetical protein 5.H.a Hypothetical protein 2 2.083333333 
1190420 N G A GGC AGC G S STY1236 3-oxoacyl-[acyl-carrier-protein] synthase II 1.H Fatty acid biosynthesis 1 1.041666667 
1194025 N G A GGC AGC G S STY1240 DNA polymerase III, delta' subunit 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
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1194365 N A G GAG GGG E G STY1240 DNA polymerase III, delta' subunit 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
1195346 N G A GCC ACC A T STY1241 conserved hypothetical protein 5.H.b Hypothetical protein 4 4.166666667 
1208580 N C T GGT AGT G S STY1256 transcription-repair coupling factor (TrcF) 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
2 2.083333333 
1210415 N C T CGT CAT R H STY1256 transcription-repair coupling factor (TrcF) 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
1216818 N G A GTG ATG V M cobB putative regulatory protein 2 Broad regulatory function 1 1.041666667 
1221269 2 C T TGG TAG W * STY1265 
spermidine/putrescine 
transport system permease 
protein PotB 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
1230675 N C T GCG ACG A T STY1273 conserved hypothetical protein 5.H.a Hypothetical protein 3 3.125 
1233131 N G A CCC TCC P S STY1277 
putative ribosomal large 
subunit pseudouridine 
synthase B 
3.A.3 Ribosomes - 
maturation and modification 1 1.041666667 
1239073 N A G AGT GGT S G STY1284 putative invasin 4.I Pathogenicity 6 6.25 
1239209 N C T CCT CTT P L STY1284 putative invasin 4.I Pathogenicity 1 1.041666667 
1283954 N C A TGA TTA * L STY1326 indole-3-glycerol phosphate synthase 
1.D.4 Aromatic Amino 
Acid 1 1.041666667 
1285353 N C T GGC AGC G S STY1327 
anthranilate synthase 
component II; anthranilate 
phosphoribosyltransferase 
1.D.4 Aromatic Amino 
Acid 1 1.041666667 
1288407 N A G ACC GCC T A STY1330 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1306213 N C T GCG ACG A T STY1347 putative regulatory protein 2 Broad regulatory function 6 6.25 
1316960 N T C CAA CGA Q R STY1355 peptide transport system ATP-binding protein SapF 4.A.6 Transport Other 1 1.041666667 
1318086 N G A CCC CTC P L STY1356 peptide transport system ATP-binding protein SapD 4.A.6 Transport Other 2 2.083333333 
1332408 N C T GCC GTC A V STY1378 transcriptional regulatory protein TyrR 2 Broad regulatory function 1 1.041666667 
1332544 N G A ATG ATA M I STY1378 transcriptional regulatory protein TyrR 2 Broad regulatory function 1 1.041666667 
1333454 N G A GAC AAC D N STY1378 transcriptional regulatory protein TyrR 2 Broad regulatory function 1 1.041666667 
1335943 2 G A TGG TAG W * STY1382 
putative mandelate racemase 
/ muconate lactonizing 
enzyme family protein 
5.I Unknown 1 1.041666667 
1342083 N C T GGA GAA G E STY1389 putative oxidoreductase 5.I Unknown 5 5.208333333 
1342916 N G A GGA GAA G E STY1390 putative transcriptional regulator 2 Broad regulatory function 1 1.041666667 
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1351519 N C T GGC AGC G S STY1399 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1358778 N G A GGA AGA G R STY1408 putative chemo-receptor protein 
4.D Chemotaxis and 
mobility 1 1.041666667 
1378120 N T C AAC AGC N S STY1427 acyl carrier protein phosphodiesterase 1.H Fatty acid biosynthesis 1 1.041666667 
1379147 N A G ACC GCC T A STY1428 ATP-dependent helicase HrpA 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
1397389 N C T ACG ATG T M STY1444 putative glycolate oxidase 5.I Unknown 1 1.041666667 
1399474 N C T GAT AAT D N STY1447 putative ribulose-5-phosphate 3-epimerase 5.I Unknown 1 1.041666667 
1402707 N T C GAC GGC D G STY1451 putative phosphotransferase enzyme 
4.A Transport/binding 
proteins 1 1.041666667 
1403493 N C T GAT AAT D N STY1452 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
1410199 N C T CCC TCC P S STY1460 putative peptidase 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
2 2.083333333 
1424538 N C T GTC ATC V I srfA putative virulence effector protein 4.I Pathogenicity 1 1.041666667 
1433892 N A C TCC GCC S A ansP L-asparagine permease 4.A.1 Transport amino acid and amines 1 1.041666667 
1446984 N G A CAC TAC H Y STY1490 putative regulatory protein 2 Broad regulatory function 1 1.041666667 
1447910 N G T TGG TTG W L smvA methyl viologen resistance protein SmvA 5.I Unknown 1 1.041666667 
1453048 N G A ACC ATC T I STY1494 NAD-linked malic enzyme; malate oxidoreductase 1.C.2 Gluconeogenesis 2 2.083333333 
1458457 2 G A TGG TAG W * STY1502 putative secreted protein 3.C.1 Membranes lipoprotein 1 1.041666667 
1462308 N G T CAG CAT Q H STY1504 putative hydrolase 5.I Unknown 1 1.041666667 
1464345 2 C T CAG TAG Q * STY1505 putative glycogen debranching protein 
3.B.4 Degradations of 
polysaccharides 1 1.041666667 
1467534 N G T TGG TTG W L STY1509 hypothetical protein 5.I Unknown 1 1.041666667 
1485774 N A C AAT ACT N T hyaF2 hydrogenase-1 operon protein HyaF2 1.B.7.a Aerobic Respiration 1 1.041666667 
1499896 N A G AAC GAC N D STY1547 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1507830 N T C AAG GAG K E STY1554 putative membrane transport protein 
4.A Transport/binding 
proteins 2 2.083333333 
1516980 N C T TCC TTC S F STY1566 putative dimethyl sulphoxide reductase subunit 
1.A.1 Degradation of 
carbohydrates 2 2.083333333 
1519220 N T C GTA GCA V A STY1568 putative dimethyl sulphoxide reductase subunit 
1.A.1 Degradation of 
carbohydrates 5 5.208333333 
1521052 N T C TTC TCC F S STY1571 putative ABC transporter periplasmic binding protein 
4.A Transport/binding 
proteins 1 1.041666667 
1527528 N C T GGC GAC G D STY1578 putative regulatory protein 2 Broad regulatory function 6 6.25 
  233 
1530677 N G A GGT AGT G S STY1582 putative secreted stress response protein 5.I Unknown 1 1.041666667 
1582360 N G A CCG CTG P L STY1653 fumarate hydratase class II 1.B.3 Tricarboxylic acid cycle 1 1.041666667 
1582393 N G A GCG GTG A V STY1653 fumarate hydratase class II 1.B.3 Tricarboxylic acid cycle 1 1.041666667 
1592955 N G A GGC AGC G S STY1664 
putative ferredoxin-like 
protein, cytoplasmic 
membrane 
1.C Central Intermediary 
metabolism 2 2.083333333 
1601552 N C T GGT AGT G S pdxY pyridoxamine kinase 1.C Central Intermediary metabolism 2 2.083333333 
1615120 N G A CCG CTG P L STY1689 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
1622704 N C T GTG ATG V M STY1696 riboflavin synthase alpha chain 1.G.9 Riboflavin 1 1.041666667 
1656084 N A G ACC GCC T A ttrB tetrathionate reductase subunit B SPI-2 2 2.083333333 
1657492 N A G ACA GCA T A ttrA tetrathionate reductase subunit A SPI-2 1 1.041666667 
1658116 N G A GGC AGC G S ttrA tetrathionate reductase subunit A SPI-2 1 1.041666667 
1658494 N A C ACC CCC T P ttrA tetrathionate reductase subunit A SPI-2 2 2.083333333 
1659856 N T C TTT CTT F L ttrA tetrathionate reductase subunit A SPI-2 4 4.166666667 
1676627 N G A CAT TAT H Y STY1757 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1707915 N A C AAA ACA K T STY1786 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
1717530 N A G TAT CAT Y H STY1797 phospho-beta-glucosidase B 1.A.1 Degradation of carbohydrates 5 5.208333333 
1720562 N C A GAG GAT E D celB PTS system, cellobiose-specific IIC component 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
1725400 N G A CAT TAT H Y astE succinylglutamate desuccinylase 
1.A.2 Degradation of amino 
acids 2 2.083333333 
1726378 N A G GTG GCG V A astB succinylarginine dihydrolase 1.A.2 Degradation of amino acids 1 1.041666667 
1749721 N G A GGC AGC G S STY1831 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1751929 N T C TTT TCT F S STY1832 conserved hypothetical protein 5.H.b Hypothetical protein 3 3.125 
1757283 N C T CGT TGT R C STY1840 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
1771368 N G A CCG CTG P L STY1862 putative ABC transport ATP-binding protein 
4.A Transport/binding 
proteins 4 4.166666667 
1782708 N G A AGG AAG R K pagD putative outer membrane virulence protein 4.I Pathogenicity 1 1.041666667 
1812529 N G A GTG ATG V M appC cytochrome bd-II oxidase subunit I (pseudogene) 1.B.7.c Electron Transport 1 1.041666667 
1821293 N G A GGT GAT G D STY1928 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
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1836701 N T C GAG GGG E G STY1947 ribonuclease D 3.B.1 Degradation of RNA 1 1.041666667 
1843733 N G A GGT AGT G S STY1954 para-aminobenzoate synthase component I 1.G.2 Folic Acid 1 1.041666667 
1856446 N G A CCT TCT P S ftsI2 penicillin-binding protein 4.C Cell division 1 1.041666667 
1863982 N C T GGT AGT G S STY1976 tail-specific protease precursor 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
2 2.083333333 
1884909 N G A CGT TGT R C STY2004 putative hydrolase 5.I Unknown 1 1.041666667 
1938130 N C T GGT AGT G S STY2085 oligopeptidase 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
1 1.041666667 
1940521 N T A ATC TTC I F STY2087 putative exported protein 3.C.1 Membranes lipoprotein 2 2.083333333 
1951699 N C T GGC GAC G D STY2098 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
1965470 N G A GAC AAC D N STY2114 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1996037 2 C T TGG TAG W * STY2146 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
1996313 N C T CGG CAG R Q STY2146 conserved hypothetical protein 5.H.b Hypothetical protein 6 6.25 
1997612 N T C ACC GCC T A STY2149 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2001948 N G T CCC ACC P T STY2154 excinuclease ABC subunit C 3.B.2 Degradation of DNA 1 1.041666667 
2013806 N T A CTG CAG L Q fliD flagellar hook associated protein 2 3.C.3 Surface structures 1 1.041666667 
2018745 N T C TCC CCC S P STY2174 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
2053440 N G A CCG TCG P S STY2218 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2054602 N G A ACC ATC T I STY2219 
nicotinate-nucleotide--
dimethylbenzimidazole 
phosphoribosyl transferase 
1.G.13 Cobalamin 1 1.041666667 
2077040 N A G AAA GAA K E pduE diol dehydratase small subunit 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
2102317 N G A GCA ACA A T STY2276 exodeoxyribonuclease I 3.B.2 Degradation of DNA 1 1.041666667 
2126184 N G A TCT TTT S F rfbX putative O-antigen transporter 
3.C.2 Surface 
polysaccharides & antigens 1 1.041666667 
2128153 N T C AAT GAT N D rfbS paratose synthase 3.C.2 Surface polysaccharides & antigens 2 2.083333333 
2139553 N A G TTC CTC F L STY2310 putative glycosyltransferase 3.C.2 Surface polysaccharides & antigens 1 1.041666667 
2149716 N G A CCG CTG P L STY2320 GDP-fucose synthetase 1.C.3 Sugar-nucleotide biosynthesis, conversions 1 1.041666667 
2156901 N C T GGC GAC G D wzc putative tyrosine-protein kinase 
3.A.8 Protein translation 
and modification 1 1.041666667 
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2157615 N G A CCG CTG P L wzc putative tyrosine-protein kinase 
3.A.8 Protein translation 
and modification 1 1.041666667 
2158497 N C T GGC GAC G D wzc putative tyrosine-protein kinase 
3.A.8 Protein translation 
and modification 1 1.041666667 
2169314 N A G CAG CGG Q R STY2336 putative membrane protein 3.C.1 Membranes lipoprotein 6 6.25 
2175898 N C T CCG CTG P L STY2340 putative RND-family transporter protein 
4.A Transport/binding 
proteins 1 1.041666667 
2177044 N C T ACC ATC T I STY2341 putative RND-family transporter protein 
4.A Transport/binding 
proteins 1 1.041666667 
2184586 N C T GCC GTC A V STY2346 hypothetical protein 5.I Unknown 1 1.041666667 
2186873 N A G GAA GGA E G STY2348 hypothetical protein 5.I Unknown 7 7.291666667 
2188648 N T G AGT CGT S R STY2350 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2190440 N C T GCT ACT A T STY2353 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2190646 N A G GTG GCG V A STY2353 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2193219 N C T GAA AAA E K STY2359 hypothetical protein 5.I Unknown 1 1.041666667 
2204169 N G A CGG CAG R Q STY2373 putative sugar kinase 1.C Central Intermediary metabolism 1 1.041666667 
2205213 N G A CCG CTG P L STY2374 putative gntR-family transcriptional regulator 2 Broad regulatory function 1 1.041666667 
2212052 N G A CCA CTA P L stcB putative fimbrial chaperone protein 3.C.3 Surface structures 1 1.041666667 
2218346 N T C ATC ACC I T STY2386 putative lipoprotein 3.C.1 Membranes lipoprotein 1 1.041666667 
2219526 N A C TTT GTT F V STY2388 putative two-component system response regulator 2 Broad regulatory function 1 1.041666667 
2219654 N T G CAG CCG Q P STY2388 putative two-component system response regulator 2 Broad regulatory function 1 1.041666667 
2219655 2 G A CAG TAG Q * STY2388 putative two-component system response regulator 2 Broad regulatory function 1 1.041666667 
2220514 N A T CTG CAG L Q STY2389 putative two-component system sensor kinase 2 Broad regulatory function 1 1.041666667 
2220658 N G A GCC GTC A V STY2389 putative two-component system sensor kinase 2 Broad regulatory function 1 1.041666667 
2221033 N C T AGT AAT S N STY2389 putative two-component system sensor kinase 2 Broad regulatory function 1 1.041666667 
2221417 N C T GGC GAC G D STY2389 putative two-component system sensor kinase 2 Broad regulatory function 1 1.041666667 
2235092 N T C AAA GAA K E STY2402 putative lipoprotein 3.C.1 Membranes lipoprotein 2 2.083333333 
2237767 2 G A CAG TAG Q * STY2405 putative n-hydroxybenzoate hydroxylase 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
2244495 N A T CAG CTG Q L STY2412 puatative membrane protein 3.C.1 Membranes lipoprotein 2 2.083333333 
2256327 N T G AGT CGT S R STY2426 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
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2258325 N G A CGC CAC R H STY2428 putative esterase 5.I Unknown 2 2.083333333 
2267741 N C T GTG ATG V M STY2436 putative transcriptional regulator 2 Broad regulatory function 1 1.041666667 
2267997 N C T CCT TCT P S STY2437 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2272180 N C T GTC ATC V I STY2441 1-phosphofructokinase 1.B.1 Glycolysis 1 1.041666667 
2272181 N C T ATG ATA M I STY2441 1-phosphofructokinase 1.B.1 Glycolysis 1 1.041666667 
2274674 N G A CGC CAC R H STY2443 sugar efflux transporter 4.A Transport/binding proteins 1 1.041666667 
2326118 N G A GAT AAT D N STY2494 putative two-component system sensor kinase 2 Broad regulatory function 1 1.041666667 
2329159 N G A GCG GTG A V rcsC sensor protein RcsC 2 Broad regulatory function 1 1.041666667 
2344308 N C T GCG GTG A V STY2510 putative transcriptional regulator 2 Broad regulatory function 1 1.041666667 
2349126 N G A AGT AAT S N STY2513 
anaerobic glycerol-3-
phosphate dehydrogenase 
subunit A 
1.B.7.b Anaerobic 
Respiration 2 2.083333333 
2363792 N G A GCG ACG A T STY2529 putative lipopolysaccharide modification protein 
3.C.2 Surface 
polysaccharides & antigens 1 1.041666667 
2384852 N C T GCG ACG A T STY2550 NADH dehydrogenase I chain J 1.B.7.a Aerobic Respiration 1 1.041666667 
2388486 N G A GCG GTG A V nuoG NADH dehydrogenase I chain G 1.B.7.a Aerobic Respiration 1 1.041666667 
2426730 N A G GTT GCT V A STY2590 putative amino acid decarboxylase 
1.D Amino Acid 
Biosynthesis 1 1.041666667 
2450980 N T G GAT GCT D A STY2617 conserved hypothetical protein 5.I Unknown 1 1.041666667 
2458075 N G A GCG ACG A T STY2623 long-chain fatty acid transport protein precursor 4.A.6 Transport Other 1 1.041666667 
2479104 N G A CAT TAT H Y STY2644 glucokinase 1.A.1 Degradation of carbohydrates 1 1.041666667 
2483383 N T C CTC CCC L P STY2647 putative ion-channel protein 4.A.2 Transport Cations 2 2.083333333 
2486342 N A C ATC CTC I L STY2650 nucleoside permease NupC 4.A.6 Transport Other 1 1.041666667 
2496221 2 G A CGA TGA R * STY2658 xanthosine phosphorylase 1.F.5 Miscellaneous 1 1.041666667 
2502367 N G C CCG GCG P A STY2664 cell division protein 4.C Cell division 1 1.041666667 
2512520 N C T GGC GAC G D STY2677 cysteine synthase B 1.D.3 Serine Family 1 1.041666667 
2512550 N G A CCG CTG P L STY2677 cysteine synthase B 1.D.3 Serine Family 2 2.083333333 
2513837 N G A CCG CTG P L STY2678 sulphate transport ATP-binding protein CysA 4.A.5 Transport Anions 1 1.041666667 
2514286 2 G A CAG TAG Q * STY2679 sulphate transport system permease protein CysW 4.A.5 Transport Anions 1 1.041666667 
2524516 N C T CGC CAC R H STY2691 ethanolamine operon transcriptional regulator 2 Broad regulatory function 1 1.041666667 
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2527158 N C T CGC CAC R H eutC ethanolamine ammonia-lyase light chain 1.A Degradation 1 1.041666667 
2531257 N G A CCG CTG P L STY2697 putative membrane protein 3.C.1 Membranes lipoprotein 2 2.083333333 
2532336 N G A CGC TGC R C eutG putative alchohol dehydrogenase 1.A Degradation 1 1.041666667 
2535319 N C T GCG ACG A T eutN putative ethanolamine utilization protein EutN 1.A Degradation 1 1.041666667 
2535661 N A C TCA GCA S A eutN putative ethanolamine utilization protein EutN 1.A Degradation 1 1.041666667 
2545292 N C T CCG CTG P L STY2711 transketolase 2 1.B.5.b Non-oxydative branch 1 1.041666667 
2546678 2 C T TGG TAG W * STY2713 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2560281 N G A GCG GTG A V STY2723 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
2578401 N G A GAT AAT D N STY2741 phosphoribosylglycinamidine myltransferase 
1.F.1 Purine ribonucleotide 
biosynthesis 1 1.041666667 
2579223 N G A CGC CAC R H STY2742 polyphosphate kinase 1.C Central Intermediary metabolism 1 1.041666667 
2606065 N G T AAC AAA N K STY2760 putative exported protein 4.I Pathogenicity 7 7.291666667 
2616492 N C T GTA ATA V I STY2764 putative GTP-binding protein 5.I Unknown 2 2.083333333 
2616845 N G A CCG CTG P L STY2764 putative GTP-binding protein 5.I Unknown 1 1.041666667 
2621661 N G A CCG CTG P L STY2769 putative DNA-binding protein 5.I Unknown 1 1.041666667 
2623817 N T C CAG CGG Q R STY2770 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
2624579 N C T GGC AGC G S STY2771 nucleoside diphosphate kinase (ndk) 
1.F.1 Purine ribonucleotide 
biosynthesis 1 1.041666667 
2671118 N G A CTT TTT L F STY2811 putative sensor kinase protein 2 Broad regulatory function 5 5.208333333 
2678943 2 C T TGG TGA W * STY2815 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
2683796 N A G GTA GCA V A STY2820 putative transmembrane transport protein 
4.A Transport/binding 
proteins 1 1.041666667 
2684372 N A G TTG TCG L S STY2820 putative transmembrane transport protein 
4.A Transport/binding 
proteins 2 2.083333333 
2694835 N T C ATA ATG I M STY2832 sigma-E factor negative regulatory protein 2 Broad regulatory function 1 1.041666667 
2727753 2 G A CAG TAG Q * STY2857 
phospho-2-dehydro-3-
deoxyheptonate aldolase, 
tyr-sensitive 
1.D.4 Aromatic Amino 
Acid 1 1.041666667 
2744407 N A G ACC GCC T A STY2875 large repetitive protein SPI-9 2 2.083333333 
2746073 N G A GGC GAC G D STY2875 large repetitive protein SPI-9 1 1.041666667 
2747171 N C T GCG GTG A V STY2875 large repetitive protein SPI-9 1 1.041666667 
  238 
2790994 N C T CTC TTC L F STY2909 gab protein homolog 5.I Unknown 1 1.041666667 
2792931 N C T GCA GTA A V STY2910 putative GAB DTP gene cluster repressor 5.I Unknown 5 5.208333333 
2795907 N G A ATG ATA M I STY2913 GabA permease (4-amino butyrate transport carrier) 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
2820645 N T C AAT GAT N D STY2944 gamma-glutamylcysteine synthetase 1.G.10 Thioredoxin 6 6.25 
2873905 N T C TCG CCG S P iagB cell invasion protein SPI-1 2 2.083333333 
2882909 N C T GAA AAA E K spaT unknown function SPI-1 1 1.041666667 
2898283 N G A GAC AAC D N STY3027 hypothetical protein SPI-1 5 5.208333333 
2909874 N C T ATG ATA M I STY3041 possible sugar aldolase 1.A.1 Degradation of carbohydrates 6 6.25 
2915639 N G A ACA ATA T I rpoS RNA polymerase sigma subunit RpoS (sigma-38) 2 Broad regulatory function 1 1.041666667 
2920444 N G C CTG GTG L V ygbP 
2-C-methyl-D-erythritol 4-
phosphate 
cytidylyltransferase 
5.I Unknown 2 2.083333333 
2921062 N C T GGG AGG G R STY3056 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
2922117 N G A GCT GTT A V cysC adenosine 5-phosphosulfate kinase 1.C.5 Sulphur Metabolism 1 1.041666667 
2922180 N T C CAA CGA Q R cysC adenosine 5-phosphosulfate kinase 1.C.5 Sulphur Metabolism 1 1.041666667 
2924510 2 G A CAG TAG Q * cysD 
ATP sulfurylase 
(ATP:sulfate 
adenyltransferase) 
1.C.5 Sulphur Metabolism 1 1.041666667 
2924810 N G A CGT TGT R C cysD 
ATP sulfurylase 
(ATP:sulfate 
adenyltransferase) 
1.C.5 Sulphur Metabolism 1 1.041666667 
2933498 2 G A TGG TAG W * STY3071 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
2944324 2 G A CAG TAG Q * STY3081 enolase 1.B.1 Glycolysis 1 1.041666667 
2951288 N T C TCG CCG S P steB outer membrane usher protein 3.C Cell envelope 1 1.041666667 
2954233 N G A GGT AGT G S steF fimbrial subunit 3.C.3 Surface structures 1 1.041666667 
2974429 N T G CTG CGG L R STY3108 conserved hypothetical protein 5.H.a Hypothetical protein 6 6.25 
2983229 2 C T CAA TAA Q * STY3115 L-fucose permease 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
2 2.083333333 
2987279 N G A GTA ATA V I STY3118 fuscose operon fucU protein 1.A.1 Degradation of carbohydrates 5 5.208333333 
2987784 N C T GCC GTC A V STY3119 l-fucose operon activator 1.A.1 Degradation of carbohydrates 1 1.041666667 
2988676 N G T CCG CAG P Q STY3120 conserved hypothetical 5.H.b Hypothetical protein 1 1.041666667 
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protein 
3002057 N G A CCG CTG P L recB exonuclease V subunit 3.B.2 Degradation of DNA 1 1.041666667 
3006403 N G A CCG TCG P S STY3133 protease III precursor (pitrilysin) 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
1 1.041666667 
3021088 N G A GTT ATT V I STY3149 putative membrane protein 3.C.1 Membranes lipoprotein 2 2.083333333 
3025188 N G A CCG TCG P S STY3153 
2-
acylglycerophosphoethanola
mine acyl transferase/acyl 
carrier protein synthetase 
1.H Fatty acid biosynthesis 1 1.041666667 
3035138 N G A CGC TGC R C STY3162 2-keto-3-deoxygluconate oxidoreductase 1.H Fatty acid biosynthesis 1 1.041666667 
3039476 N G A ATG ATA M I STY3167 probable amino acid transport protein 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
3046278 2 G A CAG TAG Q * stdB probable outer membrane fimbrial usher protein 3.C.3 Surface structures 1 1.041666667 
3068338 N G A AGC AAC S N STY3201 flavodoxin II 1.B.7.a Aerobic Respiration 1 1.041666667 
3072213 N A C ACC CCC T P STY3207 6-phospho-beta-glucosidase 1.A.1 Degradation of carbohydrates 1 1.041666667 
3088543 N G A GTG ATG V M STY3220 chromosome intitiation inhibitor 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
3098424 N T A CTC CAC L H STY3232 
possible ABC-transport 
protein, ATP-binding 
component 
4.A Transport/binding 
proteins 1 1.041666667 
3111928 N T C TCG CCG S P STY3247 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
3128126 N G A GGG AGG G R STY3268 nucleoside permease 4.A.6 Transport Other 1 1.041666667 
3128789 N C T CCG TCG P S STY3268 nucleoside permease 4.A.6 Transport Other 1 1.041666667 
3136486 N G A GTA ATA V I STY3285 putative exported protein SPI-8 1 1.041666667 
3138646 N G A GCA GTA A V STY3290 hypothetical protein 5.H.a Hypothetical protein 2 2.083333333 
3140066 N G A GCC ACC A T STY3293 LysR-family transcriptional regulator 2 Broad regulatory function 1 1.041666667 
3147262 2 G A CAG TAG Q * STY3300 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
3151151 N G A GCG GTG A V STY3305 hexuronate transporter 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
3183175 2 G A TGG TAG W * STY3340 possible membrane transport protein 
4.A Transport/binding 
proteins 2 2.083333333 
3195738 N C T AGC AAC S N STY3351 topoisomerase IV subunit A 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
3217295 N C T GCG GTG A V STY3377 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
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3219040 N G A GCG ACG A T STY3378 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
3224368 N G A TCA TTA S L STY3380 adenyl-transferase 3.A.8 Protein translation and modification 1 1.041666667 
3246839 N T C AAT GAT N D STY3400 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
3247366 N G A GCC ACC A T STY3401 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
3254191 N G A CGT CAT R H STY3408 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
3258933 2 C T CAA TAA Q * STY3416 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
3259259 N G A GCG ACG A T STY3417 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
3288370 N G A GAA AAA E K STY3444 galactitol-1-phosphate dehydrogenase 
1.A.1 Degradation of 
carbohydrates 2 2.083333333 
3292861 N T C TTT TCT F S yraN conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
3361086 N G T CCG ACG P T STY3519 putative sialic acid transporter 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
3371173 N G A GAA AAA E K degS serine protease 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
1 1.041666667 
3382903 2 C T CAG TAG Q * STY3543 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
3444980 N T G ATT AGT I S STY3592 putative hydrolase 5.I Unknown 5 5.208333333 
3455162 N G A CGC TGC R C recQ ATP-dependent DNA helicase 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
3506652 N C T CAT TAT H Y STY3649 LysR-family regulatory protein for ilvC expression 1.D.6 Pyruvate Family 1 1.041666667 
3507253 N C T CCG CTG P L STY3649 LysR-family regulatory protein for ilvC expression 1.D.6 Pyruvate Family 2 2.083333333 
3508762 N A C TCT GCT S A STY3652 threonine deaminase 1.D.6 Pyruvate Family 1 1.041666667 
3566895 N G A CCA TCA P S nfi putative endonuclease 3.B.2 Degradation of DNA 1 1.041666667 
3570766 N G A GTC ATC V I STY3721 thiamine biosynthesis protein 1.G.8 Thiamine 1 1.041666667 
3574272 N C T CGT TGT R C STY3725 thiamine biosynthesis protein 1.G.8 Thiamine 1 1.041666667 
3603732 N G A GCG ACG A T STY3745 tRNA (uracil-5)-methyltransferase 
3.A.5 Aminoacyl tRNA 
synthetase 5 5.208333333 
3614668 N G A TGC TAC C Y STY3754 phosphoenolpyruvate carboxylase 1.B.8 Fermentation 1 1.041666667 
3616596 N C T CCC TCC P S STY3755 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
3634106 N C T GGG GAG G E STY3768 
bifunctional aspartokinase 
II/homoserine 
dehydrogenase IIcan I write 
1.D.2 Aspartate Family 7 7.291666667 
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3642604 N G A CGA CAA R Q STY3776 transcriptional repressor 2 Broad regulatory function 1 1.041666667 
3653696 N G A GGA AGA G R STY3788 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
3656589 N A T CTG CAG L Q STY3792 putative aldolase 5.I Unknown 1 1.041666667 
3669388 N G A CGC TGC R C STY3806 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
3700304 N A G AAG AGG K R fdoG formate dehydrogenase-O, major subunit 
1.B.7.b Anaerobic 
Respiration 2 2.083333333 
3702097 N G A CGC CAC R H STY3842 formate dehydrogenase-O gamma subunit 
1.B.7.b Anaerobic 
Respiration 1 1.041666667 
3714939 N T C TTG TCG L S STY3859 putative glycosyl hydrolase 5.I Unknown 2 2.083333333 
3719502 N G A GGC GAC G D STY3861 putative membrane permease 
4.A Transport/binding 
proteins 1 1.041666667 
3719775 N G A GCC ACC A T STY3862 conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
3729652 N C T GCG GTG A V STY3874 glutamine synthetase 1.D.1 Glutamate Family 1 1.041666667 
3756565 N G A CGC TGC R C STY3896 high affinity ribose transport protein 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
2 2.083333333 
3757030 N C T GGC AGC G S STY3896 high affinity ribose transport protein 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
3770081 N G A GTT ATT V I STY3908 ATP synthase subunit C 1.A Degradation 1 1.041666667 
3786020 N C T ATG ATA M I STY3923 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
3810322 N C T TCC TTC S F STY3943 DNA gyrase subunit B 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
3 3.125 
3812138 N C T GAA AAA E K STY3944 putative LysR-family transcriptioanl regulator 2 Broad regulatory function 1 1.041666667 
3828144 N G T GAT TAT D Y STY3957 TorD protein 1.B.7.b Anaerobic Respiration 1 1.041666667 
3828146 N T A GAT GAA D E STY3957 TorD protein 1.B.7.b Anaerobic Respiration 1 1.041666667 
3828148 N T C TTT TCT F S STY3957 TorD protein 1.B.7.b Anaerobic Respiration 1 1.041666667 
3828149 N T A TTT TTA F L STY3957 TorD protein 1.B.7.b Anaerobic Respiration 1 1.041666667 
3848849 N C T GGC GAC G D STY3981 multidrug resistance protein D 
5.D Drug/Analogue 
sensitivity 1 1.041666667 
3865841 N C T CGT TGT R C STY4000 putative PTS system IIC component 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
3872668 N T C AAG AGG K R STY4009 putative glycosyl hydrolase 5.I Unknown 1 1.041666667 
3886919 N T C TAC CAC Y H mgtB Magnesium transport ATPase, P-type 2 SPI-3 2 2.083333333 
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3901514 N A G GAC GGC D G STY4043 sodium:galactoside family symporter 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
2 2.083333333 
3918863 N C T GTA ATA V I STY4057 putative beta-lactamase 5.I Unknown 1 1.041666667 
3967115 2 C T TGG TAG W * STY4106 putative lipoprotein 3.C.1 Membranes lipoprotein 2 2.083333333 
3978351 N C T GGC AGC G S STY4115 putative sugar kinase 5.I Unknown 1 1.041666667 
3982726 N C T GCG GTG A V STY4118 putative transcriptional regulator 2 Broad regulatory function 6 6.25 
3999907 N A G GTC GCC V A STY4136 xylose operon regulatory protein 2 Broad regulatory function 1 1.041666667 
4002684 N G A CGG CAG R Q STY4138 xylulose kinase 1.A.1 Degradation of carbohydrates 1 1.041666667 
4010228 N C T CGT TGT R C STY4148 putative acetyltransferase 5.I Unknown 1 1.041666667 
4019716 N G T GCT GAT A D STY4160 3-methyladenine DNA glycosylase I, constitutive 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
4033249 N A G TGG CGG W R STY4173 putative amino acid permease 
4.A.1 Transport amino acid 
and amines 1 1.041666667 
4042727 N C T GCG GTG A V STY4182 
putative polysaccharide 
biosynthesis protein subunit 
B 
3.C.2 Surface 
polysaccharides & antigens 1 1.041666667 
4057031 N A G GAC GGC D G STY4193 putative membrane protein 3.C.1 Membranes lipoprotein 5 5.208333333 
4058591 N A G AAC AGC N S STY4193 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4061821 N T C GAG GGG E G STY4196 hypothetical lysR-family transcriptional regulator 2 Broad regulatory function 2 2.083333333 
4071260 N T C AAC AGC N S STY4205 glutathione reductase 1.G.10 Thioredoxin 1 1.041666667 
4072370 N C T GAA AAA E K STY4206 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
4087366 N C T GGA GAA G E STY4222 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4087979 N C T GCA ACA A T STY4222 putative membrane protein 3.C.1 Membranes lipoprotein 5 5.208333333 
4090514 N G A GAT AAT D N STY4224 
hypothetical ABC 
transporter ATP-binding 
protein 
4.A Transport/binding 
proteins 2 2.083333333 
4092099 N C T GCA GTA A V STY4224 
hypothetical ABC 
transporter ATP-binding 
protein 
4.A Transport/binding 
proteins 1 1.041666667 
4095057 N C T GAT AAT D N STY4228 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
4108285 N C A GCG GAG A E ftsX cell division protein 4.C Cell division 4 4.166666667 
4134238 N G A AGC AAC S N gntK putative gluconokinase 1.C Central Intermediary metabolism 1 1.041666667 
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4137928 2 C T CAG TAG Q * glgB 1,4-alpha-glucan branching enzyme 
3.A.10 Polysaccharides - 
(cytoplasmic) 2 2.083333333 
4137929 N A G CAG CGG Q R glgB 1,4-alpha-glucan branching enzyme 
3.A.10 Polysaccharides - 
(cytoplasmic) 2 2.083333333 
4141884 N C T GCC GTC A V glgC glucose-1-phosphate adenylyltransferase 
3.A.10 Polysaccharides - 
(cytoplasmic) 1 1.041666667 
4150649 N G A GGT AGT G S glpR glycerol-3-phosphate regulon repressor 
1.B.7.b Anaerobic 
Respiration 1 1.041666667 
4155227 N C T CGC TGC R C STY4282 maltodextrin phosphorylase 1.A.1 Degradation of carbohydrates 2 2.083333333 
4178175 N C T GTT ATT V I yrfG putative hydrolase 5.I Unknown 1 1.041666667 
4190284 N C T ACC ATC T I damX DamX protein 4.C Cell division 6 6.25 
4192170 N C T GCC GTC A V rpe ribulose-phosphate 3-epimerase 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
4219044 N T G GAC GCC D A yheS probable ABC transporter ATP-binding protein 
4.A Transport/binding 
proteins 1 1.041666667 
4225205 2 C A TGC TGA C * yheO conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
4249038 N A G TAC CAC Y H trkA potassium transport protein 4.A.2 Transport Cations 1 1.041666667 
4253546 N G T TTG TTT L F STY4392 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
4282989 N C T GCC ACC A T STY4415 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4289522 N G A GGC AGC G S STY4421 putative lipoprotein 3.C.1 Membranes lipoprotein 2 2.083333333 
4293291 N C T AGC AAC S N STY4424 maltose transport inner membrane protein 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
2 2.083333333 
4296632 N C T CGC TGC R C STY4426 
maltose/maltodextrin 
transport ATP-binding 
protein 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
4296800 N C T CCG TCG P S STY4426 
maltose/maltodextrin 
transport ATP-binding 
protein 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 1.041666667 
4301966 N C A GAG GAT E D STY4431 glycerol-3-phosphate acyltransferase 3.A.11 Phospholipids 1 1.041666667 
4308235 N G A GAT AAT D N STY4438 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4337777 N G A GGC AGC G S STY4459 large repetitive protein SPI-4 2 2.083333333 
4355566 N T A GTA GAA V E STY4469 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4358445 2 C T TGG TAG W * STY4472 putative membrane protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4365926 N C T GCG GTG A V STY4479 cytochrome c-type biogenesis protein 
1.B.7.b Anaerobic 
Respiration 1 1.041666667 
4385697 N C A GCC TCC A S adi arginine decarboxylase 1.A.2 Degradation of amino acids 1 1.041666667 
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4402460 N C T GGG AGG G R STY4510 putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4409661 N G A GTA ATA V I STY4521 hypothetical protein SPI-7 1 1.041666667 
4418337 N G A CGG CAG R Q STY4529 hypothetical protein SPI-7 1 1.041666667 
4421765 N G A GCA ACA A T STY4534 hypothetical protein SPI-7 1 1.041666667 
4422155 N C T GCT GTT A V ssB single strand binding protein SPI-7 1 1.041666667 
4427699 N T C TCC CCC S P pilO putative pilus assembly protein SPI-7 1 1.041666667 
4430073 N G A GCC ACC A T pilQ nucleotide-binding protein SPI-7 2 2.083333333 
4430715 N C T CTT TTT L F pilQ nucleotide-binding protein SPI-7 1 1.041666667 
4440280 N C T CTT TTT L F STY4558 putative exported protein SPI-7 6 6.25 
4457340 N G A GGG GAG G E STY4579 putative membrane protein SPI-7 1 1.041666667 
4460065 N A G ATC GTC I V STY4583 conserved hypothetical protein SPI-7 1 1.041666667 
4461142 N C T GCA GTA A V STY4584 conserved hypothetical protein SPI-7 1 1.041666667 
4465215 2 G A TGG TAG W * STY4587 hypothetical protein SPI-7 2 2.083333333 
4471515 N G A GAG AAG E K STY4594 hypothetical protein SPI-7 1 1.041666667 
4516839 N A G TTT CTT F L tviE 
Vi polysaccharide 
biosynthesis protein TviE, 
Glycosyl transferases group 
1 
ViaB operon 6 6.25 
4516889 N G A GCC GTC A V tviE 
Vi polysaccharide 
biosynthesis protein TviE, 
Glycosyl transferases group 
1 
ViaB operon 1 1.041666667 
4517865 N A G TGT CGT C R tviE 
Vi polysaccharide 
biosynthesis protein TviE, 
Glycosyl transferases group 
1 
ViaB operon 1 1.041666667 
4518191 N A G GTT GCT V A tviE 
Vi polysaccharide 
biosynthesis protein TviE, 
Glycosyl transferases group 
1 
ViaB operon 1 1.041666667 
4519127 2 C A GGA TGA G * tviD Vi polysaccharide biosynthesis protein ViaB operon 1 1.041666667 
4521049 N T G AAT ACT N T tviD Vi polysaccharide biosynthesis protein ViaB operon 2 2.083333333 
4521241 N G A GCC GTC A V tviD Vi polysaccharide biosynthesis protein ViaB operon 2 2.083333333 
4553988 N G A CTT TTT L F yjeJ hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
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4563879 N C T GCG GTG A V yjeM putative amino acid permease 
4.A Transport/binding 
proteins 1 1.041666667 
4574488 N C T AGC AAC S N yjeS putative 4Fe-4S binding protein 5.I Unknown 1 1.041666667 
4575322 N G A GGC AGC G S yjeF conserved hypothetical protein 5.H.b Hypothetical protein 6 6.25 
4580561 N C T TCA TTA S L miaA 
tRNA delta-2-
isopentenylpyrophosphate 
(IPP) transferase 
3.A.5 Aminoacyl tRNA 
synthetase 2 2.083333333 
4580600 N G A GGA GAA G E miaA 
tRNA delta-2-
isopentenylpyrophosphate 
(IPP) transferase 
3.A.5 Aminoacyl tRNA 
synthetase 1 1.041666667 
4595445 N C T GCT GTT A V aidB probable acyl Co-A dehydrogenase 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
4596506 2 G T GAA TAA E * aidB probable acyl Co-A dehydrogenase 
1.A.1 Degradation of 
carbohydrates 1 1.041666667 
4600253 N C T GGC AGC G S yjfR conserved hypothetical protein 5.H.a Hypothetical protein 1 1.041666667 
4621008 2 C T TGG TAG W * ytfJ putative exported protein 3.C.1 Membranes lipoprotein 2 2.083333333 
4627402 N C T CCG TCG P S ytfN putative exported protein 3.C.1 Membranes lipoprotein 1 1.041666667 
4650675 N C T GGA AGA G R nrdD anaerobic ribonucleoside-triphosphate reductase 
1.F.3 2'-
Deoxyribonucleotide 
metabolism 
2 2.083333333 
4669035 N C T ACG ATG T M STY4808 conserved hypothetical protein 5.H.b Hypothetical protein 2 2.083333333 
4681321 N C T GAT AAT D N STY4819 regulatory protein 2 Broad regulatory function 1 1.041666667 
4716667 N C T CGC TGC R C STY4853 hypothetical protein SPI-10 1 1.041666667 
4724452 N C G GCC CCC A P STY4861 hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
4728683 N C T TCG TTG S L STY4866 probable aspartate racemase 1.C Central Intermediary metabolism 1 1.041666667 
4759459 N C T ATG ATA M I dnaC probable DNA replication protein 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
4773929 N C T ACA ATA T I STY4914 conserved hypothetical protein 5.H.b Hypothetical protein 1 1.041666667 
4786646 N A T AGC TGC S C radA putative DNA repair protein 
3.A.7 DNA - replication, 
repair, 
restriction./modification 
1 1.041666667 
4788023 N G A GCC ACC A T nadR conserved hypothetical transcriptional regulator 2 Broad regulatory function 4 4.166666667 
4798548 N A G AGA GGA R G STY4937 inner membrane protein CreD 5.B Colicin-related function 1 1.041666667 
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2725 2725 N G T GCA TCA A S STY0002 aspartokinase I/homoserine dehydrogenase I 1.D.2 Aspartate Family 1 4.17 
122281 122281 N C A CGC CTC R L STY0120 L-ribulokinase 1.A.1 Degradation of carbohydrate 1 4.17 
135985 135985 N G A ATG ATA M I STY0134 probable activator protein in leuABCD operon 1.D.6 Pyruvate Family 1 4.17 
204001 204001 N G A GCT GTT A V STY0193 carbonic anhydrase 5.I Unknown 1 4.17 
241338 241338 2 G T GAA TAA E * STY0230 deoxyguanosinetriphosphate triphosphohydrolase 
1.C Central 
intermediary 
metabolism 
1 4.17 
266063 266063 N A T CAC CTC H L STY0253 ribonuclease HII 3.B.1 Degradation of RNA 1 4.17 
275632 275632 N G A GAT AAT D N STY0259 lysine decarboxylase 1.B.2 Pyruvate dehydrogenase 1 4.17 
281721 281721 N C T GTC ATC V I STY0269 prolyl-tRNA synthetase 
3.A.5 Amino acyl tRNA 
synthesis; tRNA 
modification 
1 4.17 
285329 285329 N A G TAT CAT Y H STY0274 putative ABC transporter ATP-binding protein 
4.A Transport/binding 
proteins 1 4.17 
308726 308726 N C T ATG ATA M I STY0293 hypothetical protein SPI-6 1 4.17 
341744 341744 N G A GTG ATG V M safA probable lipoprotein SPI-6 1 4.17 
343595 343595 N T C TAC CAC Y H safB periplasmic fimbrial chaperone protein SPI-6 1 4.17 
355324 355324 N G A GGG AGG G R tsaC outer membrane fimbrial usher protein SPI-6 1 4.17 
378535 378535 2 C A TGC TGA C * STY0368 probable secreted protein 3.C.1 Membranes lipoprotein 1 4.17 
438939 438939 N A G CTG CCG L P STY0429 exonuclease SbcC 3.B.2 Degradation of DNA 1 4.17 
439695 439695 N C T CGT CAT R H STY0429 exonuclease SbcC 3.B.2 Degradation of DNA 1 4.17 
464238 464238 N C T GCA GTA A V STY0458 thiamine-monophosphate kinase 1.G.8 Thiamine 1 4.17 
526144 526144 N C T GAT AAT D N STY0520 acriflavin resistance protein A precursor 
5.D Drug/Analogue 
sensitivity 1 4.17 
531394 531394 N C T GCC ACC A T STY0523 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
582703 582703 N C T GGC AGC G S allC allantoate amidohydrolase 1.A.1 Degradation of carbohydrate 1 4.17 
588547 588547 N G A GTG ATG V M arcC carbamate kinase 1.A.1 Degradation of carbohydrate 1 4.17 
599161 599161 2 C T CAG TAG Q * fimD outer membrane usher protein FimD precursor 3.C.3 Surface structure 1 4.17 
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661378 661378 N G A GAA AAA E K STY0661 
molybdopterin-containing 
oxidoreductase membrane anchor 
subunit 
5.I Unknown 1 4.17 
661390 661390 N G A GTG ATG V M STY0661 
molybdopterin-containing 
oxidoreductase membrane anchor 
subunit 
5.I Unknown 1 4.17 
697519 697519 N G T GGC TGC G C STY0701 putative hydrolase C-terminus 5.I Unknown 1 4.17 
698447 698447 N G A GCG ACG A T STY0702 probable permease 4.A Transport/binding proteins 1 4.17 
699681 699681 N A G ACC GCC T A STY0703 putative sigma-54 dependent transcriptional regulator 
2 Broad regulatory 
function 1 4.17 
707587 707587 N C T GAA AAA E K STY0711 apolipoprotein N-acyltransferase 3.C.1 Membranes lipoprotein 1 4.17 
725712 725712 N A G ACT GCT T A ybfM putative outer membrane protein 3.C Cell envelope 1 4.17 
745075 745075 N T G GAT GCT D A STY0744 sensor protein KdpD 2 Broad regulatory function 1 4.17 
760747 760747 N T C TCA CCA S P STY0760 putative glycosyl transferase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
773094 773094 N G A CGC CAC R H STY0775 succinate dehydrogenase cytochrome b-556 subunit 
1.B.3 Tricarboxylic acid 
cycle 1 4.17 
796312 796312 N C T CGC CAC R H ybgR probable cation transport protein 4.A.2 Transport Cations 1 4.17 
825652 825652 N C T CCG CTG P L STY0827 biotin synthetase 1.G.1 Biotin 1 4.17 
834261 834261 N C T GCG ACG A T STY0835 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
836054 836054 N G A CGC CAC R H STY0836 molybdenum cofactor biosynthesis protein A 1.G.4 Molybdopterin 1 4.17 
866031 866031 N G A CCT CTT P L ybiP putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
884217 884217 N C T CGC TGC R C yliC hypothetical ABC transporter permease protein 
4.A Transport/binding 
proteins 2 8.33 
919324 919324 2 C T TGA TAA * * STY0929 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
938733 938733 N G A ACG ATG T M STY0948 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
962365 962365 N G A ATG ATA M I ycaM probable transport protein 4.A Transport/binding proteins 1 4.17 
969891 969891 N C T GCC ACC A T STY0975 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
987013 987013 N C T GGG AGG G R STY0992 putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
990266 990266 N C T CCG CTG P L STY0995 KicA protein 4.H Cell Killing 1 4.17 
993768 993768 N T C TAC CAC Y H mukB cell division protein 4.C Cell division 1 4.17 
1051566 1051566 N C T GGT GAT G D STY1076 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
1158627 1158627 N G A CAT TAT H Y STY1200 damage-inducible protein 5.I Unknown 1 4.17 
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1187285 1187285 N G A GGT AGT G S STY1232 3-oxoacyl-[acyl-carrier-protein] synthase III 
1.H Fatty acid 
biosynthesis 1 4.17 
1196367 1196367 N A G CAC CGC H R STY1242 PTS system, glucose-specific IIBC component 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 4.17 
1196978 1196978 N G A GCG ACG A T STY1242 PTS system, glucose-specific IIBC component 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 4.17 
1196990 1196990 N G A GGT AGT G S STY1242 PTS system, glucose-specific IIBC component 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 4.17 
1208535 1208535 N A T TGG AGG W R STY1256 transcription-repair coupling factor (TrcF) 
3.A.7 DNA - 
replication, repair, 
restriction./modification 
1 4.17 
1241292 1241292 N A G CTG CCG L P STY1286 nitrate/nitrite sensor protein NarX 1.B.7.b Anaerobic Respiration 1 4.17 
1278803 1278803 N T G AAA CAA K Q STY1321 conserved hypothetical protein 5.H.a Hypothetical protein 1 4.17 
1283955 1283955 N A T,G TGA CGA/AGA */* R/R STY1326 
indole-3-glycerol phosphate 
synthase 
1.D.4 Aromatic Amino 
Acid 2 8.33 
1289493 1289493 N T G GAT GAG D E STY1331 putative pseudouridine synthase 
3.A.3 Ribosomes - 
maturation and 
modification 
1 4.17 
1296666 1296666 N G A GGC AGC G S STY1337 cys regulon transcriptional activator 1.D.3 Serine Family 1 4.17 
1308498 1308498 N C T AGG AAG R K STY1349 conserved hypothetical protein 5.I Unknown 1 4.17 
1313439 1313439 N C T GGC AGC G S STY1352 enoyl-[acyl-carrier-protein] reductase (NADH) 
1.H Fatty acid 
biosynthesis 1 4.17 
1318260 1318260 N G T CCG CAG P Q STY1356 peptide transport system ATP-binding protein SapD 4.A.6 Transport Other 1 4.17 
1325649 1325649 N A G TTC CTC F L STY1369 peptide transport periplasmic protein SapA precursor 4.A.6 Transport Other 1 4.17 
1399300 1399300 N C T GAG AAG E K STY1447 putative ribulose-5-phosphate 3-epimerase 5.I Unknown 1 4.17 
1399483 1399483 N T C ATT GTT I V STY1447 putative ribulose-5-phosphate 3-epimerase 5.I Unknown 1 4.17 
1425078 1425078 N G A CCT TCT P S srfA putative virulence effector protein 4.I Pathogenicity 1 4.17 
1445458 1445458 N G A GCG GTG A V STY1489 nitrite extrusion protein 4.A Transport/binding proteins 1 4.17 
1458466 1458466 2 G A TGG TAG W * STY1502 putative secreted protein 3.C.1 Membranes lipoprotein 1 4.17 
1485540 1485540 N T C CTG CCG L P hyaF2 hydrogenase-1 operon protein HyaF2 
1.B.7.a Aerobic 
Respiration 1 4.17 
1536085 1536085 N C T GCG ACG A T STY1589 pyridine nucleotide transhydrogenase subunit-alpha 
1.C Central 
intermediary 
metabolism 
1 4.17 
1589539 1589539 N C T GCG GTG A V STY1658 adenosine deaminase 
1.F.4 Salvage of 
nucleosides and 
nucleotides 
1 4.17 
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1601143 1601143 N C T CAT TAT H Y STY1671 glutathione S-transferase 1.G.10 Thioredoxin 1 4.17 
1606270 1606270 N G A ATG ATA M I STY1677 outer membrane lipoprotein SlyB precursor 3.C Cell envelope 1 4.17 
1656792 1656792 N G T GAC TAC D Y ttrC tetrathionate reductase subunit C (membrane protein) SPI-2 2 8.33 
1701598 1701598 N A G ATA ATG I M rfc O-antigen polymerase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
1721795 1721795 2 G A CAG TAG Q * STY1802 osmotically inducible lipoprotein E precursor 5.I Unknown 1 4.17 
1725197 1725197 N C T ATG ATA M I astE succinylglutamate desuccinylase 1.A.2 Degradation of amino acids 1 4.17 
1756933 1756933 N G T CTC ATC L I STY1839 putative transcriptional regulator 2 Broad regulatory function 2 8.33 
1770310 1770310 N T C GAG GGG E G STY1861 putative ABC transport ATP-binding subunit 
4.A Transport/binding 
proteins 1 4.17 
1772818 1772818 N C T GAT AAT D N STY1864 putative inner membrane transport protein 
4.A Transport/binding 
proteins 1 4.17 
1773651 1773651 N C T GCC ACC A T STY1865 putative substrate-binding transport protein 
4.A Transport/binding 
proteins 1 4.17 
1813911 1813911 N A G ACC GCC T A STY1921 probable cytochrome oxidase subunit II 
1.B.7.c Electron 
Transport 1 4.17 
1861881 1861881 N T C TAC TGC Y C STY1975 heat shock protein 5.F Adaptions and atypical conditions 1 4.17 
1876919 1876919 N C T GGG GAG G E STY1991 putative acetyltransferase 5.I Unknown 2 8.33 
1988113 1988113 N T C GTG GCG V A STY2136 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
1995782 1995782 N G A GTC ATC V I STY2145 tyrosine-specific transport protein 4.A.1 Transport amino acid and amines 1 4.17 
2006311 2006311 N G A GCG GTG A V STY2161 putative deaminase 1.A Degradation 1 4.17 
2051229 2051229 N C T ATG ATA M I STY2216 putative inner membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
2054384 2054384 N A C TTT GTT F V STY2219 
nicotinate-nucleotide--
dimethylbenzimidazole 
phosphoribosyl transferase 
1.G.13 Cobalamin 1 4.17 
2066384 2066384 N C T CGG CAG R Q cbiE 
precorrin-6Y C5,15-
methyltransferase 
[decarboxylating] 
1.A.1 Degradation of 
carbohydrate 1 4.17 
2075855 2075855 N T C TAT CAT Y H pduC glycerol dehydratase large subunit 1.A.1 Degradation of carbohydrate 1 4.17 
2079993 2079993 N G A GCC ACC A T pduJ putative propanediol utilization protein PduJ 
1.A.1 Degradation of 
carbohydrate 1 4.17 
2120553 2120553 N G T CCT CAT P H STY2292 phosphomannomutase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
2127235 2127235 N A G GTC GCC V A rfbE CDP-tyvelose-2-epimerase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
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2145889 2145889 N T C GAC GGC D G manB phosphomannomutase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
2151043 2151043 N C G GAG GAC E D STY2321 GDP-mannose 4,6-dehydratase 
1.C.3 Sugar-nucleotide 
biosynthesis, 
conversions 
1 4.17 
2162476 2162476 N C T CAT TAT H Y yegH putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
2162537 2162537 N T C GTC GCC V A yegH putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
2167085 2167085 N T G CTG CGG L R STY2336 putative membrane protein 3.C.1 Membranes lipoprotein 2 8.33 
2176236 2176236 N G A GAT AAT D N STY2340 putative RND-family transporter protein 
4.A Transport/binding 
proteins 1 4.17 
2185609 2185609 N G A GCC ACC A T STY2348 hypothetical protein 5.I Unknown 1 4.17 
2191798 2191798 N G A CCT CTT P L STY2357 hypothetical protein 5.I Unknown 1 4.17 
2220061 2220061 N G A CCA CTA P L STY2389 putative two-component system sensor kinase 
2 Broad regulatory 
function 1 4.17 
2221672 2221672 N A G GTC GCC V A STY2389 putative two-component system sensor kinase 
2 Broad regulatory 
function 1 4.17 
2239555 2239555 N C T CGT CAT R H STY2407 FAA-hydrolase-family protein 5.I Unknown 1 4.17 
2268919 2268919 N T C ATC ACC I T STY2437 putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
2331540 2331540 N G A CTT TTT L F STY2499 DNA gyrase subunit A 
3.A.7 DNA - 
replication, repair, 
restriction./modification 
1 4.17 
2333751 2333751 N C T GAC AAC D N STY2499 DNA gyrase subunit A 
3.A.7 DNA - 
replication, repair, 
restriction./modification 
1 4.17 
2343416 2343416 N G A CGC TGC R C STY2509 putative transmembrane transport protein 
4.A Transport/binding 
proteins 1 4.17 
2350279 2350279 N A G CAG CGG Q R STY2514 anaerobic glycerol-3-phosphate dehydrogenase subunit B 
1.B.7.b Anaerobic 
Respiration 1 4.17 
2366071 2366071 N G A GAG AAG E K STY2530 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
2400798 2400798 N C T GTC ATC V I STY2563 putative sodium/sulphate transporter 5.I Unknown 1 4.17 
2419570 2419570 N C T GAC AAC D N STY2584 histidine-binding periplasmic protein 
4.A.1 Transport amino 
acid and amines 1 4.17 
2463468 2463468 N T C TGG CGG W R STY2629 putative lipopolysaccharide modification acyltransferase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
2493604 2493604 N C T GAA AAA E K STY2655 xanthosine operon transcriptional regulator 
2 Broad regulatory 
function 1 4.17 
2493630 2493630 N G A GCG GTG A V STY2655 xanthosine operon transcriptional regulator 
2 Broad regulatory 
function 1 4.17 
2514750 2514750 2 C T TGG TAG W * STY2679 sulphate transport system permease protein CysW 4.A.5 Transport Anions 1 4.17 
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2515747 2515747 N C T GGA GAA G E STY2681 thiosulphate-binding protein precursor 4.A.5 Transport Anions 1 4.17 
2533579 2533579 N A T TGG AGG W R STY2699 putative ethanolamine utilization protein EutJ 1.A Degradation 1 4.17 
2540803 2540803 N C A GGC TGC G C maeB NADP-dependent malate dehydrogenase (decarboxylating) 
1.D.4 Aromatic Amino 
Acid 1 4.17 
2567455 2567455 N G A TCA TTA S L STY2730 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
2568142 2568142 N G A CCG TCG P S STY2731 putative permease 4.A Transport/binding proteins 1 4.17 
2572830 2572830 N C T CTC TTC L F STY2735 putative exported protein 3.C.1 Membranes lipoprotein 1 4.17 
2590496 2590496 N G A CCG TCG P S STY2752 inosine-5'-monophosphate dehydrogenase 
1.F.1 Purine 
ribonucleotide 
biosynthesis 
1 4.17 
2609489 2609489 N G A GCT GTT A V STY2760 putative exported protein 4.I Pathogenicity 1 4.17 
2611167 2611167 N C T GCG ACG A T STY2760 putative exported protein 4.I Pathogenicity 1 4.17 
2611377 2611377 N C T GCC ACC A T STY2760 putative exported protein 4.I Pathogenicity 1 4.17 
2626146 2626146 N A G TTC TCC F S STY2773 putative anaerobic reductase component 
1.B.7.b Anaerobic 
Respiration 1 4.17 
2630309 2630309 2 G A CAG TAG Q * pbpC penicillin-binding protein 1C 3.C.4 Murein sacculus, peptidoglycan 1 4.17 
2654483 2654483 N G A CCG TCG P S STY2799 putative exported protein 3.C.1 Membranes lipoprotein 1 4.17 
2655783 2655783 N T C ATG ACG M T STY2800 stationary phase inducible protein CsiE 5.I Unknown 1 4.17 
2677249 2677249 N G A GGG AGG G R STY2813 putative exported protein 3.C.1 Membranes lipoprotein 1 4.17 
2694734 2694734 N G A CCG CTG P L STY2832 sigma-E factor negative regulatory protein 
2 Broad regulatory 
function 1 4.17 
2704993 2704993 N C T GCG GTG A V STY2843 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
2725661 2725661 N T C TAC TGC Y C STY2855 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
2733558 2733558 N C A GAT TAT D Y STY2864 signal recognition particle protein 3.A.8 Protein translation and modification 2 8.33 
2748017 2748017 N G A GGC GAC G D STY2875 large repetitive protein SPI-9 1 4.17 
2805601 2805601 N C T GCC GTC A V STY2932 ribonucleoside-diphosphate reductase 2 alpha chain 1.F.5 Miscellaneous 1 4.17 
2840369 2840369 N G A GCG ACG A T STY2963 putative rubredoxin reductase 5.I Unknown 1 4.17 
2848073 2848073 N A G TGG CGG W R STY2971 formate hydrogenlyase subunit 5 1.B.8 Fermentation 1 4.17 
2854109 2854109 N G A GGT AGT G S hypC hydrogenase isoenzymes formation protein HypC 
1.B.7.b Anaerobic 
Respiration 1 4.17 
2870474 2870474 N A G AAG GAG K E STY2996 AraC-family transcriptional regulator SPI-1 1 4.17 
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2904779 2904779 N G A CCG CTG P L STY3036 possible membrane transport protein 
4.A Transport/binding 
proteins 1 4.17 
2915322 2915322 N T G ACG CCG T P rpoS RNA polymerase sigma subunit RpoS (sigma-38) 
2 Broad regulatory 
function 1 4.17 
2915330 2915330 N T A GAA GTA E V rpoS RNA polymerase sigma subunit RpoS (sigma-38) 
2 Broad regulatory 
function 1 4.17 
2915627 2915627 2 C T TGG TAG W * rpoS RNA polymerase sigma subunit RpoS (sigma-38) 
2 Broad regulatory 
function 1 4.17 
2918204 2918204 N C T GGT AGT G S STY3052 stationary-phase survival protein 5.I Unknown 1 4.17 
2936316 2936316 N G A ATG ATA M I sopD possible secreted protein 4.I Pathogenicity 1 4.17 
2955365 2955365 N G A GTT ATT V I STY3091 possible secreted protein 3.C.1 Membranes lipoprotein 1 4.17 
2992175 2992175 N G A GGT AGT G S STY3124 possible aminotransferase 5.I Unknown 1 4.17 
2994859 2994859 N G A ACG ATG T M STY3127 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
3051986 3051986 N G A CGG TGG R W STY3183 hypothetical protein (assiciated with virulence) 4.I Pathogenicity 1 4.17 
3053028 3053028 N G A GCC ACC A T STY3186 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
3109192 3109192 N G A GTG ATG V M STY3244 galactose-proton symport (galactose transporter) 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 4.17 
3117804 3117804 N G A GAC AAC D N STY3254 putative membrane protein 3.C.1 Membranes lipoprotein 2 8.33 
3128447 3128447 N G A GAC AAC D N STY3268 nucleoside permease 4.A.6 Transport Other 1 4.17 
3239753 3239753 N C T GGT AGT G S cheM methyl-accepting chemotaxis protein II 
4.D Chemotaxis and 
mobility 1 4.17 
3311882 3311882 N G A CCT CTT P L STY3467 protein chain initiation factor 2 3.A.8 Protein translation and modification 1 4.17 
3323883 3323883 N C T CCA CTA P L STY3479 
Penicillin-binding protein (D-
alanyl-D-alanine 
carboxypeptidase) 
3.C.4 Murein sacculus, 
peptidoglycan 1 4.17 
3326564 3326564 N C A GGC TGC G C STY3481 putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
3329720 3329720 N C T GGC AGC G S STY3486 UDP-N-acetylglucosamine 1-carboxyvinyltransferase 
3.C.4 Murein sacculus, 
peptidoglycan 1 4.17 
3364345 3364345 N C T ATG ATA M I STY3521 putative GntR-family transcriptional regulator 
2 Broad regulatory 
function 1 4.17 
3370871 3370871 N T C GTG GCG V A degS serine protease 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
1 4.17 
3371437 3371437 N G A GAG AAG E K degS serine protease 
3.B.3 Degradation of 
proteins, peptides, 
glycoproteins 
1 4.17 
3378518 3378518 N C T GCT ACT A T STY3536 possible membrane transport protein 
4.A Transport/binding 
proteins 1 4.17 
3379980 3379980 N C T GGT AGT G S STY3538 possible GntR-family transcriptional regulator 
2 Broad regulatory 
function 1 4.17 
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3437215 3437215 N T C TAC TGC Y C tatD putative deoxyribonuclease 3.B.2 Degradation of DNA 1 4.17 
3449225 3449225 N C A TGG TGT W C STY3594 
5-
methyltetrahydropteroyltriglutama
te-homocysteine methyltransferase 
1.D.2 Aspartate Family 1 4.17 
3552039 3552039 N G T GAT TAT D Y STY3708 possible LysR-family transcriptional regulatory protein 
2 Broad regulatory 
function 1 4.17 
3602082 3602082 2 C T TGG TAG W * STY3744 vitamin B12 receptor protein 3.C Cell envelope 1 4.17 
3652101 3652101 N A G ACG GCG T A STY3785 putative glycerol metabolic protein 
1.C Central 
intermediary 
metabolism 
1 4.17 
3669615 3669615 N C T CGC CAC R H STY3806 putative membrane protein 3.C Cell envelope 1 4.17 
3680371 3680371 N C A CTC ATC L I STY3819 possible membrane transport protein 
4.A Transport/binding 
proteins 1 4.17 
3688431 3688431 N G A GCC ACC A T STY3827 L-rhamnose isomerase 1.A.1 Degradation of carbohydrate 1 4.17 
3716547 3716547 N G T GGC GTC G V STY3859 putative glycosyl hydrolase 5.I Unknown 1 4.17 
3718028 3718028 N C T CTC TTC L F STY3860 putative membrane permease 4.A Transport/binding proteins 1 4.17 
3754576 3754576 N G A GCG GTG A V STY3894 D-ribose-binding periplasmic protein 
1.A.1 Degradation of 
carbohydrate 1 4.17 
3759518 3759518 N C T GGT AGT G S STY3898 membrane transport protein 4.A Transport/binding proteins 1 4.17 
3774538 3774538 N A G ACT GCT T A STY3913 ATP synthase beta subunit 1.A Degradation 1 4.17 
3795418 3795418 2 C T CAG TAG Q * STY3932 putative membrane transport protein 
4.A Transport/binding 
proteins 1 4.17 
3808610 3808610 N G A GAC AAC D N STY3942 recF protein 
3.A.7 DNA - 
replication, repair, 
restriction./modification 
1 4.17 
3820902 3820902 N G A CGC TGC R C STY3951 Two-component sensor protein histidine protein kinase. 
1.B.7.b Anaerobic 
Respiration 1 4.17 
3826057 3826057 N G A ATG ATA M I STY3956 trimethylamine-N-oxide reductase precursor 
1.B.7.b Anaerobic 
Respiration 1 4.17 
3828882 3828882 N G A GGT AGT G S yhjA probable cytochrome c peroxidase 5.I Unknown 1 4.17 
3903736 3903736 N G A GGG GAG G E STY4044 putative glycosyl hydrolase 5.I Unknown 1 4.17 
3926993 3926993 N G A GGC AGC G S STY4068 formamidopyrimidine-DNA glycosylase 
3.A.7 DNA - 
replication, repair, 
restriction./modification 
1 4.17 
3931488 3931488 N G A GCT ACT A T waaG lipopolysaccharide core biosynthesis protein 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
3943300 3943300 N C T CGT CAT R H rfaD ADP-L-Glycero-D-mannoheptose-6-epimerase 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
3954677 3954677 N G A GGT AGT G S cysE serine acetyltransferase 1.D.3 Serine Family 1 4.17 
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4001985 4001985 N C T GCG GTG A V STY4137 D-xylose isomerase 1.A.1 Degradation of carbohydrate 1 4.17 
4038663 4038663 2 C T TGG TGA W * STY4178 conserved hypothetical protein 5.H.a Hypothetical protein 1 4.17 
4042168 4042168 N T A CTG CAG L Q yhjO 
putative polysaccharide 
biosynthesis protein catalytic 
subunit 
3.C.2 Surface 
polysaccharides & 
antigens 
1 4.17 
4051472 4051472 N G A ATG ATA M I STY4188 conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
4117689 4117689 N C T ACG ATG T M STY4253 putative exported protein 3.C.1 Membranes lipoprotein 1 4.17 
4119751 4119751 N C T CGT TGT R C STY4255 glycerol-3-phosphate transport system permease protein 
4.A.3 Transport 
Carbohydrates, organic 
acids and alcohols 
1 4.17 
4124948 4124948 2 C T CAA TAA Q * ggt gamma-glutamyltranspeptidase precursor 1.G.10 Thioredoxin 1 4.17 
4186093 4186093 N G C GGT GCT G A yrfA conserved hypothetical protein 5.H.a Hypothetical protein 1 4.17 
4225021 4225021 N G A GGG GAG G E yheO conserved hypothetical protein 5.H.b Hypothetical protein 1 4.17 
4299207 4299207 N T C TTT TCT F S STY4428 maltose operon periplasmic protein 
3.C.1 Membranes 
lipoprotein 1 4.17 
4304442 4304442 N G A ATG ATA M I STY4433 LexA repressor 2 Broad regulatory function 1 4.17 
4308440 4308440 2 G A TGG TAG W * STY4438 putative exported protein 3.C.1 Membranes lipoprotein 1 4.17 
4331402 4331402 N G A GGT AGT G S STY4458 large repetitive protein SPI-4 1 4.17 
4356323 4356323 N A G GAA GGA E G STY4470 putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
4359035 4359035 N C T GAG AAG E K acs acetyl-coenzyme A synthetase 1.H Fatty acid biosynthesis 1 4.17 
4363103 4363103 N G A GTC ATC V I STY4476 cytochrome c-type protein NrfB precursor 
1.B.7.b Anaerobic 
Respiration 1 4.17 
4369734 4369734 N C T GGT AGT G S yjcO putative exported protein 3.C.1 Membranes lipoprotein 1 4.17 
4412203 4412203 N C T ACA ATA T I STY4523 hypothetical protein SPI-7 1 4.17 
4416872 4416872 N T G TTC GTC F V STY4528 hypothetical protein SPI-7 1 4.17 
4428141 4428141 N C T CCA CTA P L pilO putative pilus assembly protein SPI-7 1 4.17 
4442998 4442998 2 G A TGG TAG W * STY4562 hypothetical protein SPI-7 2 8.33 
4516890 4516890 N C T GCC ACC A T tviE 
Vi polysaccharide biosynthesis 
protein TviE, Glycosyl 
transferases group 1 
ViaB operon 1 4.17 
4518117 4518117 N G A CAT TAT H Y tviE 
Vi polysaccharide biosynthesis 
protein TviE, Glycosyl 
transferases group 1 
ViaB operon 1 4.17 
4519552 4519552 N G T CCG CAG P Q tviD Vi polysaccharide biosynthesis protein ViaB operon 1 4.17 
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4520023 4520023 N C T CGC CAC R H tviD Vi polysaccharide biosynthesis protein ViaB operon 1 4.17 
4520030 4520030 N C T GTT ATT V I tviD Vi polysaccharide biosynthesis protein ViaB operon 1 4.17 
4520036 4520036 N C A GGT TGT G C tviD Vi polysaccharide biosynthesis protein ViaB operon 1 4.17 
4521040 4521040 N T A CAG CTG Q L tviD Vi polysaccharide biosynthesis protein ViaB operon 1 4.17 
4521233 4521233 N A G TTC CTC F L tviD Vi polysaccharide biosynthesis protein ViaB operon 1 4.17 
4523460 4523460 N C T GAT AAT D N tviB 
Vi polysaccharide biosynthesis 
protein, UDP-glucose/GDP-
mannose dehydrogenase 
ViaB operon 1 4.17 
4528484 4528484 N A G CAG CGG Q R STY4665 hypothetical protein SPI-7 1 4.17 
4529343 4529343 N A G GAG GGG E G STY4666 probable phage integrase SPI-7 1 4.17 
4561764 4561764 N C T GCG ACG A T frdA fumarate reductase, flavoprotein subunit SPI-7 1 4.17 
4585807 4585807 N C T CGT TGT R C purA adenylosuccinate synthetase 
1.F.1 Purine 
ribonucleotide 
biosynthesis 
1 4.17 
4594305 4594305 2 G A TGG TAG W * yjfC conserved hypothetical protein 5.H.a Hypothetical protein 1 4.17 
4607828 4607828 N C T GCG GTG A V STY4751 putative membrane protein 3.C.1 Membranes lipoprotein 1 4.17 
4644476 4644476 N T C GTA GCA V A STY4785 hypothetical protein 5.I Unknown 1 4.17 
4726489 4726489 N G A ACC ATC T I trpS2 probable tryptophanyl-tRNA synthetase 
3.A.5 Amino acyl tRNA 
synthesis; tRNA 
modification 
1 4.17 
4748848 4748848 N C T ACA ATA T I mrr mrr restriction system protein 
3.A.7 DNA - 
replication, repair, 
restriction./modification 
1 4.17 
4757795 4757795 N C T GGC GAC G D mdoB putative phosphoglycerol transferase 5.I Unknown 2 8.33 
4773347 4773347 N C T CCC CTC P L STY4912 hypothetical protein 5.I Unknown 1 4.17 
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